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Abstract 
 
Currently, regulators make marketing authorisation decisions based on the benefit-risk balance of a 
treatment with little input from patients and the public.  The aims of this thesis are to apply 
systematic methods of benefit-risk assessment proposed for use in regulatory decision-making, and 
examine how they can incorporate patient and public involvement.  These aims were met through 
the investigation of three case studies: efalizumab, rimonabant, and natalizumab.   
Efalizumab (indication: plaque psoriasis) was withdrawn from the market due to the occurrence of 
progressive multifocal leukoencephalopathy.  I examined the feasibility of applying descriptive and 
quantitative frameworks to determine the benefit-risk balance of efalizumab, and evaluated where 
patient and public involvement can be applied in the decision-making process. 
Rimonabant (indication: overweight and obesity) was withdrawn from the market due to the 
occurrence of psychiatric disorders.  I conducted a discrete choice experiment to elicit patient and 
public preferences regarding the benefits and risks of treatment, and developed a probabilistic 
analysis method to analyse the preference data and determine the benefit-risk balance of 
rimonabant. 
Natalizumab (indication: relapsing remitting multiple sclerosis) received authorisation, but the 
benefit-risk balance was reassessed due to the occurrence of progressive multifocal 
leukoencephalopathy.  Authorisation was maintained with risk minimisation measures.  I developed 
a framework to guide the application, reporting, and evaluation of patient and public involvement in 
benefit-risk assessment.  I then tested the feasibility of the framework with protocols designed to 
elicit patient and public preferences on the benefits and risks of natalizumab. 
Based on the findings of these case studies, preferences can be elicited from patients and the public 
and used to determine the benefit-risk balance of a medicine.   This thesis provides a methodological 
foundation to guide the application, reporting and evaluation of PPI in the benefit-risk assessment of 
medicines and improve the legitimacy, transparency, and quality of regulatory decision-making.   
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1 Introduction 
The regulatory decision of whether to authorise a medicine or not is extremely complicated, and 
requires careful consideration of benefits and risks.  Regulators have the task of deciding if the 
significance and magnitude of risk is reasonable given the significance and magnitude of the 
expected benefit; this trade-off determines the benefit-risk balance of a medicine.  If the benefit-risk 
balance is considered to be positive, the medicine either receives or maintains marketing 
authorisation, depending on the stage of the product lifecycle.  Conversely, if the benefit-risk 
balance is found to be negative, the medicine does not receive marketing authorisation, or 
marketing authorisation is varied if there is a specific population subset for which the benefit-risk 
balance would still remain positive, or marketing authorisation is suspended.  Regulators perform 
marketing authorisation decisions on behalf of patients and the public.  Ultimately, they determine 
which medicines are marketed, for which indications, and for which patient population(s).   
Often it is implicit how regulators make their decisions and determine the benefit-risk balance of a 
treatment; it is not transparent how they assign values to the perceived significance and magnitude 
of the benefits and risks, and subsequently trade them off against each other.  In order to improve 
the transparency of marketing authorisation decisions, there are suggestions for regulators to use 
systematic methods of benefit-risk assessment to guide and communicate their decision-making.  
There is also wide discussion regarding how patients and the public can be involved in regulatory 
decision-making, and how it can be possible to elicit their values on how they perceive the 
significance and magnitude of the benefits and risks (Eichler et al., 2012).  Despite this, there is a lack 
of evidence to suggest which systematic methods of benefit-risk assessment are best suited to a 
regulatory setting, and how patients and the public can be meaningfully involved in regulatory 
decision-making.  This thesis addresses these concerns by applying and evaluating systematic 
methods of benefit-risk assessment which have been proposed for use within a regulatory decision-
making context, and in particular investigates how patient and public involvement (PPI) can be 
applied, evaluated and reported in conjunction with these methods.   
1.1 Regulatory decision-making 
The thalidomide tragedy highlighted the need for medicines to have formalised testing and 
authorisation procedures.  Thalidomide is a sedative which was available over the counter to treat 
insomnia in the late 1950s and early 1960s.  The medicine was also found to reduce morning 
sickness during pregnancy, and a large number of pregnant women took the drug to relieve their 
symptoms.  However, thalidomide was able to pass through the placental barrier and damage the 
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growing foetus.  This resulted in potentially fatal foetal deformities.  Phocomelia is an example of a 
foetal deformity which resulted from thalidomide; it is commonly characterised by the shortening or 
absence of long bones, hands or feet attached as “flippers” or absent altogether (Taussig, 1962).  In 
the British Commonwealth, over 800 children were affected.  The tragedy brought to the foreground 
the importance of rigorous testing and authorisation procedures for medicines; this was the 
beginning of modern drug regulation.  As a consequence, Directive 65/65/EEC1 was established to 
harmonise the standards for the approval of medicines within the European Economic Community 
(EEC).   
This thesis focusses on the European Medicines Agency (EMA) market authorisation processes.  The 
EMA is a European Union (EU) body which collaborates with member states and the European 
Commission (EC) to harmonise the work of national medicine regulatory agencies.  Regulators at the 
organisation decide if a medicine should be authorised or not for a specific indication, based on a 
thorough assessment of its benefits and risks.  This requires the examination and evaluation of 
complex data collected from clinical trials, and also post-marketing surveillance data if it is available.  
There are two common stages of a product life-cycle where authorisation decisions are made, (a) 
the initial assessment of a new substance for marketing authorisation before it is placed on the 
market, (b) the decision to maintain, vary or suspend the marketing authorisation of a drug currently 
on the market prompted by post-marketing surveillance, Phase IV clinical trials, epidemiological data 
suggestive of limited efficacy, and/or increased safety concerns.   
 Requirements for Marketing Authorisation  1.1.1
Article 13 of Regulation (EC) No 726/2004 states that quality, safety, and efficacy standards must be 
met before marketing authorisation can be granted.  Marketing authorisation is refused if one or 
more of the following criteria are met: (a) the benefit-risk balance is not considered to be 
favourable, (b) the therapeutic efficacy is insufficiently substantiated, or (c) its qualitative and 
quantitative composition is not as declared (Article 26 of Directive 2001/83/EC).   As quality is 
considered to be a prerequisite before applying for marketing authorisation, the benefit-risk 
assessment essentially relies on therapeutic efficacy and known and potential safety risks.   
 European Medicines Agency process for Marketing Authorisation 1.1.2
When pharmaceutical organisations wish to introduce a new medicine to the market in the EU, the 
company applies to the EMA for authorisation (European Parliament, 2004).  The EMA then initiates 
a single evaluation process.  One of the EMA’s scientific advisory committees, the Committee for 
Medicinal Products for Human Use (CHMP), appoints two of its members as Rapporteur and a Co-
Rapporteur.  It is the duty of these two positions to coordinate the scientific evaluation of the 
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product, and each position manages an independent assessment team of scientific experts from 
national marketing authorisation bodies.   
Each Rapporteur reports a preliminary opinion on the benefit-risk balance, which are circulated to 
the applicant, and CHMP members who are invited to submit their additional comments.  If the 
Rapporteurs wish to make a recommendation regarding marketing authorisation, they have to issue 
a statement concerning the benefit-risk balance of the drug.  The two reports, i.e. one from each 
Rapporteur, are then combined in a formal Joint Assessment Report.   
The Joint Assessment Report contains the provisional opinion of the CHMP, a preliminary 
recommendation regarding authorisation, and a List of Questions (e.g. quality issues, request for 
additional data or clarification on reported results).  After the company provides a written response 
to the List of Questions, the Rapporteurs then conduct a secondary assessment of the drug.  They 
also revise the initial Joint Assessment Report, and produce a List of Outstanding Issues for the 
applicant to address.  A written response from the company is required to address the List of 
Outstanding Issues, and in some cases an oral explanation is required.   
A Final Assessment Report is then compiled which contains the decision on marketing authorisation 
adopted by the CHMP.  If the results of the report are favourable, marketing authorisation is granted 
and valid for all markets within the EU.  The time limit for the evaluation process from the start of 
the procedure to the adoption of the final decision is 210 days. 
1.2 Benefit and risk assessment of medicinal products 
 Introduction to benefit and risk 1.2.1
In this thesis, benefits are defined as, “the positive results of a given treatment for an individual or a 
population”, and risks are defined broadly as, “the negative results (adverse outcomes) of a given 
treatment for an individual or a population in terms of probability of occurrence having considered 
the magnitude of severity” (Mt-Isa et al., 2013).  Within this thesis, benefits and risks are also 
referred to as favourable effects, and unfavourable effects, respectively.  It is worth noting that the 
definitions of benefit and risk are widely disputed, and a myriad of definitions exist within a 
regulatory context to describe them.  There are, “no standard, widely acknowledged definitions of 
the terms benefit and risk as applied to medicine and particularly to medicinal products” (CIOMS 
Working Group IV, 1998), and even within the participating agencies of the EMA, over 20 different 
definitions were provided by regulators to describe benefit and risk when interviewed (EMA, 2009h).   
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 Systematic approaches to benefit-risk assessment 1.2.2
Although systematic methods of benefit-risk assessment offer a structured approach to decision-
making and are widely used in other fields, their use has not been established in the benefit-risk 
assessment of medicines.  Multiple different benefit-risk assessment methodologies can potentially 
be applied within a regulatory setting to determine the benefit-risk balance of a medicine, and there 
is not a single widely accepted method.  There are four main families of benefit-risk assessment 
methods: frameworks, metrics, estimation techniques, and utility survey techniques (Mt-Isa et al., 
2013).  Frameworks are used to structure the decision problem, and guide the process.  They can 
either be: (a) descriptive and offer stepwise instructions; or (b) quantitative and use statistics to 
combine data on benefits and risks, with the use of sensitivity analyses.   Metrics are split into three 
types: those that provide indices that are used as thresholds, those that implicitly trade off benefits 
and risks, and those that explicitly trade off benefits and risks in a quantitative manner.  Estimation 
techniques are tools for synthesising evidence, modelling statistics and estimating parameters so 
that the evidence on benefits and risks can be quantified and communicated to decision-makers.  
Utility survey techniques incorporate the value judgements of stakeholders into benefit-risk 
assessment.  Multiple complementary methodologies can be used, in conjunction with one another 
to assess a specific decision-making scenario and determine the benefit-risk balance of a treatment.   
Currently, regulatory benefit-risk assessment is relatively implicit; it is not known how regulators 
formally assess the benefits of a treatment against its risks in order to determine the benefit-risk 
balance.  The lack of transparency can make it difficult for regulators to defend their benefit-risk 
balance and authorisation decisions.  Systematic methods of benefit-risk assessment, such as 
frameworks, metrics, estimation techniques, and utility survey techniques can be used to guide the 
decision-making process and analyse and balance the benefits and risks of treatment—qualitatively, 
and/or quantitatively in a transparent manner.  However, at the time of initiating this thesis, there is 
a lack of knowledge or guidance regarding which benefit-risk assessment methodologies can or 
should be applied within a regulatory context.   
1.3 Patient and public involvement 
There are many reasons why it is desirable to engage patients and members of the public in 
regulatory decision-making.  Involve (http://www.involve.org.uk/) states that there are four 
principles regarding why members of the public should engage in policy processes: (1) improved 
governance; (2) social capital and social justice, (3) improved quality of services, projects and 
programmes; and (4) capacity building and learning (Brodie et al., 2009).  Specifically in the field of 
regulatory decision-making, regulators are increasingly expected to engage in PPI as it increases the 
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legitimacy of the marketing authorisation process by improving transparency, and thus enhances 
public trust (Eichler et al., 2012).  Patients and the public can provide valuable contributions to 
evidence based medicine, through individual descriptions of illness, social circumstances, habits and 
behaviours, and attitudes towards risk, values and preferences (Rycroft-Malone et al., 2004).  
PPI in regulatory decision-making relies on an active partnership between regulators and patients.  
In this thesis, the words “patient” and “involvement” are defined as: 
Patient and public:  Clinical trial participants, patients and potential patients, disabled people, 
parents and guardians, people who use health and/or social care services, 
carers, members of the public, and the organisations who represent the 
interests of these individuals. 
Involvement: An active partnership between all stakeholders, i.e. patients, public, 
researchers, pharmaceutical companies and regulators in the decision-
making process, rather than the use of patients and the public as the 
‘subjects’ of decision-making. Patient and public involvement can be defined 
as decision-making ‘with’ or ‘by’ patients and the public, rather than ‘to’, 
‘about’ or ‘for’ the patients and the public.  
These definitions were adapted from INVOLVE (Staley, 2009), a national advisory group which 
supports greater public involvement in National Health Service (NHS).   
The EMA currently involve patients, consumers, and their organisations through a “framework of 
interaction”(EMA, 2012).  Patients are formal members of three scientific committees: Committee 
for Orphan Medicinal Products, Paediatric Committee, and Committee for Advanced Therapies.  
However, there is not a legal basis for patients to be involved in a number of other committees, 
which include the Committee for Medicinal Products for Human Use (CHMP), and the Committee on 
Herbal Medicinal Products.  The EMA Patients' and Consumers' Working Party (PCWP) provides 
recommendations to the EMA regarding, “all matters of direct or indirect interest to patients” (EMA, 
2013).  The PCWP holds four plenary session meetings per year, and a member from each of the 
scientific committees attends.  Members of the EU Pharmacovigilance Risk Assessment Committee 
(PRAC) are nominated by the European Commission and can include representatives of patient 
organisations.  The PRAC is an EMA scientific committee which was established in July 2012 
following changes to EU pharmacovigilance laws; it is responsible for the assessment and monitoring 
of the safety of medicines, which includes the detection, analysis, risk minimisation and 
communication of adverse reactions.  One important consideration of benefit-risk decision-making 
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methodology is to promote the development and utilisation of patient and public involvement 
strategies.  There are a distinct lack of guidelines which address the specific methodological aspects 
and challenges which may arise when applying patient and public involvement within a regulatory 
decision-making context.   
1.4 Motivation for the study 
This thesis began as the result of increasing questions and challenges about the use of systematic 
methods of benefit-risk assessment, and the importance of patient and public involvement in 
benefit-risk assessment decisions.  Regulatory decision-making is often an unstructured implicit 
process, poorly communicated to patients and the public; it is often difficult to understand which 
benefits and risks have been considered, and how their magnitudes and severities have been 
compared and traded-off against each other.  Although many comprehensive, structured and 
systematic methods to evaluate and trade-off benefits and risks exist within other decision-making 
settings, they have not been tested within a regulatory context.  There is also a strong ethical belief 
that it is a democratic right for patients and the public to be involved in regulatory decisions which 
directly affect them—specifically the marketing approval of medicines; structured benefit-risk 
assessments can offer them an opportunity for them to be involved.  Despite an ideological shift in 
the field of regulatory decision-making to encourage representation of the patient perspective, to 
engage in it remains a major challenge due to the lack of methodological guidelines.  Many PPI 
strategies remain either untested or unreported.  Although it is widely believed that systematic 
methods of benefit-risk assessment have the advantage of transparency, and PPI is desirable, this 
issue has not been addressed.  As a consequence, there are many methodological questions 
regarding its application.  The motivation for this thesis is drawn from the desire to evaluate 
systematic methods of benefit-risk assessment, and the lack of guidance to support the 
incorporation of PPI into regulatory decision-making processes.   
1.5 Research aim and objectives 
The aim of this thesis is to test and evaluate how PPI can be applied to systematic methods of 
benefit-risk assessment within a regulatory context. 
There are two themes in this thesis which form the research question: 
1) The application of systematic methods of benefit-risk assessment which have been proposed 
for use within a regulatory context 
2) The application and evaluation of how PPI can be incorporated into systematic methods of 
benefit-risk assessment 
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For the first theme, the objectives are to apply the following benefit-risk assessment methods to 
selected regulatory case studies: 
 Descriptive  framework methods of benefit-risk assessment (PrOACT-URL and BRAT) 
 Quantitative framework methods of benefit-risk assessment (MCDA and SMAA) 
 Discrete choice experiment (DCE) 
 Swing-weighting, analytic hierarchy process (AHP) 
 Measuring Attractiveness by a Categorical Based Evaluation Technique (MACBETH) 
For the second theme, the objectives are to: 
 Examine where and when in the benefit-risk assessment decision-making process PPI is 
desirable and/or feasible  
 Illustrate how quantitative methods of benefit-risk assessment can incorporate subjective 
values and preferences into benefit-risk assessment 
 Examine the feasibility of eliciting patient and public preferences on the benefits and risks of 
treatment 
 Develop a protocol to elicit preferences from patients and the public regarding the benefits 
and risks of treatment  
 Develop a framework which can guide the application and reporting of PPI in benefit-risk 
assessment 
More specific objectives can be found in each of the case study chapters. 
1.6 Background to the thesis 
Pharmacoepidemiological Research on Outcomes of Therapeutics in a European Consortium 
(PROTECT) is a project with over 30 private and public sector partners set up under the Innovative 
Medicines Initiative (IMI), and coordinated by the EMA.  It aims to improve and strengthen the 
monitoring of the benefit-risk of medicines marketed in the EU. There are seven work packages in 
PROTECT, and the work in this thesis was undertaken in the context of Work Package Five (WP5).   
WP5 focuses on the integration and representation of benefits and risks to evaluate the benefit-risk 
balance.   Integrating and representing benefits and risks is a crucial process which is important for a 
multitude of stakeholders, e.g. patients and the public, health care providers, regulators, and 
pharmaceutical companies.  It can take place at many stages of a product’s lifecycle; from early 
development where evidence on the benefits and risks of treatment is emerging, to post-marketing 
32 
 
where evidence on the benefits and risks from treatment has accrued during clinical development, 
post-marketing surveillance, and epidemiological studies.  
There were two waves of case studies in WP5.  The main aim of each case study was to simulate the 
regulatory decision which had taken place using publicly available data and applying systematic 
methods of benefit-risk assessment.  All of the case studies have at one point been removed from 
the market based on EMA regulatory decisions, which were considered to be controversial by some 
due to the benefits, risks and how their relative importance was perceived by regulators.  Wave One 
examined four case studies: natalizumab (indication: relapsing remitting multiple sclerosis), 
efalizumab (indication: moderate to severe plaque psoriasis), telithromycin (indication: mild to 
moderate pneumonia) and rimonabant (indication: overweight with weight related comorbidities, 
obesity).  I was a member of the efalizumab case study.  Wave Two further extended the work on 
the benefit-risk methodologies; the case studies of natalizumab and rimonabant were retained, and 
two new case studies were added, rosiglitazone (indication: type two diabetes) and warfarin 
(indication: prevention of stroke in patients with atrial fibrillation).  I was a member of the 
natalizumab and rimonabant case study teams.   
When applying PPI within a regulatory decision-making context, WP5 noted that there were a 
distinct lack of guidelines which address the specific methodological aspects and challenges which 
may arise in its practice.  Although there are strong arguments to engage in PPI, there is a dearth of 
knowledge to guide how it should or could be applied to the benefit-risk decision-making process.  
From the outset of WP5 it was anticipated that, “the perspectives of patients, physicians, regulators 
and other stakeholders such as societal views” would be investigated in the context of benefit-risk 
assessment (WP5 Charter).  Despite there being commitment in the Charter to investigate PPI, WP5 
did not explicitly plan any potential activities which could be implemented to meet this aim.  I was 
given the opportunity to explore this in the IMI PROTECT project and focus on it as the topic of my 
thesis.  Following Wave One and Wave Two, I also led a team to investigate PPI in the benefit-risk 
assessment of medicines.   
Throughout the thesis, I use “we” to refer to the joint decisions made as part of the PROTECT case 
study teams, of which I was also a member.  This is to emphasise that this work was collaborative, 
and that the decisions about the applications of the methodologies, and subsequent discussions 
were made as a group.  Otherwise I use “I” to reflect my own contributions to this thesis.  The work 
in this thesis has been included in the case study and PPI team reports.   
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1.7 Overview of thesis structure 
This section provides a brief overview of the thesis; more detailed descriptions can be found in the 
introduction to each chapter.   
Chapter 2 describes the methods used in this thesis:  It states why each of the case studies in this 
thesis, i.e. efalizumab, rimonabant, and natalizumab, were selected for examination, how data on 
the favourable and unfavourable effects of treatment were extracted and synthesised for use, and 
the general steps of each of the benefit-risk assessment methodologies applied in this thesis.   
Chapter 3 focuses on the case study of efalizumab.  It describes the medical condition of plaque 
psoriasis, and the authorisation history of the treatment.  Then, it applies the systematic benefit-risk 
methodologies of PrOACT-URL, BRAT, MCDA, and SMAA to the case study and presents the results.  
Following this, the decision-making pathway for benefit-risk assessment is described, and it is 
carefully evaluated where and when PPI can be applied to the process.   
Chapter 4 focuses on the case study of rimonabant.  It describes the medical condition of obesity, 
and the authorisation history of the treatment.  Then, it examines the feasibility of eliciting patient 
and public preferences on the benefits and risks of treatments for obesity, through the application of 
the benefit-risk methodologies of DCE, and SMAA, and presents the results.   
Chapter 5 focuses on the case study of natalizumab.  It describes the medical condition of relapsing 
remitting multiple sclerosis and the authorisation history of the treatment.  Then, it develops a 
framework to guide the application, reporting, and evaluation of PPI in the benefit-risk assessment 
of medicines, and tests its feasibility by applying it to a protocol designed to investigate multiple 
different methods of eliciting preferences from patients and the public (i.e. swing-weighting, 
MACBETH, AHP).   
Chapter 6 provides a summary of how the aims of this thesis were met, discusses the strengths and 
limitations of the work completed and suggests recommendations for future research.   
34 
 
  
35 
 
2 Methods  
As stated in the previous chapter, the aim of this thesis is to test and evaluate how PPI can be 
applied to systematic methods of benefit-risk assessment suitable within a regulatory context.  This 
aim will be met through the careful examination of three case studies: efalizumab, rimonabant and 
natalizumab.  These are the case studies which I was involved in for Wave One and Wave Two of IMI 
PROTECT WP5.  They were selected by the WP5 management committee to represent a broad range 
of regulatory scenarios which could be used to test the feasibility of systematic methods of benefit-
risk assessment. 
In this chapter I describe why each of the case studies presented in this thesis were selected for 
examination by WP5, and the methods which were used by myself and the case study teams to 
systematically evaluate the benefit-risk balance of each treatment (Section 2.1).  Next, I describe 
how data regarding the favourable and unfavourable effects of treatment were extracted and 
synthesised for use (Section 2.2).  Lastly, I describe the general steps of each of the benefit-risk 
assessment methodologies applied in this thesis (Section 2.3); more detail regarding the specific 
application and tailoring of the methodologies can be found the relevant case study chapters. 
2.1 Selection of case studies  
 Case study I: efalizumab 2.1.1
Efalizumab, indicated for the treatment of plaque psoriasis, was selected as a Wave One case study 
because WP5 members believed that it would be interesting to study in the context of benefit-risk 
evaluation: the efficacy of the treatment was considered as modest by the regulators, and the risk 
which lead to the suspension of its marketing authorisation— progressive multifocal 
leukoencephalopathy (PML), was rare but very severe.  To support its selection as a WP5 case study, 
publicly available and reliable data on the favourable and unfavourable effects of treatment were 
accessible on the EMA website.   
The case study of efalizumab was used in WP5 to illustrate the feasibility of applying benefit-risk 
assessment methodologies to a regulatory decision-making scenario.  It has been hypothesised that 
the use of benefit-risk assessment methodologies in a regulatory context results in structured, 
consistent and transparent decision-making (Mt-Isa et al., 2013).  However, there has been little 
examination of their feasibility within the context of drug regulation.  To examine this, the Wave 
One efalizumab team chose to apply the following benefit-risk assessment methodologies to the 
case study: (1) the Benefit Risk Assessment Team (BRAT) framework (Section 2.3.1.2), (2) the 
PrOACT-URL framework (Section 2.3.1.1), (3) multi-criteria decision analysis (MCDA) (Section 
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2.3.2.1), and (4) benefit-risk ratio (BRR).  As a member of the efalizumab case study team, I 
completed the descriptive frameworks of BRAT with Diana Hughes (physician employed in the  
pharmaceutical industry) and PrOACT-URL with Alain Micaleff (physician employed in the  
pharmaceutical industry), with wider review and comments from the team.  I also participated in an 
MCDA decision conference led by Lawrence Phillips (decision scientist).  The results of these benefit-
risk assessment methodologies are presented in this thesis and the case study report (Micaleff et al., 
2013).  Also, I further extended the case study of efalizumab in this thesis to test the feasibility of an 
additional quantitative framework, stochastic multi-objective acceptability analysis (SMAA), to 
present an alternative way of handing preference data in benefit-risk assessment.      
Towards the end of the case study, I hypothesise where and when PPI can be applied in the benefit-
risk assessment pathway.  The pathway was comprehensively elucidated from the benefit-risk 
assessment methodologies applied in Wave One and Wave Two by the WP5 Recommendations 
team (of which I was a member); I critically evaluated where and when PPI could be applied to the 
pathway, with discussion, and comments from the PPI team.   
 Case study II: rimonabant 2.1.2
Rimonabant, indicated for the treatment of overweight with associated comorbidities and obesity, 
was selected as a Wave One case study because WP5 members considered it interesting how the 
regulatory benefit-risk balance shifted from positive at the time marketing authorisation was 
granted to negative.  The treatment was withdrawn from the market due to new clinical trial data 
collected which reported the risk of psychiatric disorders.  Once again, to support the feasibility of 
investigating rimonabant in the context of benefit-risk assessment, publicly available clinical trial and 
post-marketing surveillance data were available on the EMA website, and published in academic 
peer reviewed journals. 
The aim of the Wave One rimonabant case study was to evaluate the benefit-risk balance of the 
treatment using the methodologies of PrOACT-URL, BRAT, MCDA, SMAA, number needed to treat 
(NNT), BRR, probabilistic simulation methods (PSM), and impact numbers.  The Wave One team 
found that the results of each of the methodologies were highly dependent on the elicited values 
and preferences, and thus one of the specific objectives of Wave Two was to further investigate the 
values and preferences of patients and the public on the benefits and risks of treatment. 
Although I was not a member of the WP5 Wave One rimonabant case study team, I led the 
preference elicitation sub-team in the Wave Two rimonabant case study.  The aim of the sub-team 
was to investigate the use of discrete choice experiment (DCE) (Section 2.3.3.1) to determine the 
benefit-risk balance of rimonabant.  I designed and conducted a DCE which evaluated the 
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attractiveness of weight loss treatments by observing how patients and the public choose between 
treatments while comparing and trading off specified levels of benefits and risks.  I also developed a 
simulation-based benefit-risk assessment method which combines estimates of the favourable and 
unfavourable effects of treatment with preference estimates obtained from DCE results. 
 Case study III: natalizumab 2.1.3
Natalizumab, indicated for the treatment of relapsing remitting multiple sclerosis (RRMS), was 
investigated in the first and second wave of WP5 case studies.  In Wave One, the case study 
employed a number of benefit-risk methods: PrOACT-URL, BRAT, mixed treatment comparison 
(MTC), BRR, number needed to treat and number needed to harm (NNT-NNH), MCDA, and direct 
utility elicitation.  In Wave Two, the natalizumab case study work was extended to incorporate 
probabilistic uncertainty in the clinical data measures, test visualisation methods, and hoped to 
explore methods which can be used to elicit values and preferences from patients and the public.  It 
was anticipated that MCDA swing-weighting (Section 2.3.2.1), MACBETH (2.3.2.3), and analytic 
hierarchy process (AHP) (Section 2.3.2.4) would all be used to elicit patient and public preferences 
on the benefits and risks of treatments for RRMS.  However, due to the time required for the ethical 
approval process, to set up funding arrangements, and fulfil organisational requirements, this work 
was not completed in time: instead, the work was initiated by the Wave Two natalizumab team, and 
transferred to the PPI team following the end of the Wave Two case studies.  I led the development 
of the protocol for weight elicitation with Adam Elmachtoub (PhD student) in Wave Two, and 
continued to lead the work once it changed into the remit of the PPI team.   
2.2 Data 
Benefit-risk assessment requires the identification of source documents, and information on the 
favourable and unfavourable effects of treatment; usually, this is efficacy and safety data collected 
from clinical trials and post-marketing surveillance.  Ideally, all available information needs to be 
taken into consideration, which requires data from multiple sources to be synthesised in order to 
provide accurate estimates for assessment. 
 Data extraction 2.2.1
The work in this thesis intended to replicate real life decision-making scenarios which occurred 
during the product lifecycle of the case study treatments.  A number of regulatory documents 
produced by the EMA are publicly available online (http://www.ema.europa.eu/ema/), or by request 
for those interested in regulatory processes and authorisation decisions.  EPARs often contain 
clinical trial and regulatory post-marketing surveillance data.  PSURs are also publicly available but 
they are not available online and have to be specifically requested from the EMA.  The “product 
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information” and “scientific discussion” documents are also available to view online on the EMA 
website.  I extracted efficacy and safety data from these documents, assuming that regulators 
presented information on the most important data to consider for each of the case study 
treatments.  Extracting data from publicly available sources also provided the case studies with a 
high degree of transparency, allowing others to closely follow, replicate or compare different 
methodologies through clearly illustrated examples.    
 Data synthesis 2.2.2
Publicly available data were collated from regulatory sources and the uncertainty in the safety and 
efficacy estimates were derived. To do so, trial-specific data, aggregated trial data, and post-
marketing surveillance data were considered separately. 
2.2.2.1 Trial-specific data 
Efficacy and safety data were extracted for each trial separately if available.  This included the 
number of patients in each arm of the trial, the number of events recorded for each efficacy and 
safety outcome for those expressed as counts (or percentages), and mean and standard deviation 
(SD) for those expressed as change from baseline.  Due to some heterogeneity in participant 
inclusion criteria among trials included, a random-effects meta-analysis model was preferred for 
aggregating estimates from individual clinical trials.  Random effects meta-analyses are used to 
combine results from several studies while allowing for each study to have a unique treatment effect 
which is assumed to vary around an overall mean treatment effect.  
A Bayesian random-effects meta-analysis model was selected to estimate the uncertainty in efficacy 
estimates, which has the specific advantage of allowing for all parameter uncertainty and for the 
inclusion of data, such as that not missing at random, that would normally be disregarded (Sutton 
and Abrams, 2001).  
For outcomes reported as percentages experiencing a specific safety or efficacy outcome, the 
number of outcomes (                   ) observed in each study and in each treatment group 
was assumed to follow a binomial distribution. The probability of success (                      ) 
in each binomial distribution was expressed as a logistic model with a study-specific constant 
(             ) and a study-specific treatment coefficient (                ). The constants and 
treatment coefficients were assumed to follow a normal distribution, with means equal to the true 
parameter and study specific precision.
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The median probability and 95% Bayesian credible interval (CrI) for each efficacy measure was then 
extracted by generating the probability by treatment group from the posterior distributions of the 
constant for placebo, and constant plus treatment coefficient for the treatment groups. This analysis 
was carried out in WinBUGS (the model code, adapted from Ntzoufras (2011), is presented Appendix 
Figure 1). 
This model also estimated the risk difference and relative risk between two treatment groups, 
required by some of the benefit-risk methodologies. The risk difference was calculated as the 
difference in the posterior probabilities between two treatment groups, whereas the relative risk 
was calculated as the ratio of these same probabilities. 
Some efficacy outcomes were expressed as changes from baseline. For these, the minimum required 
information for calculation of pooled estimates was the sample size and mean and SD of the change 
from baseline.  The pooled mean, median, and 95% credible interval could then be estimated (code 
in Appendix Figure 2).  Due to the nature of these measures, risk differences or relative risks could 
not be calculated. 
2.2.2.2 Aggregated trial data 
For several safety and efficacy outcomes, results were presented aggregated across trials. For these 
outcomes, a simpler model was specified to calculate the 95% CrI of their probabilities assuming a 
binomial distribution for each outcome.  The number of events was assumed to follow a binomial 
distribution, and the probability of success was given a flat beta prior.  The model also calculated the 
risk difference and relative risk, required for some decision making frameworks (code in Appendix 
Figure 3). 
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2.2.2.3 Post-marketing surveillance data 
Information for several rare safety outcomes were only available from spontaneous reporting data 
collected during the post-marketing surveillance period, and was expressed as incidence per person-
years. 
To calculate the 95% CrI of these rates, the number of events (        ) was assumed to follow a 
Poisson distribution with parameter       .  Rates were given a flat gamma prior.  The yearly 
event probability (                  ) was then estimated using exponential distribution 
properties. 
 
                       
                          
    
           
  
 
In order to calculate a risk difference, or to aid decision making, the background incidence in the 
general population should normally be available for each safety outcome.  However, as none were 
among the list of “Notifiable Diseases” in the United Kingdom, an estimate for the population 
incidence could not be found.  Thus, placebo rates were assumed to be 0, which would entail a more 
conservative approach during decision making (code in Appendix Figure 4). 
2.3 Systematic methods of benefit-risk assessment 
This section describes the general steps of each of the benefit-risk assessment methodologies 
applied in this thesis.  It is important to note that in some cases, it was difficult to follow the 
stepwise instructions of the methodologies.  Therefore, more specific details concerning their 
application to the case studies are described in the relevant chapters.   
 Descriptive framework methodologies 2.3.1
Descriptive frameworks provide a structured approach to benefit-risk decision-making.  They 
address favourable and unfavourable effects systematically, and can incorporate qualitative and 
quantitative data.  The PROTECT Benefit-risk Appraisal Report (Mt-Isa et al., 2013) identified and 
recommended two descriptive framework methodologies for further testing: BRAT and PrOACT-URL.   
2.3.1.1 PrOACT-URL framework 
PrOACT-URL is a decision-making framework which aims to describe the Problem, Objectives, 
Alternatives, Consequences, Trade-offs, Uncertainty, Risk tolerance and Linked decisions of a 
decision-making scenario.  The framework was originally conceived by Hammond, Keeney and Raiffa 
(Hammond et al., 1999) and later adapted for the evaluating the benefit-risk balance of medicinal 
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products (Phillips et al., 2010).  The Phillips et al. (2010) adaption of the steps is provided in Table 
2.1.  The application of PrOACT-URL to the efalizumab case study can be found in Section 2.3.1.1. 
Table 2.1 PrOACT-URL steps 
STEP DESCRIBE 
PrOBLEM 
1. Determine the nature of the 
problem and its context. 
 
 
 
 
 
 
2. Frame the problem. 
 
1a. The medicinal product (e.g., new or marketed chemical or 
biological entity, device, generic). 
1b. Indication(s) for use. 
1c. The therapeutic area and disease epidemiology 
1d. The unmet medical need, severity and morbidity of 
condition, affected population, patients’ and physicians’ 
concerns, time frame for health outcomes.  
1e. The decision problem (what is to be decided and by whom, 
e.g., industry, regulator, prescriber, patient) 
2a. Whether this is mainly a problem of uncertainty, or of 
multiple conflicting objectives, or some combination of the 
two, or something else (e.g., health states’ time progression). 
2b. The factors to be considered in solving the problem (e.g., 
study design, sources and adequacy of data, disease 
epidemiology, presence of alternative treatments). 
OBJECTIVES 
3. Establish objectives that indicate 
the overall purposes to be 
achieved. 
 
4. Identify criteria for 
a) favourable effects 
b) unfavourable effects  
 
3. The aim (e.g., to evaluate the benefit-risk balance, to 
determine what additional information is required, to assess 
change in the benefit-risk balance, to recommend restrictions). 
4. A full set of criteria covering the favourable and 
unfavourable effects (e.g., endpoints, relevant health states, 
clinical outcomes).  An operational definition for each criterion 
along with a measurement scale with two points defined to 
encompass the range of performance of the alternatives (not 
just reported measures of central tendency, but also 
confidence intervals).  Considerations of the clinical relevance 
of the criteria—some are of more concern to decision makers 
than others. 
ALTERNATIVES 
5. Identify the options to be 
evaluated against the criteria. 
 
5a. Pre-approval: dosage, timing of treatment, drug  vs. 
placebo and/or active comparator; the decision or 
recommendation required (e.g., approve/disapprove, restrict, 
withdraw). 
5b. Post-approval: do nothing, limit duration, restrict 
indication, suspend. 
CONSEQUENCES 
6. Describe how the alternatives 
perform for each of the criteria, 
i.e., the magnitudes of all effects, 
and their desirability or severity, 
and the incidence of all effects. 
 
6. The consequences separately for each alternative on each 
criterion (e.g., efficacy and safety effects that are clinically 
relevant, positive and negative health outcomes), summarised 
in an ‘Effects Table’ with alternatives in columns and criteria in 
rows.  Qualitative and quantitative descriptions of the effects 
in each cell, including statistical summaries with confidence 
intervals, and references to source data, graphs and plots.  
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STEP DESCRIBE 
TRADE-OFFS 
7. Assess the balance between 
favourable and unfavourable 
effects. 
 
7. The judgement about the benefit-risk balance, and the 
rationale for the judgement.   
At this point, only issues concerning the favourable and unfavourable effects, and their balance, 
have been considered.  The next three steps are relevant in considering how the benefit-risk 
balance is affected by taking account of uncertainties. 
UNCERTAINTY 
8. Report the uncertainty 
associated with the favourable and 
unfavourable effects. 
 
 
9. Consider how the balance 
between favourable and 
unfavourable effects is affected by 
uncertainty. 
 
8. The basis for and extent of uncertainty in addition to 
statistical probabilities (e.g., possible biases in the data, 
soundness and representativeness of the clinical trials, 
potential for unobserved adverse effects) 
 
 
9. The extent to which the benefit-risk balance in step 7 is 
reduced by considering all sources of uncertainty, to provide a 
benefit-risk balance, and the reasons for the reduction. 
 
RISK TOLERANCE 
10. Judge the relative importance 
of the decision maker’s risk 
attitude for this product. 
 
11. Report how this affected the 
balance reported in step 9. 
 
 
10. Any considerations that could or should affect the decision 
maker’s attitude toward risk for this product (e.g., orphan drug 
status, special population, unmet medical need, risk 
management plan). 
 
11. The basis for the decision maker’s decision as to how 
tolerable the benefit-risk balance is judged to be (taking into 
account stakeholders’ views of risk?). 
LINKED DECISIONS 
12. Consider the consistency of 
this decision with similar past 
decisions, and assess whether 
taking this decision could impact 
future decisions. 
 
12. How this decision, and the value judgements and data on 
which it is based, might set a precedent or make similar 
decisions in the future easier or more difficult. 
 
2.3.1.2 BRAT framework 
The Pharmaceutical Research and Manufacturers of America (PhRMA) Benefit Risk Action Team 
(BRAT) Framework offers a set of processes and tools for decision-makers to use to select, organise, 
summarise, interpret and understand evidence relevant to decisions for benefit–risk assessments.  
Three key sources were used to guide its application in this thesis, Coplan et al. (2011), Levitan et al. 
(2010), and the PhRMA BRAT framework handbook (The Benefit-Risk Action Team, 2011).  The 
application of the BRAT framework to the efalizumab case study can be found in Section 2.3.1.2. 
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The PhRMA BRAT framework consists of a series of steps.  The key six steps in the process are 
outlined in Figure 2.1. 
 
Figure 2.1  Processes in the PhRMA BRAT framework (Coplan et al., 2011) 
     
 Quantitative framework methodologies 2.3.2
Similarly to descriptive frameworks, quantitative frameworks also offer a series of steps designed to 
guide decision-making.  However, unlike descriptive frameworks, they also offer statistical 
recommendations regarding how to handle favourable and unfavourable effects. 
2.3.2.1 Multi-criteria decision analysis 
MCDA is a decision-making method which can take into account multiple favourable and 
unfavourable effects simultaneously.  It breaks a decision-making scenario into its constituent 
elements, and derives the value of each element in a piecewise fashion before analysing them to 
provide a solution.  MCDA is applied in this thesis with the use of HiView3 (Catalyze Ltd and 
Enterprise LSE, 2008); the software was a contribution in kind to IMI PROTECT Work Package Five 
from a project partner.  The application of MCDA to the efalizumab case study can be found in 
Section 3.7.1. 
There are eight steps to performing an MCDA.   
(1)   Establish the decision context 
In this step, the decision question to be evaluated is established.  
(2) Identify the alternatives 
Potential options, solutions, or actions (referred to as alternatives) which can be taken by the 
decision maker(s) are identified.   
(3)  Identify criteria 
The favourable and unfavourable effects of treatment (referred to as criteria) are used to construct a 
value tree, in which a root node branches out to other nodes grouping these effects.   
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(4) Score the alternatives against the criteria 
Once all the criteria have been identified, it is necessary to input into the model how well each 
alternative performs according to the criteria under consideration, i.e. data on the favourable and 
unfavourable effects of treatment.   
(5) Create value functions 
There are three different types of value functions: a) linear:  the scores inputted for a criterion are 
normalised across the 0-100 score proportionately to their values, b) piecewise linear: this is an 
approximation for normalising continuous data on a non-linear scale at specified linear intervals, c) 
discrete: these assign values to input scores based on categories of the data via a step function.   
(6)  Weighting 
MCDA compares the value of a change in the amount of one favourable or unfavourable effect 
criterion with the value of a change in the amount of another favourable or unfavourable effect 
criterion.  At this stage in the modelling, options have already been scored and these scores have 
been converted to values on the same scale, which allow them to be compared directly to each 
other. Now the changes or "swings" over these scales are considered by the decision-maker(s) to 
assign weights. 
(7) Analysis 
The total weighted score for each alternative is derived from input scores, value functions, and 
weights for each individual favourable and unfavourable effect criterion, using the value tree.  A 
sensitivity analysis can then be performed to assess how robust the final decision is to variations in 
the weights assigned to each criterion by the decision-maker(s).   
2.3.2.2 Stochastic multi-objective acceptability analysis 
SMAA is a simulation-based decision-making approach which has been developed for situations 
where values of favourable and unfavourable effect criteria or weights may be unknown or 
imprecise.  Preference information is represented by distributions which can be specified using 
partially known or total lack of information. 
SMAA models offer several measures for decision support which mainly include (1) the rank 
acceptability index which describes the share of values that make an alternative preferred or of a 
given rank, (2) the central weight vector which gives the expected centre of gravity of the favourable 
weight space (i.e. the weights a typical decision maker supporting a specific alternative would give), 
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and (3) the confidence factor which measures the degree of confidence in the selected alternative 
given the accuracy in other measurements.  The mathematical details of SMAA are not presented in 
this thesis, but can be found in Lahdelma et al. (1998).  Instead, steps to carry out an SMAA using 
specialised software, such as JSMAA, are described (Tervonen et al., 2011, Tervonen and Figueira, 
2008); JSMAA is a free open source software which can be downloaded from the website 
http://smaa.fi/jsmaa/.  The application of SMAA to the efalizumab and rimonabant case studies can 
be found in Sections 3.7.2 and 4.8, respectively. 
(1)  Define a set of alternatives and criteria 
Favourable and unfavourable effect criteria considered important are selected and alternatives are 
defined. It is not necessary to have full knowledge on the performance of each alternative for every 
criterion. 
(2)  Performance estimates and uncertainty 
For each alternative, their performance in each criterion is defined. This can be fixed, but 
distributions, to account for uncertainty or lack of knowledge, may also be specified. 
(3)  Define value function 
Current SMAA software allows only for linear value functions, where the largest and smallest values 
possible for each favourable and unfavourable effect criterion are fitted with an ascending or 
descending function with value 0 to 1. Hence, in this step, it is only necessary to specify whether the 
value function for a criterion is ascending or descending. 
(4)  Preference information 
Three options are available for defining preference weights: 
a) No preference information: SMAA methodology is designed to handle missing preference 
information. 
b) Ordinal preference information: the criteria are ranked from most to least important. 
c) Cardinal preference information: the criteria are assigned cardinal weights. 
 
(5)  Sensitivity analysis 
If information is available, it is useful to check the impact on SMAA output when switching between 
the three preference information specifications. This can illustrate how subjective information has 
altered the ranking of alternatives. 
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2.3.2.3 MACBETH 
MACBETH stands for Measuring Attractiveness by a Categorical-Based Evaluation Technique.   It is a 
decision-making methodology implemented through software, with a key aim to elicit and 
numerically represent value judgments based on stated criteria (Bana e Costa and Vansnick, 1999).  
The method measures the value of favourable and unfavourable effect criteria under consideration 
through non-numerical pairwise comparisons, where decision-makers assign one of seven 
qualitative categories of difference in value.  Using these qualitative judgements, value scores for 
options and weights for criteria are then derived mathematically.  
In total, there are five steps to performing MACBETH.  They are: (1) defining criteria, (2) constructing 
a multi-dimensional scale, (3) inter-criteria evaluation, (4) intra-criteria evaluation, and (5) analysis.   
Bana e Costa et al. (2012) provide the core reference used to guide the application of MACBETH in 
this thesis.  The application of MACBETH to the natalizumab case study can be found in Section 
5.6.5.2.  Each step is described below.   
(1) Defining criteria 
The first step is to define a set of criteria necessary for decision-making, i.e. the favourable and 
unfavourable effect criteria to be incorporated into the MACBETH model.  
(2)  Construct a multi-dimensional scale 
MACBETH constructs a multidimensional performance scale by using the “determinants technique”. 
This technique involves a three-step process to be achieved after defining criteria and before 
initiating the weighting process. 
This requires two values to be assigned to each criterion: 
a) A minimum value, called “neutral”, which represents the value of a criterion at which an 
alternative would be minimally attractive, but still acceptable. This is not necessarily the 
minimum value a criterion can take; it is only the threshold value at which it is considered 
“minimally attractive”. 
b) A maximum value, called “good”, which represents the value of a criterion at which an 
alternative would be satisfactory. This is not necessarily the maximum value a criterion can 
take; it is only the threshold value at which is it considered satisfactory. 
Assigned limits are then used scaled so that the “neutral” value is 0 and the “good” value is 100. 
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Next, each criterion is labelled as either “determinant” (D), “important” (I), or “secondary” (S). A 
determinant criterion is pivotal to a decision; therefore, if the performance of an alternative in a 
determinant criterion is negative, it is a sufficient condition for the alternative as a whole to be 
considered negative. 
Lastly for this step, a reference of good and neutral performance must be defined on the set of 
criteria.  This step requires the DM to determine two reference profiles: 
a) A good reference: one where all determinant criteria are satisfactory and a majority of 
important criteria are satisfactory 
b) A neutral reference: one where a majority of determinant and important criteria are neutral, 
without any criteria being negative 
MACBETH uses cardinal value information— where the attractiveness of criteria is not only ordered, 
but its numerical difference can also be derived. To do this, MACBETH uses a non-numerical pairwise 
comparison questioning mode which elicits qualitative judgments rather than quantitative ones, 
from which an interval value scale can be constructed.  Pairwise comparisons are made using a 
qualitative scale that includes seven options: neutral, very weak, weak, moderate, strong, very 
strong, and extreme. 
(3)   Inter-criteria evaluation 
Pairwise comparisons are made between criteria using the qualitative scale to generate an ordinal, 
pre-cardinal, and cardinal scale.  
a) Ordinal information 
Pairwise comparisons of criteria are made.  For each pairwise comparison, the decision-maker(s) 
is/are asked, “Is one of the two criteria more attractive than the other and if yes, which one?”   
b) Pre-cardinal information 
Using the ordinal information, the criteria are ordered by most to least important. The decision-
maker(s) is/are then asked to judge the difference of attractiveness using the qualitative scale of a 
swing from neutral to good through pairwise comparisons of combinations of criteria. 
Disagreements or hesitations between two neighbouring categories are allowed. Inconsistencies 
need to be addressed; judgements need to be consistent. 
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c) Cardinal information 
The qualitative information is not generally sufficient as many possible scales can respect the elicited 
information. Hence, the decision-maker(s) is/are asked to observe the MACBETH scale axis to 
compare value intervals. The interval between elements, i.e. the difference in attractiveness, can be 
adjusted within the limits that respect previous information, to generate a final cardinal scale. 
(4)  Intra-criteria evaluation 
This evaluation involves the comparison of levels of single criteria. Two methods are proposed: 
direct and indirect evaluation. Generally, only one method is used for each criterion. 
a) Direct evaluation 
Direct evaluation involves making pairwise comparisons of the performance of alternatives with that 
of the good and neutral reference within single criteria using the qualitative scale.  
b) Indirect evaluation 
Indirect evaluation involves building value functions by making pairwise comparisons of different 
values of criteria using the qualitative scale. It is an indirect technique as the attractiveness of an 
alternative is calculated based on its performance and the derived value function. 
(5) Analysis 
The framework provides three means of analysing results: the main, sensitivity, and robustness 
analyses. 
a) Main analysis 
The attractiveness of each option is derived based on the cardinal scale, which uses all the 
information from the weighting process. 
b) Sensitivity analysis 
It is important to verify how the recommendation for an option would change based on the values 
assigned to some criteria. The sensitivity analysis can represent the attractiveness of each option as 
a function of the weight of single criteria. The threshold weight at which the best option changes is 
an important value to note when considering the uncertainty in the value weights. 
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c) Robustness analysis 
This analysis checks whether the best option changes when taking into account ordinal and/or pre-
cardinal intra-criteria and inter-criteria information. This step will inform whether there is “additive 
dominance” between two alternatives, or if the alternatives show “incomparability”. The first means 
that one option was globally more attractive than the other, whereas the latter means that neither 
option is more attractive than the other.  Overall scores should measure the relative attractiveness 
of all the options across all the criteria. 
2.3.2.4 Analytic hierarchy process 
AHP is another decision-making method that can take into account multiple risks and benefits 
simultaneously.  There are several steps involved in the design and analysis of an AHP which overlap 
with other decision-making methods such as MACBETH and MCDA.  Saaty (1990) provides the core 
reference used to guide the application of AHP in this thesis.  The application of AHP to the 
natalizumab case study can be found in Section 5.6.5.3.   
(1) Defining criteria and sub-criteria 
The first step is to define a set of criteria and sub-criteria necessary for decision-making.  The 
number of criteria and sub-criteria should be limited and cover the most important ones involved in 
the decision-making process.   
(2) Define alternatives 
Potential solutions to the decision-making problem are determined.  The performance of each 
solution among criteria or sub-criteria is then defined.   
(3) Criteria and sub-criteria weighting 
The weighting of criteria and sub-criteria is then carried out.  Weighting is performed in a similar 
fashion to MACBETH, with the exception that consistency is not checked.  AHP uses a quantitative 
scale with a range of 1 to 9 (Table 2.2).  The weighting process takes place as follows: the respondent 
is first asked which of two criteria is most important, and second to quantify the intensity at which it 
is more important.  This is performed for each pair of criteria, and each pair of sub-criteria within 
each criterion.  This means that for an AHP with three criteria, each with three sub-criteria (Figure 
2.2), a total of 12 (i.e. 3 + 3 x 3) pairwise comparisons need to be made.
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Table 2.2 Analytical hierarchical process (AHP) weighting scale 
Intensity of 
importance 
Definition Explanation 
1 Equal importance Two elements contribute equally to the objective 
3 Moderate 
importance 
Experience and judgement moderately favour one 
element over another 
5 Strong 
importance 
Experience and judgement strongly favour one element 
over another 
7 Very strong 
importance 
One element is favoured very strongly over another; its 
dominance is demonstrated in practice 
9 Extreme 
importance 
The evidence favouring one element over another is of 
the highest possible order of affirmation 
Intensities of 2, 4, 6, and 8 can be used to express intermediate values.  Intensities of 1.1, 1.2, 1.3, 
etc. can be used for elements that are very close in importance.   
(Saaty, 1990) 
(4) Weighting of alternatives 
The next step is to weight the performance of alternatives at the lowest levels of AHP hierarchy.  
Similarly to weighting criteria, pairwise comparisons of alternatives are made according to their 
performance.  For an AHP with 3 criteria, each with 3 sub-criteria, and 3 alternatives (Figure 2.2), this 
means that a total of 27 (i.e. 3x3x3) comparisons need to be made.  In some circumstances where it 
is justifiable, the weighting of alternatives can be skipped for a subset of comparisons.  In these 
cases, assumptions need to be made on how the weight of each alternative is calculated, such as by 
assuming a linear relation between weight and performance. 
 
Figure 2.2 Illustration of an analytical hierarchical process including 3 criteria, each with 3 sub-criteria, and 3 alternatives 
 
 
Decision 
Criterion 1 
Sub-
criterion 1 
Alternative 
1 
Sub-
criterion 2 
Sub-
criterion 3 
Criterion 2 
Sub-
criterion 1 
Alternative 
2 
Sub-
criterion 2 
Sub-
criterion 3 
Criterion 3 
Sub-
criterion 1 
Alternative 
3 
Sub-
criterion 2 
Sub-
criterion 3 
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(5) Calculation of weights and the consistency ratio 
Once the weighting process is completed, the weights of criteria, sub-criteria, and alternatives can 
be calculated.  This is normally achieved through matrix algebra, where the most suitable 
combination of weights which fit the comparisons is determined.  As consistency is not guaranteed 
or strictly required in AHP, a consistency ratio can also be calculated, for which a value of 0.1 or less 
is generally considered as suitable. 
(6) Interpretation 
The ranking of alternatives is made by descending weight, and the alternative with the highest 
weight can be considered as the preferred option.  However, results should be interpreted with care 
if the consistency ratio is higher than the threshold of 0.1. 
 Utility survey technique methodologies 2.3.3
Utility survey techniques elicit subjective values and preferences from relevant stakeholder and 
incorporate them into benefit-risk decision-making.  The values and preferences are obtained 
through the evaluation of hypothetical scenarios derived specifically for a particular decision 
problem.   
2.3.3.1 Discrete choice experiments 
Discrete choice experiments (DCE) are surveys which observe choices and measure preferences.  
They provide explicit measures of benefit and risk valuation for assessing alternative treatment 
options, by evaluating the choice behaviour of participants to infer values.  The application of DCE to 
the rimonabant case study can be found in Section 4.6.   
Four steps are used to guide the application of DCE:  
1. Identify attributes and assign levels 
2. Experimental design and construction of choice sets 
3. Questionnaire design 
4. Analysis of responses 
Two core references are extensively used to guide the application of DCE in this thesis: courseware 
provided by Health Economics Research Unit (2010) during a three day workshop I attended, and a 
book written by Ryan and Gerard (2003).  
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2.3.3.1.1 Identify attributes and assign levels 
In a DCE, participants are shown a specific number of hypothetical choice scenarios.  Each scenario 
involves the presentation of a decision-making situation, which can be resolved with two or more 
possible options.  The participant is required to make a decision, and select the option which they 
consider to be most preferable.  Options within choice sets are described by levels of specific 
attributes which are characteristics.  They are used within a DCE to evaluate the attractiveness of an 
option by describing benefits and risks.   
When determining the inclusion or exclusion of attributes, it is important to retain the most realistic 
and plausible attributes which most greatly impact the attractiveness of an option.  The selection of 
attributes can be informed by primary data, e.g. focus groups and interviews, or secondary data, e.g. 
policy documents and published literature.  Generally, three to seven attributes are recommended 
in a DCE.  This is because it has been acknowledged that the greater the number of attributes, the 
greater the occurrence of compensatory decision-making.  That is, as the volume of presented data 
to the respondent increases, respondents will simplify their decision-making to only select options 
which present them with the most favourable level of the attribute they consider to be most 
important. 
After deciding which attributes should be included in the DCE, levels (i.e. measurement units) must 
be assigned to each attribute.  They may be quantitative (e.g. time, cost, distance) or qualitative (e.g. 
ordinal or categorical).  The levels should be realistic and plausible.  For example, 100% efficacy 
should not be presented as a level if it is not possible with current treatment options.   
2.3.3.1.2 Experimental design and construction of choice sets 
A DCE systematically varies the attribute levels in order to elicit a behavioural response from which 
the determinants of choice can be investigated.  The respondent will select the most attractive 
option. 
A DCE must adhere to systematic methods of experimental design.  This is to cover four main 
objectives (Health Economics Research Unit, 2010): 
i. To estimate the desired forms of utility function (including non-linearity if required)  
ii. To ensure the statistical efficiency of the experiment allows for precise estimation of 
parameters  
iii. To not place an excessive cognitive burden on respondents 
iv. To ensure realistic choice process and presentation of choices  
In order to create options, full factorial designs or fractional factorial designs (FFD) can be used. 
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2.3.3.1.2.1 Full factorial designs 
The total number of possible profiles, i.e. combinations of attributes and profiles for a given number 
of levels (L) and number of attributes (A) is calculated using the formula LA.  A greater number of 
attributes and/or levels results in a greater number of possible profiles.  If the number of profiles is 
unmanageably large, it should be reduced to prevent decision-making fatigue which can 
compromise the validity of responses.   
There are three main ways to decrease the number of profiles, (a) reduce the number of attributes 
or levels, (b) block the design, (c) use a subset of profiles obtained via FFD.  Reducing the number of 
attributes and levels where possible is the first recommendation.  If this is not possible or does not 
result in a sufficiently reduced number of profiles, FFD is the next recommended step.  The profiles 
should not be reduced at random because correlations in the data may prevent model estimation, 
and multicolinearity may be introduced when there is not enough variation, and variables may move 
in the same direction which presents difficulties when trying to determine the drivers of preference.   
2.3.3.1.2.2 Fractional factorial designs  
Fractional factorial designs (FFD) reduce the total number of profiles from a full factorial design into 
a subset of all possible combinations of attribute levels.   
A good fractional factorial design should result in (Health Economics Research Unit, 2010): 
1. Level balance:  all levels of each attribute should occur with equal frequency  
2. Orthogonality: the levels of each attribute vary independently of each other with minimal 
correlations.  For any two attributes all combinations of pairs of levels appear with 
proportional frequencies.  
3. Minimal overlap: the probability that an attribute level repeats itself in each choice set 
should be as small as possible.  We can achieve this if the difference between the number of 
times that any two levels of an attribute are replicated is at most one. 
4. Utility balance: options within a choice set should be equally attractive to respondents  
Designs can be created by statistical software (e.g. SAS), catalogues, websites, and consultations 
with experts.   
Choice sets may either be forced where an alternative must be chosen, or there may be the inclusion 
of an opt-out/”neither” option which would apply to individuals who refuse to select the alternatives 
provided.   
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2.3.3.1.3 Questionnaire design 
In this stage, the choice sets are represented within a questionnaire.  The format of the 
questionnaire is also decided on, e.g. paper, online, interview with facilitator to guide the 
participant. 
2.3.3.1.4 Analysis of responses 
The most widely used model for analysing DCE responses is the multinomial logit (MNL).  However, 
alternative analysis methods are also used and include probit, random effects probit, logit, random 
effects logit, nested logit, mixed logit, and latent class.   
The utility derived by an individual (u) is an observable systematic component (v), with an 
unobservable random component (ε).  Essentially, u = v + ε 
The information we obtain from a DCE is the observable systematic component: 
                           
 α – alternative specific constant (ASC)  
 X – attributes 
 β – parameters 
From this equation, it is possible to calculate the trade-offs between attributes or marginal rates of 
substitution which is given by the ratio of attribute coefficients               .  
 Selection of benefit-risk assessment methodologies for application to the case 2.3.4
studies 
This thesis builds on a literature review which was completed in an earlier phase of WP5 (Mt-Isa et 
al., 2013).  It recommends which benefit-risk assessment methodologies warrant further 
consideration for use in a regulatory context: the PrOACT-URL and BRAT frameworks, MCDA, SMAA, 
NNT and NNH, PSM, mixed treatment comparison (MTC), DCE, Impact Numbers, Quality Adjusted 
Life Years (QALY), Quality adjusted Time Without Symptoms (Q-TWiST), Incremental Net Health 
Benefit (INHB), and BRR.  Due to feasibility and resources, it was not possible to investigate all of the 
recommended methodologies in this thesis or WP5.  Therefore, only a subset of methodologies is 
presented in this thesis:  PrOACT-URL, BRAT, MCDA, SMAA, MACBETH, DCE, and AHP.  Table 2.3  
states the rationale for including specific methodologies. 
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Table 2.3 List of benefit-risk assessment methodologies applied in this thesis  
Methodology Rationale for inclusion 
Descriptive frameworks: PrOACT-URL, BRAT  They break down complex decision-
making scenarios into smaller more 
manageable steps 
 They improve the communication of the 
results to stakeholders and improve 
transparency 
 They offer interesting graphical 
presentations 
Quantitative frameworks: MCDA, SMAA  They can handle multiple benefits and 
risks simultaneously 
 They offer statistical guidance regarding 
how benefits and risks can be traded-off 
and integrated  
Utility elicitation: DCE  It elicits preference values using 
hypothetical scenarios 
 It is a very comprehensive  utility survey 
technique 
Preference elicitation: swing-weighting, 
MACBETH, AHP 
 They represent a broad range of 
questioning formats which can be used 
to elicit treatment preferences  
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3 Case study I: Efalizumab 
3.1 Introduction 
The first case study presented in this thesis is efalizumab (Raptiva®), which was authorised in the 
European Union (EU) for the indication of moderate to severe plaque psoriasis from September 2004 
to June 2009.  It was the first monoclonal antibody treatment to be withdrawn from the market in 
the EU and United States (US).  The continuous accrual of safety information over four years lead to 
several major labelling changes in the EU Summary of Product Characteristics (SPC); following the 
emergence of progressive multifocal leukoencephalopathy (PML) as an adverse event, the marketing 
authorisation of efalizumab was suspended.   
 
This thesis began by stating that there are many questions regarding the use of systematic methods 
in the benefit-risk assessment of medicines, and a lack of methodological guidelines to involve 
patients and the public in regulatory decision-making.  This chapter begins to address this by 
applying two different types of benefit-risk assessment frameworks—descriptive and quantitative, 
to the case study of efalizumab.  It also critically evaluates where and when PPI can be applied in the 
benefit-risk assessment process described by these methodologies.   
 
In this chapter I describe the medical condition of plaque psoriasis (Section 3.2), and the treatment 
of efalizumab (Section 3.3).  Next, I detail the aims and objectives of the case study (Section 3.4), and 
describe the data sources, extraction, and synthesis methods I used to provide information on the 
favourable and unfavourable effects of treatment (Section 3.5).  I then apply two descriptive benefit-
risk assessment frameworks, PrOACT-URL and BRAT, to the decision-making scenario under 
consideration (Section 3.6).  Next, I report how the efalizumab case study team applied the 
quantitative benefit-risk assessment methodology of MCDA to efalizumab, and I also apply another 
quantitative framework methodology, SMAA, to the same decision-making scenario (Section 3.7).  
Later, I draw from work completed by the WP5 recommendations team—of which I was also a 
member— to reflect on the benefit-risk assessment pathway described by the descriptive and 
quantitative methodologies under consideration, and describe how I believe PPI can be applied to 
the process (Section 3.8).  Lastly, I discuss the case study in Section 3.9. 
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3.2 Plaque psoriasis 
 Background and epidemiology 3.2.1
Skin cells are produced in the dermis, which is the deepest level of the skin.  As the cells mature, 
they move up through the layers of the skin until they reach the outermost layer, i.e. the epidermis, 
where they die and flake off.  Whereas the entire process takes approximately three to four weeks in 
healthy individuals, it only lasts three to seven days in individuals with plaque psoriasis.  (NHS 
Choices, 2013).  Consequently, immature cells build up rapidly on the surface of the skin, causing 
sharply demarcated red or pink erythematous plaques covered with silvery white scales.  The 
plaques can present as a variety of shapes and sizes, and can affect any region of the body, e.g. 
elbows, knees, lower back.   
Originally, plaque psoriasis was believed to be a disorder of the epidermal keratinocytes (Griffiths 
and Barker, 2007).  Now however, it is recognised as an immune mediated disorder.  It is understood 
to have a partially genetic aetiology; nine different loci have been identified with a susceptibility to 
psoriasis, PSOR1-9 (Bowcock and Krueger, 2005).  Several of the implicated loci are shared by other 
autoimmune and inflammatory diseases such as inflammatory bowel disease, type one diabetes, 
multiple sclerosis, and atopic dermatitis, suggesting that similar mechanisms underlie many common 
genetically complex inflammatory diseases (Bowcock and Krueger, 2005).  Immunological and 
environmental factors have also been implicated in the aetiology of plaque psoriasis (Smith and 
Barker, 2006).   
According to General Practice Research Database (GPRD) data collected from 8 million patients from 
1987 to 2002, the UK prevalence of psoriasis was 115,000 individuals—approximately 1.5% of the 
total population (Gelfand et al., 2005).  Of this cohort, 91.8% of patients with a diagnostic code for 
psoriasis received a prescription for therapy consistent with psoriasis on or after the date of their 
first diagnostic code.  55.2% of patients received only one or two prescriptions for psoriasis in the 
first year after the first GPRD record of psoriasis and a large number of patients (23.9%) received five 
or more prescriptions.  The large proportion of psoriasis patients receiving five or more prescriptions 
indicates the unmet medical need for safe and effective treatments to manage the condition.   
Plaque psoriasis is a chronic condition, although the severity of symptoms may improve or get worse 
over time.  The condition cannot be cured, and so treatments focus on improving the symptoms 
and/or appearance of the disease.  Therapeutic efficacy, safety, and other features of administration 
vary by treatment.  A variety of topical therapies are used to treat plaque psoriasis, e.g. 
corticosteroids, vitamin D3 derivatives, tar, retinoids, calcitriol inhibitors.  However, adherence is 
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often poor (Smith and Barker, 2006).  Phototherapy in the form of narrow band ultraviolet B light 
(311-313 nm) can also be used to treat plaque psoriasis.  There is firm evidence to support its use, 
but it is not known how long the period of remission is once the treatment is stopped, or how 
efficacious treatment is with continuous or intermittent use (Smith and Barker, 2006).  Systemic 
treatments such as methotrexate and cyclosporine can also be used to treat plaque psoriasis.  
However, adverse reactions include kidney dysfunction, liver fibrosis and cirrhosis.  Biologics are a 
relatively new line of agents to treat plaque psoriasis, and are in high demand due to the widespread 
patient dissatisfaction with standard treatments (Stern et al., 2004).  There are two main types of 
biologics; those which target the cytokine tumour necrosis factor α (e.g. etanercept, infliximab, 
adalimumab) and those which target T cells or antigen presenting cells (e.g. efalizumab).   
 Impact of psoriasis on quality of life 3.2.2
Plaque psoriasis is incurable, difficult to treat, and has a remitting and relapsing nature (Nelson et 
al., 2006).  Relapses are often unpredictable and do not have an obvious cause; the area, severity 
(e.g. redness, thickness, scaling), and region affected can vary from individual to individual, and from 
one period of time to another for the same individual.  Because there is no cure, treatments focus on 
managing the disease activity and symptoms and to improve and allow an acceptable quality of life 
with minimal toxicity from treatment (Smith and Barker, 2006).  It has been noted that those with 
psoriasis are often marginalised and the condition is under recognised by society because it does not 
directly result in a shorter life expectancy (Fortune et al., 2005).  Also, physicians—including 
dermatologists, often fail to understand how debilitating plaque psoriasis can be for those who 
experience it.   
Despite this, researchers have found that plaque psoriasis greatly affects the lives of those who have 
it, and its impact is similar to that of other serious chronic conditions (Rapp et al., 1999).  Smith and 
Barker (2006) outline three main ways psoriasis affects patients.  The first are skin related 
symptoms, such as scaling, chronic itching, and bleeding which can be very unpleasant to 
experience.  The second are the characteristics of treatments commonly used to treat plaque 
psoriasis.  They can be messy, have an unpleasant odour, be inconvenient to administer, and be time 
consuming.  Lastly, the physical nature of psoriasis means that it can significantly affect quality of life 
in a negative manner.  It is a disease which manifests visibly and has a physical, social, and mental 
impact, which subsequently affects self-esteem and relationships.  There may be a social stigma and 
negative comments from others, which can result in a loss of self-confidence and shame (Weiss et 
al., 2002). 
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Understanding the patient perspective when making treatment decisions is important; one author 
states that, “Although based on relevant parameters, patient preferences and satisfaction with 
therapies have been neglected in guideline development” (Lecluse et al., 2009).  Clinical guidelines 
primarily focus on the severity of disease, but may fail to account for the preferences of the 
individual patient (Zug et al., 1995).  For better care within a clinical setting, decision-making should 
incorporate measures of disease severity, improve outcomes which matter to patients, and account 
for patient satisfaction.  Numerous studies have investigated quality of life measures in patients with 
psoriasis, and although many agree that patients are in the best position to assess how the disease 
impacts their life, few researchers have investigated this (Fortune et al., 1997).  The patient 
perspective is lacking when investigating treatment satisfaction, disease education, and support 
(Wahl et al., 1999).   
3.3 Description of treatment 
Efalizumab is a recombinant, humanized IgG1 monoclonal antibody that targets CD11a, the α-
subunit of leukocyte function associated antigen 1 (LFA-1) (EMA, 2004b).  It was the first biologic 
indicated for the treatment of plaque psoriasis,  “in adult patients who have failed to respond to, or 
who have a contraindication to, or are intolerant to other systemic therapies including cyclosporine, 
methotrexate and PUVA [psoralen combined with ultraviolet A treatment]” (EMA, 2004b).   An initial 
single dose of 0.7 mg/kg body weight was given to patients receiving the treatment, followed by 
weekly injections of 1.0 mg/kg body weight, subcutaneously. 
 
After marketing authorisation was granted, four cases of PML attributable to efalizumab were 
recorded; three of which were fatal (EMA, 2008b).  The patients involved in these cases did not have 
any risk factors for the development of PML, such as human immunodeficiency virus (HIV), cancer, 
or organ transplantation (Brooks, 2011).  Although moderate to severe plaque psoriasis is not 
regarded as a life-threatening disease, PML at the time was an unpredictable, unpreventable, 
untreatable and frequently fatal adverse effect.  PML is caused by reactivation of the John 
Cunningham virus (JCV), which is present in 80% of the population.  It is a rare disease characterized 
by multiple foci of demyelination affecting mainly the subcortical white matter in the brain and can 
result in a variety of neurological symptoms, including visual deficits, motor weakness, and 
behaviour or cognitive changes (Love, 2006).  As a consequence, efalizumab was withdrawn from the 
market.   
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 Marketing history 3.3.1
Efalizumab was authorised from September 2004 to June 2009.  Its full procedural history can be 
found on the EMA website (EMA, 2009c).  Important events relating to authorisation decisions from 
publicly available regulatory documents are summarised below: 
 20th September 2004: The marketing authorisation for efalizumab was granted.   
 December 2008: The CHMP convened the Scientific Advisory Group on clinical 
neurosciences to discuss the benefits and risks of efalizumab and its place in therapy 
following three confirmed and one unconfirmed case of PML.  There were concerns that, 
“the margin of benefits over risks had narrowed since the medicine’s approval”, but the 
SAG-CNS agreed that despite, “modest efficacy and increased risk reported to date, 
efalizumab still represents a useful treatment option albeit with a restricted role in the 
treatment of moderate and severe psoriasis… and with limited evidence to document the 
actual response rate in non-responders to previous systemic treatments” (EMA, 2009e).   
 16th January 2009:  The EC requested that the CHMP assess the benefit-risk balance of 
efalizumab and whether the marketing authorisation for the product should be maintained, 
varied, or suspended.  The CHMP requested that the MAH submit further data on the safety 
concerns.  
 19th February 2009: The CHMP recommended suspension of the marketing authorisation for 
efalizumab due to modest efficacy and the risk of serious side effects (including PML).   
 12th May 2009: The MAH for efalizumab (Serono Europe Limited) notified the EC of its 
decision to voluntarily withdraw the marketing authorisation for the product. 
 9th June 2009: EC issued a decision to withdraw the marketing authorisation for efalizumab.  
3.4 Aim and objectives 
The aims of the efalizumab case study in this thesis are: (a) to test the feasibility of descriptive and 
quantitative frameworks of benefit-risk assessment, and (b) to examine where and when in the 
benefit-risk assessment process PPI is desirable and/or feasible. 
To meet these aims, the objectives are: 
 To extract and synthesise favourable and unfavourable effects data presented in publicly 
available regulatory documents, e.g. EPARs and Periodic Safety Update Reports (PSUR) 
 To apply descriptive benefit-risk assessment frameworks to the case study of efalizumab, i.e. 
PrOACT-URL and BRAT 
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 To apply quantitative benefit-risk assessment frameworks to the case study of efalizumab, 
i.e. MCDA and SMAA, and to use MCDA to illustrate how variations in the inclusion of 
measures might affect the benefit-risk balance 
 To evaluate the decision-making stages described by the descriptive and quantitative 
framework methodologies and assess where and when PPI can be applied in the decision-
making process 
3.5 Data 
 Data sources 3.5.1
Regulatory documents which relate to efalizumab and are publicly available on the EMA website 
were considered in the case study (Table 3.1).   
Table 3.1 Publicly available regulatory documents relating to efalizumab which are available on the EMA website and 
were considered in the case study 
Document EMEA reference 
number 
Date 
published 
Raptiva: EPAR – Scientific discussion (EMA, 2004b) None listed 2004 
Raptiva: EPAR - Procedural steps taken before 
authorisation (EMA, 2004a) 
None listed 2004 
Raptiva: EPAR – Summary for the public (EMA, 2007b) EMEA/H/C/542 10/2007 
Raptiva: EPAR – Variation Assessment Report (EMA, 
2008b) 
EMEA/H/C/542/II/19 24/04/2008 
Raptiva: EPAR - Scientific conclusions (EMA, 2009e) EMEA/83006/2009 17/04/2009 
Raptiva: EPAR – Product information (EMA, 2009f) EMEA/H/C/000542 -
II/0026 
04/08/2009 
Raptiva: EPAR - All authorised presentations (EMA, 
2009d) 
None listed 04/08/2009 
Raptiva: EPAR - Procedural steps taken and scientific 
information after authorisation (EMA, 2009c) 
None listed 04/08/2009 
 Data extraction 3.5.2
The regulatory documents listed in Table 3.1 yielded substantial amounts of information on the 
favourable effects (Section 3.5.2.1) and unfavourable effects (Section 3.5.2.2) of efalizumab 
(information on these are provided in Appendix Table 3). 
3.5.2.1 Favourable effects 
Data on the favourable effects of efalizumab were primarily sourced from five pivotal phase III 
clinical trials included in the submission dossier prior to authorisation:  ACD2058g. ACD2059g, 
ACD2390g, ACD2600g, and IMP24011 (Appendix Table 1 and Appendix Table 2).   
Additional clinical trials that examined the use of efalizumab were described in the regulatory 
documents (EMA, 2004b), but I excluded these because they occurred prior to Phase III, and/or 
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examined different indications (e.g. primary renal transplant, allergic asthma), and/or investigated 
alternative doses.  These trials included ACD2243g, 25300, 25161, 25030, ACD2244g, ACD2391g, 
ACD2601g, ACD2782g, and HUPS300. 
The favourable effects which were publicly reported in the EPARs from all or some of the five clinical 
trials included:  Psoriasis Area Severity Index (PASI) 75 improvement, PASI 50 improvement, Overall 
Lesion Severity (OLS) rating of minimal or clear, mean improvement in the Itching Scale, Physician 
Global Assessment (PGA) rating of cleared or excellent, mean improvement in the thickness 
component of the PASI score, mean improvement in the percentage of Body Surface Area (BSA) 
affected by psoriasis, mean percentage of PASI improvement over time, mean improvement in the 
Dermatology Life Quality Index (DLQI), and mean improvement in the frequency and severity 
subscales of the PGA. 
The results of clinical trials completed following authorisation, i.e. IMP2400, and 25300, provided 
additional information on the duration of efficacy.  IMP2400 found that the median time to relapse 
(classified as >50% loss of response), was 58 days post-treatment (n=164).  Trial 25300 found that 
the median time to relapse was 56 days, and reported that retreatment achieved similar efficacy 
values to the first treatment period (12 weeks).   
3.5.2.2 Unfavourable effects 
Publicly available data on the unfavourable effects of efalizumab were also obtained from the same 
five pivotal clinical trials (i.e. ACD2058g. ACD2059g, ACD2390g, ACD2600g, and IMP24011).  
Additional data which were collected during the post-marketing surveillance period were also 
extracted from publicly available regulatory documents. 
3.5.2.2.1 Unfavourable effects data reported from trials included in the submission dossier 
Adverse events which occurred in three percent or more of patients treated with 1mg/kg/wk 
efalizumab for trials ACD2058g, ACD2059g, ACD2390g, and ACD2600g were publicly reported in the 
EPAR (Table 3.2) (EMA, 2004b).  GNE and XOMA are bioequivalent formulations of efalizumab.    
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Table 3.2 Number of adverse events which occurred in ≥3% or more of patients for trials ACD2058g, ACD2059g, 
ACD2390g, and ACD2600g 
 Number of adverse events reported in the 
treatment groups 
COSTART body system 
Preferred term 
Placebo  
(n=455) 
Efalizumab  
GNE 
(n=930) 
Placebo  
(n=260) 
Efalizumab 
XOMA 
(n=690) 
Body as a whole     
Headache 86 294 73 248 
Infection 76 134 34 91 
Chills 19 112 13 95 
Pain 20 82 18 85 
Back pain 8 33 6 42 
Fever 9 55 15 71 
Flu syndrome 20 76 9 26 
Asthenia 16 54 21 65 
Accidental injury 32 47 13 48 
Digestive     
Nausea 25 92 26 92 
Diarrhoea 28 50 20 52 
Muscoskeletal myalgia 22 84 13 50 
Arthralgia 10 31 9 35 
Respiratory     
Pharyngitis 29 72 18 47 
Rhinitis 26 59 20 39 
Cough increased 20 40 11 25 
Sinusitis 28 48 6 29 
Skin/appendages     
Herpes simplex 10 37 14 37 
Acne 3 33 1 23 
Pruritus 26 59 14 30 
 
Table 3.3 lists all of the adverse events which occurred in clinical trials prior to authorisation and 
were reported in the regulatory documents.  All of the original units as reported in the regulatory 
documents are conserved in the table.  The method of pooling the data across trials is not described.   
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Table 3.3 Adverse events which occurred in clinical trials prior to the authorisation of efalizumab 
Adverse event Clinical trials Placebo Efalizumab 
Mild to moderate dose 
related acute flu-like 
symptoms (including 
headache, fever, chills, 
nausea, myalgia) 
ACD2058g. 
ACD2059g, 
ACD2390g, 
ACD2600g 
24% 41% 
Serious adverse 
event/death 
Unknown Infrequent; no consistent pattern suggestive of a 
relationship 
Infections:  percentage of 
subjects with at least one 
infection related adverse 
event 
ACD2058g. 
ACD2059g, 
ACD2390g, 
ACD2600g 
28.6% 26.3% 
Infections:  percentage of 
subjects with at least one 
infection related adverse 
event 
IMP24011 22.3% 25.7% 
Incidence of infections and 
infestations 
IMP24011 11.2% 21% 
Infections:  incidence of 
infections requiring 
hospitalisation  
ACD2058g. 
ACD2059g, 
ACD2390g, 
ACD2600g 
12-weeks: 1.4 per 100 
patient-years 
Long-term: 1.08 per 100 
patient-years 
12-weeks: 2.8 per  
100pt-years  
Long term: 1.61 per 100 
patient-years 
Malignancy Pooled 3 cancers for 185 patient 
years of exposure, 
yielding an incidence of 
1.62 cases per 100 
patient-years 
30 for 1780 patient 
years of exposure, 
yielding an incidence of 
1.68 cases per 100 
patient-years 
Recurrence of psoriasis 
after discontinuation 
Pooled 13% 16% 
Erythrodermic psoriasis 
(during treatment or after 
discontinuation) 
Pooled 4 cases in 979 patients 29 cases in 3291 
patients 
Pustular psoriasis (during 
treatment or after 
discontinuation) 
Pooled Not reported 10 cases in 3291 
patients 
Deafness Pooled 0.6% 1% for 1mg/kg/wk, 
3.7% for 2mg/kg/wk 
Thrombocytopenia Pooled Not reported 9 cases out of 3291 
patients (less than 
52,000 cells per µl 
reported), and four of 
these patients had 
clinical signs 
Arthritis Pooled 4 cases (n=219) 1mg/kg: 10 cases 
(n=420); 2mg/kg: 5 
cases (n=61) 
Arthritis IMP24011 (interim) 10 cases (n=125) 28 cases (n=252) 
Arthralgia Pooled Not reported 4.8% 
Arthritis Pooled Not reported 4%, 
Back pain Pooled Not reported 3.6% 
Arthrosis Pooled Not reported 1.2% 
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3.5.2.2.2 Reporting of unfavourable effects during the post-marketing surveillance period 
At the time of the Variation Assessment Report (24th April, 2008) the safety database included over 
7000 patients (n>6000 receiving efalizumab, n>1400 receiving placebo), and the overall exposure to 
efalizumab was approximately 2800 patient-years. 
Several risks were discussed in the Variation Assessment Report (EMA, 2008b): 
 Leucocytosis and lymphocytosis 
 Thrombocytopenia 
 Hypersensitivity and allergic disorders 
 Malignancies 
 Serious infections 
Also, there were new additions to the SPC:  Septic meningitis, infections (including opportunistic 
infections such as tuberculosis), immune related haemolytic anaemia, antibodies during 
vaccinations, interstitial pneumonitis, arthritis, erythema multiforme, inflammatory 
polyradiculoneuropathy, lymphomas and other malignancies, and liver disorders. 
Adverse events were also reported within the PSURs.  Table 3.4 gives a summary of unfavourable 
effects which were highlighted by each PSUR. 
Table 3.4 Reporting of adverse events of efalizumab in the Period Safety Update Reports  
Source Adverse event 
PSUR 1 Meningitis aseptic, headaches 
PSUR 2 Opportunistic infections and tuberculosis, immune mediated haemolytic anaemia, 
arthritis, interstitial pneumonitis, erythema multiforme, lowered T-cell dependent 
antibody response affecting tetanus toxoid booster and pneumococcal vaccinations 
PSUR 4 Increased risk or severity of infections (tuberculosis, pneumonia, reactivation of 
latent chronic infections), arthritis following discontinuation, unclear association 
with lymphoproliferative disorders  
PSUR 9 and PSUR 10 PML, tuberculosis, lymphoma, meningitis, CNS infections, non-melanoma skin cancer 
and malignancies 
MAH global safety 
database 
 
Inflammatory neuropathy syndromes (including myelitis), Guillain–Barré syndrome, 
Miller Fisher syndrome 
MAH cumulative 
review of facial palsy 
Facial palsy (Bell’s palsy) with “uncommon” frequency 
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Additional post-marketing surveillance data were extracted from the PSURs by Merck Serono (Alain 
Micaleff, personal communication) and made available to the study team (Table 3.5). 
 
Table 3.5 Additional post-marketing surveillance data extracted from the Periodic Safety Update Reports by Merck 
Serono 
Outcome Source Units Placebo Efalizumab 
Aseptic Meningitis Post-marketing 
surveillance 
N N/A 29 
Opportunistic infections Post-marketing 
surveillance 
N N/A 111 
Haemolytic Anaemia Post-marketing 
surveillance 
N N/A 24 
Polyradiculopathy Post-marketing 
surveillance 
N N/A 4 
Interstitial lung disease Post-marketing 
surveillance 
N N/A 18 
Serious cases of exacerbation of 
rebound 
Post-marketing 
surveillance 
N N/A 390 
 
3.5.2.2.3 PML 
PML is an important adverse event because it is not associated with psoriasis. It is difficult to 
diagnose as the initial symptoms are very similar to a MS relapse, fast progressing, and the sequelae 
of disease is difficult to reverse.  It is extremely severe and usually fatal.  Symptoms include severe 
neurological symptoms, such as headaches, memory loss, changes in mental status, speech and 
vision difficulties, loss of strength, limb weakness, seizures, partial paralysis and loss of coordination.  
The symptoms may rapidly worsen and typically result in severe disability or death. Immune 
modulating and/or suppressive medications typically play a major role in the development of PML, 
i.e. transplantation, human immunodeficiency virus (HIV), cytotoxic agents and immunosuppressant 
drugs. 
No cases of PML were reported in clinical trials.  Following authorisation, three cases of PML 
emerged.  Consequently, the MAH concluded that “the risk of PML identified during long-term 
exposure does not seem to outweigh benefits in high need patients with limited treatment 
alternatives, and who benefit most from treatment, provided that treatment duration will be limited 
up to a maximum of two years” (EMA, 2009e)  Following this announcement, a fourth case of PML 
then emerged (Table 3.6). 
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Table 3.6 Reported cases of PML in patients treated with efalizumab 
Reported 
reaction 
Onset latency Event 
Outcome 
Concomitant 
medication / 
relevant past drugs 
Co-morbidities / Risk 
factors 
Progressive 
multifocal 
leukoenceph
alopathy 
4 years Fatal Pravastatin, aspirin Coronary artery 
disease, 
hyperlipidemia, 
angioplasty, stent 
placement 
Progressive 
multifocal 
leukoenceph
alopathy 
(degenerativ
e 
neurological 
symptoms) 
 
3.75 years Fatal Statins, 
temazepam, 
escitalopram 
oxalate, aspirin, 
estrogens 
Hyperlipidemia, 
diverticulum, 
depression 
Progressive 
multifocal 
leukoenceph
alopathy 
(suspected) 
4 years Fatal Sertraline 
hydrochloride, 
esomeprazole, 
statins, aspirin 
Hyperlipidemia, 
hypertension, sleep 
apnoea syndrome, 
chronic obstructive 
pulmonary disease, 
basal cell carcinoma 
Progressive 
multifocal 
leukoenceph
alopathy 
3.25 years Hospitalised Acitretin (2000-
2001); fumaric acid 
in 2002 and 
methotrexate 
(2002-2003) 
Obesitas 
 
 Data synthesis 3.5.3
3.5.3.1 Data selection  
Trial-specific data on favourable effects were extracted from the EPARs.  There was no further 
information regarding the favourable effects of efalizumab reported in publicly available post-
marketing surveillance data.  Safety data on unfavourable outcomes were extracted from the EPARs, 
and included data pooled from trials and from post-marketing surveillance. 
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3.5.3.2 Effects table 
Results obtained from the sources were collated into two tables.  Table 3.7 provides a summary of 
the treatment probabilities of efficacy outcomes by arm.  Estimates for PASI75, PGA, and OLS were 
obtained through random-effects meta-analysis of individual trial data, for PASI50 were obtained 
from pooled data and for DLQI using pooled mean change estimation.  The mean change from 
baseline in the DLQI score was higher in the efalizumab arm, 5.5 (95% CrI: 5.2–5.7) compared to the 
placebo arm, 1.8 (95% CrI: 1.5-2.1).  Risk differences for efficacy outcomes were positive, implying 
that the 95% CrI of treatment probabilities were higher in the efalizumab arm compared to the 
placebo arm.  Meta-analysis results also showed that participants taking efalizumab were 7.8 (95% 
CrI: 5.0-12.4) times more likely to achieve PASI75 than those taking placebo (Appendix Table 4, 
Appendix Table 5).   
Table 3.7 Effects table displaying favourable outcomes 
Outcome Source Units 
Efalizumab Placebo 
Median 
(%) 95% CrI 
Median 
(%) 95% CrI 
PASI75 
Meta-analysis 
Median 
proportion 
achieving 
outcome 
(%) 
         28.0     18.1     40.7              3.6       2.2       5.7  
PGA          30.5     18.3     46.5              5.2       3.0       8.7  
OLS          29.2     17.5     44.0              3.7       2.0       6.4  
PASI50 Pooled data  54.9 51.5 58.1 16.9 13.6 20.5 
DLQI Meta-analysis 
Change 
from 
baseline 
(DLQI score) 
5.5 5.2 5.7 1.8 1.5 2.1 
 
A summary table of safety outcomes provides the probability or rate per 10,000 person-years of 
experiencing an adverse event (Table 3.8).  Data sources for overall safety outcomes included pooled 
trial data and post-marketing surveillance data obtained from EPARs.  Not all adverse events were 
more common in efalizumab:  there were large overlaps in the posterior distributions of the rates of 
respiratory events, infection, accidental injury, arthralgia, diarrhoea, herpes simplex, pruritus, 
erythroderma, thrombocytopenia, arthritis, and hypersensitivity (Appendix Table 5). 
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Table 3.8 Effects table displaying unfavourable outcomes 
Outcome Source Units 
Efalizumab Placebo 
Median   Median   
(%) 95% CrI  (%) 95% CrI 
Body as a whole 
Pooled data* 
Proportion 
achieving 
outcome (%) 
  
Headache 33.5 (31.2 - 35.8) 22.3 (19.3 - 25.4) 
Infection 13.9 (12.3 - 15.7) 15.4 (13.0 - 18.2) 
Chills 12.8 (11.2 - 14.5) 4.6 (3.2 - 6.3) 
Pain 10.3 (8.9 - 11.9) 5.4 (3.9 - 7.2) 
Back pain 4.7 (3.7 - 5.8) 2.1 (1.2 - 3.3) 
Fever 7.8 (6.6 - 9.2) 3.4 (2.3 - 4.9) 
Flu syndrome 6.3 (5.2 - 7.6) 4.1 (2.9 - 5.8) 
Asthenia 7.4 (6.2 - 8.7) 5.3 (3.8 – 7.0) 
Accidental injury 5.9 (4.8 - 7.1) 6.4 (4.7 - 8.3) 
Digestive    
Nausea 11.4 (9.9 - 13) 7.2 (5.5 - 9.3) 
Diarrhoea 6.3 (5.2 - 7.6) 6.8 (5.1 - 8.8) 
Myalgia 8.3 (7.0 - 9.7) 5.0 (3.5 - 6.7) 
Arthralgia 4.1 (3.2 - 5.2) 2.7 (1.7 - 4.1) 
Respiratory     
Pharyngitis 7.4 (6.2 - 8.7) 6.7 (5.0 - 8.6) 
Rhinitis 6.1 (5.0 - 7.3) 6.5 (4.9 - 8.5) 
Cough increased 4.0 (3.2 - 5.1) 4.4 (3.1 - 6.1) 
Sinusitis 4.8 (3.8 - 5.9) 4.8 (3.4 - 6.6) 
Skin / appendages    
Herpes simplex 4.6 (3.6 - 5.7) 3.4 (2.3 – 5/0) 
Acne 3.5 (2.7 - 4.5) 0.7 (0.2 - 1.4) 
Pruritus 5.5 (4.5 - 6.7) 5.7 (4.1 - 7.5) 
Other   
ADR (mild to moderate) 41.0 (38.7 - 43.3) 24.0 (21.3 - 26.7) 
Erythroderma 0.9 (0.6 - 1.3) 0.5 (0.2 - 1.0) 
Thrombocytopenia 0.3 (0.1 - 0.5) 0.07 (0.003 - 0.4) 
Hypersensitivity  8.0 (7.0 - 9.1) 7.1 (5.6 - 8.8) 
Adverse event of arthritis 2.5 (1.3 - 4.3) 2.1 (0.8 - 4.6) 
PML (all) 
Post-marketing 
surveillance 
data (Poisson 
model) 
Rate per 
10,000 
patient-
years 
0.8 (0.2 - 1.9) 
Unknown (not 
reported) 
ILD 3.8 (2.3 - 5.8) 
Opportunistic infections 24 (19.4 - 28.2) 
Haemolytic anaemia 5.0 (3.3 - 7.3) 
Polyradiculopathy 0.8 (0.2 - 1.9) 
Exacerbation Rebound 83.0 (74.6 - 90.9) 
Aseptic Meningitis 6.1 (4.1 - 8.6) 
Serious infections 61 (54.0 - 68.1) 
Serious infections   
<12 weeks treatment 282 (201 - 383) 137 (37 - 350) 
>12 to 144 weeks 183 (143 - 232) Unknown 
* As reported in the literature; method of pooling is unknown 
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Estimates presented in the efficacy (Table 3.7) and safety (Table 3.8) summary tables are used in the 
benefit-risk assessment methodologies presented in this case study. 
3.6 Descriptive frameworks 
This section describes the application of two descriptive framework methodologies for benefit-risk 
assessment, i.e. PrOACT-URL and BRAT, to the case study of efalizumab.  The general steps relating 
to each of the methodologies have been described in this thesis prior to this chapter (Section 2.3.1). 
 Application of PrOACT-URL framework 3.6.1
3.6.1.1 Problem 
3.6.1.1.1 Step 1: Determine the nature of the problem and its context 
Step 1 of the PrOACT-URL guidelines lists several key data fields which must be completed.  The 
application of this step is presented in Table 3.9. 
3.6.1.1.1 Step 2: Frame the problem 
For the first part of Step 2, PrOACT-URL requires the decision-maker to state if the problem is due to 
uncertainty, multiple conflicting objectives, or other factors (e.g. health states’ time progression) 
(Phillips et al., 2010).  Uncertainty was an important factor for the case study of efalizumab.  This is 
because as each of the four case reports of PML emerged—three confirmed and one unconfirmed— 
there was the question of whether PML was associated with, or caused by the treatment.  Multiple 
conflicting objectives were also a concern; for the subset of “high need” individuals affected by 
plaque psoriasis it was important to balance the benefit of favourable outcomes against the risk of 
unfavourable outcomes.  Lastly, the seriousness of PML was extremely important to consider.    
The second part of Step 2 requires the decision-maker to state the factors to be considered in 
solving the problem (e.g., study design, sources and adequacy of data, disease epidemiology, and 
presence of alternative treatments).  The sources of data which were available to the regulatory 
decision-makers at the time were clinical trial databases.  However, for this case study publicly 
available sources of data published on the EMA website were used.  The total cumulative exposure 
to efalizumab was approximately 47,000 patient-years. 
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Table 3.9 Application of Step 1 in the PrOACT-URL framework to the efalizumab case study 
Step 1: Key data fields Application to the efalizumab case study 
The medicinal product Efalizumab: a recombinant, humanized IgG1 
monoclonal antibody humanised that targets 
CD11a, the α-subunit of LFA-1 (EMA, 2004b).   
Indication(s) for use Efalizumab is indicated for the treatment of 
“high need” adult patients with moderate to 
severe chronic plaque psoriasis who have failed 
to respond to, or who have a contraindication to, 
or are intolerant to other systemic therapies 
including cyclosporine, methotrexate and PUVA 
(EMA, 2004b).    
Therapeutic area and disease epidemiology The therapeutic area is moderate to severe 
plaque psoriasis.  Psoriasis is a chronic, 
squamous dermatitis with polygenic inheritance. 
Principal histological findings are Munro micro 
abscesses and spongiform pustules; also seen 
are rounded, circumscribed, erythematous, dry, 
scaling patches of various sizes, covered by 
greyish white or silvery white, umbilicated and 
lamellar scales, usually on extensor surfaces, 
nails, scalp, genitalia and the lumbosacral region.  
Unmet medical need, severity and morbidity of 
condition, affected population, patients’ and 
physicians’ concerns, time frame for health 
outcomes 
Unmet medical need: The indication was granted 
as a last line therapy on the grounds of modest 
efficacy and lack of long term safety data.   
Severity: Plaque psoriasis is not a fatal condition, 
although it can be very severe. 
Affected population: A “high-need” population 
(see response for “Indication(s) for use”). 
Patients’ and physicians’ concerns: The 
occurrence of the rare but frequently fatal PML. 
Time frame for health outcomes: Cumulative 
exposure to efalizumab since launch in 2003 in 
the US, and 2004 in the EU (and rest of the 
world) was approximately 47,000 patient-years 
at time of decision-making.  In the EU, the 
average duration of exposure was estimated at 
10.5 months.  The duration of exposure for PML 
before onset of symptoms was more than three 
years and nine months (EMEA/H/C/00542/).  The 
time frame for efficacy and relief of plaque 
psoriasis clinical symptoms was 12 weeks (EMA, 
2008b). 
The decision problem (what is to be decided and 
by whom, e.g., industry, regulator, prescriber, 
patient) 
The decision problem in this case study is to 
examine whether the marketing authorisation 
for efalizumab should be maintained, varied, 
suspended or withdrawn.  This is intended to 
recreate the decision-making scenario faced by 
EMA regulators when they evaluated the benefit 
and risk data from clinical trials and post-
marketing surveillance in January 2009.  
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For “high need” adult patients with moderate to severe chronic plaque psoriasis, it was carefully 
considered how important or essential it was for efalizumab to be available for those who cannot 
tolerate systemic therapies or find them ineffective.   However, other non-systemic, alternative 
treatments for the indication of plaque psoriasis had since been authorised following efalizumab 
with more favourable safety profiles; etanercept received EU authorisation for the treatment of 
plaque psoriasis in September 2004, infliximab was approved for the same indication in September 
2005, followed by adalimumab in December 2007.   
3.6.1.2 Objectives 
3.6.1.2.1 Step 3: Establish objectives that indicate the overall purposes to be achieved 
PrOACT-URL requires the decision-making aim to be explicitly stated: The aim of the decision-making 
scenario in this case study was to evaluate the benefit-risk balance of efalizumab with the use of 
publicly available safety and efficacy data obtained from clinical trials and post-marketing 
surveillance in January 2009. 
3.6.1.2.2 Step 4: Identify criteria for favourable effects and unfavourable effects 
For this step, the operational definition of each unfavourable and favourable effect needs to be 
defined, and placed on a measurement scale—with confidence intervals, to represent the 
performance for efalizumab and placebo.   
3.6.1.2.2.1 Favourable effects 
Favourable effects were operationally defined in the case study to describe which outcomes were 
used to evaluate the efficacy of efalizumab.  The primary efficacy endpoint for plaque psoriasis 
clinical trials is PASI75.  PASI75 represents the proportion of subjects with a 75% or more 
improvement from baseline in the Psoriasis Area and Severity Index (PASI) score.  The PASI score 
measures the severity and extent of plaque psoriasis based on the redness, thickness, scaling, body 
surface area and affected regions.   
Data for PASI75 were obtained from five clinical trials: ACD2058g, ACD2059g, ACD2390g, ACD2600g 
and IMP24011.  All of these clinical trials had a similar study design and were double blinded and 
placebo controlled.  The main inclusion criteria for participants were a minimum PASI score of 12.0 
at screening before entering the trial, plaque psoriasis covering ≥10% of total BSA, and a need for 
systemic treatment. 
Other favourable effects recorded in the regulatory documents were PGA, OLS, DLQI, and PASI50.  
Data for these effects were also obtained from the same five clinical trials.   
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3.6.1.2.2.2 Unfavourable effects 
Unfavourable effects were operationally defined in the case study to describe which outcomes were 
used to evaluate the safety of efalizumab.  Safety data were extracted from regulatory documents 
(Table 3.1).   
The unfavourable effect which prompted the regulatory decision-making scenario was PML.  No 
cases of PML were reported with the use of efalizumab in clinical trials conducted prior to marketing 
authorisation. However, following September 2008, four cases (three confirmed, and one 
unconfirmed) of PML were reported by the MAH.   
3.6.1.2.2.3 Effects table 
An effects table was designed to list and describe the occurrence and magnitude of the favourable 
and unfavourable effects under consideration in the case study (Table 3.7 and Table 3.8).  
3.6.1.3 Alternatives 
3.6.1.3.1 Step 5: Identify the options to be evaluated against the criteria 
As the decision-making problem in the case study was constructed to replicate the regulatory 
scenario, it hoped to adopt the alternatives considered by the regulator at the time of decision-
making.  That is, the options to be evaluated were: Should the marketing authorisation for 
efalizumab be (a) maintained, (b) varied, (c) suspended, or (d) withdrawn.  If the drug was to be 
varied, there were specific restrictions to the indication which could have been considered:  (i) 2 
year treatment duration limitation, (ii) target population change.   The risk reduction strategies of 
passively monitoring and/or actively collecting further data were not considered because although 
causality was not established with the initial cases of PML, it was a very serious adverse event and 
was considered as inappropriate following the emergence of four cases.  Its seriousness also meant 
that the option to change the product label was not considered.    
There was insufficient publicly available information regarding favourable and unfavourable effects 
for the case study to examine the potential alternatives of varying the marketing authorisation for 
efalizumab; there was not any data which could be used to investigate how differing time periods of 
exposure to the treatment might affect the benefit-risk balance, or data on specific population 
subsets to investigate if there may have been a specific group of patients for whom the benefit-risk 
balance might be positive.  Similarly to the regulatory perspective, the drug was evaluated in this 
case study only against placebo and no active comparators were considered.   
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Essentially, the alternatives to be compared were: 
a) Efalizumab at time of regulatory decision-making in January 2009 
b) Placebo in 2004/Background epidemiological rates 
3.6.1.4 Consequences 
3.6.1.4.1 Step 6: Describe how the alternatives perform for each of the criteria 
The data were summarised within an effects table to demonstrate how well each alternative 
performed for each of the favourable (Table 3.7) and unfavourable effects (Table 3.8). 
3.6.1.5 Trade-offs 
3.6.1.5.1 Step 7: Assess the balance between favourable and unfavourable effects 
At the time of regulatory decision-making in January 2009, the benefit-risk balance of efalizumab 
was found to be negative by the CHMP, which subsequently led to the suspension of its marketing 
authorisation.  In the case study, the benefit-risk balance between favourable and unfavourable 
effects was determined via the quantitative benefit-risk assessment frameworks of MCDA and 
SMAA.  The MCDA results show that the overall value of the benefit-risk score for efalizumab was 
higher than placebo, i.e. the benefit-risk balance is more positive for efalizumab than placebo.  The 
SMAA results show that the probability of efalizumab being ranked first above placebo is much 
greater than placebo being ranked first, which also indicated that the benefit-risk balance for 
efalizumab is more positive than placebo.   
3.6.1.6 Uncertainty 
3.6.1.6.1 Step 8: Report the uncertainty associated with the favourable and unfavourable 
effects 
The individual uncertainty in the rates for each favourable and unfavourable effect was established 
by the calculation of 95% CrIs.  These are presented in Table 3.7 for favourable outcomes and Table 
3.8 for favourable unfavourable outcomes. The uncertainty in the subjective valuation of favourable 
and unfavourable effects was assessed by varying the importance attributed to them through 
sensitivity analyses.   
3.6.1.6.2 Step 9: Consider how the balance between favourable and unfavourable effects is 
affected by uncertainty 
The uncertainty in favourable effects was minimal as the risk difference was significantly positive for 
all measures.  Hence, most of the uncertainty was observed in unfavourable effects.  If a scenario 
where all the unfavourable effects were fixed at their maximum for efalizumab was considered, the 
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balance between favourable and unfavourable effects would be affected.  However, the risk 
difference of PML would still be considerable even if fixed to its minimum, and as PML was 
responsible for marketing authorisation suspension of efalizumab, it was not believed that the 
balance would be affected by the uncertainty in PML. 
3.6.1.7 Risk tolerance 
3.6.1.7.1 Step 10: Judge the relative importance of the decision maker’s risk attitude for this 
product 
The risk attitude of the decision marker(s) is likely to be influenced by the severity of the indication 
and the severity of the adverse event:  Although plaque psoriasis is not a life threatening disease, it 
can severely affect quality of life; PML is also likely to affect risk tolerance as it results in high 
morbidity and mortality.  Additionally, the availability of alternative treatments for the same 
indication would have likely influenced the decision-maker’s risk attitude. 
3.6.1.7.2 Step 11: Report how this affected the balance reported in step 9 
The positive benefit-risk balance for efalizumab using MCDA (Section 3.7.1) did not shift to negative 
until large increases in the importance attributed to unfavourable effects were investigated, 
suggesting that the positive balance is conserved even after accounting for large uncertainties in the 
valuation of unfavourable effects.  However, when equal importance was given to a swing of PML 
from 0 to 5 cases and a swing in PASI75 from 0% to 60%, the balance was null, suggesting equal 
preference for placebo and efalizumab.  The uncertainty in rates of effects was not taken into 
account in this application.  Using SMAA, although efalizumab was the preferred option when using 
ordinal and cardinal preference weights obtained from MCDA, it was preferred only 67% of the time 
when preferences were missing and the model was data driven (Figure 3.11). 
3.6.1.8 Linked decisions 
3.6.1.8.1 Step 12: Consider the consistency of this decision with similar past decisions, and 
assess whether taking this decision could impact future decisions 
Although the decision to maintain the marketing authorisation of efalizumab in the case study 
context using MCDA and SMAA to assess the benefit-risk balance, in January 2009 the benefit-risk 
balance was found to be negative by the CHMP, and its marketing authorisation was suspended.   
Prior to this decision, only one other treatment was withdrawn from the market due to the 
occurrence of PML. This was natalizumab. It was initially approved in the US in 2004 and voluntarily 
withdrawn by the marketing authorisation holder in February 2005, but later reintroduced in June 
2006.  It was approved by the EMA in April 2006 with strict risk minimisation measures.  However, 
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the indication of natalizumab—relapsing remitting multiple sclerosis, is for a much more serious 
disease and is associated with higher levels of morbidity and mortality than plaque psoriasis.  
Efalizumab was the first monoclonal antibody to be irreversibly removed from the market.  The 
withdrawal of efalizumab was initiated approximately at the same time by the EMA for Europe, and 
the FDA for the US (FDA, 2009).  If may affect future decisions for other monoclonal antibodies, as it 
brings to the foreground the need to consider potential long-term effects which may not be known 
at the time of initial approval.  This could be potentially addressed through drug development by 
modifying the design, duration and follow-up of clinical trials.  This is particularly relevant if the drug 
is designed for a non-fatal disease for which alternative treatments are available.   
 Application of BRAT framework 3.6.2
3.6.2.1 Step 1: Define the decision context 
The first step is to define the decision context (Table 3.10).  This involves stating the objective and 
assumptions of assessment by specifying and defining the therapeutic context, comparator, time 
horizon (i.e. the duration of exposure to the product and the time period over which benefit–risk 
events are measured), and noting whose perspective is to be adopted (The Benefit-Risk Action 
Team, 2011).   
Table 3.10 Application of Step 1 in the BRAT framework to the efalizumab case study: The decision context 
Suggested data fields to define the 
decision context 
Description 
Objective To evaluate the benefit-risk balance of efalizumab with the 
use of safety and efficacy data obtained from clinical trials 
and cumulative post-marketing safety information 
Drug Efalizumab (Raptiva) 
Dose An initial single dose of 0.7 mg/kg body weight is given 
followed by weekly injections of 1.0 mg/kg body weight, 
subcutaneously 
Drug class Monoclonal antibody 
Formulation All (e.g. GNE SC, XOMA SC) 
Indication under consideration Moderate to severe plaque psoriasis 
Intended patient population of 
interest (including contraindications 
to treatment and baseline disease 
characteristics) 
“high need” adult patients with moderate to severe chronic 
plaque psoriasis who have failed to respond to, or who have 
a contraindication to, or are intolerant to other systemic 
therapies including cyclosporine, methotrexate and PUVA 
Comparator(s) Placebo 
Time horizon i.e. time frame for 
treatment and for follow-up for 
relevant clinical outcomes 
12 weeks for PASI 75 (efficacy), 3 years for PML (safety) 
Decision-maker perspective (e.g. 
regulator, sponsor, patient, 
physician) 
Regulator  
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3.6.2.2 Step 2: Identify outcomes 
The second step is to identify and select relevant benefit and risk outcomes via literature reviews, 
regulatory precedents and meetings with clinical experts (The Benefit-Risk Action Team, 2011).  The 
outcomes which should be included are those believed to most importantly influence the benefit-
risk balance.   
3.6.2.2.1 Measures 
Table 3.11 contains a list of measures which were considered to most importantly influence the 
benefit-risk balance of efalizumab, i.e. all of the measures which were mentioned in the publicly 
available documents and considered at the time of decision-making by the regulators; e.g. drug 
specific safety issues, changes to SPC, reported spontaneous AEs. 
Table 3.11 Application of Step 2 in the BRAT framework to the efalizumab case study: Measures most likely to 
importantly influence the benefit-risk balance  
Favourable effects: 
 PASI75 
 PGA 
 OLS 
 DLQI 
 PASI50 
 
Unfavourable effects: 
 Mild to moderate adverse drug reactions 
 Severe adverse drug reactions 
 Meningitis aseptic 
 Serious infections (e.g. pneumonia, sepsis, cellulitis) 
 Opportunistic infections (e.g. fungal infections, tuberculosis, herpes virus, EBV, 
cytomegalovirus) 
 Serious thrombocytopenia 
 Immune haemolytic anaemia 
 Erythrodermic and pustular psoriasis 
 Nervous system disorders (e.g. Inflammatory polyradiculopathy,  Facial Palsy, Guillain–
Barré syndrome, Fisher Miller Syndrome) 
 Interstitial lung diseases (e.g. lung infiltration, pulmonary fibrosis) 
 Serious cases of psoriasis exacerbation or rebound 
 Brain infections including encephalitis and PML 
 
 
3.6.2.2.2 Value tree 
An initial value tree (Figure 3.1) which contains all benefit and risk measures from Table 3.11 was 
compiled.  This tree was then further developed in the subsequent steps to only include available, 
precisely defined, reliable and accurate end-point measures available to the regulator at time of 
decision-making.  
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Figure 3.1 Application of Step 3 in the BRAT framework to the efalizumab case study: Initial value tree built using BRAT 
framework tool 
3.6.2.3 Step 3: Identify data sources 
The third step describes the identification and selection of data sources, in addition to organising 
them and extracting the relevant data (The Benefit-Risk Action Team, 2011).  For the case study of 
efalizumab, any document which would have been available to the decision-maker, i.e. the regulator 
 Identified Benefit or Risk Category 
Identified benefit/ risk Outcome 
Potential Outcome or B/R category 
Hidden Node 
PASI75 
PGA 
Favourable 
effects (i.e. 
efficacy) 
OLS 
DLQI 
PASI50 
Brain infections  
ADR (mild to moderate) 
ADR (severe) 
Meningitis aseptic 
Serious infections 
(including pneumonia, 
sepsis, cellulitis) Severe thrombocytopenia Unfavourable 
effects (i.e. 
safety) 
Opportunistic infections 
(including  fungal 
infections, tuberculosis, 
herpes virus, EBV, CMV) 
Immune haemolytic 
anemia 
Psoriasis severe forms  
Nervous System disorders 
(including inflamm. 
polyradiculopathy,  facial 
palsy, GBS, Fisher Miller) 
Interstitial lung diseases 
(including lung 
infiltration, pulmonary 
fibrosis) 
Serious cases of psoriasis
(exacerbation or 
rebound) 
Benefit
s 
Risks 
Benefit-
Risk 
Balance 
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was included if was publicly available at the time of decision-making, or could be publicly provided 
upon request.  This step was already completed and is described in detail in Section 2.2. 
3.6.2.3.1 Inclusion of measures based on available data 
The rationale for the inclusion or exclusion of measures is documented in Table 3.12.  Specifically, 
measures were only included if there was sufficient information to complete the required data 
source table fields in Step 4, e.g. background epidemiology of placebo known.  The population 
incidence of PML was not reported in any documentation; however, because PML precipitated the 
suspension of marketing authorisation, it would have to be included.  Thus, a brief literature search 
was performed to obtain estimates of population incidence, leading to an assumed population 
incidence of 4.4 per million (Eng et al., 2006). 
Table 3.12 Application of Step 3 in the BRAT framework to the efalizumab case study: Measures and inclusion of 
outcomes based on available data 
Measure Source Inclusion Rationale 
PASI75 Clinical trials Yes Complete data 
PGA Clinical trials Yes Complete data 
OLS Clinical trials Yes Complete data 
DLQI Clinical trials No 
Inadequate format 
(change from baseline 
so OR and RD cannot be 
calculated) 
PASI50 Clinical trials Yes Complete data 
ADR (mild to moderate) Pooled Yes Complete data 
ADR (severe) Pooled No 
Percentage of events in 
placebo group not 
given; percentage of 
events for efalizumab 
not precise (range 
given) 
Meningitis aseptic PSUR10 No 
Background 
epidemiology not 
known 
Serious infections 
including pneumonia, 
sepsis, cellulitis 
Pooled Yes 
Background 
epidemiology not 
known 
Opportunistic infections 
including  fungal 
infections, tuberculosis, 
herpes virus infections, 
EBV, CMV 
PSUR10 No 
Background 
epidemiology not 
known  
Serious thrombocytopenia PSUR10 No 
Background 
epidemiology not 
known 
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Measure Source Inclusion Rationale 
Immune haemolytic 
anaemia 
 
PSUR10 No 
Background 
epidemiology not 
known 
Erythrodermic psoriasis Pooled No Complete data 
Pustular psoriasis Pooled No Placebo rate not reported 
Nervous System disorders 
including Inflammatory 
polyradiculopathy,  Facial 
Palsy, GBS, Fisher Miller 
Syndrome 
 
PSUR10 No 
Background 
epidemiology not 
known 
Interstitial lung diseases 
including lung infiltration, 
pulmonary fibrosis 
 
PSUR10 No 
Background 
epidemiology not 
known 
Serious cases of psoriasis 
exacerbation or rebound  
 
PSUR10 No 
Background 
epidemiology not 
known 
Brain infections including 
Encephalitis and PML 
 
PSUR10 Yes 
Background risk 
assumed 4.4 per million 
(Eng et al., 2006) 
 
3.6.2.4 Step 4:  Customise framework 
Step four customises the framework: The initial value tree created in step two is modified to account 
for clinical expertise and the data reviewed in step three.  Outcomes considered irrelevant to the 
benefit- risk assessment or for specific stakeholder groups are either refined to obtain relevance or 
removed (The Benefit-Risk Action Team, 2011). 
 
Outcomes which were considered components of other included outcomes, and which were similar 
to other outcomes were excluded to prevent double counting and overestimation of effects.  An 
example of this was PASI50 and PASI75 which were the proportion of participants who achieved a 
50% and 75% reduction respectively in their score on a disease severity scale.  Thus, including both 
these outcomes would result in double counting since all participants who achieved a 75% reduction 
would also achieve a 50% reduction. 
In addition to this, outcomes which provided non-significant risk difference or relative risk estimates 
were also excluded.  This was because there was insufficient evidence suggesting increased risk, and 
because it overcomplicate the model and result in confusion in the understanding and interpretation 
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of results.  As a result, efficacy measures included PASI75, PGA, and OLS, and safety measures 
included PML, and ADR. 
Table 3.13 Application of Step 4 in the BRAT framework to the efalizumab case study: Final list of outcome measures 
Outcome Description 
PASI75 Proportion of patients who achieve a 75% reduction in PASI scores.  The PASI score is 
derived by evaluating erythema, scaling and thickness and then weighting the coverage 
according to the area covered, i.e. head, trunk, upper extremities and lower extremities.  
The scores can range from 0 (least severe) to 72 (most severe). 
PGA A measure of the psoriatic lesions taken at a single time point.  The scores can range 
from 7 (least severe) to 1 (most severe). 
 
OLS A global rating of psoriasis severity according to plaque elevation, scaling, and erythema 
at a given time point.  The scores can range from 0 (least severe) to 5 (most severe).   
PML A demyelinating disease caused by reactivation of the John Cunningham virus. 
ADR Mild to moderate dose related acute flu-like symptoms. 
 
3.6.2.4.1 Data source table 
The BRAT software requires a spread sheet detailing the treatment rate point estimates, the risk 
difference, and the relative risk for each of the two treatment groups (including credible intervals) 
for all the measures defined in the value tree (Table 3.14). 
Interestingly, the 95% CrI for the PML risk difference included 0.  However, the 95% CrI of relative 
risk of PML for efalizumab compared to placebo was above 1.  This was likely due to its extreme 
rarity.   This is likely to be because the standard errors are calculated using approximations that do 
not work when the underlying risk is small.   
As stated in the previous step, there were differences in the design, and outcome measures 
between clinical trials and post-marketing surveillance.  For example, two of the clinical trials pooled 
the data for Raptiva 1mg/kg/wk, and Raptiva 2mg/kg/wk when calculating unfavourable effects for 
ADR (mild to moderate).  It is assumed the effect will be small and result in a minor overestimation 
of adverse events.  Additionally, the follow-up time for clinical trials was set to twelve weeks, 
whereas the follow up time for post-marketing surveillance was cumulative and lasted for 47,000 
patient-years. 
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Table 3.14 Application of Step 4 in the BRAT framework to the efalizumab case study: The data source table 
Outcome 
name 
Treatment 1 
rate point 
estimate 
Treatment 1 
rate lower CI 
Treatment 1 
rate upper CI 
Treatment 1 
number of 
patients 
Treatment 1 
number of 
events 
Duration treatment 
1 (weeks) 
PASI75 0.28 0.18 0.41 1742 485 12 
PGA 0.3 0.18 0.46 1742 531 12 
OLS 0.29 0.18 0.44 1742 508 12 
PML 8.51 10
-5 
1.72 10
-6 
1.69 10
-4 
47000 4  Post-marketing 
ADR 0.41 0.39 0.43 1742 714  12 
Outcome 
name 
Treatment 2 
rate point 
estimate 
Treatment 2 
rate lower CI 
Treatment 2 
rate upper CI 
Treatment 2 
number of 
patients 
Treatment 2 
number of 
events 
Duration treatment 
2 (weeks) 
PASI75 0.04 0.02 0.06 979 36 12 
PGA 0.05 0.03 0.09 979 51 12 
OLS 0.04 0.02 0.06 979 36 12 
PML 4.40 10
-6 
3.10 10
-6 
5.70 10
-6 
10000000 44 Post-marketing 
ADR 0.24 0.21 0.27 979 235  12 
Outcome 
name 
Risk 
difference 
point 
estimate 
Risk 
difference 
lower CI 
Risk 
difference 
upper CI 
Relative risk 
point estimate 
Relative risk 
lower CI 
Relative risk upper 
CI 
PASI75 0.24 0.15 0.36 7.82 5 12.38 
PGA 0.25 0.14 0.4 5.78 3.6 9.34 
OLS 0.25 0.15 0.39 7.81 4.73 13.27 
PML 8.07 10
-5 
-2.70 10
-6 
1.64 10
-4 
19.34 6.95 53.83 
ADR 0.17 0.13 0.21 1.71 1.51 1.93 
 
3.6.2.4.2 Updated value tree 
Tuning was performed in accordance with the data available and the significance of relative risks 
(Figure 3.2). 
 
 
 
 
Figure 3.2 Application of Step 4 in the BRAT framework to the efalizumab case study: Modified value tree 
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3.6.2.5 Step 5: Assess outcome importance 
In this step, outcomes are assessed for their importance to decision-makers and other stakeholders, 
and the subsequent rankings and weightings are applied to the decision tree.  It is important to note 
that the BRAT framework does not advocate a specific method to weigh the preferences of 
outcomes in the value tree.  This case study assessed outcome importance through MCDA using a 
decision conference and I further analysed the case study preferences elicited during the decision 
conference with SMAA.   
3.6.2.6 Step 6: Display and interpret key benefit-risk metrics 
Table 3.15 places the source data into a key benefit–risk summary table which summarises the key 
information required to quantify outcomes in the value tree.   The table aids interpretation of 
benefits and risks; Treatment A is efalizumab, and Treatment B is placebo.  
Table 3.15 Application of Step 6 in the BRAT framework to the efalizumab case study: Key benefit-risk summary table 
  
Outcome Treatment A 
Risk / 1000 
pts 
Treatment B 
Risk / 1000 
pts 
Risk Difference  
(95% CI)/ 1000 pts 
Relative Risk  
(95% CI) 
 
B
e
n
e
fi
ts
 
Efficacy 
PASI75 280 36 244 (151, 362) 7.89 (4.99, 12.4) 
PGA 305 52 251 (141, 396) 5.78 (3.60, 9.34) 
OLS 292 37 254 (145, 392) 7.81 (4.73, 13.3) 
                     
R
is
k
s
 
Safety 
PML
1 
0.085 0.0044 0.081  (-0.027, 1.6) 19.3 (6.95, 53.8) 
ADR 410 240 170 (135, 205) 1.71 (1.51, 1.94) 
1 rate per 1000 patient-years 
The framework states that the key benefit-risk summary table and forest plot delivers easily 
interpretable information to stakeholder groups-- such as patients and healthcare professionals, so 
they can make informed decisions based on their own preferences.   
3.6.2.6.1 Forest plot 
The forest plot records all of the measures on a standardised scale, allowing for the evaluation of 
each measure relative to other measures.  Plots were generated for risk difference per 1,000 
patients and relative risk.  
The forest plot for the risk difference between efalizumab and placebo lead to some confusion over 
PML (Figure 3.3).  This was due to the extremely rare occurrence of the event, leading to a very small 
risk difference.  As a result, it was hard to interpret differences in PML on the same scale as for other 
safety and efficacy outcomes, as it appears to be null. 
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Figure 3.3 Application of Step 6 in the BRAT framework to the efalizumab case study: Forest plot of risk difference for 
efficacy and safety outcomes per 1,000 patients of efalizumab (A) and placebo (B) 
 
Figure 3.4 Application of Step 6 in the BRAT framework to the efalizumab case study:  Forest plot of relative risk for 
efficacy and safety outcomes between efalizumab (A) and placebo (B) 
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The forest plot for relative risk provided a clearer comparison of safety and efficacy outcomes 
(Figure 3.4).  In contrast with risk difference, the relative risk of PML for those taking efalizumab 
compared to placebo was extremely high.  Thus, representation of relative risks provided a more 
appropriate scale for comparing outcomes with common and extremely rare occurrence.   
3.7 Quantitative frameworks 
This section demonstrates how the quantitative benefit-risk assessment frameworks MCDA and 
SMAA can be adopted by the case study of efalizumab.  The application of MCDA is further extended 
to demonstrate how the inclusion of correlated measures may affect the determination of the 
benefit-risk balance.   
 Application of multi-criteria decision analysis 3.7.1
MCDA refers to a family of multi-criteria analysis methodologies; the specific MCDA methodology 
used in this case study was implemented using the software HiView3 (Catalyze Ltd and Enterprise 
LSE, 2008).  The preferences for the model were obtained via a decision conference (Phillips, 1991) 
facilitated by Lawrence Phillips using a preliminary version of the WP5 case study effects table 
(Appendix Table 9).  All of the members of the WP5 case study team met together in person to share 
perspectives, discuss, and complete the MCDA tasks.   
 
(1)   Establishing the decision context 
As previously stated, the decision problem is to examine whether the marketing authorisation for 
efalizumab should be maintained, varied, suspended or withdrawn. 
(2)   Identify the alternatives 
After considering the available data, the team decided that the MCDA model should consider the 
options of (a) efalizumab using data available in 2009, and (b) placebo using data available in 2004. 
(3)  Identify criteria 
The value tree presented in Figure 3.5 was adopted by the team.  It represents five favourable 
effects (FEs): PASI75, PASI50, PGA, OLS, DLQI, and ten unfavourable effects (UFEs): mild to moderate 
dose related acute flu-like symptoms (AEs), serious infections, severe thrombocytopenia, severe 
psoriasis, hypersensitivity reactions, interstitial lung disease, polyradiculopathy, haemolytic anaemia 
PML and aseptic meningitis.  These were the outcomes which the team considered to be most 
pertinent to the decision-making problem from the regulatory perspective.   
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Figure 3.5 Value tree which displays all of the favourable effects and unfavourable effects adopted by the efalizumab 
case study team in the decision conference  
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(4) Score the alternatives against the criteria 
Data on the favourable and unfavourable effects of treatment, i.e. scientific data regarding the 
efficacy and safety performance of efalizumab in 2009 and placebo in 2004, were placed into the 
model using the software HiView3.   
(5) Create value functions 
Each criterion was then assigned an upper bound, a lower bound, and units to represent a “swing” 
from worst to best performance which enables criteria to be compared (Appendix Table 9).  For 
example, PASI75 was assigned a range of 0.0% to 60.0% whereas PML a range of 0 to 5 cases. This 
would mean that if comparing PASI75 to PML, a swing from 0% to 60% in PASI75 would be compared 
to a swing from 0 to 5 cases of PML. The software then converted the scores of each criterion from 
100 to 0.  For the favourable outcomes, direct linear transformations were used (100 most 
preferred), whereas for unfavourable outcomes, inverse linear transformations were used (0 most 
preferred).  However, for PML, the team determined a non-linear value function which was defined 
in a piecewise manner through discussions (Figure 3.6).   
 
 
Figure 3.6 The non-linear value function for PML as determined by the efalizumab case study team 
(6) Weighting 
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Weights were then assigned to each criterion to quantify its importance in comparison to others.  To 
do this, the changes or swings on the performance scales were considered by the case study team.  
More information on the weighting process is provided in the publicly available case study report 
(Micaleff et al., 2013).  Figure 3.7 displays all of the swing-weights which were assigned during the 
decision conference.   
 
 
Figure 3.7 The originally-assessed swing-weights, divided by 100, assigned at all nodes 
(7) Analysis 
Figure 3.8 displays the overall benefit-risk balance of efalizumab compared to placebo.  The green 
bars represent more benefit; the length of the green bar is longer for efalizumab, which 
demonstrates that efalizumab has more benefit than placebo.  The red bars represent more safety; 
the length of the red bar is longer for placebo which demonstrates that placebo is safer than 
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efalizumab.  However, efalizumab has better benefit-risk balance profile overall compared to 
placebo (51 versus 31). 
 
 
Figure 3.8 Overall benefit-risk balance for efalizumab compared to placebo 
3.7.1.1 Extended application of multi-criteria decision analysis 
It is possible that including the complete list of outcomes in the previous application might result in 
bias: the model implements a number of favourable outcomes which use similar scales as 
independent outcomes; this may bias the judgement towards the active comparator as the score 
representing the contribution of favourable effects may be overestimated.   
 
To illustrate how bias may potentially affect the results, MCDA is applied a second time where only a 
single favourable outcome is retained: PASI75.  The corresponding value tree is presented in Figure 
3.9. 
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Figure 3.9 Value tree which displays a reduced number of favourable effects and unfavourable effects 
Once again, data for these favourable and unfavourable effects of treatment, i.e. scientific data 
regarding the efficacy and safety performance of efalizumab in 2009 and placebo in 2004, were 
placed into the model; the original weights elicited from the efalizumab case study team during a 
decision conference were retained and the value functions remained the same from the previous 
analysis.   
With the new model specification, Figure 3.8 displays the overall benefit-risk balance of efalizumab 
compared to placebo.  Similar to the previous analysis, efalizumab has better benefit-risk balance 
profile overall compared to placebo.  However, the scores are different: this model calculates a score 
of 40 for efalizumab and 26 for placebo whereas the previous model calculated a score of 51 for 
efalizumab versus 31 for placebo—which corresponds to a 21.57% decrease in the efalizumab 
treatment score versus a 16.13% decrease in the placebo treatment score.   
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Figure 3.10 Overall benefit-risk balance for efalizumab compared to placebo when only a single favourable effect is 
retained 
Including a large number of favourable effects with a small number of unfavourable effects might 
bias the results towards a positive benefit-risk balance.  This is particularly relevant if favourable 
outcomes are correlated— e.g. individuals who achieve one favourable outcome are at a greater 
likelihood of achieving a second favourable outcome.  Conversely, including a small number of 
favourable effects with a large number of unfavourable effects might bias the results towards a 
negative benefit-risk balance.   
 Application of stochastic multi-criteria acceptability analysis 3.7.2
(1) Define set of alternatives and criteria 
The two alternatives considered in the SMAA model were 1mg/kg/wk efalizumab, against placebo 
for the time point of February 2009.  The outcomes considered in the model were the same as those 
included in the BRAT framework, i.e. PASI75, PGA, OLS, PML, and ADR.   
(2) Data on favourable and unfavourable effects and uncertainty 
The performance of efalizumab and placebo for each criterion was defined using JSMAA 
(http://smaa.fi/jsmaa/).  JSMAA is a free Java-based software which can be downloaded online.  The 
credible interval was input for each criterion as an “Interval” into JSMAA.  The one exception to this 
was PML, for which an “Exact” performance was input.  By using distributions the model can account 
for uncertainty.   
(3) Define value function 
For simplicity, a linear value function was used for all of the criteria. Efficacy measures were defined 
with ascending value functions, whereas safety measures used descending value functions.   
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(4)  Preference information 
Three options for defining preference information were investigated: no preference information, 
ordinal preference information, and cardinal preference information. 
a) No preference information 
In the first instance, preference information was not introduced into the model.  Without any 
preference information, after 10,000 iterations, the rank acceptability index for efalizumab was 0.67. 
This indicates that efalizumab was the preferred alternative in 67% of iterations, whereas placebo 
was preferred in only 33%. 
Table 3.16 JSMAA software tabular output displaying the probability of the alternatives being ranked first and second 
using no preference information 
 Rank 1 Rank 2 
Efalizumab 0.67 0.33 
Placebo 0.33 0.67 
 
This is visually displayed by the software in Figure 3.11, where the red bar represents the probability 
of the given alternative being ranked first, and the blue bar represents the probability of the 
alternative being ranked second. 
 
Figure 3.11 JSMAA software graphical output displaying the probability of the alternatives being ranked first and second 
using no preference information 
Examining the central weight vectors can help explain the ranking.  Figure 3.12 shows examples of 
criteria weighting to support each alternative as the first ranking, while accounting for any 
preference information also included in the model.  For example, if the decision-maker(s) were to 
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prefer placebo, we can tell from Figure 3.12 that according to the central weight profile, PML and 
ADR would have the highest weighting amongst all of the criteria.   
 
Figure 3.12 JSMAA software output displaying central weighting vectors for efalizumab and placebo using no preference 
information 
b) Ordinal preference information 
Using the weights obtained from the MCDA decision conference, it was possible to input ordinal 
preference information into the model. 
Table 3.17 Criteria ranked in accordance with the weights assigned in the MCDA decision conference 
Criteria Rank 
PASI75 1 
PGA 2 
PML 3 
OLS 4 
ADR 5 
 
With ordinal preference information, after 10,000 iterations, the rank acceptability index for 
efalizumab was 1.00. This indicates that efalizumab was the preferred alternative in 100% of 
iterations, whereas placebo was not preferred in any iteration. 
Table 3.18 JSMAA software tabular output displaying the probability of the alternatives being ranked first and second 
using ordinal preference information 
 Rank 1 Rank 2 
Efalizumab 1.00 0.00 
Placebo 0.00 1.00 
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Figure 3.13 JSMAA software graphical output displaying the probability of the alternatives being ranked first and second 
using ordinal preference information 
 
Figure 3.14 JSMAA software output displaying central weighting vectors for efalizumab and placebo using ordinal 
preference information 
c) Cardinal preference information 
Once again, using the weights obtained from the MCDA decision conference, it was possible to input 
cardinal preference information into the model after rescaling. 
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Figure 3.15 Rescaled criteria weights using preference information from the MCDA decision conference 
Criteria Weight Rescaled Weight 
PASI75 25.5 0.388 
PGA 20.4 0.311 
PML 12.8 0.195 
OLS 6.4 0.098 
ADR 0.5 0.008 
 
With cardinal preference information, after 10,000 iterations, the rank acceptability index for 
efalizumab was 1.00. This indicates that efalizumab was the preferred alternative in 100% of 
iterations, whereas placebo was not preferred in any of the iterations. 
Table 3.19 JSMAA software tabular output displaying the probability of the alternatives being ranked first and second 
using cardinal preference information 
 Rank 1 Rank 2 
Efalizumab 1.00 0.00 
Placebo 0.00 1.00 
 
 
 
Figure 3.16 JSMAA software graphical output displaying the probability of the alternatives being ranked first and second 
using cardinal preference information 
 
(5)  Sensitivity analysis 
Three different preference information specifications were addressed in the previous step; this form 
of sensitivity analysis illustrates how the input of subjective information can alter the ranking of 
alternatives.    
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3.8 Patient and public involvement in the benefit-risk assessment 
methodologies 
In the previous section, the benefit-risk assessment framework methodologies of PrOACT-URL, 
BRAT, MCDA, and SMAA were applied to the case study of efalizumab.  While applying each of these 
methodologies, it became clear that each of them offer a structured set of steps to guide the 
benefit-risk assessment process.  Through examining the steps of the methodologies applied in this 
chapter and the WP5 case studies, the WP5 recommendations team—of which I was a member, 
found that they could be summarised into a generic benefit-risk assessment pathway.  This section 
evaluates the pathway from a PPI perspective, which allows it to become clearer how it can be 
applied in the following two case studies.   
 Introduction 3.8.1
Depending on the aim and objectives of PPI when applied to benefit-risk methodologies, there are 
multiple stages in the product lifecycle where involvement can occur; it is possible to select from 
different degrees of involvement; and there are multiple stages in each benefit-risk methodology 
where involvement can be applied. 
3.8.1.1 Varying stages 
Although PPI may occur throughout the decision-making process, there may be specific stages in 
each benefit-risk methodology where PPI may be more feasible or desirable.  For example, PPI may 
be considered important during (a) the selection, inclusion and exclusion of relevant outcome 
measures, or (b) the ranking and weighting of outcome measures.  It is important to note that these 
two examples are not exhaustive, and there are many more examples of where patient involvement 
may be considered important.   
3.8.1.2 Varying degrees 
It is necessary to establish the desired level of involvement and consider how much of an active role 
patients and the public should take in the decision-making process.  The degree of involvement may 
vary according to which decision-making stage it is applied to in a specific methodology, or it may 
remain at a constant level throughout the whole process (i.e. from setting the decision context to 
final reporting).  There are two main categories which reflect the degree of patient involvement in 
regulatory decision-making (adapted from Hanley et al. (2001)): 
Consultation: regulators elicit the patient perspective to inform the decision-making stage or entire 
decision-making process. 
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Collaboration: regulators and patients and the public form an active partnership and jointly 
participate in the decision-making stage or entire decision-making process. 
3.8.1.3 Varying time points in the product lifecycle 
It is also necessary to acknowledge that PPI may occur at any time point in the product lifecycle.  For 
example, PPI applied to the design of early stage clinical trials might affect which outcomes are 
investigated in the Development Programme, which in turn will directly affect which outcomes have 
sufficient data to be included when assessing the benefit-risk balance for marketing authorisation 
decisions.  Another potential application for PPI is when choosing the dose regimen following a dose 
ranging clinical trial.  One of the aims of such studies is to identify the regimens in the therapeutic 
window where sufficient efficacy is demonstrated whilst maintaining acceptable safety. The choice is 
essentially to assess the regimen that gives the optimal benefit-risk balance.  In WP5 the case studies 
specifically focus on the decision-making time point of evaluating the benefit-risk balance during 
initial marketing authorisation decisions, and/or when it was necessary to re-evaluate the benefit-
risk balance following the occurrence of adverse events detected during post-marketing surveillance.  
In this section we focus on these two specific time points, and examine where PPI can potentially 
occur in benefit-risk methodologies rather than focussing on which stages of the product lifecycle we 
can apply PPI.   
 Current adoption of PPI in the benefit-risk assessment process 3.8.2
PPI is currently recommended by PrOACT-URL and BRAT frameworks for the stages of preparation 
and analysis.   
The involvement of patient advocates is indicated several times in “The PhRMA BRAT Framework for 
Benefit-Risk Assessment: User’s Guide to the Process” (The Benefit-Risk Action Team, 2011).  It 
specifically suggests that patient advocates may be included as optional stakeholders in the BRAT 
framework development team and provide external input at two key stages: Step 2: Identify 
Outcomes, and Step 5: Assess Outcome Importance.  Additionally, PrOACT-URL briefly mentions the 
role of patients in a few steps, although does not detail their explicit involvement.   
While the brevity of PPI instructions for adoption in both frameworks is noted, it should be 
acknowledged that both frameworks are intended to guide the decision-making process rather than 
consist of a fixed set of exhaustive and prescriptive tasks to complete.  Therefore it is expected that 
where PPI could be applied is not fully developed in either framework.   However, their description 
of decision-making processes can still provide insight by helping to identify where PPI can potentially 
be adopted. 
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 Potential adoption of PPI throughout the entirety of the benefit-risk decision-3.8.3
making process  
Many believe that PPI can and should be applied throughout the lifecycle of a product.  This includes 
incorporating PPI into all the regulatory benefit-risk decision-making processes which determine the 
marketing authorisation decision.   
Although there are strong arguments to support the application of PPI throughout the entirety of 
the benefit-risk decision-making process, it should be acknowledged that this might not be possible 
due to the lack of methodological guidelines, feasibility, and/or a lack of time and resources.  As PPI 
is still a relatively novel concept in benefit-risk decision-making, many decision-makers do not know 
where it can be applied, what might be necessary or facilitate its application, what potential barriers 
may exist, and how involvement can be most meaningful and valid.   
Because of these reasons, it is very difficult to try to simultaneously apply PPI to multiple points 
throughout the entirety of the regulatory authorisation and post-authorisation process.  Therefore it 
is advisable to systematically approach each step of the pathway in turn; and investigate what would 
be the most meaningful and beneficial methods to involve patients for each part.   
 The benefit-risk assessment pathway and application of PPI 3.8.4
Via a careful examination of the descriptive and quantitative benefit-risk methodology frameworks 
used within PROTECT WP5 and this thesis—which make explicit recommended steps  to guide 
benefit-risk assessment, it is possible to carefully evaluate which specific points in the decision-
making process are most suitable for the application of PPI.   
The WP5 Recommendations team—of which I was a member, analysed the various benefit-risk 
methodologies which were applied to the WP5 case studies in order to determine the decision-
making pathway.  Each stage in the pathway represents a point in the decision-making process 
where some or all decision-maker(s) are required to come together in order to evaluate current 
findings, and make interim decisions.  We identified five key stages: planning, evidence gathering 
and preparation, analysis, exploration and decision and dissemination.  This section describes each 
of the stages in depth.   
In this section, I provide a summary of the key steps in the critical pathway common to both PrOACT-
URL and BRAT: (1) planning, (2) evidence gathering and data preparation, (3) analysis, (4) 
exploration, and (5) conclusion and dissemination, and discuss how I believe PPI can be applied to 
each of the activities performed within each stage.   
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3.8.4.1 Planning 
In the planning stage the problem statement is established, and a number of key contextual factors 
are made explicit and documented.  They include critical issues such as stating who the decision-
maker is, the perspective they are adopting (e.g. if they are deciding for themselves or on behalf of 
others), the indication for treatment with the product and the severity of the condition, the affected 
population, and the treatments under consideration in the decision-making scenario.  The relevant 
favourable effects and unfavourable effects to be included in subsequent steps of the decision-
making process are also identified based on expert opinion, literature searches and relevance to key 
stakeholders.  It is also decided which benefit-risk methodologies will be used—e.g. BRAT or 
PrOACT-URL.   
All stakeholders—including patients and the public, can be included when defining the decision 
problem.  It needs to be identified who the decision-maker is, on whose behalf the decision is being 
made, and who all of the stakeholders are.  Patients and the public are key stakeholders and can 
potentially be included in the group of decision-makers, and/or decision-makers may elicit patient 
and public views and opinions to incorporate into the decision-making process.  If the patient and 
public perspective is insufficiently addressed and/or incorporated into the problem statement in the 
planning stage, the decision-making scenario may inadequately represent the immediate concerns 
of those who have first-hand knowledge and experience of the indication under consideration.    An 
incorrect or insufficient problem statement which does not appropriately reflect patient and public 
concerns can potentially lead a significant amount of resources spent on benefit-risk assessments 
where the results may be of questionable benefit to patients.  One important difference between 
regulators and patients which needs to be addressed, is that regulators make decisions at a 
population level, whereas patients make decisions at an individual level.  It is necessary for future 
work to acknowledge and account for this fundamental difference when defining the problem 
statement.   
Hypothetically, everyone directly affected by the decision should participate in decision-making 
discussions.  There may be differences in opinion regarding which critical issues should be included 
in the decision problem, e.g. the objectives of the assessment, options under consideration, and 
facts to be included in the analysis.  Ideally, there should be agreement between all stakeholders.  
Many consider it desirable to organise meetings which bring stakeholder groups together for clearly 
structured discussions to establish the purpose and context of decision-making, and come to 
consensus.  There are a multitude of different skillsets, knowledge bases, and expertise represented 
by each of the stakeholder groups, e.g. empirical, statistical, decision analysis, medical, regulatory, 
scientific and epidemiological.  All of these perspectives can be complementary.  It is not currently 
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clear what the best way of balancing different or opposing perspectives may be in benefit-risk 
decision-making.   
Patients and the public are likely to lack the technical expertise to identify and select which benefit-
risk assessment methodologies are best suited to address a specific problem statement, and PPI for 
this task may be limited.  In this step, professional expertise may be necessary to lead the decision-
making process.  Additionally, patients and the public are not likely to know how their values and 
preferences can be interpreted and incorporated into the regulatory assessment of medicines.  
Again, professional expertise may be necessary in the acquisition, interpretation, and incorporation 
of patient preference values into the regulatory assessment of a medicine.  However, PPI can 
potentially be possible through presenting patients and the public with options of how they can be 
involved in the decision-making process, and they can be given the option to select where they feel 
their input would be most valuable.  If PPI is to be organised by experts, clear communication of the 
activities and processes to be undertaken as part of the decision-making methodologies is essential.   
It is important to document the process and results of decision-making methodologies in a 
transparent manner, ensuring that they are available to all stakeholder groups.  Clear, user friendly 
and accessible materials should be developed not only to report the planning stage, but to report all 
of the decision-making processes.  It needs to be determined and agreed where, when, and how the 
processes and results of the methodologies are communicated to patients and the public in suitable 
format(s), with the use of visualisation(s) where appropriate.  Once the process of a decision-making 
methodology becomes transparent, it automatically opens up the process to audit; it becomes clear 
where the patient perspective has been adopted.  However, this also means that if the patient and 
public perspective is investigated but not explicitly incorporated into the results, they may feel 
disenfranchised which could result lack of trust and motivation to participate in the future.   
3.8.4.2 Evidence gathering and data preparation 
The evidence gathering and data preparation stage is when evidence related to the benefit-risk 
assessment is identified and extracted, including data on the performance of each alternative 
treatment in relation to each of the favourable and unfavourable effect criteria.  The source data is 
clearly documented, together with details of any data manipulations. 
A great amount of technical expertise is required to gather evidence and prepare data for a benefit-
risk assessment.  Epidemiological and statistical expertise is required to handle data, and clinical and 
patient and public expertise can be used to ensure that appropriate judgements are made regarding 
the relevance of favourable and unfavourable effects criteria.  Although patients and the public 
might lack data handling expertise (e.g. data transformation, aggregating evidence from multiple 
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sources and exploring statistical uncertainty), they can provide justification on which favourable and 
unfavourable effects they believe should be included in the benefit-risk assessment. The only 
disadvantage is that patients and the public might consider it desirable to include favourable and 
unfavourable effects for which data has not been collected.   
There are a multitude of sources which can be used to identify benefits and risks for inclusion—both 
epidemiological and empirical; the patient perspective should be included.  Patients have a wealth of 
understanding and expertise in how a specific indication can affect quality of life and activities of 
daily living, and even prior experience of other medications used to treat the same indication.  It is 
imperative that patient and public knowledge and expertise is not disregarded; decision-makers 
should aim to ensure that all sources of evidence appropriate to the decision problem are accounted 
for—including patient knowledge, while also accounting for other forms of objective scientific data.   
Despite this, it should be noted that when extracting favourable and unfavourable effects data on 
the performance of each treatment under consideration, the information which patients and the 
public may know might be anecdotal and subject to bias.  There is also a distinction between publicly 
available information, and confidential information which might be listed in the submission 
dossier—only accessible to regulators and the pharmaceutical industry.   
The evidence gathering and data preparation stage should be clearly documented for replication 
purposes.  It may also be useful to document the process for other stakeholder groups; 
communication can enhance transparency and trust.  However, there are many challenges when 
trying to articulate evidence gathering and data preparation, which may include complex data 
manipulations, to a lay audience.  There may be a reduction in the level of reported detail, and 
whilst a reduction in the number of technical terms used may increase comprehension, it may also 
result in a loss of precision.   
3.8.4.3 Analysis 
The analysis stage is where performance data are analysed to quantify the magnitudes of benefits 
and risks for the treatment(s) of interest.  Depending on the purpose and context of the benefit-risk 
assessment, the favourable and unfavourable effects may be weighted and integrated to provide a 
quantitative measure of the benefit-risk balance.  Descriptive (qualitative) or quantitative benefit-
risk methodologies may be applied according to the complexity of favourable and unfavourable 
effects data and/or level of transparency desired by the decision-maker(s).  Quantitative decision 
models such as MCDA disaggregate a complex problem into simpler components that are easier to 
understand and weigh up, and then use methods to integrate the components into a measure of the 
overall benefit-risk balance.   
103 
 
It may be possible for a decision at the analysis stage to be made implicitly, based on the evidence 
from the previous stage.  If the decision is made qualitatively or implicitly, this indicates that it was 
not necessary for the decision-maker(s) to quantify the difference in importance between the 
favourable and unfavourable effects in order to make a sound decision.  However, the patient and 
public perspective could be sought to verify if they would agree with the decision-maker(s) 
conclusion.  If there is a disagreement when a decision is made implicitly, and/or a greater degree of 
transparency is required to articulate the thought processes and interim decisions of the decision-
maker(s), quantitative decision decision-making methodologies may help.   
Quantitative decision-making methodologies have the advantage of identifying where discrepancies 
may lie when comparing stakeholder perspectives, and see if they can be resolved.  There may be 
variations in how different stakeholders evaluate the importance of favourable and unfavourable 
effects, and quantitative models lend themselves very readily to the application of PPI.  Once 
patients and the public understand the favourable and unfavourable effects included in the model, it 
is possible to elicit their weights and then integrate the components into a measure of the overall 
benefit-risk balance.  However, quantitative models demand more technical expertise and resources 
than descriptive methods.   
3.8.4.4 Exploration 
In the exploration stage, the results are assessed for robustness and sensitivity to the various 
assumptions and sources of uncertainties.  Areas of uncertainty which should be investigated in 
quantitative benefit-risk methodologies include data on the favourable and unfavourable effects, 
and preference weights, and it is essential to establish how robust the results are while accounting 
for these uncertainties.  It is also important to explore further the consequences of a benefit-risk 
decision, and consider whether the results of the benefit-risk assessment may inform related 
decisions on risk management plans or benefit-risk assessments of similar treatments. 
The level of PPI is likely to be minimal in assessing the robustness and sensitivity to the various 
assumptions and sources of uncertainties.  This is because of the high level of technical and 
statistical expertise required.  Despite this, if preference weights were elicited in the analysis stage 
with PPI, these are now further examined to determine the robustness of the final decision 
regarding the benefit-risk balance.  It is possible to look at how variations in the inputs of a 
quantitative model—in this case elicited preference weights, can affect the resulting benefit-risk 
balance.  These variations may exist due to reasons such as poorly framed questions, the 
generalizability of participant weights compared to patient and public populations, and sampling 
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errors.  Attitudes towards uncertainty may vary between stakeholders, depending upon the degree 
of risk averseness or desired level of caution.    
3.8.4.5 Decision and dissemination 
The last stage is where the final decision is made and the results are communicated to relevant 
stakeholders.  It makes explicit that the findings of the benefit-risk assessment have logically led to a 
decision that will influence future actions. It emphasises the need for a transparent audit trail of the 
whole assessment process from the planning stage to the exploration stage.  This last stage of the 
process brings everything together and sets the stage for action to be taken. 
Quantitative models often reduce multi-faceted problems to a single number representing the 
benefit-risk balance, and this number firmly depends on the preference values used or elicited by 
the model which may vary from one stakeholder group to another, and even within each 
stakeholder group.  Stakeholders (including patients and the public) might feel concerned about the 
reductionist processes applied to their wealth of knowledge and experience and how this is 
combined with favourable and unfavourable data, either from trials at the point of marketing 
authorisation or from various sources after the point of marketing authorisation, such as 
observational studies, spontaneous reports or further trials.  There may be a danger that the output 
of quantitative models may be misinterpreted, and without effective communication there may be a 
degree of distrust.  Once again, it must be reiterated that the process and results of the decision-
making process should be clearly and effectively communicated to all stakeholders in an appropriate 
format with unambiguous language.   
3.9 Discussion 
The aims of this chapter were: (a) to test the feasibility of descriptive and quantitative framework 
benefit-risk assessment methodologies and (b) to examine where and when in the decision-making 
process outlined by these methodologies, PPI can occur.  To meet the first aim, two descriptive 
framework methodologies, i.e. PrOACT-URL and BRAT, and two quantitative framework 
methodologies, i.e. MCDA and SMAA, were applied to the EMA regulatory decision-making scenario 
of evaluating the benefit-risk balance of efalizumab in January 2009 following several cases of PML.  
To meet the second aim, the steps outlined by the framework benefit-risk assessment 
methodologies were described in depth, and the compatibility of applying PPI to the tasks involved 
in each step was carefully evaluated.   
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 Main findings 3.9.1
3.9.1.1 Feasibility of the benefit-risk assessment methodologies 
The results of this chapter demonstrate that it is feasible to apply the descriptive frameworks of 
PrOACT-URL and BRAT, and the quantitative frameworks of MCDA and SMAA to determine the 
benefit-risk balance of the regulatory decision-making scenario represented by the efalizumab case 
study.  Additionally, PPI can be applied to almost every stage of the decision-making process. 
PrOACT-URL and BRAT are both descriptive framework methodologies and were found to be 
extremely similar; each successfully deconstructed the complicated decision-making scenario 
considered in the case study into smaller more manageable constituent pieces which could be 
addressed individually in a stepwise manner.  Both of the frameworks enabled a clear overview of 
the process, and focussed on key issues such as the context of the problem, who the decision-maker 
is, and which data are available.  They offer insight, transparency and can act as a method of 
communication to those who might not have been present or directly involved in the decision-
making process.  They can also be used to create records and a clear audit trail so it can be traced 
how the decision was made.   
MCDA and SMAA are quantitative frameworks that offer statistical recommendations regarding how 
benefits and risks can be handled to determine the benefit-risk balance of a treatment.  When 
applied to the efalizumab case study, they illustrated two different methods of incorporating 
subjective values and preferences into benefit-risk assessment.  Both of the methodologies required 
scientific data on the efficacy and safety performance of efalizumab and placebo, and preference 
data regarding the outcomes under consideration.   
SMAA is more flexible than MCDA in the handling of performance estimates and preference 
information.  Performance estimates can be input as a point estimate, or using a distribution.   
Preferences can be input as missing, ordinal—i.e. outcomes are ranked, or cardinal—i.e. the exact 
value or the interval of the preference data can be specified. Distributions can be used to describe 
the performance estimates and preference information in an SMAA model, which allow for: (a) the 
incorporation of uncertainty in the performance of a treatment—e.g. the effect of confidence 
intervals on the decision can be investigated, and/or (b) the incorporation of uncertainty in 
preferences—e.g. the effect of varying preferences can be accommodated if stakeholders do not 
come to consensus. 
The two descriptive frameworks of PrOACT-URL and BRAT do not formally analyse and/or integrate 
the favourable and unfavourable effects, i.e. they guide the decision-making process and do not 
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explicitly assess how the favourable and unfavourable effects are traded-off, and subsequently, do 
not formally determine the benefit-risk balance.  However, MCDA and SMAA explicitly trade-off the 
favourable and unfavourable effects and the benefit-risk balance was found to be more favourable 
for efalizumab than placebo according to MCDA and SMAA (using no preference information, and 
ordinal and cardinal preference information).  The extended application of MCDA demonstrates that 
bias may be introduced into systematic methods of benefit-risk assessment if multiple efficacy 
measures are included which share similar correlated scales; this is because they are treated as 
independent measures in the analysis and there is a risk of double counting and an overestimation in 
the amount of benefit represented by the treatment.   
3.9.1.2 Patient and public involvement in benefit-risk assessment methodologies 
By carefully examining the decision-making pathway defined by the benefit-risk assessment 
methodologies, the task of critically evaluating where PPI may be desirable and/or be feasible in the 
benefit-risk assessment process was made easier.  Because PPI is a concept which cross-cuts almost 
every single stage of the decision-making process, it can be it can be applied to almost every part of 
the benefit-risk assessment process.  Therefore, before deciding how to adopt PPI into a specific 
benefit-risk assessment scenario, it is essential for the decision-maker(s) to carefully consider what 
the aim and objectives of applying PPI are, and which resources are available.   
 Limitations of the case study 3.9.2
3.9.2.1 The positive benefit-risk balance of efalizumab in the case study 
It is interesting that both of the quantitative methodologies which formally traded-off the favourable 
effects against the unfavourable effects determined that the benefit-risk balance of efalizumab was 
positive when compared against placebo, contrary to the CHMP opinion at the time.  However, it is 
important to note that the results of the benefit-risk assessment methodologies in this thesis and 
WP5 are illustrative only, and intend to test the feasibility of the benefit-risk assessment 
methodologies; the results of the benefit-risk assessment methodologies do not wish to comment 
on or replace prior regulatory decisions.  The results of MCDA and SMAA might have differed from 
the CHMP opinion at the time because:  (a) this case study used publicly available efficacy and safety 
data which might have differed from the data available to the regulators, (b) the preferences of the 
case study team might have differed from regulatory preferences at the time.   
3.9.2.2 The favourable and unfavourable effects of treatment 
All of the benefit-risk assessment methodologies examined in this chapter required data on the 
favourable and unfavourable effects of treatment, i.e. scientific data regarding the efficacy and 
safety performance of efalizumab and placebo.  For this, it was necessary to extract data.  I opted to 
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extract data from publicly available regulatory documents, i.e. EPARs and PSURs due to the large 
amount of resources which would have been required for a full literature review.   
Extracting and synthesising the data from publicly available regulatory documents was extremely 
challenging and required a skilled degree of statistical knowledge, e.g. aggregatingtrial data and 
calculating the relative risks and risk differences with credible intervals.  The data was extremely 
difficult to handle and very often there was missing, incomplete, or inconsistent data described in 
the regulatory documents.  For example, effects were very often reported using a mixed approach to 
measurement units, e.g. absolute numbers without denominators, percentages, and percent per 
hundred patient years.   
It was difficult to determine which favourable and unfavourable effects should be included or 
excluded in the benefit-risk assessment; to include all of the effects would provide a comprehensive 
description of the decision-making scenario but could potentially overcomplicate the model, 
whereas only retaining the most important effects avoids this—but which effects are retained might 
vary according to whose perspective is adopted.  This brings to the foreground the importance of 
transparency, the need to adopt the perspective of stakeholders, and the necessity for clear 
communication to state why specific effects were included or excluded.   
One major limitation was the availability and details of data relating to rare serious adverse events 
such as PML.  The model used to calculate the probability of PML assumed a constant rate through 
time.  This was due to a lack of time-dependent data as only overall patients-years accumulated in 
post-marketing surveillance and the number of PML cases was available to the study.  However, it is 
possible that PML cases are more likely to occur after a certain period of exposure. Table 3.6 
provides details on the four cases of PML observed in post-marketing surveillance:  the onset of all 
cases happened after three years of exposure.  This could mean that the rate of PML would be much 
higher if, for example, one were to replicate the analysis among patients who have already accrued a 
certain amount, e.g. 2 or 3 years, of exposure to efalizumab.  It is therefore important that 
information on patient-years accrued by years of exposure be made available in order to reliably 
calculate the risk of PML and other serious adverse events. 
3.9.2.3 Preference data 
Preferences for the favourable and unfavourable effects of treatment were elicited from the WP5 
case study team during a decision conference.  It is extremely important to note that we may have 
had limitations in our knowledge regarding the conditions under consideration, and we may have 
had a different perspective to the regulators.  Our case study team consisted of pharmaceutical 
employees, physicians, statisticians, and a regulator.  Our personal and professional experiences—in 
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addition to our knowledge of plaque psoriasis and the treatment outcomes, are likely to have 
impacted our preferences for the favourable and unfavourable outcomes.  Personally, I found it very 
hard to provide preferences as (a) I had a limited understanding of short term and long term effects 
of the medical conditions, and (b) I imagined myself in the position of a patient when providing my 
preferences.  Regulators decide, “Should this treatment with these outcomes be authorised for a 
population?” which was succinctly different from my perspective, which was, “Would I take this 
treatment with these outcomes?”   
3.9.2.4 Application of patient and public involvement to the benefit-risk assessment 
pathway 
The work critically evaluated the benefit-risk assessment pathway, and determined where PPI could 
occur in the process.  It discusses a theoretical application, and does not examine real world 
feasibility.  It is also important to note that my subjective opinion of where PPI can occur was based 
on a critical evaluation of the pathway, and other stakeholders (including patients and the public) 
might have different opinions of where they believe PPI can potentially occur, and where they feel it 
would be most desirable to apply.   
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4 Case Study II: Rimonabant 
4.1 Introduction 
The second case study presented in this thesis is rimonabant (Acomplia®), which was authorised in 
the European Union (EU) for the indication of overweight (with associated risk factors, e.g. 
dyslipidaemia) and obesity from April 2006 to January 2009.  Its marketing authorisation was 
suspended due to data collected from clinical trials conducted after the treatment was authorised 
which showed, “an approximate doubling of the risk of psychiatric disorders in obese or overweight 
patients taking Acomplia compared to those taking placebo” (EMA, 2008a). 
 
Whereas the previous chapter tested the feasibility of applying descriptive and quantitative 
frameworks of benefit-risk assessment to the case study of efalizumab, this case study tests the 
feasibility of applying a different type of benefit-risk methodology—the utility survey technique of 
DCE, to the case study of rimonabant.  Thus far, this thesis has identified where and when PPI can be 
applied in the benefit-risk assessment decision-making process.  This chapter develops this work 
further and uses DCE to explore the feasibility of applying PPI to a specific stage of the benefit-risk 
assessment process, i.e. the analysis stage, to elicit preferences from patients and the public 
regarding the favourable and unfavourable treatment effects of rimonabant.  The results of the DCE 
are then compared against SMAA, which is another methodology which can be used to assess 
patient and public preferences.   
 
In this chapter I describe the medical condition of obesity and overweight, and the treatment of 
rimonabant (Section 4.2 and 4.3).  Next, I detail the aim and objectives of the case study (Section 
4.4), and which data sources, extraction and synthesis methods I used to provide information on the 
benefits and risks of treatment (Section 4.5).  I then apply two quantitative benefit-risk assessment 
methods, DCE (Section 4.6  and 4.7) and SMAA (Section 4.8) to the decision-making scenario under 
consideration and present the results.  Lastly, I discuss the findings of the case study (Section 4.9).   
4.2 Obesity and overweight 
 Background and epidemiology 4.2.1
Obesity and overweight are commonly defined in research and clinical settings using body mass 
index (BMI).  BMI is calculated as the weight of an individual in kilograms divided by the square of 
their height in metres (kg/m2).  Individuals with a BMI of ≥25 to <30 kg/m2 are classified as 
overweight, and individuals with a BMI of ≥30 kg/m2 are classified as obese.  An energy imbalance 
often precedes overweight and obesity, i.e. energy intake exceeds energy expenditure (Hill and 
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Peters, 1998).  This energy imbalance is believed to be caused by a, “complex, multifaceted system 
of determinants”, which include biology (e.g. genetic and hormonal effects), early life and growth 
patterns (e.g. intergenerational components, metabolic plasticity),   behaviour (e.g. habits, beliefs), 
environment (e.g. social, cultural, and infrastructural conditions), technology (e.g. fewer manual 
tasks), opportunities for physical activity, and food and drink access and availability (Butland et al., 
2007).     
Overweight and obesity are major public health concerns, and there is a large unmet need for safe 
and effective treatments (Witkamp, 2011).  The prevalence of obesity has significantly increased 
over recent decades, and it is a global issue which affects developed and developing countries, and 
all ages, sexes, races, and socioeconomic groups (Kelly et al., 2008).  In England from 1993 to 2004, 
the prevalence of obesity has increased from 13.6% to 24% for men, and from 16.9% to 24.4% for 
women (Zaninotto et al., 2009).  By 2025, the government programme Foresight has hypothesised 
that 40% of Britons will be classed as obese (Butland et al., 2007).   
Obesity can be treated with non-pharmacological and pharmacological treatments (EMA, 2006b).  
Non-pharmacological treatments include nutritional education and modification (e.g. calorie 
restriction), behaviour modification, and increased levels of physical activity.  In cases of severe 
obesity, non-pharmacological treatments may include surgery and very low calorie diets.  
Pharmacological treatments can be used as an adjunct to physical activity and diet.  There are two 
main types of treatments: (a) anorectic which are appetite suppressants, and (b) those which inhibit 
the absorption of nutrients (EMA, 2006b).  Pharmacological agents are also used to treat co-morbid 
conditions associated with overweight and obesity, e.g. anti-diabetic and antihypertensive drugs. 
 Impact of overweight and obesity on quality of life 4.2.2
Obesity is an excessive accumulation of body fat.  There are many comorbid conditions associated 
with obesity such as heart disease, diabetes mellitus, and specific types of cancer (e.g. breast and 
colon)(Calle and Kaaks, 2004, WHO, 2000).  It is also associated with premature mortality, and a 
reduction in quality of life.  Approximately 58% of diabetes mellitus cases, 21% of ischemic heart 
disease cases, and 8% to 42% of cases of specific types of cancer are directly attributable to excess 
body weight (WHO, 2000).   
Obesity can affect quality of life through negatively impacting general health, physical functioning, 
and psychological functioning.  Obese individuals have been found to rate their general health more 
poorly than healthy weight individuals (Kolotkin et al., 2001).  When considering physical 
functioning, obesity is known to affect, “the heart and vascular system (blood and oxygen exchange), 
respiratory system (oxygen and carbon dioxide exchange), musculoskeletal system (mobility and 
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weight bearing), and skin (heat loss and hygiene)” (Kushner and Foster, 2000).  The psychological 
burden of obesity is large, and there is a high prevalence of depression, anxiety, body image 
dissatisfaction, and binge eating disorder in obese individuals.  Obese and overweight individuals 
have also been found to be discriminated against because of their weight (Kolotkin et al., 2001). 
4.3 Description of treatment 
Rimonabant is a selective antagonist of the cannabinoid type I (CB1) receptors (EMA, 2006b).  CB1 
receptors are found in the central nervous system which controls food intake.  The drug indirectly 
decreases dopamine release in different brain areas by blocking the CB1 receptors, and interferes 
with feelings of hunger and satiety in the hypothalamic region and peripheral adipocytes (EMA, 
2006b).  Rimonabant was a first-in-class treatment indicated as an adjunct to a reduced calorie diet 
and increased physical activity for the treatment of adults who are (a) obese with a BMI equal to or 
greater than 30kg/m2; or (b) overweight with a BMI equal to or greater than 27kg/m2 in the presence 
of additional risk factors, e.g. diabetes mellitus, dyslipidaemia (EMA, 2006b).  The treatment requires 
a prescription from a physician, and is administered to patients as a single once daily tablet (20mg) 
taken before breakfast.   
 Marketing history 4.3.1
Rimonabant was authorised in the EU from June 2006 until January 2009; important events are 
summarised from the regulatory documents and described below (EMA, 2009b):  
 17th April 2006: Marketing authorisation for rimonabant was granted.   
 July 2007: The CHMP recommended changes to the prescribing information: (1) warning to 
contraindicate the use of rimonabant in patients with on-going major depression or taking 
antidepressants; (2) warning that treatment with rimonabant should stop if a patient 
develops depression (EMA, 2009b). 
 March 2008: PSUR 3 noted an increase in the reporting rate for depressive disorders for the 
most recent 6 month period compared to the first one year period of marketing (24 cases 
per 10,000 treated patients versus 13); MAH was requested to provide further analysis on 
this topic. 
 April 2008: Results of the STRADIVARIUS trial had a higher absolute reporting rate of 
psychiatric adverse events compared to previous studies (43.4% versus 28.4%, p<0.001 for 
rimonabant and placebo, respectively)(Nissen et al., 2008, EMA, 2009b); CHMP convened 
the Scientific Advisory Group (SAG) on Diabetes and Endocrinology to discuss the benefits 
and risks of rimonabant. 
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 June 2008: SAG examined all available data on the benefits and risks of rimonabant; they 
were concerned that the margin of benefits over risks had narrowed since approval, but 
agreed more data was needed before a conclusion could be reached. 
 July 2008: The CHMP considered the uncertainty of the benefit-risk balance of rimonabant, 
and requested the MAH to submit further analyses regarding the psychiatric safety 
concerns, duration of treatment, and potential subgroups for whom the benefit-risk balance 
may be more positive.  The data confirmed the safety concerns, and did not identify any 
subgroups with a potentially more favourable benefit-risk balance. 
 October 2008: The EC requested that the CHMP assess the impact of psychiatric concerns on 
the benefit-risk balance for rimonabant and whether the marketing authorisation should be 
maintained, varied, suspended, or withdrawn. 
 November 2008: The marketing authorisation of rimonabant was suspended in all the 
Member States 
 December 2008: The MAH responsible for rimonabant, Sanofi-Aventis, voluntarily withdrew 
the marketing authorisation. 
 January 2009: EC withdrew the marketing authorisation for rimonabant on the ground of 
negative benefit-risk balance based on post-marketing data. 
 Regulatory assessment of the benefit-risk balance 4.3.2
Publicly available regulatory documents provide clear insight into how the benefit-risk balance was 
determined.  At the time of marketing approval, the scientific discussion stated that,  
"The demonstrated body weight reduction in overweight patients with additional risk factors 
and in obese patients has been sufficiently demonstrated and the magnitude of these effects is 
clinically relevant and appears to be maintained over time. The benefit-risk assessment for this 
indication in overweight/obese patients is positive, also in light of the psychiatric AEs that may 
develop over time and the pre-clinical uncertainties that still exist." (EMA, 2006b) 
However, in October 2008, the CHMP reviewed the data submitted by the MAH and concluded that, 
“The expected benefits are considered as more limited compared to what was foreseen at the time 
of approval” (EMA, 2007a).  This is because there was a “shorter duration of treatment in real life”, 
and this reduction in time limited the efficacy of the treatment.  The CHMP also commented that, 
“The absolute risk of psychiatric adverse event in clinical practice may be more common compared 
to what was seen at the time of approval.”  Although strengthened warnings and contraindications 
had been added to the product information, and Dear Healthcare Provider letters were circulated, 
adherence to the warnings was low and the concomitant use of antidepressants in patients 
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prescribed rimonabant was a concerning 6% to 20%.  Consequently, the CHMP concluded that the 
benefit-risk balance for rimonabant was considered negative and recommended the suspension of 
its marketing authorisation.   
4.4 Aim and objectives 
The aim of the rimonabant case study in this thesis is to examine the feasibility of eliciting patient 
and public preferences on the benefits and risks of treatment using the benefit-risk assessment 
methodologies of DCE and SMAA. 
To meet this aim, the objectives are: 
 To extract and synthesise the favourable and unfavourable effects of rimonabant presented 
in publicly available regulatory documents, e.g. EPAR and PSUR, with supplementary data 
obtained from published academic journal articles where appropriate 
 To design, conduct and analyse a DCE which elicits patient and public preferences on the 
benefits and risks of rimonabant 
 To analyse additional ranking data collected in the DCE survey with SMAA, and examine how 
the results compare to the DCE 
 To examine which other benefit and risk outcomes participants consider important when 
deciding between treatments for weight loss, and how they viewed the process of 
participating in the DCE 
 To investigate how to communicate the results of the DCE to participants 
4.5 Data 
Similar to the previous case study of efalizumab, it was necessary to identify source documents, and 
extract information regarding the favourable and unfavourable effects of treatment, i.e. relevant 
efficacy and safety data.  However, whereas the efalizumab case study comprehensively extracted 
information on all of the favourable and unfavourable effects of treatment, the Wave Two 
rimonabant case study pre-specified that we would only collect data on the favourable and 
unfavourable effects which were considered to be of greatest importance to the regulator at the 
time of decision-making.  We considered the most important favourable effects to be: (1) the 
proportion of individuals who achieved a 10% reduction in body weight, and (2) improvements in 
high-density lipoprotein (HDL) cholesterol.  We considered the most important unfavourable effects 
to be: (1) psychiatric disorders, (2) cardiovascular disorders, and (3) gastrointestinal disorders.  
Although the Wave Two rimonabant case study team extracted and analysed data on the favourable 
and unfavourable outcomes, I also did this independently as I perceived that different data should 
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be included or excluded for the purposes of this thesis.  This is because the team focussed on testing 
the benefit-risk assessment methodologies with demonstrative data, whereas I decided to apply 
more stringent inclusion and exclusion criteria (e.g. limit the indication and dose considered).    
 Sources of evidence 4.5.1
The primary documents which were considered in the case study are publicly available on the EMA 
website (Table 4.1). 
Table 4.1 Publicly available regulatory documents relating to rimonabant which are available on the EMA website and 
were considered in the case study 
Document EMEA procedure number Date 
Acomplia: EPAR – Scientific Discussion (Initial 
marketing authorisation) (EMA, 2006b) 
N/A 2006 
Acomplia: EPAR – Procedural steps taken before 
authorisation (Initial marketing authorisation) (EMA, 
2006a) 
N/A 2006 
Acomplia: EPAR – Scientific Discussion - Variation 
(Changes since initial authorisation) (EMA, 2007a) 
EMEA/H/C/666/II/04 23/10/ 
2007 
Acomplia: EPAR – Procedural steps taken and 
scientific information after authorisation (Changes 
since initial authorisation) (EMA, 2009b) 
N/A 30/01/2009 
Acomplia: EPAR – Assessment Report - Variation 
(Changes since initial authorisation) (EMA, 2009a) 
EMEA/H/C/000666/A20/0012 16/01/2009 
 
The publicly available documents state that the clinical dossier submitted for the application for 
marketing authorisation contained two sections, each relating to a different indication of 
rimonabant; one concerning obesity and related disorders, and the second concerning smoking 
cessation.  This thesis and the WP5 case study only examined the indication of obesity and 
overweight, and so efficacy and safety data from clinical trials relating to the indication of smoking 
cessation were excluded.   
The EPARs explicitly list which clinical trials were used in the submission dossier to evaluate the 
efficacy and safety of rimonabant.  However, I did not evaluate data from all of the trials listed in the 
submission dossier: I excluded data from non-phase III clinical trials (i.e. the dose ranging study 
DRI3388), and clinical trials which examine different doses of rimonabant (i.e. PDY3796 which 
examines a 40mg dose).   Consequently, the evidence regarding the indication of 20mg rimonabant 
in overweight (with associated risk factors) or obese individuals was based on four pivotal clinical 
trials, i.e. RIO-North America, RIO-Europe, RIO-Lipids and RIO-Diabetes).  However, data in the EPARs 
regarding individual clinical trials were sometimes missing, incomplete or inconsistent: thus, results 
from the included trials were directly extracted from relevant academic publications (Table 4.2).  In 
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addition to these studies, extensive data on the safety of rimonabant were available in three clinical 
trials conducted after marketing authorisation was granted, i.e. CRESCENDO (Topol et al., 2010), 
STRADIVARIUS (Nissen et al., 2008), and SERENADE (Rosenstock et al., 2008), and the data were 
extracted and considered in this case study.  Once again, efficacy and safety data were extracted 
primarily from regulatory documents and supplemented with extra information from key academic 
publications where necessary (Table 4.2). 
Table 4.2 Key publications used to support missing or incomplete clinical trial information listed in the regulatory 
documents 
Time of data collection Trial Key Publication 
Before MA was granted RIO-North America (Pi-Sunyer et al., 2006) 
Before MA was granted RIO-Europe (Van Gaal et al., 2005) 
Before MA was granted RIO-Lipids (Després et al., 2005) 
Before MA was granted RIO-Diabetes (Scheen et al., 2006) 
After MA was granted CRESCENDO (Topol et al., 2010) 
After MA was granted STRADIVARIUS (Nissen et al., 2008) 
After MA was granted SERENADE (Rosenstock et al., 2008) 
 
 Data selection 4.5.2
The regulatory documents and key publications relating to the trials under consideration yielded 
substantial amounts of information on both the favourable and unfavourable effects of rimonabant. 
4.5.2.1 Favourable effects 
Data on the favourable effects of rimonabant were primarily sourced from four clinical trials 
summarised in the regulatory documents: RIO-North America, RIO-Europe, RIO-Lipids, and RIO-
Diabetes (Table 4.3).  The data from these trials were reported by the regulatory documents to have 
been included in the submission dossier for marketing authorisation approval.  Clinical trial data on 
the favourable effects were obtained from publications directly instead of EPAR documents due to 
issues with the comprehensiveness and quality of data.  For one favourable effect—HDL cholesterol, 
additional data were available in one of the clinical trials conducted after marketing authorisation 
was granted, i.e. STRADIVARIUS.  Data were not extracted from CRESCENDO or SERENADE, as 
different measures of efficacy were used to evaluate the favourable effects of treatment. 
4.5.2.2 Unfavourable effects 
The data on the unfavourable effects of rimonabant were also obtained from the same four clinical 
trials (RIO-North America, RIO-Europe, RIO-Lipids, and RIO-Diabetes), with additional data provided 
by three clinical trials which were conducted after marketing authorisation was granted, and were 
not included in the submission dossier: CRESCENDO, STRADIVARIUS, and SERENADE.  Data on all 
reported serious adverse events (SAEs) and adverse events (AEs) were extracted from each trial.  As 
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AEs were only reported in academic peer reviewed publications if they occurred in ≥5% of 
participants for the RIO trials, some information was missing, and data on discontinuation was 
sought when AEs were not reported within trials (Table 4.4).  AEs with reported percentage ≥1% 
were included in the EPAR but trial specific data were not available, or pooled across trials.  As more 
safety outcomes were reported in the EPARs, additional AE data were also extracted from them 
(Table 4.5).  
There were three sources of data for the unfavourable effects of rimonabant: pooled data from the 
four RIO trials obtained from EPAR reports,  individual trial data from the same trials obtained from 
academic publications, and data from three trials performed after marketing authorisation was 
obtained (i.e. CRESCENDO, SERENADE, and STRADIVARIUS).  As the case study intended to replicate 
the regulatory perspective, two estimates were obtained: one representing the time at initial 
marketing authorisation which grouped the four RIO trials, and one which also included the three 
trials performed after marketing authorisation was granted to characterise the point at which the 
benefit-risk balance was reassessed due to psychiatric concerns.
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Table 4.3 Favourable effects of rimonabant as reported by four clinical trials performed prior to marketing approval and one performed after 
Efficacy outcome Study Placebo Rimonabant 20mg 
 ITT n % 95% CI ITT n % 95% CI 
 
10%  
weight  
loss 
RIO - North America 607 52 8.6 (6.4-10.8) 1219 307 25.2 (22.8-27.6) 
RIO - Europe 305 22 7.2 (4.3-10.1) 599 164 27.4 (23.8-31.0) 
RIO - Lipids 342 25 7.3 (4.5-10.1) 346 113 32.7 (27.8-37.6) 
RIO - Diabetes 348 7 2.0 (0.5-3.5) 339 55 16.2 (12.3-20.1) 
 
 
HDL  
cholesterol  
(mmol/l) 
 ITT Mean change SD 95% CI ITT Mean change SD 95% CI 
RIO - North America 607 0.07 0.22 (0.05-0.09) 1219 0.16 0.22 (0.14-0.18) 
RIO - Europe 305 0.15 0.23 (0.12-0.18) 599 0.26 0.26 (0.23-0.29) 
RIO - Lipids 342 0.12 0.17 (0.10-0.14) 346 0.21 0.23 (0.19-0.24) 
RIO - Diabetes 348 0.07 0.15 (0.05-0.09) 339 0.17 0.20 (0.15-0.19) 
STRADIVARIUS 341 0.05 0.24 (0.02-0.07) 335 0.15 0.23 (0.13-0.18) 
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Table 4.4 Unfavourable effects of rimonabant as reported by four clinical trials performed prior to marketing approval 
Safety outcome Study Placebo Rimonabant 20mg 
Psychiatric disorders  ITT Number % 95% CI ITT Number % 95% CI 
 
Depressed mood 
RIO - North America 607 15 2.5 (1.3-3.7) 1219 54 4.4 (3.2-5.6) 
RIO - Europe 305  <5  599  <5  
RIO - Lipids 342  <5  346  <5  
RIO - Diabetes 348  <5  339  <5  
 
Anxiety 
RIO - North America 607 10 1.6 (0.6-2.6) 1219 64 5.3 (4.0-6.6) 
RIO - Europe 305  <5  599  <5  
RIO - Lipids 342 13 3.8 (1.8-5.8) 346 30 8.7 (5.7-11.7) 
RIO - Diabetes 348 9 2.6 (0.9-4.3) 339 17 5.0 (2.7-7.3) 
 
Insomnia 
RIO - North America 607 22 3.6 (2.1-5.1) 1219 60 4.9 (3.7-6.1) 
RIO - Europe 305  <5  599  <5  
RIO - Lipids 342 9 2.6 (0.9-4.3) 346 22 6.4 (3.8-9.0) 
RIO - Diabetes 348  <5  339  <5  
 
Psychiatric disorders (SAE) 
RIO - North America 607 0   1219 0   
RIO - Europe 305 1 0.3 (0.0-0.9) 599 9 1.5 (0.5-2.5) 
RIO - Lipids 342 1 0.3 (0.0-0.9) 346 1 0.3 (0.0-0.9) 
RIO - Diabetes 348 0   339 0   
Cardiovascular disorders  ITT Number % 95% CI ITT Number % 95% CI 
 
Cardiac disorders (SAE) 
RIO - North America 607 0   1219 0   
RIO - Europe 305 0   599 2 0.3 (0.0-0.7) 
RIO - Lipids 342 0   346 1 0.3 (0.0-0.9) 
RIO - Diabetes 348 0   339 0   
 
Vascular disorders (SAE) 
RIO - North America 607 0   1219 0   
RIO - Europe 305 0   599 3 0.5 (0.0-1.1) 
RIO - Lipids 342 1 0.3 (0.0-0.9) 346 0   
RIO - Diabetes 348 0   339 0   
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Gastrointestinal disorders  ITT Number % 95% CI ITT Number % 95% CI 
 
Diarrhoea 
RIO - North America 607 25 4.1 (2.5-5.7) 1219 55 4.5 (3.3-5.7) 
RIO - Europe 305 9 3.0 (1.1-4.9) 599 43 7.2 (5.1-9.3) 
RIO - Lipids 342 14 4.1 (2.0-6.2) 346 25 7.2 (4.5-9.9) 
RIO - Diabetes 348 23 6.6 (4.0-9.2) 339 25 7.4 (4.6-10.2) 
 
Nausea 
RIO - North America 607 29 4.8 (3.1-6.5) 1219 117 9.6 (7.9-11.3) 
RIO - Europe 305 13 4.3 (2.0-6.6) 599 77 12.9 (10.2-15.6) 
RIO - Lipids 342 11 3.2 (1.3-5.1) 346 44 12.7 (9.2-16.2) 
RIO - Diabetes 348 20 5.7 (3.3-8.1) 339 41 12.1 (8.6-15.6) 
 
Gastrointestinal disorders (SAE) 
RIO - North America 607 0   1219 0   
RIO - Europe 305 3 1.0 (0.0-2.1) 599 2 0.3 (0.0-0.7) 
RIO - Lipids 342 1 0.3 (0.0-0.9) 346 1 0.3 (0.0-0.9) 
RIO - Diabetes 348 0   339 0   
Reasons for discontinuation          
Psychiatric disorders  ITT Number % 95% CI ITT Number % 95% CI 
 
Depressed mood 
RIO - Europe 305 9 3.0 (1.1-4.9) 599 22 3.7 (2.2-5.2) 
RIO - Lipids 342 0 0  346 2 0.6 (0.0-1.4) 
RIO - Diabetes 348 3 0.9 (0.0-1.9) 339 11 3.2 (1.3-5.1) 
Anxiety RIO - Europe 305 1 0.3 (0.0-0.9) 599 6 1.0 (0.2-1.8) 
Sleep disorders RIO - Europe 305 0 0  599 1 0.2 (0.0-0.6) 
RIO - Diabetes 348 0 0  339 0 0  
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Table 4.5 Unfavourable effects of rimonabant as reported by three clinical trials performed after marketing approval 
Safety outcome Study Duration   Placebo     Rimonabant 20mg 
  
  
ITT Number % 95% CI ITT Number % 95% CI 
Cardiovascular disorders 
  
                
Cardiovascular death 
CRESCENDO 13.8 months 9314 123 1.3 (1.1-1.5) 9381 122 1.3 (1.1-1.5) 
STRADIVARIUS 18 months 416 2 0.5 (0.0-1.2) 422 0 0   
SERENADE 6 months 140   <2   138   <2   
MI 
CRESCENDO 13.8 months 9314 144 1.5 (1.3-1.7) 9381 138 1.5 (1.3-1.7) 
STRADIVARIUS 18 months 416 4 1.0 (0.0-2.0) 422 9 2.1 (0.7-3.5) 
SERENADE 6 months 140   <2   138   <2   
Stroke 
CRESCENDO 13.8 months 9314 146 1.6 (1.3-1.9) 9381 135 1.4 (1.2-1.6) 
STRADIVARIUS 18 months 416 1 0.2 (0.0-0.6) 422 4 0.9 (0.0-1.8) 
SERENADE 6 months 140   <2   138   <2   
Gastrointestinal disorders                     
Nausea 
CRESCENDO 13.8 months 9302 436 4.7 (4.3-5.1) 9369 1362 14.5 (13.8-15.2) 
STRADIVARIUS 18 months 416 23 5.5 (3.3-7.7) 422 63 14.9 (11.5-18.3) 
SERENADE 6 months 140 5 3.6 (0.5-6.7) 138 12 8.7 (4.0-13.4) 
Diarrhoea 
CRESCENDO 13.8 months 9302 521 5.6 (5.1-6.1) 9369 760 8.1 (7.5-8.7) 
STRADIVARIUS 18 months 416 14 3.4 (1.7-5.1) 422 33 7.8 (5.2-10.4) 
SERENADE 6 months 140 6 4.3 (0.9-7.7) 138 6 4.3 (0.9-7.7) 
Psychiatric disorders                     
Anxiety 
CRESCENDO 13.8 months 9302 533 5.7 (5.2-6.2) 9369 902 9.6 (9.0-10.2) 
STRADIVARIUS 18 months 416 49 11.8 (8.7-14.9) 422 76 18.0 (14.3-21.7) 
SERENADE 6 months 140 5 3.6 (0.5-6.7) 138 8 5.8 (1.9-9.7) 
Depression 
CRESCENDO 13.8 months 9302 424 4.6 (4.2-5.0) 9369 716 7.6 (7.1-8.1) 
STRADIVARIUS 18 months 416 47 11.3 (8.3-14.3) 422 71 16.8 (13.2-20.4) 
SERENADE 6 months 140   <2   138   <2   
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Depressed mood 
CRESCENDO 13.8 months 9302 317 3.4 (3-3.8) 9369 539 5.8 (5.3-6.3) 
STRADIVARIUS 18 months 416 20 4.8 (2.7-6.9) 422 29 6.9 (4.5-9.3) 
SERENADE 6 months 140 1 0.7 (0-2.1) 138 8 5.8 (1.9-9.7) 
Insomnia 
CRESCENDO 13.8 months 9302 427 4.6 (4.2-5.0) 9369 521 5.6 (5.1-6.1) 
STRADIVARIUS 18 months 416 38 9.1 (6.3-11.9) 422 52 12.3 (9.2-15.4) 
SERENADE 6 months 140 3 2.1 (0.0-4.5) 138 3 2.2 (0.0-4.6) 
Reasons for discontinuation         
Severe psychiatric disorders STRADIVARIUS 18 months 416 16 3.8 (2.0-5.6) 422 20 4.7 (2.7-6.7) 
Depression SERENADE 6 months 140 0 0   138 3 2.2 (0.0-4.6) 
 
 122 
 
Table 4.6 Summary of safety outcomes (with reporting rate of at least 1%) included within EPAR reports 
Safety outcome (reported in EPAR) Rimonabant Placebo 
 (n = 2503 ) (n = 1602 ) 
 n n 
Psychiatric disorders 
Anxiety 140 38 
Insomnia 135 51 
Depressed mood 120 50 
Mood alterations with depressive symptoms 80 26 
Irritability 48 10 
Parasomnia 38 3 
Nervousness 30 3 
Sleep disorders 25 6 
Serious adverse events 12 2 
Cardiovascular disorders 
Hot flushes 48 11 
Serious adverse events 12 4 
Gastrointestinal disorders 
Nausea 298 78 
Diarrhoea 155 77 
Vomiting 100 35 
 
 Effects table 4.5.3
4.5.3.1 Favourable effects 
The proportion of individuals who achieved a 10% reduction in bodyweight for each study was 
pooled using a Bayesian random-effects meta-analysis model (Section 2.2.2.1), and the mean change 
from baseline of HDL cholesterol was calculated using a pooled mean estimation method.  10% 
reduction in bodyweight was considered as a primary efficacy endpoint in pre-marketing approval 
trials only, hence one estimate was calculated.  However, change in HDL cholesterol was also 
available in the STRADIVARIUS trial, thus a post-approval estimate was calculated by combining 
results from the four RIO trials and the STRADIVARIUS trial.  The percentage of participants achieving 
a 10% reduction in bodyweight was higher in the rimonabant group compared to the placebo group, 
whereas the 95% CrIs of the mean change from baseline of HDL overlapped in both groups (Table 
4.7). 
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Table 4.7 Pooled estimates of favourable effects of rimonabant 
  
Rimonabant (20mg) Placebo 
Efficacy Unit Mean Median 95% CrI Mean Median 95% CrI 
10% 
reduction in 
bodyweight % 25.1 24.7 (14.6, 38.2) 6.22 6.09 (3.54, 9.72) 
        HDL 
cholesterol (mmol/l) 
      Pre-approval Mean change 0.2 0.2 (0.03, 0.37) 0.1 0.1 (-0.08, 0.28) 
Post-approval Mean change 0.19 0.19 (0.05, 0.34) 0.09 0.09 (-0.05, 0.24) 
 
4.5.3.2 Unfavourable effects 
Unfavourable effects were included in the case study if they were classified as psychological, 
cardiovascular, or gastrointestinal disorders.  After some consideration, data reported within the 
EPARs were analysed (Table 4.6) and individual trial data extracted from academic publications were 
excluded (Table 4.4 and Table 4.5).  This is because: (a) the data reported from individual trials were 
not consistently reported across publications, and (b) there would be complexities in handling the 
missingness of AE data for events which occurred ≤5% of the time.  Pooled data reported in the 
EPAR included all safety outcomes which occurred ≥1% of the time. The method of pooling was not 
stated. 
Table 4.8 summarises results obtained using pooled data from the four RIO trials reported in the 
EPAR for pre-approval and combined with that from three trials performed after marketing 
authorisation was granted (CRESCENDO, STRADIVARIUS, SERENADE).  Pre-approval, the risk of 
several psychiatric disorders (i.e. anxiety, insomnia, depressive disorders, irritability, parasomnia, 
and nervousness), one of two cardiovascular disorders (hot flush), and two of three gastrointestinal 
disorders (i.e. nausea and vomiting) was higher in the rimonabant group compared to the placebo 
group.  For all grouped conditions, the risk of an event was higher for rimonabant compared to 
placebo.  Once the three trials performed after marketing authorisation was granted were included, 
uncertainty in the estimates increased considerably compared to the use of pooled EPAR data from 
the four RIO trials to such an extent that the 95% CrIs for rimonabant and placebo had large overlap 
for any of the safety outcomes.  This was partially due to the use of a Bayesian random-effects meta-
analysis model, and to large heterogeneity across post-approval studies, especially for psychiatric 
conditions. However, the point estimates for all of conditions increased considerably: for example, 
the mean risk of having a psychiatric disorder increased from 25.4% in pre-approval to 47.0% in post-
 124 
 
approval for rimonabant, and from 12.3% to 25.5%, respectively, for placebo.  This represented an 
almost doubling of the risk difference for psychiatric disorders, from 13.1% pre-approval to 21.5% 
post-approval. 
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Table 4.8 Pooled estimates of unfavourable effects of rimonabant obtained using a meta-analysis of data from pooled data from four trials performed prior to marketing approval (pre-
approval) and with the addition of three trials performed afterwards (post-approval)  
Safety 
 
Pre-approval (EPAR) Post-approval (EPAR, SERENADE, CRESCENDO, STRADIVARIUS) 
  
Rimonabant (20mg) Placebo Rimonabant (20mg) Placebo 
 
  Pooled data Bayesian random effects meta-analysis 
  Unit Mean 95% CrI Mean 95% CrI Mean 95% CrI Mean 95% CrI 
Psychiatric disorders1 % 25.4 (23.5 - 27.4) 12.3 (10.7 - 14.1) 47.0 (29.1 - 100.7) 25.5 (16.8 - 48.4) 
Depressed mood % 4.8 (4.0 - 5.7) 3.2 (2.4 - 4.1) 5.8 (2.9 - 10.3) 3.3 (1.9 - 5.2) 
Anxiety % 5.6 (4.8 - 6.6) 2.4 (1.7 - 3.2) 9.5 (4.0 - 18.5) 5.3 (2.4 - 9.8) 
Insomnia % 5.4 (4.6 - 6.4) 3.2 (2.4 - 4.1) 6.1 (2.6 - 11.8) 4.5 (2.2 - 7.8) 
Depressive disorders % 3.2 (2.6 - 4.0) 1.7 (1.1 - 2.4) 8.8 (2.4 - 22.2) 5.1 (1.5 - 12.6) 
Irritability % 2.0 (1.5 - 2.5) 0.7 (0.3 - 1.1) 3.6 (0.2 - 16.6) 1.1 (0.1 - 3.2) 
Parasomnia % 1.6 (1.1 - 2.1) 0.3 (0.1 - 0.5) 2.9 (0.2 - 13.0) 0.4 (0.0 - 1.1) 
Nervousness % 1.2 (0.8 - 1.7) 0.2 (0.1 - 0.6) 2.4 (0.1 - 10.4) 0.4 (0.0 - 1.0) 
Sleep disorders % 1.0 (0.7 - 1.5) 0.4 (0.2 - 0.8) 4.4 (0.9 - 13.0) 3.1 (0.7 - 8.7) 
Serious adverse events % 0.5 (0.3 - 0.8) 0.2 (0.0 - 0.4) 3.6 (0.1 - 20.8) 2.2 (0.1 - 11.5) 
          Cardiovascular disorders1 % 2.5 (1.9 - 3.1) 1.1 (0.6 - 1.6) 6.1 (1.3 - 23.6) 3.2 (0.8 - 9.4) 
Hot flush % 2.0 (1.4 - 2.5) 0.7 (0.4 - 1.2) 3.6 (0.2 - 16.7) 1.2 (0.1 - 3.4) 
Serious adverse events % 0.5 (0.3 - 0.8) 0.3 (0.1 - 0.6) 2.5 (0.4 - 8.8) 2.0 (0.3 - 6.4) 
          Gastrointestinal disorders1 % 22.2 (20.5 - 24.0) 12.3 (10.7 - 14.1) 26.1 (15.5 - 50.0) 12.5 (8.3 - 20.0) 
Diarrhoea % 6.2 (5.3 - 7.2) 4.9 (3.9 - 6.0) 6.8 (3.4 - 11.9) 4.6 (2.8 - 7.0) 
Nausea % 11.9 (10.7 - 13.2) 4.9 (3.9 - 6.0) 12.8 (6.9 - 21.1) 4.7 (2.9 - 7.2) 
Vomiting % 4.0 (3.3 - 4.8) 2.2 (1.6 - 3.0) 6.5 (0.5 - 29.5) 3.2 (0.5 - 10.2) 
1 sum of all the safety outcomes included within each broad category of conditions
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4.6 Application of discrete choice experiment 
The steps to conducting a general DCE have been previously described in Section 2.3.3.  Here, I 
discuss the application of the methodology to the case study of rimonabant, with a view to eliciting 
preferences from patients and the public regarding the favourable and unfavourable treatment 
effects of rimonabant in a benefit-risk assessment context.   
 Identify attributes  4.6.1
Attributes are characteristics; in this case study, they are the favourable and unfavourable treatment 
effects of rimonabant. Attributes which were considered by the Wave Two rimonabant case study 
team to most greatly impact the attractiveness of rimonabant from a regulator’s perspective were 
represented in the DCE.   These were: (1) HDL cholesterol levels, (2) ten percent weight loss, (3) 
psychiatric conditions, (4) cardiovascular conditions, and (5) gastrointestinal conditions.  As a pre-
requisite before initiating the statistical design of the DCE, the team deemed correlation and 
interaction to be minimal between the attributes.   
 Assign levels to attributes 4.6.2
After deciding which favourable and unfavourable effects should be included in the DCE, levels—i.e. 
units of measurement, are assigned to each attribute.  Again, these were determined by the Wave 
Two rimonabant case study team.  Details of the attributes and levels used in the DCE are provided 
in Table 4.9. 
 Experimental design and construction of choice sets 4.6.3
To present five attributes, each with four levels in a survey would produce a total of 1024 (i.e. 45) 
hypothetical treatment scenarios.  Asking participants to evaluate this number of scenarios is 
unrealistic due to the high level cognitive demand and time it would require.  Therefore a fractional 
factorial design was used. 
A fractional factorial design with choice sets was created in SAS (SAS Institute Inc., 2013) using the 
%mktruns and %choiceff macros (Kuhfeld, 2010), which maintained the important principles of level 
balance, minimal overlap, and orthogonality (SAS output presented in Appendix 4).  The choice sets 
were “forced”, whereby individuals had to choose between Treatment A or Treatment B for each 
choice set.  The smallest design that could be used to estimate main effects for the number of 
attributes and levels using two hypothetical treatment options was 16.  An additional choice set was 
added to the 16, where one treatment clearly performed more beneficially than the other.  This 
choice set acted as a consistency test, to evaluate participant comprehension of the task and the 
reliability of responses. 
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Table 4.9 A description of the attributes and levels used in the DCE to elicit patient and public preferences for 
rimonabant 
Attribute Definition Attribute levels 
Physician’s view on 
HDL cholesterol levels 
A high overall cholesterol level can cause 
a chance of heart attacks and stroke. 
However, there are different types of 
cholesterol and not all cholesterol is bad. 
High density lipoprotein (HDL) is a good 
cholesterol and is associated with a lower 
chance of heart attack or stroke. 
 Moderate 
improvement  
 Mild improvement  
 No change  
 Got worse  
Number of people who 
experience a 10% 
weight loss 
Obesity is associated with an increased 
risk of diabetes, heart disease and stroke. 
If a person is obese, by losing ten percent 
of their bodyweight they can lower the 
chance of these conditions. 
 10 out of 1000  
 150 out of 1000  
 300 out of 1000  
 450 out of 1000  
Number of people who 
experience psychiatric 
conditions 
Psychiatric conditions is a broad term 
used to describe mild anxiety to severe 
depression. The scenarios mainly refer to 
mild psychiatric events, for example 
anxiety attacks and depression that can 
be managed by your family doctor. These 
disorders occur during the course of 
treatment.  
Anxiety is a common condition and 
describes a state of worry, nervousness or 
unease.  
Depression can be described as feeling 
sad all time, finding it difficult to fall 
asleep and waking up early, feeling 
unenergetic, and individuals may lose 
interest in activities. In a small number of 
cases, those with severe depression may 
contemplate self-harm or suicidal 
thoughts. 
 None  
 1 person out of 1000  
 10 people out of 1000  
 100 people out of 
1000 
 
Number of people who 
experience 
cardiovascular 
conditions 
Cardiovascular diseases are illnesses that 
involve the heart and blood vessels where 
not enough blood flows to vital organs. 
The scenarios in the following questions 
refer to severe, disabling or potentially 
fatal illnesses, such as heart attacks and 
stroke that happen during treatment. 
 None  
 1 person out of 1000  
 10 people out of 1000  
 100 people out of 
1000  
Number of people who 
experience 
gastrointestinal 
conditions 
Gastrointestinal disorders affect the 
bowel and stomach.  The following 
scenarios mainly refer to mild types of 
side effects that cause discomfort or 
inconvenience, e.g. diarrhoea or 
constipation, stool spotting, heart burn 
and flatulence that happen during 
treatment period. 
 None  
 1 person out of 1000  
 10 people out of 1000  
 100 people out of 
1000  
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After piloting with colleagues, feedback indicated that 17 choice sets were considered to be too 
many for participants to complete.  The length of the task was found to be fatiguing, and therefore 
the validity of the study subsequently could have been compromised if participants either gave up, 
or began to rush through the final questions to reach the end of the survey.  To resolve this, the 16 
choice sets were randomised into two sets of 8 questions, which made a total of 9 once the 
additional consistency question was included, i.e. two separate surveys were created.    
 Collecting data 4.6.4
The visualisation of choice sets underwent numerous changes from conception to launch.  Help was 
provided by the visualisation sub-team of the WP5 Wave Two rimonabant case study team led by 
Shahrul Mt-Isa, who suggested the labelling and segregation of outcomes into benefits and risks, 
colour coding, and carefully aligning the numerical denominator for risks.  An example of a choice 
set which was used in the survey can be found in Figure 4.1. 
 
Figure 4.1 Example of a choice set in the discrete choice experiment which displays how the benefits and risks were 
visually represented 
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The DCE were then circulated to the members of the obesity organization Weight Concern, which is 
an organisation established in 1997 to address the raising obesity-related issues in the United 
Kingdom (http://www.weightconcern.org.uk/).  The membership list received an email informing 
them about the study, with a link to a questionnaire hosted by SurveyMonkey 
(http://www.surveymonkey.com/).  The membership list was randomised, so that one half received 
a link to the first questionnaire, and the second half received a link to the second questionnaire.   
The questionnaire also contained a number of demographic questions, including the age range of 
the respondent, gender, and whether they have ever been or are currently obese.  In addition, 
respondents were asked to rank each of the attributes on a Likert scale from 1 (extremely weak) to 9 
(extremely strong) regarding how strongly they believed each of the attributes drove their treatment 
choices in the scenarios.  They were also invited to provide free-text comments about their 
experience completing the DCE. Imperial College Research Ethics Committee granted ethical 
approval for the study (ICREC Ref. 12_2_7). 
 Data input 4.6.5
Questionnaire responses were retrieved on 18th August 2012, and a total of 192 responses were 
received, 101 of which were for the first subset of 8 questions and 91 for the second subset of 8 
questions. 
All of the responses from a questionnaire were excluded from analysis if the consistency question 
was not correctly answered, or the questionnaire had not been completed up to the consistency 
question: as a result, 26 questionnaires were excluded from analysis, 24 (14 in subset 1, 10 in subset 
2) of which did not complete the questionnaire up to the consistency question, and 2 (1 in each 
subset) of which incorrectly answered the consistency questionnaire. 
Each questionnaire response was coded into two rows of data. Each row represented one 
alternative within a choice set and included the respondent number, question number (1 to 16), 
alternative number (A, B), and whether the alternative was selected (yes, no), along with the criteria 
levels used to described the alternative (5 parameters with 4 levels ranging from 1 to 4), age group 
(18 to 20, 21 to 29, 30 to 39, 40 to 49, 50 to 59, 60 and above, not disclosed), gender (male, female, 
not disclosed), and current status of obesity (obese, not obese). 
 Data analysis 4.6.6
In DCE data analysis, the changes in a binary response variable expressing choice are estimated 
according to levels of a set of attributes.  Accordingly, a general expression of DCE analyses can be 
formulated as, 
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        (   |      )                 , 
where α is a constant, commonly referred to as the alternative specific constant (ASC), and        are 
a set of coefficients that quantify the influence of attributes        on the probability that an 
alternative will be chosen. 
There are various statistical methods available to analyse DCE data, each based on different 
underlying assumptions; because DCE have rarely been used in a medical decision-making context, 
there is no established consensus regarding which should be used (de Bekker-Grob et al., 2012).  
Therefore, two analysis methods were investigated in this thesis in order to ascertain how the 
interpretations and recommendations may vary by analysis method: conditional logistic regression 
and conditional probit regression.  Also, two alternative preference functions were considered: a 
linear function, where attribute levels were recoded to the values used in their description, and a 
piecewise function, where attribute levels were assigned dummy variables.  Analyses were also 
stratified by age (<40, ≥40), gender, and current obesity status, to observe any heterogeneity in 
preference among subgroups. 
Logistic regression methods compare differences in the levels of attributes between alternatives that 
are chosen and not chosen.  However, the main limitation of this method is that selected and 
unselected alternatives are analysed as two independent groups, which may be considered as an 
unrealistic assumption given that the choice of an alternative over another is highly dependent on 
the attributes of the unselected alternative.  Conditional logistic regression methods, traditionally 
used for matched case-control studies, propose an alternative to logistic regression where the 
investigation of the differences in attribute levels between alternatives can be done on a choice per 
choice basis, meaning that each set of options are analysed individually, which minimises potential 
biases associated with the assumption of independence between samples (here, selected and 
unselected alternatives) in unconditional logistic regression.  As a result, the main advantage of a 
conditional logistic regression model is that it offers a matched analysis design for choice sets (Train, 
1986).   
An alternative to conditional logistic regression is a conditional probit regression model, sometimes 
used in the analysis of DCEs.  Conceptually, probit regression models are highly comparable to 
logistic regression models in that they are both generalised linear models used to model a binary 
response variable.  However, probit and logistic models differ in terms of their link functions, 
whereby logistic models use a logit link function and probit models use the cumulative distribution 
function of the standard normal distribution.  Probit models are generally preferred in situations 
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where the observed binary response is dependent on a hidden normally distributed variable, for 
example in cases where exceeding a threshold in a continuous measure results in being classified as 
having or not having a condition expressed in terms of a binary outcome.  However, probit 
regression models are not as easily interpretable as logistic models and may require substantial 
methodological development for use in a benefit-risk assessment context (Train, 1986). 
The association between attributes and preference were analysed assuming linear and piecewise 
functions.  Linear associations were modelled by redefining attribute levels so that they represented 
the numerical proportion described within the attribute level.  For example, attribute levels 
described as 1 per 1000, 10 per 1000, and 100 per 1000, levels were recoded as 1, 10, and 100, 
respectively.  For the physician’s view on HDL cholesterol levels, described as “got worse”, “no 
change”, “mild improvement”, and “moderate improvement”, equivalent numerical changes in 
cholesterol levels were sought from Edmond Chan, who was a physician in the Wave Two 
rimonabant case study team.  These were <0 mg/dL change for “got worse”, 0-2.5 mg/dL for “no 
change”, 2.5-5.0 mg/dL for “mild improvement”, and >5.0 mg/dL for “moderate improvement”.  As a 
result, the parameter for physician’s view on changes in cholesterol were recoded as 0, 1.25 
(midpoint in between 0 and 2.5), 3.75 (midpoint in between 2.5 and 5), and 5, respectively, for 
estimating a linear preference function.  Given that changes in cholesterol levels reported within 
trials were expressed in mmol/L, values in mg/dL were divided by 38.7.  For defining piecewise 
preference functions, attribute levels were recoded as dummy variables with the lowest levels 
omitted for each attribute, meaning that the lowest level would be considered as the reference 
category. 
Conditional logistic and conditional probit regression analyses were carried out in Stata (Stata Corp., 
2011) using the clogit, and asmprobit commands.  Dummy variables were coded by using the i. 
prefix.  Significance of coefficient estimates was evaluated at an α-error of 5%, meaning that p-
values of less or equal to 0.05 were interpreted as statistically significant. 
 Interpretation 4.6.7
4.6.7.1 Model coefficient estimates 
For each regression model and underlying preference function, the coefficient estimates, 95% 
confidence intervals, and p-value were reported.  Coefficients were interpreted in terms of their 
significance, their sign (positive or negative), and their size.  Negative coefficients were associated 
with a decrease in preference with an increase in the level of the attribute, whereas positive 
coefficients were associated with an increase in preference with an increase in the level of the 
attribute.  For linear preference functions, an attribute with a larger coefficient, on the absolute 
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scale, was interpreted as being more important in the context of preference.  For piecewise 
preference functions, the importance of attributes were not directly interpretable based on the size 
of coefficients, and was therefore not considered.  For stratified analyses, subgroups were assumed 
to be heterogeneous in terms of preference if at least one coefficient was significantly different, i.e. 
confidence intervals do not overlap, between subgroups. 
4.6.7.2 Marginal rates of substitution 
Another interpretation of model results was offered by calculating marginal rates of substitution 
between attributes.  This is a measure which quantifies the amount of a favourable or unfavourable 
attribute that would be substituted for a gain or loss in an unfavourable or favourable attribute, 
respectively, whilst retaining the same level of overall preference (Lancsar et al., 2007).  This 
provides a numerical comparison of attributes relative to one or several attributes and can aid in the 
interpretation of preference, and was calculated as the ratio between the coefficients for the 
attribute of interest and the attribute being substituted.  Substituted attributes are generally 
selected from favourable attributes, whereas attributes being compared are selected from 
unfavourable attributes, and substitution rates between two favourable or unfavourable attributes 
are not usually calculated.  Rates were interpreted as the number of occurrences of the substituted 
attribute that would be traded for one occurrence of the second attribute, except for physician’s 
view on cholesterol levels which was the only attribute not expressed in numbers per 1000.  This 
was interpreted as the amount of change per mmol/L in cholesterol levels that would be substituted 
for one occurrence of the second attribute. 
Marginal rates of substitution were calculated using coefficients from the linear logistic regression 
model. These rates require a linear function for calculation and could not be derived for the 
categorical analysis model.  This was because rates of substitution would be dependent on the levels 
of attributes that are being compared, and would therefore be different for each possible 
combination of attribute levels. 
4.6.7.3 Comparison of linear and piecewise preference functions 
Coefficient estimates were obtained from models using a linear or piecewise specification of 
attributes and were compared graphically.  First, a preference function varying from 0 to 1 was 
constructed for each attribute.  The linear function was a straight line from the lowest to highest 
attribute level, ascending for favourable and descending for unfavourable attributes.  Piecewise 
functions were constructed by rescaling model coefficients so that the coefficient for the least 
preferable level (lowest for benefit, highest for risk) had a value of 0 and the most preferable level 
(highest for benefit, lowest for risk) had a value of 1.  Another comparison was made by plotting 
 133 
 
coefficients for all attributes simultaneously without any rescaling, the Y-axis providing the 
coefficient, and X-axis the attribute level. 
 Development of a benefit-risk assessment method for use with DCE studies 4.6.8
Interpretation of DCE results are normally confined to a comparison of coefficients and calculation of 
marginal rates of substitution.  In addition, coefficients estimated within DCE analyses may also 
provide an ideal frame for the direct comparison of preference for two or more drugs, which can be 
used in benefit-risk assessment.  However, DCE coefficients are not suited to be directly inputted to 
a benefit-risk assessment method such as SMAA.  Such a comparison could use estimates of the 
favourable and unfavourable of treatments within the attributes obtained from clinical trials and 
post-marketing surveillance and of preference for the same attributes obtained from a DCE analysis. 
The proposed method for comparing preference for two drugs arise from the ability to 
probabilistically predict preference for a set of attribute levels based on results from a logistic or 
probit regression model.  The exact calculation of the predicted probability will vary depending on 
the regression model used, and here, calculation methods for logistic regression analyses are 
presented. 
For a logistic model, the preference for a particular drug (     ) within a set of J alternatives given 
attribute levels (               ) can be calculated using: 
                  
      
∑         
 
                       , 
where        are model coefficients. 
In the context of a conditional logistic model, the preference for a particular drug A is calculated in 
comparison to a reference B, and thus, for comparison between two alternatives is given by, 
     
                             
    
   
   
  
     
  
   
  
     
  
By combining favourable and unfavourable treatment effects estimates and preference estimates 
obtained from a DCE, the preference for two treatment options can be calculated and compared; 
the treatment option with the highest preference would be the most favourable in terms of the 
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benefit-risk balance.  However, this estimate would not incorporate multiple uncertainties including 
in estimates of the favourable and unfavourable effects of treatment and in estimates of preference.  
Therefore, an approach that could account for these uncertainties, and provide a ranking of 
preference for the alternatives under consideration with an estimate of the certainty of that ranking, 
would provide a more suitable tool for the evaluation of benefit-risk trade-balance. 
The benefit-risk assessment method I proposed for comparing two treatments which address these 
key uncertainties included the following iterative steps: 
1) Estimation of uncertainties in the favourable and unfavourable effects of alternatives 
included in the process: ideally, this would be achieved through meta-analysis of clinical trial 
data and/or post-marketing surveillance data. 
2) Estimation of uncertainties in the preferences for attributes: in practice, preference for 
attribute levels would need to be sampled from the distribution of the model coefficients. 
Coefficients of logistic regression models are normally distributed, and thus, the distribution 
of coefficient estimates are completely defined using their mean and standard deviation. 
3) Calculation of preference for alternatives using a predictive model specific to the DCE 
analysis model: a potential value of the performance of each attribute for each alternative 
and of the preference coefficient for each attribute is sampled from their respective 
posterior distribution, from which the probability of selecting each alternative is defined. 
4) Calculation of a measure for comparing alternatives in terms of ranking and of the impact of 
uncertainty: several measures are suggested here and include a plot of the posterior 
distributions of the probabilities of selecting each alternative, the percentage of iterations 
where the probability of selecting a given alternative is highest, and the relative contribution 
of each attribute on the difference in value between two alternatives or overall value for 
one alternative. 
I developed this assessment method myself using WinBUGS 14 (Spiegelhalter et al., 1999), adopting 
the models initially described for meta-analysis of rimonabant and placebo favourable and 
unfavourable effects data, combined with sampling tool from DCE model coefficient distributions, 
and with the calculation of preference and proposed comparison measures.  Due to multiple levels 
of uncertainty, a large number of iterations were preferred to cover the range of possible 
combinations between performance and preference values.  Thus, 100,000 iterations were 
performed after an initial burn-in of 50,000. 
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4.7 Results of the discrete choice experiment 
 Demographic information 4.7.1
In total, 191 individuals responded to the questionnaires (of which 100 responded to questionnaire 
one and 91 responded to questionnaire two).  Of all those who responded, one individual did not 
pass the consistency test and all of the subsequent responses provided by this individual were 
excluded from further analyses of results (Table 4.10).  24 individuals did not complete all of the nine 
choice sets.  However, any responses that they did provide were still retained in the analyses.  The 
most frequently reported age groups were age 40 to 49 and 50 to 59 years old, and 90% of the 
respondents were female.   
Table 4.10 Demographic characteristics of DCE questionnaire respondents 
 Respondents 
 n % 
All responses 191  
Incomplete 24 12.6 
Failed consistency 1 0.5 
Retained in 
analysis 
166  
   
Age group n % 
21 to 29 9 5.4 
30 to 39 26 15.7 
40 to 49 56 33.7 
50 to 59 55 33.1 
60 and over 20 12.0 
  166  
Gender   
Male 15 9.0 
Female 150 90.4 
Unknown 1 0.6 
 166  
 
 Favourable effect and unfavourable effect coefficients 4.7.2
Results for the conditional probit regression model are presented and discussed in   
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Appendix 5. Table 4.11 shows coefficient estimates for the conditional logistic regression model 
which assumes a linear preference function for all attributes.  This was achieved by recoding levels 
of attributes according to the numbers used to define them.  Asides from HDL cholesterol levels, the 
coefficient for each attribute reflects its impact on choice for a 1‰ increment in the level of that 
attribute.  The coefficient for HDL cholesterol level reflects the shift in preference for a change in 
cholesterol levels of 1 mmol/L.  
All of the coefficients were statistically significant (p-value<0.001), indicating that all two favourable 
effects and three unfavourable effects were important factors affecting treatment preference.  The 
two favourable effects, HDL improvement and 10% weight loss had positive coefficients, meaning 
that as the level of each favourable effect increased, a respondent was more likely to select the 
treatment in the choice set.  Conversely, the three unfavourable effects, psychological, 
cardiovascular and gastrointestinal conditions all had negative coefficients.  This indicates that as the 
levels of each unfavourable effect increased, a respondent was less likely to select the treatment in 
the choice set. 
From the coefficients, it is possible to determine the ranking of favourable and unfavourable effects 
by importance for a one per thousand incremental change, although HDL cholesterol levels are 
excluded from this ranking as the attribute does not use the same scale.  The most important 
outcomes with the largest coefficient were psychological conditions, followed by cardiovascular 
conditions, gastrointestinal conditions, and lastly, weight loss.  However, the size of coefficients of 
weight loss and gastrointestinal conditions were very similar.  
Table 4.11 Results from conditional logistic regression models used to analyse a discrete choice experiment of weight 
loss drugs assuming linear preference functions 
 
Conditional 
 
logistic model 
Attribute Coefficient 95% CI p-value 
10% weight loss (1% change) 0.0042 (0.0036 to 0.0047) <0.001 
Cholesterol (1 mmol/L change) 7.6961 (5.5725 to 9.8197) <0.001 
Psychiatric conditions (1% change) -0.015 (-0.0178 to -0.0122) <0.001 
Cardiovascular conditions (1% change) -0.0112 (-0.0134 to -0.009) <0.001 
Gastrointestinal conditions (1% change) -0.0043 (-0.0064 to -0.0022) <0.001 
 
Table 4.12 presents the results of a categorical analysis of attributes.  For all of the attributes, the 
lowest level, representing the lowest level of favourable or unfavourable effect, was used as a 
reference category.  Only one regression coefficient was not significant.  For several attributes, such 
as psychiatric conditions, the sizes of coefficients were smaller for higher levels of that attribute 
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compared to lower ones.  For example, the coefficient for the 1 out of 1000 level for psychiatric 
conditions was -0.90 (-1.42 to -0.36), compared to -0.50 (-0.86 to -0.14) for the 10 out of 1000 level, 
which would normally be interpreted as more favourable than the former level. 
In analyses stratified by age, gender, and current obesity, there were no significant differences 
between coefficients (results not shown).  In addition, point estimates were comparable between 
subgroups, albeit with larger confidence interval due to reduced sample size.  There was therefore 
no evidence suggestive of heterogeneity in preference between subgroups. 
Table 4.12 Results of a categorical analysis of a discrete choice experiment for weight loss drugs using a conditional 
logistic regression model 
 
Conditional logistic model 
Attribute and level Coefficient 95% CI p-value 
10% weight loss 
   10 out of 1000 Reference 
150 out of 1000 1.11 (0.66 to 1.56) <0.001 
300 out of 1000 2.07 (1.54 to 2.59) <0.001 
450 out of 1000 2.12 (1.74 to 2.49) <0.001 
HDL cholesterol 
   Got worse Reference 
No change 0.89 (0.56 to 1.26) <0.001 
Mild 1.91 (1.30 to 2.52) <0.001 
Moderate 1.44 (0.89 to 1.99) <0.001 
Psychiatric conditions 
   0 out of 1000 Reference 
1 out of 1000 -0.90 (-1.43 to -0.36) 0.001 
10 out of 1000 -0.50 (-0.86 to -0.14) 0.007 
100 out of 1000 -2.41 (-2.90 to -1.92) <0.001 
Cardiovascular conditions 
   0 out of 1000 Reference 
1 out of 1000 0.32 (-0.41 to 1.05) 0.392 
10 out of 1000 -0.82 (-1.52 to -0.12) 0.022 
100 out of 1000 -1.24 (-1.74 to -0.75) <0.001 
Gastrointestinal conditions 
   0 or 1 out of 1000 Reference 
10 out of 1000 -0.85 (-1.28 to -0.42) <0.001 
100 out of 1000 -0.89 (-1.20 to -0.57) <0.001 
 
 Marginal rates of substitution 4.7.3
Using the results from the conditional logistic regression model, it was possible to calculate the 
marginal rates of substitution between the two favourable effects, i.e. number of individuals 
achieving a 10% weight loss and change in HDL levels, and the three unfavourable effects, i.e. 
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psychological, gastrointestinal, cardiovascular disorders (more detail can be found in 4.6.7.2).  
Essentially, this calculated how much of a favourable effect a respondent was willing to trade off in 
order to avoid a specified amount of unfavourable effect whilst retaining the same level of overall 
preference (Table 4.13). 
Table 4.13 Marginal rates of substitution calculated from conditional logistic regression result of a discrete choice 
experiment for weight loss drugs 
Marginal rates of substitution 
Risk attribute Description 
Willingness to 
forgo a % 
reduction in the 
percentage of 
those achieving 
10% weight loss 
(95% CI) 
Willingness to 
forgo a mmol/L 
increase in HDL 
cholesterol  
(95% CI) 
Psychological 
conditions (%) 
1% reduction in risk of 
psychological conditions 3.6 (2.6 - 4.9) 0.0019 
(0.0012 - 
0.0032) 
Cardiovascular 
conditions (%) 
1% reduction in risk of 
cardiovascular conditions 2.7 (1.9 - 3.7) 0.0015 
(0.0009 - 
0.0024) 
Gastrointestinal 
conditions (%) 
1% reduction in risk of 
gastrointestinal conditions 1.0 (0.5 - 1.8) 0.0006 
(0.0002 - 
0.0012) 
 
In order to avoid one percent of psychological conditions, respondents were willing to forgo a 3.6% 
(2.6% to 4.9%) reduction in the percentage of those achieving a 10% weight loss, or a 0.0019 (0.0012 
to 0.0032) mmol/L reduction in HDL cholesterol levels.  To reduce the unfavourable effect of having 
a cardiovascular condition by one percent, respondents were willing to give up a 2.7% (1.9% to 3.7%) 
chance at achieving a 10% weight loss or to have their HDL cholesterol decrease by 0.0015 (0.0009 
to 0.0024) mmol/L.  Respondents were willing to exchange the smallest amount of favourable effect 
for a 1% reduction in the risk of gastrointestinal conditions, a 1.0% reduction in the percentage 
achieving a 10% weight loss and a 0.0006 (0.0002 to 0.0012) mmol/L decrease in HDL cholesterol. 
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 Graphical assessment of discrete choice experiment analysis coefficients 4.7.4
 
 
Figure 4.2 Analysis results of a discrete choice experiment for weight loss drugs with a (A) linear or (B) categorical 
preference function. For weight loss, levels 0, 1, 2, 3 corresponded to 50, 150, 300, and 450 out of 1000 achieving a 10% 
reduction in body weight. For cholesterol, levels represented negative change, no change, mild improvement, and 
moderate improvement, respectively. For psychological, cardiovascular, and gastrointestinal disorders, levels 
corresponded to a risk of 0, 1, 10, and 100 patients out of 1,000 experiencing an adverse event. 
The coefficient estimates obtained from linear and categorical analysis models are plotted in Figure 
4.2.  The linear function for risks were not linear in the scale presented according to levels due to the 
logarithmic values associated with these risk (0, 1, 10, 100 out of 1000), whereas the function for 
weight loss appeared linear as each levels were approximately equally apart from each other (50, 
150, 300, 450 out of 1000).  For the categorical analysis, there were some inconsistencies in point 
estimates: for example, the preference associated with a moderate increase in the physician’s view 
on cholesterol was smaller than a mild increase, which is counterintuitive considering that a 
moderate increase was higher than a mild increase.  The same was observed in psychiatric 
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conditions, where the second level had lower preference than the third level.  It is possible that this 
could have been due to having half of the questions answered by each participant if not all of 6 
possible combinations of attribute levels were present in each of the two questionnaires. However, 
all of these combinations were present in each questionnaire for psychiatric conditions: therefore, it 
is unlikely slight imbalances in questionnaires would have contributed to these inconsistencies.  Note 
that none of these inconsistencies were at a statistically significant level, which may indicate that a 
larger sample size would be needed to obtain precise estimates in the categorical analysis. 
 
Figure 4.3 Comparison of attribute utility functions derived from linear and categorical preference coefficients obtained 
from a conditional logistic regression model for a discrete choice experiment for weight loss drugs.  Plot x-axes 
represent, for 10% weight loss, the number of patient per 10,000 achieving the outcome, for cholesterol levels, the 
amount of change in HDL cholesterol in mg/dl, and for psychiatric, cardiovascular, and gastrointestinal conditions, the 
risk of presenting with the condition per 1,000.  The y-axes give the utility derived from DCE preference coefficients. 
However, a comparison of the utility functions derived from linear and categorical analyses 
coefficients, presented in Figure 4.3, revealed large deviations from the linear utility function 
commonly assumed in benefit-risk assessments.  For favourable effects, the utility associated with 
early increases in performance were higher than in the linear utility function, diminishing as the 
performance for the favourable effect increased.  For risk attributes, categorical utility functions 
were very different from linear utility functions, especially for cardiovascular and gastrointestinal 
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conditions.  In these two attributes, the utility dropped greatly with a risk of 10 out of 1000, and the 
difference in utility between 10 and 100 out of 1000 was small. 
 Benefit-risk assessment using discrete choice experiment data 4.7.5
The preference for placebo was significantly higher than the preference for rimonabant: at point of 
approval, the mean probability of selecting placebo was 79.5% compared to 20.5% for rimonabant.  
Furthermore, the percentage of simulations where placebo was preferred, i.e. the probability of 
selecting placebo was higher than rimonabant, was 94.2% compared to 5.8% only for rimonabant.  
After initial approval (i.e. once an increased incidence of psychiatric AEs had been detected), the 
preference for placebo increased to 91.3% and the preference for rimonabant decrease to 8.7% and 
placebo was preferred in 98.8% out of the 100,000 simulations (Table 4.14, Figure 4.4, and Figure 
4.5). 
Table 4.14 Results of preference analysis for placebo and rimonabant using DCE results 
 Pre-approval Post-approval 
 Mean 
(median) 
Percentile Mean 
 (median) 
Percentile 
 2.5% 97.5% 2.5% 97.5% 
Preference for placebo (%) 79.5 (83.6) 38.3 97.5 
91.3 
(95.2) 59.9 99.9 
Preference for rimonabant (%) 20.5 (16.4) 2.5 61.7 
8.7 
(4.8) 0.1 40.1 
Placebo preferred (%) 94.2 Not applicable 98.8 Not applicable 
Rimonabant preferred (%) 5.8 Not applicable 1.2 Not applicable 
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Figure 4.4 Percent of simulations where the probability of selecting on alternative was higher at point of first approval 
and after initial approval. Placebo had a higher selection probability than rimonabant in 94% of 100,000 simulations. 
 
 
Figure 4.5 Posterior distribution of the probability of selecting an alternative among the set of alternatives for placebo 
and rimonabant 
The relative contribution of each attribute to the difference in value between rimonabant and 
placebo were investigated.  This provides a measure of the proportion of the difference in value that 
can be attributed to a particular attribute.  Psychiatric conditions had the highest influence on the 
difference in value between rimonabant and placebo out of all five attributes with a contribution of 
41% of the total difference in value.  In contrast, cardiovascular conditions, which had the second 
largest coefficient size in the DCE analysis, had the lowest contribution to the difference in value 
between the two alternatives with a mean of 1.3%.  Furthermore, the negative contribution of 
psychiatric conditions alone was enough in some cases to overcome the positive contribution of 
weight loss and cholesterol attributes i.e. the sum of the mean contribution of 10% weight loss 
(0.16) and HDL cholesterol levels (0.18) was smaller than the contribution of psychiatric conditions 
(0.41) (Table 4.15). 
Table 4.15 Proportion contribution of attributes to the difference in value between rimonabant and placebo (pre-
approval). 
 
Mean 95% CrI 
10% weight loss 0.16 (0.09 - 0.26) 
HDL cholesterol levels 0.18 (0.01 - 0.42) 
Psychiatric conditions 0.41 (0.27 - 0.54) 
Cardiovascular conditions 0.01 (0.00 - 0.02) 
Gastrointestinal conditions 0.24 (0.15 - 0.33) 
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 Free text responses 4.7.6
4.7.6.1 Other considerations important to decision-making from a participant perspective 
Many participants provided free text responses to describe which other considerations were 
important to them if they were in a position to select a treatment for weight loss.  The breadth of 
responses is displayed in Table 4.16. 
Table 4.16 Considerations important to decision-making from a participant perspective when selecting a treatment for 
weight loss 
Category  Consideration  
Treatment  Ease of access 
 Method of administration, e.g. degree of 
invasiveness, frequency 
 Biological mechanism e.g. one that 
blocks hormone production or “speeds 
metabolism” 
 Potential interactions with other 
treatments  
 Duration of treatment  
 Speed and maintenance of weight loss, 
plus ability to “wean off” without 
rebound weight gain or “yo-yoing” 
 Addictiveness  
 No animal testing and vegetarian 
friendly 
 Cost to the National Health Service 
General health and quality of life  Quality of life 
 Mental health 
 Feel better physically  
 Stress placed on the body and energy 
levels 
 Ability to integrate into life and lifestyle 
restrictions 
 Maintaining commitments: work, family, 
gym and exercise, study 
Diet, exercise, and support  A supportive environment 
 No major restrictions on what to eat and 
drink 
 Knowledge of health benefits 
 Professional (e.g. physician, 
physiotherapist) and peer (e.g. friends, 
family, others losing weight) support 
 Dietetic and exercise advice and medical, 
psychological support, such as cognitive 
behavioural therapy, counselling, 
support groups, personal one-on-one 
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Category  Consideration  
support offered through general 
practitioner surgery, weight loss clubs, 
online support networks, educational 
materials and buddy schemes 
 Follow-up support once weight has been 
lost 
Other favourable and unfavourable effects  Appearance 
 Blood pressure 
 Cholesterol levels 
 Cardiovascular fitness 
 Headaches 
 Light headedness and dizziness 
 Drowsiness 
 Joint pain 
 Lowering risk of diabetes 
 Diarrhoea 
 Acne and skin allergies 
 Hair loss 
 Osteoarthritis, arthritis and skeletal 
issues 
 Excess skin 
 Malabsorption of vitamins and minerals 
 Visceral fat 
 Kidney stones 
 
In addition to this, many participants voiced their varying perceptions towards benefit and risk: 
 “To be honest I would not want to take treatment if there were side effects that could effect 
[sic] my HDL levels [sic], psychiatric, cardiovascular or gastrointestinal conditions.” 
 “If a treatment would guarantee a 10% weight loss but would give me cardio-vascular 
problems, I would rather not have the treatment but be encouraged to lose weight through 
diet and exercise.” 
 “i have no other considerations and in fact would be prepared for quite a high degree of 
short-term discomfort for help with weightloss.” 
 “It's important to me that a treatment has little or no side effects or risks associated with it, 
even if that means it's not as successful as another drug which may be more effective but 
have detrimental effects on my health.” 
 “any side effects at all would put me off any treatment.” 
 “I would be prepared to take small risk with most of the above conditions to achieve a 
healthy body mass index. “ 
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 “When it came to choosing the treatment options, I was looking for the one which had the 
greatest chance of weight loss, the other factors were negligible [sic] for me.” 
Rimonabant was even mentioned in a response from one of the participants, “For the record, I loved 
accomplia [sic] - changed my interest in food completely. Then it was withdrawn from the market...” 
4.7.6.2 Critique and improvements to the survey 
Many participants provided positive feedback, and stated that the survey was interesting, thought-
provoking, and easy to fill in.  However, there was also some criticism which is described in Table 
4.17.  Potential improvements to address the critique are also described in the table.   
Table 4.17 Potential improvements which could be made to resolve critique of the DCE 
Critique Potential improvements  
Questioning was too narrow and closed and 
there were difficulties selecting between 
treatment A and B 
Include a “neither” option for participants to 
select if they desire 
High level of English was necessary to complete 
the tasks: (a) complicated phrasing describing 
tasks, (b) difficulties understanding the 
seriousness of psychiatric or cardiovascular 
problems 
More rigorous piloting to test participant 
comprehension of the tasks, and further testing 
of the glossary 
The pages are too similar (identically displayed 
and the same colour) and it can get confusing 
The visual display of the question could be 
changed or page/question numbers could be 
added to assure reader that it is a new page 
Difficulties interpreting the treatments after 
repeating the task multiple times 
This suggests cognitive fatigue, and so it is 
important not to overburden the participants 
with too many choice sets 
Statistics were hard to grasp and work out; 
suggested use of visualisations to display the 
benefits and risks 
Easily interpretable visualisations could be 
developed to describe the benefits and risks 
 
 Communication of results to participants 4.7.7
As part of the agreement for the obesity organisation Weight Concern to circulate the rimonabant 
DCE survey link to their members via email, it was required for us to produce a report of the results 
which would be sent to all of their members once the study had ended.  Weight Concern consider 
the communication of results to participants an integral part of involving people in research, and 
believe that researchers should show participants how their responses contribute to scientific 
findings.  From their experience, they feel that this generates motivation for individuals to 
participate again in future surveys.   
Weight Concern were very flexible over the format of presenting of the results to a lay audience, and 
did not have a standardised template for presenting the results of studies that they conduct or 
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participate in; they were open to a wide range of writing styles and visualisations that could be used 
to present the results, as long as they could be easily understood by the recipient.   
Before beginning to draft the results, the desired length of the document was considered.  Two 
pages were deemed sufficient enough to succinctly capture the results of the study without 
overburdening the reader and placing too much of a demand on time.  The level at which to report 
the results was carefully considered based on our assumptions about the level of knowledge the 
participants would have about benefit-risk methods, statistical methods and regulatory decision-
making.   
It was challenging to decide how to present the results.  Typically, DCE results are in the form of 
coefficients obtained via a logistic regression model, and displaying results in this format to a lay 
audience was regarded as inappropriate, as it assumes a high level of mathematical knowledge and 
could be very confusing to interpret.  Therefore, a focus on describing the results was chosen 
regarding the feasibility of the methodology—i.e how individuals had found the process of 
completing the questionnaire, and the outcomes they considered to be important.   
A question and answer format was adopted in the document because it was preferred over other 
methods of presentation.   It allowed for a large amount of text—which might be considered to be 
overwhelming and daunting to face by the reader, to be broken down into more manageable 
amounts, reducing the cognitive burden.  Bolded questions also allowed the text to be easily 
navigable by the reader; those who do not want to, or may not have the time to read the entire 
document have clear signposting to areas of the document which they may consider to be the most 
interesting, or most applicable to themselves.   
An initial draft of the results was composed and circulated to Weight Concern.  Several amendments 
to the terminology used within the document were made.  Weight Concern suggested changes so 
that the language used would better suit the audience, e.g. “lay people” to “members of the public”, 
“DCE” or “discrete choice experiment” to “the experiment”, “regulatory documents and academic 
research” as “previous research”.  Several commented that the term “regulatory decisions” required 
expanding upon, as lay people are unlikely to know what regulatory decisions are, and who performs 
them.  The document was amended to include this information.   
The first draft of the document referred to readers as “you”, e.g. “How did you value the benefits 
and risks of obesity treatments?”  Weight Concern pointed out that the term “you” should be 
replaced with “the Big Panel”.  This is because the term “you” is ambiguous in its interpretation, and 
can either refer to all of the respondents in a plural manner, or just the individual reading it in a 
 147 
 
singular manner.  If interpreted in a singular manner, the results may then cause offence if 
individuals feel that what is reported does not reflect their personal perspective, and conflict with 
any responses they may have provided.  Also, the document was circulated to all members of 
Weight Concern, giving the opportunity for those who did not participate to read on results.  In this 
case, the results are also not appropriate to be interpreted as “you” singular. 
Many participants reported that they would have liked a “neither” option in the DCE.  The first draft 
of the report said that a “neither option” would be included in future.  However, after careful 
reflection, this was amended to say that we will consider using a “neither option” if appropriate.  
While writing the first draft, it was very compelling to adhere to user feedback and report that we 
will be implementing their suggestions, but the team was wary of providing promises which might 
be difficult to adhere to if they might potentially compromise the feasibility or scientific validity of 
the research.  A final version of the communication can be found in Appendix 6.  Although my email 
address was provided at the end of the results, none of the respondents chose to provide feedback 
or enter correspondence with us.  
4.8 Application of stochastic multi-criteria acceptability analysis  
 Survey results 4.8.1
After responding to the choice sets in the Weight Concern DCE survey, participants were asked to 
rate how strongly they believed each of the attributes drove their choices when deciding between 
Treatment A or Treatment B.  A Likert scale was provided to collect this information, and individuals 
were asked to rank each outcome on a nine point scale, where 1 was labelled as extremely weak, 3 
was weak, 5 was moderate, 7 was strong, and 9 was extremely strong.   The results can be found in 
Table 4.18.  They are also graphically represented in Figure 4.6. 
Table 4.18 Participant responses to the question, "Please give a score on how strongly you believe each outcome drove 
your choices when deciding between Treatment A or B." 
 Likert Scale 
Attribute 
Extremely 
weak 
 Weak  Moderate  Strong  Extremely 
strong 
1 2 3 4 5 6 7 8 9 
Physicians view on 
HDL cholesterol levels 
7% 3% 13% 7% 41% 13% 12% 1% 2% 
10% weight loss 0% 1% 2% 3% 15% 9% 24% 11% 36% 
Psychiatric conditions 2% 2% 5% 4% 22% 8% 27% 9% 21% 
Cardiovascular 
conditions 
1% 1% 4% 3% 20% 10% 28% 16% 18% 
Gastrointestinal 
conditions 
2% 4% 15% 9% 32% 9% 16% 6% 6% 
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Figure 4.6 Bar chart representation of how participants believed each attribute drove their choices when deciding 
between treatment A or B  
 Define set of alternatives and criteria 4.8.2
The two alternatives considered in the rimonabant case study are 20mg rimonabant and placebo.  
The criteria to be included are the attributes which were evaluated in the DCE, i.e. 10% weight loss, 
HDL cholesterol, cardiovascular conditions, psychiatric conditions, and gastrointestinal conditions. 
I developed twelve SMAA models, which examined all possible combinations of the following three 
options: 
1. Using data available 1)  in April 2006 at the time of initial authorisation or 2) in October 2008 
when the CHMP decided if the marketing authorisation should be maintained, varied, 
suspended, or withdrawn following the increased occurrence of psychiatric adverse events 
2. Using, for safety and efficacy attributes, 1)  a normal (Gaussian) distribution, 2) an interval 
covering the 95% credible interval range, or 3) the fixed mean (exact) 
3. Using 1) ordinal preference information according to the DCE questionnaire, or 2) missing 
preference information 
All analyses were carried out in JSMAA v1.0.2 (http://smaa.fi/jsmaa/). 
 Performance estimates and uncertainty 4.8.3
The performance of rimonabant and placebo for each criterion, defined as a Gaussian distribution, 
an interval, or a fixed value, are presented in Table 4.19.     
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Table 4.19 Rimonabant case study SMAA input parameters 
 Pre-approval 
 Rimonabant Placebo 
 Fixed 
Gaussian 
(mean ± SD) Interval Fixed 
Gaussian 
(mean ± SD) Interval 
Weight loss 0.25 0.25 ± 0.059 0.15, 0.38 0.062 0.062 ± 0.017 0.035, 0.099 
Cholesterol 0.2 0.20 ± 0.089 0.024, 0.38 0.1 0.10 ± 0.088 -0.071, 0.28 
Psychiatric 0.25 0.25 ± 0.0099 0.24, 0.27 0.12 0.12 ± 0.0087 0.11, 0.14 
Cardiovascular 0.025 0.025 ± 0.0031 0.019, 0.031 0.011 0.011 ± 0.0026 0.0062, 0.016 
Gastrointestinal 0.22 0.22 ± 0.0090 0.21, 0.24 0.12 0.12 ± 0.0085 0.10, 0.14 
 
Post-approval 
 
Rimonabant Placebo 
 
Fixed Gaussian (mean ± SD) Interval Fixed 
Gaussian 
(mean ± SD) Interval 
Weight loss 0.25 0.25 ± 0.059 0.15, 0.38 0.062 0.062 ± 0.017 0.035, 0.099 
Cholesterol 0.19 0.19 ± 0.072 0.047, 0.33 0.09 0.09 ± 0.073 -0.053, 0.24 
Psychiatric 0.47 0.47 ± 0.18 0.29, 1.00 0.26 0.26 ± 0.11 0.17, 0.48 
Cardiovascular 0.061 0.061 ± 0.087 0.013, 0.24 0.032 0.032 ± 0.053 0.0083, 0.094 
Gastrointestinal 0.26 0.26 ± 0.11 0.16, 0.50 0.13 0.13 ± 0.060 0.083, 0.20 
 
 Define value function 4.8.4
The survey did not elicit value functions from participants and so a linear value function was used for 
all criteria.  It was fitted starting from the lowest and highest limits among the credible intervals for 
both alternatives; the largest and smallest values possible for each criterion were fitted with an 
ascending or descending function with value 0 to 1.  Efficacy measures were defined with ascending 
value functions (i.e. 10% weight loss and HDL cholesterol), whereas adverse events used descending 
value functions (i.e. psychiatric, cardiovascular and gastrointestinal conditions).  For fixed means, the 
value was set to 1 for the most preferred measure and 0 for the least preferred measure.   
 Preference information 4.8.5
Two types of preference information were investigated: (a) missing, and (b) ordinal.  In SMAA 
models with missing preference information, attribute weights are derived at random. 
For ordinal preference information, only the ranking of attributes are provided and thus, attribute 
weights are unknown.  These are generated according to the ranking provided so that the random 
combinations of weights respect the specified ordinal ranking.  Ranking of attributes were derived 
from the DCE survey where participants were asked to rate each attribute on the Likert scale.  A 
mean score was calculated by multiplying each value on the Likert scale by the proportion of 
respondents rating at each scale and performing the sum over all nine levels (Table 4.20). 
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Table 4.20 Rimonabant case study ranking of criteria according to questionnaire responses 
Criteria Mean 
score 
Rank 
Weight loss 6.22 1 
Psychiatric 5.70 2 
Cardiovascular 5.45 3 
Gastrointestinal 4.23 4 
HDL cholesterol 3.78 5 
 Results 4.8.6
The rank acceptability indices for all twelve SMAA models are summarised in and discussed in 
Section 4.9.1.4.  This index provides a measure of how often a given alternative is ranked first across 
10,000 simulations covering the possible combinations of attribute performance and weight.  In nine 
out of twelve models, the rank acceptability index for placebo was higher than rimonabant.  
Rimonabant ranked first more often compared to placebo when using post-approval data with 
normal distributions and any preference information and with interval measurements and ordinal 
preference information.  
Table 4.21 Results of twelve SMAA models comparing rimonabant to placebo. Rank acceptability indices by type of 
performance measure, time point, and preference information. 
Model options Rank acceptability index 
Measurement Preference Rimonabant Placebo 
Pre-approval 
Gaussian Ordinal 0.25 0.75 
Gaussian Missing 0.15 0.85 
Interval Ordinal 0.27 0.73 
Interval Missing 0.17 0.83 
Mean (exact) Ordinal 0.41 0.59 
Mean (exact) Missing 0.31 0.69 
Post-approval 
Gaussian Ordinal 0.85 0.15 
Gaussian Missing 0.56 0.44 
Interval Ordinal 0.68 0.32 
Interval Missing 0.39 0.61 
Mean (exact) Ordinal 0.41 0.59 
Mean (exact) Missing 0.31 0.69 
 
4.9 Discussion 
The aim of this chapter was to examine the feasibility of eliciting patient and public preferences 
regarding the favourable and unfavourable effects of treatments using formal benefit-risk 
assessment methodologies.  To meet this aim, the feasibility of eliciting patient and public 
 151 
 
preferences on the favourable and unfavourable effects of rimonabant using DCE and SMAA were 
examined.  Data on favourable outcomes (i.e.10% reduction in bodyweight, reduction in HDL 
cholesterol) and unfavourable outcomes (i.e. psychiatric, cardiovascular and gastrointestinal 
conditions) were extracted and synthesised from publicly available sources.  These outcomes were 
then used as attributes in a DCE to elicit weight loss treatment preferences from members of Weight 
Concern.   The responses to the DCE were analysed using conditional logistic regression, and the 
coefficient estimates and marginal rates of substitution were calculated.  In addition to this, a 
probabilistic benefit-risk assessment method was developed for use with DCE studies and applied to 
the results of the DCE to elicit weight loss treatment preferences.  Next, additional ranking data 
which was collected in the survey was analysed using SMAA.  Lastly, participants were also asked to 
describe which other outcomes would be important to them if they were in a position to select a 
treatment for weight loss.  The results of the DCE were communicated to members of the 
participating patient organisation, Weight Concern.   
 Main findings 4.9.1
Pre-authorisation data reporting the favourable effects of rimonabant were provided by four clinical 
trials: RIO-North America, RIO-Europe, RIO-Lipids, and RIO-Diabetes.  Post-authorisation data 
reporting the unfavourable effects of rimonabant—and included the increased occurrence of 
psychiatric disorders, were provided by three clinical trials: CRESCENDO, STRADIVARIUS, and 
SERENADE.  For the favourable effects, the percentage of participants who achieved a 10% reduction 
in bodyweight was significantly higher in the rimonabant group compared to the placebo group.  The 
difference in the mean change from baseline of HDL was not significantly different in both groups.  
However, this change was significantly positive in the rimonabant group, but not in the placebo 
group.  For unfavourable effects, the risk of psychiatric, cardiovascular, and gastrointestinal 
disorders were significantly higher in rimonabant compared to placebo.  However, once post-
approval data were included and overall effects estimated using a random-effects meta-analysis 
model, there were no significant differences in risks.  However, point estimates for all risks increased 
considerably, with almost a doubling of the risk difference between rimonabant and placebo. 
This chapter found that it is feasible to elicit patient and public preferences on the favourable and 
unfavourable effects of treatments for overweight and obesity using a DCE. 191 individuals 
responded to the DCE online questionnaire (of which 100 responded to questionnaire one and 91 
responded to questionnaire two).  When analysing the preference data with conditional logistic 
regression, all of the coefficients were found to be statistically significant (p-value<0.001).  The two 
favourable effects, HDL improvement and 10% weight loss had positive coefficients: as the level of 
each favourable effect increased, a respondent was more likely to select the treatment in the choice 
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set.  Conversely, the three unfavourable effects, psychological, cardiovascular and gastrointestinal 
disorders all had negative coefficients: as the levels of each risk increased, a respondent was less 
likely to select the treatment in the choice set. 
Using the results from the conditional logistic regression model, it was possible to calculate the 
marginal rates of substitution between the two favourable effects and the three unfavourable 
effects.  In order to avoid a one percent risk of psychological conditions, one percent risk of 
cardiovascular conditions, and one percent of gastrointestinal conditions, respondents were willing 
to forgo a 3.6% (2.6% to 4.9%), 2.7% (1.9% to 3.7%), and 1.0% (0.5% to 1.8%) reduction in the 
number of those achieving a 10% weight loss, respectively.  Additionally, in order to avoid a one 
percent risk of psychological conditions, one percent risk of cardiovascular conditions, and one 
percent of gastrointestinal conditions, respondents were willing to forgo a 0.0019mmol/L 
(0.0012mmol/L to 0.0032mmol/L), a 0.0015mmol/L (0.0009mmol/L to 0.0024mmol/L), and a 
0.0006mmol/L (0.0002mmol/L to 0.0012mmol/L) reduction in HDL cholesterol levels, respectively.  
In comparison, a mild improvement in HDL cholesterol levels was quantified as an increase of 0.065 
to 0.129 mmol/L earlier in this thesis (Section 4.6.6).  
This chapter demonstrates that it is possible to formally incorporate subjective values and 
preferences obtained from a DCE to determine the benefit-risk balance of a treatment.  When using 
my proposed method for conducting benefit-risk assessment using DCE data, the preference for 
placebo was significantly higher than preference for rimonabant at time of approval, and the 
preference for placebo over rimonabant increased following approval due to the occurrence of 
psychiatric disorders. 
Additional preference data from patients and the public was collected which ranked the favourable 
and unfavourable effects, and were analysed using SMAA—another method hypothesised for use 
within regulatory decision-making to determine the benefit-risk balance of a treatment.  For SMAA, 
all six models using pre-approval data yielded a higher rank acceptability index for placebo 
compared to rimonabant.  Using post-approval data, rimonabant ranked first more often than 
placebo when using normal distributions with any preference information and using interval 
measurements with ordinal preference information.  
Participants also provided feedback on other outcomes they would consider important if they were 
in a position to decide between treatments for obesity, and the results of the DCE were 
communicated back to them.  There was a wide breadth of responses: Many participants provided 
positive feedback, and stated that the survey was interesting, thought-provoking, and easy to fill in.  
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However, there was also some criticism: many participants would have liked a “neither treatment” 
option presented alongside “Treatment A” and “Treatment B”.   
4.9.1.1 Feasibility of conducting a discrete choice experiment to elicit patient and public 
preferences 
In the context of the case study, there were a large number of outcomes, i.e. over twenty, which 
could have been adopted as potential attributes.  To resolve which attributes should be included in 
the DCE, the Wave One rimonabant team considered which outcomes they believed to most greatly 
impact the attractiveness of rimonabant from a regulatory perspective.  However, there could have 
also been the option for patients to select the outcomes which they thought would most greatly 
determine their choice of treatment.  To investigate this, focus groups and interviews have been 
used in previous studies (Pitchforth et al., 2008).  Due to the feasibility of studying this with the given 
resources of PROTECT WP5, this option was not explored.   
There are two methods of representing unfavourable effects as attributes in a DCE.  The first is to 
present a broad category of AEs as a single attribute, and the second is to select a single AE as an 
attribute.  The first option was selected by the team in this case study as it accounts for a more 
complete picture of the potential patient experience.  It also better accommodates the data; one of 
the limitations of publicly available clinical trial information is that data for specific AEs are not 
always reported across all trials, or the definition may vary across clinical trials.  However, there is 
the challenge that the category of AEs represented by the attribute might encompass a broad range 
of severities.  Thus, there may be variations in how individuals implicitly perceive the severity of the 
attributes and subsequently trade them off and may have implications for the validity of the study.  
A strength of selecting a single AE as an attribute is that the outcome can be precisely defined and 
the variation in perceived severity is reduced.   
In a DCE, attributes should be plausible enough to ensure realistic hypothetical scenarios.  However, 
an individual responded to the feedback section of the survey with, “with weight loss other 
impovements [sic] will follow because general health improves so your suggested outcomes were 
not believeable [sic]”.  It is also important that the participants do not perceive correlations between 
the attributes. However, one participant responded with feedback contrary to this, “I think that if 
10% weightloss is achievable then surely any other conditions, physically emotionally and or 
pyschologoloically [sic] would also improve”. This can be challenging because although weight loss 
does reduce the incidence of cardiovascular conditions, some pharmacological treatments for 
obesity such as sibutramine are associated with an increase in cardiovascular adverse events (James 
et al., 2010).  This may be a specific issue for consideration when DCEs are used in benefit-risk 
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assessment which can also be illustrated with the efalizumab case study; one of the adverse events 
was exacerbation or rebound in psoriasis symptoms which may seem counterintuitive to patients as 
the treatment is expected to improve the condition.   
It should be noted the levels of attributes were determined prior to data extraction and synthesis by 
the Wave One rimonabant team due to the limited timeline for Wave Two.  Both of the activities had 
to run concurrently in order to meet the deadline.  The task was extremely challenging; if DCEs are 
to be used for the benefit-risk assessment of medicines, the data should ideally be carefully 
examined before design of the DCE is initiated.  The efficacy and safety outcomes obtained during 
clinical trial and post-marketing surveillance should have been succinctly characterised into 
corresponding levels that overlap the outcome data ranges.  However, these levels needed to be set 
before the literature could be carefully examined with diligence, and because of this, these were set 
in accordance with Council for International Organizations of Medical Sciences (CIOMS) definitions.  
0 was chosen to represent the scenario of the condition not occurring, 1/1000 was chosen in 
accordance with the upper end of the CIOMS definition of a rare adverse event, 10/1000 
represented the upper end of an uncommon event, and 100/1000 represented the upper end of a 
common adverse event.   
Table 4.22 CIOMS definitions for the rate of occurrence of adverse events 
Category CIOMS definition 
Very common Greater than 100/1000 
Common 10/1000 to 100/1000  
Uncommon 1/1000 to 10/1000 
Rare 1/10000 to 1/1000 
Very Rare Less than 1/10000 
 
Similarly to the attributes, the levels should be realistic and plausible.  The lowest level assigned for 
the number of people experiencing a 10% weight loss was not set to 0 as this would be unrealistic; it 
was set to 10 out of 1000 instead.  This may be an issue for the use of DCEs in benefit-risk 
assessment; if an active treatment is compared against a placebo, the levels can plausibly cover the 
efficacy of the active treatment but it might be implausible for the levels also to cover the efficacy of 
placebo.  Therefore, there may be challenges with using placebo as a comparator.   
One challenge was determining the format of the levels.  Communicating the frequencies in an 
effective and understandable format can be difficult.  We chose to report most outcomes as natural 
frequencies which all use the same denominator (1000 individuals) to facilitate easier comparisons 
between treatments (Gigerenzer, 2003).  In future, it might be interesting to explore graphical 
representation to communicate the favourable and unfavourable effects in a DCE.  This was echoed 
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by one of the participants who suggested that an improvement to the DCE would be “perhaps 
showing the benefits and drawbacks in a bar chart because it can be difficult to understand some on 
the various variables”.   
Communicating changes in HDL cholesterol was also challenging.  When testing participant 
understanding of the attributes and levels during piloting, there was confusion.  Most people are 
familiar with low density lipoprotein cholesterol, which is the “bad” type of cholesterol and a 
reduction correlates with an improvement in health.  HDL is different, because it is the “good” type 
of cholesterol and an increase correlates with an improvement in health.  Feedback showed that 
individuals were confusing these types of cholesterol during piloting—even when the definition was 
present, and so we remedied this by framing the question through the perspective of a physician.  
We also assigned qualitative categories because it is very unlikely that many individuals can 
meaningfully compare the levels when described by a change in mmol/L.  
4.9.1.2 DCE analysis and interpretation 
In this case study, DCE questionnaire data were analysed using a conditional logistic and conditional 
probit regression model.  When compared, coefficient estimates were comparable between both 
methods.  However, results from probit regression models were not easily interpretable and 
incorporable into complementary investigations in this thesis: marginal substitution rates and 
benefit-risk assessment measures were not straightforward to calculate from probit model 
coefficients, and were thus only calculated using logistic regression coefficients. 
Comparison of the size and sign of coefficients provided an easy interpretation for DCE results, and 
with the calculation of marginal substitution rates, offered a simple quantification of trade-off 
between safety and efficacy outcomes.  However, the use of such measures was not easy to 
interpret for the attribute for cholesterol levels as they were described in terms of a change in 
cholesterol levels.  DCE data were also analysed by defining attribute levels as unordered categorical 
variables.  Upon comparison with the initial analysis which assumed a log-linear coefficient across 
the range of attribute levels, large deviations from linearity were observed in a utility function 
derived from model coefficients.  In these comparisons, it appeared that for safety attributes, utility 
dropped most in lower levels of attributes, whereas for efficacy attributes, utility increased most in 
lower levels of attributes.  The implication of such observations is hard to assess as it would be 
dependent on the attribute levels of alternatives.  For example, if the levels for both alternatives are 
high for a safety attribute, then the difference in utility would be small, whereas if both alternatives 
have low levels for the same safety attribute, the difference in utility would be much larger for an 
equivalent difference in attribute levels.  Intuitively, this may be the case as it seems plausible that 
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the reduction in utility between having 10 cases or 0 cases per 1,000 experiencing an adverse event 
should be larger than having 510 or 500 cases per 1,000 experiencing the same adverse event.  
However, this is the assumption that is made when estimating a single coefficient per attribute.  
Although the categorical analysis highlighted important limitations of the traditional analysis and 
may be more suitable for modelling preference, estimates had large uncertainties and lacked 
significance in many cases: thus, such analysis of DCE data would require a larger sample size than 
that achieved in this case study (n=192). 
In this DCE, information on several demographic characteristics including age group, gender, and 
obesity were collected, with the aim of investigating heterogeneity in preference according to these 
factors.  However, no divergence in preference was observed between subgroups in stratified 
analyses; this may have been due to small sample size within subgroups, making it difficult to reach 
significance among coefficients, to the limited number of factors included which may not be those 
that capture variations in preference, or simply the absence of heterogeneity. 
4.9.1.3 DCE for benefit-risk assessment 
Coefficients from a logistic regression model were ideal for use in calculating the probability of 
selecting a specific alternative from a set of alternatives.  In contrast, probit model results could not 
be directly combined with efficacy and safety data without further methodological development. 
In this case study, three measures were proposed to evaluate the benefit-risk balance of rimonabant 
compared to placebo: a graphical representation of the distribution of selection probabilities for 
rimonabant and placebo, calculation of the percentage of simulations where the probability of 
selecting rimonabant or placebo was higher than the other, and the relative contribution of each 
attribute on the difference in value between rimonabant and placebo. 
The graphical representation of the posterior distribution of the probability of selecting a given 
alternative was useful for representing uncertainty in preference, safety and efficacy estimates, and 
also provided a visual illustration of this through the overlap between the two distributions.  There 
was very little overlap between the two distributions, meaning that uncertainty in the preference of 
placebo over rimonabant was robust against varying preference, safety, and efficacy values over 
their range of uncertainty.  
The proportion of iterations where the treatment has a higher selection probability than other 
alternatives was a useful quantitative measure of the uncertainty, which was displayed through the 
distribution of selection probabilities.  Particularly, this measure is most useful when the distribution 
of the probability of selecting alternatives has a large overlap; it may not be clear from the graphical 
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representation which alternative is preferred most of the time.  The probability of selecting placebo 
was superior to that of selecting rimonabant in over 90% of the time, meaning that placebo was 
preferred over rimonabant over 90% of possible combinations of values across the range of 
uncertainty for preference, efficacy and safety. 
The relative contribution of each attribute on the value of an alternative or on the difference in 
value between two alternatives provides information on the relative importance of each attribute in 
the process of alternative selection.  In this case study, psychiatric conditions were the largest 
contributors in the difference in value between rimonabant and placebo whereas cardiovascular 
conditions were the smallest contributors. 
Overall, using DCE for benefit-risk assessment in a simulation context provided useful measures for 
evaluating the benefit-risk trade-off of rimonabant.  From these results, it would be concluded that 
rimonabant is not preferred over placebo.  This preference was robust when considering the range 
of uncertainty in preference, safety, and efficacy estimates; psychiatric conditions were the most 
important attribute contributing to this preference. 
4.9.1.4 Stochastic Multi-criteria Acceptability Analysis 
A total of twelve (six each for pre-approval and post-approval) SMAA models were developed for 
appraising the benefit-risk balance of rimonabant.  In nine of these, placebo had a higher rank 
acceptability index than rimonabant, meaning that placebo was preferred over rimonabant in a 
larger number of simulations covering the uncertainty in attribute performance and weight. 
Rimonabant was preferred over placebo in three of six models using data at time of re-evaluation.  
This may have been due to differences in the (a) data which was used to represent the post-approval 
setting compared to pre-approval setting, and/or (b) distributional assumptions in inputted data, 
and/or (c) use of ordinal versus missing preference.  There were several differences between post-
approval and pre-approval data which was used: firstly, much larger uncertainty for safety outcomes 
were incorporated for post-approval as a Bayesian random-effects meta-analysis model was used to 
calculate overall risks instead of calculating the uncertainty over a single proportion from pooled 
trial data for pre-approval, whereas efficacy measures were nearly identical to pre-approval 
estimates due to the lack of trials reporting comparable outcomes.  Uncertainty in risk estimates 
observed post-approval may have been further increased due to heterogeneity between included 
studies, for example in the duration of trials which varied from 6 to 18 months compared to 12 
months across all four RIO trials, in the inclusion criteria, which varied from patients at risk of 
vascular disease (CRESCENDO)  to patients with type two diabetes (SERENADE)  or metabolic 
syndrome (STRADIVARIUS) compared to only obese patients (RIO-Lipids, RIO-Europe, RIO-North 
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America) or obese patients with type two diabetes (RIO-Diabetes) in pre-approval trials.  The 
distributional assumption of the measurement data may also have impacted estimates differently 
for pre-approval and post-approval.  Having values fixed to the mean yielded comparable estimates 
between pre- and post-approval data.  When using an interval or Gaussian distribution, it is possible 
that larger uncertainty in post-approval data may have contributed in the shifting of preference 
towards rimonabant. This would have been due to a larger range in which values are calculated (for 
example, comparing 60 to 40 on a range of 20 to 60 (100-50=50) versus a range of 0 to 100 (60-
40=20)) within unfavourable effects but not in favourable effects.  The effect of changing preference 
from ordinal to missing had a consistent impact across models whereby the index for rimonabant 
decreased once preference was set to missing. 
Lastly, this may bring forward an important limitation of SMAA, where plausible variations in the 
distribution of performance measures (i.e. Gaussian, interval, exact) may lead to distinct and 
conflicting conclusions on the benefit-risk balance of a treatment.  In line with these observations, 
future studies could evaluate how assumptions on the distribution of attribute performance impact 
on subsequent recommendations over the benefit-risk balance of a treatment. 
4.9.1.5 Comparison of DCE and SMAA for the benefit-risk assessment of rimonabant 
In this case study, DCE and SMAA were used to evaluate the benefit-risk balance of rimonabant.   At 
time of marketing authorisation, both SMAA and DCE concluded that the benefit-risk balance was in 
favour of placebo.  The extent at which placebo was preferred over rimonabant in SMAA ranged 
from 59% to 79% with ordinal preference and 69% to 89% with missing preference, compared to 
95% in DCE.  At the second time point, in which three post-approval trials were included for 
estimating the performance of rimonabant and placebo, placebo remained preferred over 
rimonabant 99% of the time, whereas placebo emerged as the preferred option in only three of six 
models.  Several hypotheses over why SMAA results were conflicting were presented in this 
discussion (Section 4.9.1.4), and will not be repeated here.  
Considering all twelve SMAA results as a whole, placebo would normally emerge as the preferred 
option, which echoes the interpretation of the DCE model.  However, results are difficult to compare 
due to differences in the specification of performance and preference which are developed below. 
For attribute performance of rimonabant and placebo, data were obtained from the raw data 
simultaneously for DCE, meaning that the performance estimates were sampled directly from the 
exact posterior distributions of the overall treatment effects.  For SMAA, raw data could not be 
inputted; instead, the distribution of performance had to be approximated using one of the options 
provided by the JSMAA software.  Distributions considered plausible included a normal distribution, 
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which most closely approximated model estimates, a range covering the 95% range of the posterior 
distribution, or a fixed value equal to the posterior mean. 
Although data on preference for both models were derived from the same questionnaire, DCE and 
SMAA varied in the type of preference included. DCE coefficients incorporate information on how a 
change in the performance of an alternative can influence the preference for that alternative among 
a selection of others: thus, they integrate notions of value and weight in one single measure, 
whereas SMAA rankings, derived from an auxiliary question to the DCE questionnaire, only provides 
ordinal information on attributes.  DCE coefficients cannot be directly translated to a ranking or 
weight of attributes in such a way that they can be used in SMAA, as one would need to first obtain a 
range of performance, calculate the maximum shift in preference from that range (i.e. the range 
multiplied by the coefficient), and then rescale these to obtained a measure comparable to a swing 
weight.  However, in this process, valuable information within DCE coefficients would be lost.  This 
provided the rationale for developing a model to incorporate DCE coefficients into a benefit-risk 
assessment method. 
 Limitations of the case study 4.9.2
Estimates of the unfavourable and favourable effects of rimonabant were extracted from individual 
trial data and EPAR reports.  However, both sources of data presented limitations.  Adverse events 
reported within individual trials were limited to those that had occurred in ≥5% of participants 
within one arm of the trial.  As a result, data on AEs were not consistently available from all trials for 
each outcome of interest.  Data presented in EPAR reports were summed across trials; hence 
individual trial data was not obtainable and could not be used in a meta-analysis model.  Some 
inconsistencies were also observed when comparing data obtained from individual trials and those 
obtained from EPAR.  Notably, the number of serious adverse events quoted in the EPAR reports 
(n=12) were higher than the total obtained from individual trial data (n=10). 
Trials performed after the marketing authorisation of rimonabant reported a high percentage of 
depression, notably in the STRADIVARIUS trial, where 17% of participants in the rimonabant arm 
were affected.  STRADIVARIUS provides explicit data in individual psychiatric disorders (i.e. anxiety, 
depression, insomnia, depressed mood, major depression, suicide ideation, suicide attempt, 
completed suicide, and severe psychiatric disorders).  However, the outcome of depression was not 
reported within any individual RIO trial, which may either be due to it not exceeding the reportable 
threshold of 5% in any trial or to different categorisation of adverse events.  An outcome labelled 
“depressive disorders” reported within EPAR reports may have been comparable but it is difficult to 
determine because the individual conditions which constitute this category are not explicitly stated.   
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Although outcomes from RIO trials were available for study durations of 12 months, this varied 
across trials performed after the marketing authorisation of rimonabant was granted.  The duration 
of SERENADE, CRESCENDO, and STRADIVARIUS trials were 6, 13.8 (mean follow-up), and 18 months, 
respectively.  However, patient-years accumulated within trials required for the calculation of rates 
per 100 patient-years of adverse events were only available for the CRESCENDO trial.  Thus, time-
dependency could not be incorporated within this analysis.  Note that it may be possible that the 
high levels of psychiatric disorders observed within the STRADIVARIUS trial may have been partially 
attributable to the length of duration, which was longest across trials.  The EPAR also stated that 
variations in psychiatric adverse events across trials may have been attributable to variations in trial 
design and study population. 
A major limitation of the DCE in this case study was the small sample size for analysis. This meant 
that preference could not be accurately estimated at each level of each attribute: in the categorical 
analysis, inconsistent coefficients were observed, e.g. an attribute level which represented a higher 
risk was valued more favourable than another level with less risk.  Heterogeneity according to age, 
gender, and current obesity could also not be observed.  Although this may have been due to a lack 
of true heterogeneity in preference in this particular application, it could not be addressed. 
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5 Case study III: Natalizumab 
5.1 Introduction 
The final case study presented in this thesis is natalizumab (Tysabri®), which received marketing 
authorisation from the US Food and Drug Administration (FDA) from November 2004 to February 
2005 for the indication of relapsing remitting multiple sclerosis (RRMS).  The marketing authorisation 
was subsequently suspended due to the occurrence of PML (similarly to efalizumab), but was later 
reintroduced to the market with strict risk minimisation measures in June 2006—demand from 
patient organisations was a major factor which lead to its reintroduction.  In the EU, the EMA 
granted marketing authorisation for natalizumab in June 2006.  In 2009, the benefit-risk balance of 
the treatment was reassessed by the CHMP due to new reported cases of PML; the marketing 
authorisation was maintained with risk minimisation measures in place. 
 
This thesis has so far examined several methods of benefit-risk assessment: descriptive frameworks, 
quantitative frameworks, and the utility survey technique of DCE.  It has identified were PPI can be 
applied in the benefit-risk assessment decision-making pathway, and tested the feasibility of 
applying PPI to the analysis stage by eliciting the preferences of patients and the public on the 
benefits and risks of rimonabant.  It was extremely difficult to adopt PPI in the benefit-risk 
assessment context of rimonabant, as there were few guidelines to aid the planning, conduct, and 
evaluation of the work.  To address this, this chapter will explore the development of a framework to 
incorporate PPI into benefit-risk assessment using the case study of natalizumab, and test its 
feasibility by applying it to additional methods which can be used to elicit preferences from patients 
and the public.   
 
In this chapter I describe the medical condition of relapsing remitting multiple sclerosis (RRMS), and 
the treatment of natalizumab (Section 5.2 and 5.3).  Next, I detail the aim and objectives of the case 
study (Section 5.4), and describe the data I used to provide information on the benefits and risks of 
treatment for the work in this chapter (Section 5.5).  I then design a protocol to elicit preferences on 
the benefits and risks of treatments for RRMS using the methodologies of MCDA swing-weighting, 
MACBETH, and AHP (Section 5.6).  Following this, I present a framework which I designed to plan, 
report and evaluate PPI in the benefit-risk assessment of medicines and test its feasibility using the 
protocol for weight elicitation (Section 5.6.6 and 5.6.7).  Lastly, I discuss the work in this chapter 
(Section 5.8).   
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5.2 Relapsing remitting multiple sclerosis 
 Background and epidemiology 5.2.1
Multiple sclerosis (MS) is an autoimmune disease which attacks the central nervous system.  It is a 
chronic condition and treatments focus on improving symptoms.  In MS, periods of inflammation 
damage the protective myelin sheath surrounding nerve cells, which leave lesions or plaques.  The 
expected lifetime risk of developing MS in the UK is 5.3 per 1000 women, and 2.5 per 1000 men 
(Alonso et al., 2007).  The aetiology of MS is not fully known; the condition is believed to have 
genetic and environmental components (Milo and Kahana, 2010).  For example, there are variations 
in the prevalence of MS according to geographical location, i.e. it is more common in countries 
further from the equator, and a lack of vitamin D has been associated with MS.  Although there is 
insufficient evidence to confirm, some believe that viruses and bacteria may play a role in causing 
MS (Noseworthy, 1999).   
There are three main types of MS: relapsing remitting (which represents approximately 85% of MS 
cases) which can evolve into the second type, secondary progressive (characterised by disease 
progression and incomplete recovery following relapses), and the third type is primary progressive 
(which represents approximately 10 to 15% of MS cases) (MS Society, 2013).  RRMS is characterised 
by attacks (relapses) between periods of no symptoms (remissions).  A relapse is defined as "the 
appearance of new symptoms, or the return of old symptoms, for a period of 24 hours or more – in 
the absence of a change in core body temperature or infection" (MS Society, 2013).  Symptoms can 
be physical (e.g. vision, balance, speech, tremor, bowel functioning) and/or can affect memory, 
thinking and emotions.  Stress, infection, vaccination and pregnancy have been found by some to 
trigger relapses.   
Relapses can range from mild to severe.  If the relapse is mild, the individual may be treated at 
home.  If the relapse is more severe, hospital treatment may be required.  During a relapse, 
demyelination occurs; inflammation caused by T cells stimulates other immune cells and soluble 
factors, e.g. cytokines and antibodies to produce leaks in the blood–brain barrier.  This in turn causes 
a number of other damaging effects such as swelling, the activation of macrophages, and the 
activation of cytokines and other destructive proteins (Compston and Coles, 2008).  The duration of 
a relapse may range from a few days to many months, and they typically last for approximately four 
to six weeks.  Following this, there is a period of remission, where individuals recover from the 
symptoms.  However, if there is severe damage to the myelin, some symptoms may remain. 
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 Impact of relapsing remitting multiple sclerosis on quality of life 5.2.2
Many of the symptoms caused by RRMS have been reported by patients to negatively affect quality 
of life (Newland et al., 2012).  Unpredictable fatigue—often made worse with heat, can affect basic 
tasks such as housework, food preparation and eating.  Cognitive loss is relatively common, and can 
affect memory, concentration, and speech.  For example, individuals may forget words mid-
sentence, or be unable to recall what they have just said.  This can interfere with a number of 
activities of daily living, and include occupational difficulties.  Vision may also be affected, and 
symptoms may include partial or total blindness, blurring, or double vision.  Individuals may also 
experience a loss of balance which results in dizziness, and the experience has been reported as 
feeling similar to being intoxicated.  Another importance concern is that RRMS is chronic, and 
relapses are unpredictable.  This brings to the foreground the need for safe and effective treatments 
to control the symptoms of RRMS.   
5.3 Description of treatment 
Natalizumab is a recombinant humanised monoclonal antibody treatment.  It recognises and 
attaches to α4β1 integrin, found on the surface of most leucocytes, i.e. the white cells in the blood 
which are involved in the inflammation process.  This prevents leucocytes from travelling in the 
blood to the brain, and thus reduces the inflammation and nerve damage caused by MS (EMA, 
2010).   
Natalizumab is indicated as single disease modifying therapy in highly active RRMS for (EMA, 2009g):  
a) “Adult patients aged 18 years and over with high disease activity despite treatment with a 
beta-interferon,  i.e. at least 1 relapse in the previous year while on therapy, and have at 
least 9 T2-hyperintense lesions in cranial Magnetic Resonance Image (MRI) or at least 1 
Gadolinium-enhancing lesion or an unchanged or increased relapse rate or on-going severe 
relapses, as compared to the previous year”; or, 
b) “Adult patients aged 18 years and over with rapidly evolving severe relapsing remitting 
multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more 
Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as 
compared to a previous recent MRI.” 
300mg of natalizumab is administered by intravenous infusion to RRMS patients once every four 
weeks in a hospital or clinic.  The duration of infusion is one hour, and the patient must be 
monitored for an additional hour afterwards.  Treatment is reconsidered in those who do not 
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experience therapeutic benefit beyond six months, and there is a reassessment of the potential for 
benefit and risk after two years since initiation of the treatment.   
 Marketing history 5.3.1
Natalizumab received marketing authorisation in June 2006 from the EMA and is still authorised at 
time of writing.  The full procedural history is publicly available and can be found on the EMA 
website (EMA, 2009g, EMA, 2010).   Important events relating to authorisation decisions and PML 
are summarised from the online documents below:  
 November 2004: FDA granted marketing authorisation for natalizumab in the US. 
 February 2005: FDA suspended marketing authorisation in the US due to the occurrence of 
two cases of PML (one of which was fatal) reported in RRMS patients in the SENTINEL clinical 
trial: both patients had been treated with a combination of natalizumab and beta-interferon 
for more than two years.  Later, a third case of PML was discovered on re-evaluation of the 
Crohn’s Disease safety database for a patient enrolled in the ENACT clinical trial. 
 June 2006: FDA reintroduced natalizumab to the market with strict risk minimisation 
measures—the demand from patient organisations was a strong factor leading to its 
reintroduction. 
 27 June 2006: CHMP issued a positive opinion for granting marketing authorisation with 
special warnings in the product information and extensive risk minimisation measures, 
including physician information and management guidelines.   
 October 2008: Two cases of PML were confirmed in RRMS patients following EMA 
authorisation; for both cases natalizumab was used as a monotherapy and the treatment 
was administered for approximately 17 and 14 months.  In total 38,700 patients had been 
treated worldwide since approval, and 4,650 patients had received natalizumab in clinical 
trials. 
 July 2008 to October 2009: 23 confirmed cases of PML were reported worldwide in patients 
with MS receiving natalizumab between July 2008 and October 2009, resulting in four 
deaths.  By 20 January 2010, the total number of confirmed PML cases had risen to 31 
worldwide, of whom 23 had received natalizumab for more than two years. The EMA stated 
that this is equivalent to around one case of PML for every 1,000 patients treated with 
natalizumab for two years or more. 
 22 October 2009: The CHMP requested a review of the benefits and risks to decide if 
marketing authorisation for the product should be maintained, varied, suspended or 
withdrawn.  This was followed by the occurrence of new cases of PML, and in consideration 
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of the occurrence of Immune Reconstitution Inflammatory Syndrome (IRIS) in PML patients 
once natalizumab had been stopped and plasma exchange (PLEX) and/or immunoabsorption 
had been implemented.  The CHMP concluded that the benefit-risk profile of natalizumab 
remained positive. 
 November 2010: The MAH analysed the data of 52 natalizumab treated patients with 
confirmed PML in respect of an association with prior immunosuppressant (IS) use. The 
presented data indicated that prior IS use increases the risk of PML independent of the 
duration of natalizumab therapy. 
 April 2011: The risk of PML with natalizumab was reported to be higher if the patients (a) 
have received natalizumab for more than 2 years, and/or (b) have received prior 
immunosuppressant therapy, and/or (c) are anti-JCV antibody positive.  The EMA stated that 
patients who have all three risk factors for PML have the highest risk of PML (approximately 
9 in 1,000 patients treated). 
 April 2011: CHMP stated that it was their belief that the benefit-risk balance remained 
positive for the MS population with less than 24 months exposure to rimonabant, even in 
the presence of prior immunosuppressive treatment and seroprevalence of JCV.  However, 
they stated that post-marketing data does not provide complete evidence of how the risk 
factors could combine and affect the benefit-risk balance in long-term exposed patients.  
Therefore, the CHMP offered the opinion that one additional five year renewal on the basis 
of pharmacovigilance grounds is required. 
 April 2012: Based on continuing evaluation of PML, the PML incidence rates were updated 
based on post-marketing data, resulting in changes to the PML incidence figures for patients 
with antibodies against JCV or more additional risk factors. The CHMP considered that these 
revised PML incidence rates are not significantly different from the numbers that were 
included in the previous version and their opinion on the benefit-risk balance did not alter.  
5.4 Aims and objectives 
The aims of the natalizumab case study in this thesis are: (1) to develop a framework to guide the 
application, reporting, and evaluation of PPI in the benefit-risk assessment of medicines, and (2) to 
test the feasibility of the framework by applying it to multiple different methods of eliciting 
preferences from patients and the public.   
To meet these aims, the objectives are: 
 To develop a framework which can guide the application, reporting, and evaluation of PPI in 
benefit-risk assessment using key documents 
 166 
 
 To develop a protocol to assess and compare the process and results of different methods of 
eliciting patient and public preferences on the benefits and risks of natalizumab, i.e. MCDA 
swing-weighting, AHP, MACBETH 
 To evaluate the feasibility of the PPI framework by applying it to the protocol for preference 
elicitation 
5.5 Development of the framework to guide the application, reporting and 
evaluation of PPI 
Although frameworks to address PPI already exist, they predominantly focus on PPI in general, or on 
the context of health research and health services.  There is not a clear framework to guide the PPI 
in the benefit-risk assessment of medicines.   To address this, the principles and indicators of PPI 
published in the documents described in Section 5.5.1 were extracted and carefully considered to 
create a preliminary version of a framework to guide the application, reporting and evaluation of PPI 
in the benefit-risk assessment of medicines (Table 5.1).  The feasibility of this framework is evaluated 
later in this chapter (Section 5.6.7), by applying it to the protocol for preference elicitation presented 
in Section 5.6. 
Table 5.1 Preliminary version of the framework developed to guide the application of PPI to the benefit-risk assessment 
of medicines and regulatory decision-making 
Step  Points to consider 
Determine the purpose of PPI What is the aim? 
During which stage(s) of the methodology is involvement 
required and/or desired? 
What is the desired level of involvement for each stage? 
Ethical approval Is ethical approval required?  
Who needs to approve ethics application? 
How long is needed to obtain ethics approval? 
Address potential barriers and 
negative outcomes 
What are the potential barriers to meaningful involvement? 
What are the potential negative outcomes of involvement? 
How can the barriers and negative outcomes be alleviated? 
Training Do participants require training and support?  If so, how will 
this be addressed? 
Do researchers require training and support?  If so, how will 
this be addressed? 
Recruitment Which group of participants will be used to represent 
patients and the public?  
What is the sample size required for the methodology? 
What are the methods of recruitment? 
Design a statement of agreement 
between the researchers and 
participants 
Is it possible to provide full disclosure of the benefit-risk 
methodology being studied and the role and anticipated 
value of patient involvement? 
What are the roles and responsibilities of both the 
researcher and the participant? 
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Step  Points to consider 
Have the expected needs and contribution of both the 
researcher and the participant been defined? 
Do the participants know all of the confidentiality, 
anonymity, drop-out, and acknowledgement policies? 
Patient involvement activities What are the anticipated time scales for involvement 
activities? 
What is the method of communication? 
What is the location of involvement activities (if applicable)? 
Finances Are there finances in place to specifically support 
involvement? 
Can participants receive adequate financial support for their 
expenses and contribution? 
Reporting of outcomes What were found to be the positive outcomes of 
involvement? 
What were the negative outcomes of patient involvement? 
Reporting of conflicting 
perspectives 
Did conflicting perspectives or disagreements occur?  
At which stage of the process did they occur? 
Who did they occur between? 
What were the different perspectives? 
How were they resolved? 
Communication Is it necessary for participants to be periodically informed of 
the decision-making process as it progresses? 
How will participants be informed about the results of their 
involvement? 
How will the contribution of participants be explicitly 
acknowledged? 
How will the involvement process be reported to all 
stakeholders? 
How will the overall impact of the decision on patients be 
evaluated?   
 
 Key documents 5.5.1
Four key documents relating to the conceptualisation of PPI were identified: 
 Arnstein (1969) 
 Hanley et al. (2001)  
 Oliver et al. (2004) and Oliver et al. (2008)  
 Telford et al. (2004)  
It is important to note that these key documents are not intended to represent an exhaustive list of 
references describing PPI frameworks, principles, and indicators.  Each document is summarised 
below. 
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5.5.1.1.1 Arnstein (1969) 
Arnstein (1969) brought to the foreground the importance of citizen participation.  She viewed 
involvement as a catalyst for positive change via the inclusion of groups traditionally excluded from 
political and economic processes.  Involvement represents the cornerstone of democracy, allowing 
individuals to decide for themselves how policies are set and the allocation of resources. For 
Arnstein (1969), to engage in citizen participation is to engage in significant social reform where the 
benefits can be enjoyed by all members of society.  However, as shown in Table 5.2, the level of 
participation ranges from empty ritual to real power via manipulation, therapy, informing, 
consultation, placation, partnership, delegated power, or citizen control (Arnstein, 1969).   
Table 5.2 Arnstein's ladder of citizen participation 
Rung  Description  
1 Manipulation 
 
Substitute for genuine participation.  
Powerholders “educate” or “cure” the 
participants. 
Non-participitation 
2 Therapy 
3 Informing 
 
Citizens can hear and be heard.  However, 
they lack power to ensure their views are 
heeded.  There is no followthrough. 
Degrees of tokenism 
4 Consultation 
5 Placation There are rules for citizens to advise, but 
they do not have the right to decide.  
6 Partnership Enables citizens to negotiate and engage in 
trade-offs with traditional powerholders. 
Degrees of citizen 
power 
7 Delegated Power Citizens have full managerial power. 
8 Citizen control 
 
5.5.1.1.2 Involve (2001) 
Involve (Hanley et al., 2001) condensed Arnstein’s original ladder of citizen participation into three 
rungs that can be used to describe PPI in NHS research: consultation, collaboration, and consumer-
controlled research (Table 5.3).    
Table 5.3 Involve levels of participation 
 Definition 
Consultation 
Experts ask for consumer viewpoints to inform their decision-making.  
Although their viewpoints may not be used, they do have the potential to 
influence decision-making. 
Collaboration Experts maintain an active, on-going partnership with consumers. 
Consumer-
controlled research 
Consumers design, undertake and disseminate research and experts are only 
involved at invitation. 
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5.5.1.1.3 Oliver et al. (2004, 2008) 
Oliver et al. (2004) developed a framework to describe and report the key features of the different 
methods of involving consumers in research Table 5.4.  The columns represent decreasing levels of 
consumer involvement, and the rows represent decreasing researcher commitment to consumer 
involvement.   
Table 5.4 Oliver et al. framework for describing consumer involvement in research agenda setting 
  Consumers’ degree of engagement 
  Consumer 
Control 
Collaboration Consultation Minimal 
Researchers’ 
degree of 
engagement 
Inviting 
consumer 
groups 
    
Inviting 
individual 
consumers 
    
Responding to 
consumer 
action 
    
Minor partner 
or absent 
    
(Oliver et al., 2004) 
The work of Oliver et al. (2004, 2008) has also been adapted by Oxman et al. (2009) into a 
framework to describe and consider approaches to consumer involvement (Table 5.5). 
Table 5.5 Oxman et al. framework for describing and considering approaches to consumer involvement 
Characteristics of different approaches Examples 
Degree of consumer involvement Consultation, collaboration, consumer control 
Forum for communication Written consultation, interviews, focus groups, 
consumer panels, committee membership 
Involvement in decision-making No involvement, implicit involvement, explicit 
involvement 
Recruitment Targeted personal invitations, wide advertising, 
use of mass media, contact by 
telephone/email/mail 
Training and support Education, counselling, mentoring, introduction 
days 
Financial support No financial support, reimbursement of 
expenses, fee or honoraria  
(Oxman et al., 2009) 
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5.5.1.1.4 Telford et al. (2004) 
Telford et al. (2004) developed eight principles of successful consumer involvement in NHS research, 
via an expert workshop and a two-round Delphi process (Table 5.6). 
Table 5.6 Telford et al. principles of successful consumer involvement in NHS research 
Principles Indicator(s) 
The roles of consumers are agreed between the 
researchers and consumers involved in the 
research 
The roles of consumers in the research were 
documented 
Researchers budget appropriately for the costs 
of consumer involvement in research 
Researchers applied for funding to involve 
consumers in the research; Consumers were 
reimbursed for their travel costs; Consumers 
were reimbursed for their indirect costs (e.g. 
carer costs) 
Researchers respect the differing skills, 
knowledge and experience of consumers 
The contribution of consumers’ skills, knowledge 
and experience were included in research 
reports and papers 
Consumers are offered training and personal 
support, to enable them to be involved in 
research 
Consumers’ training needs related to their 
involvement in the research were agreed 
between consumers and researchers; Consumers 
had access to training to facilitate their 
involvement in the research; Mentors were 
available to provide personal and technical 
support to consumers 
Researchers ensure that they have the necessary 
skills to involve consumers in the research 
process 
Researchers ensured that their own training 
needs were met in relation to involving 
consumers in the research 
Consumers are involved in decisions about how 
participants are both recruited and kept 
informed about the progress of the research 
Consumers gave advice to researchers on how to 
recruit participants to the research; Consumers 
gave advice to researchers on how to keep 
participants informed about the progress of the 
research 
Consumer involvement is described in research 
reports 
The involvement of consumers in the research 
reports and publications was acknowledged; 
Details were given in the research reports and 
publications of how consumers were involved in 
the research process 
Research findings are available to consumers, in 
formats and in language they can easily 
understand 
Research findings were disseminated to 
consumers involved in the research in 
appropriate formats (e.g. large print, 
translations, audio, Braille); The distribution of 
the research findings to relevant consumer 
groups was in appropriate formats and easily 
understandable language; Consumers involved in 
the research gave their advice on the choice of 
methods used to distribute the research findings 
(Telford et al., 2004) 
 171 
 
5.6 Protocol for preference elicitation 
In IMI PROTECT WP5, PPI was considered by members to be most desirable and valuable in the 
weighting stage of the benefit-risk methodologies.  This is the stage where the benefits and risks of 
treatments—commonly efficacy and safety measures collected during clinical trials and post-
marketing surveillance, are ranked and weighted.  It was considered to be an important stage to 
investigate because the weights allocated to the favourable and unfavourable of treatments have 
the potential to substantially vary according to whose perspective(s) is/are sought, and 
consequently, may have a substantial impact on determining the benefit-risk balance of a treatment.  
Therefore, a protocol was developed to investigate three weight elicitation methodologies: MCDA 
swing-weighting (Section 2.3.2.1), MACBETH (Section 2.3.2.3), and AHP (Section 2.3.2.4).  These 
methodologies were selected because of interest from the team.  
MCDA swing-weighting, MACBETH, and AHP require efficacy and safety data.  They also require 
preference data, i.e. the value function and weight, which can potentially vary from one stakeholder 
to another.  The efficacy and safety data, and preference data are then statistically combined to 
evaluate the overall value of a treatment option.  The protocol is designed to address the benefit-
risk balance of four treatment options for relapsing remitting multiple sclerosis: natalizumab, beta 
interferon-1a, glatiramer acetate, and placebo.  Although the protocol is used within this thesis to 
test the feasibility of the PPI framework, the planned study will be conducted in PROTECT WP5 
following the submission of this thesis.  The aim of the protocol in WP5 is to design a study which 
can examine if and/or how preferences may vary depending upon the elicitation method, and the 
subsequent impact this may have on the determination of the benefit-risk balance for specific RRMS 
treatments.  Past tense is used to indicate work which has already been completed, and future tense 
is used to describe work which is still in progress or planned. 
The protocol firstly defines important benefit-risk assessment terminology which will be used in this 
case study (Section 5.6.1).  Next it describes the methods of recruitment and sample (Section 5.6.3).  
Preliminary work and the preference elicitation activities for each of the benefit-risk assessment 
methodologies are then described in turn (Section 5.6.4 and 5.6.5).   
 Data 5.6.1
Data for use in the design of the protocol were extracted from EPARs, and relevant studies identified 
via a literature search by the Wave One and Wave Two natalizumab case study teams (Table 5.7).  
Details of how the data were selected, extracted and analysed can be found in the case study 
reports which are publicly available online (Nixon et al., 2013a, Nixon et al., 2013b).   
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Table 5.7 Data extracted and analysed by the Wave One and Wave Two natalizumab case study teams regarding the performance of placebo, natalizumab, interferon beta-1a, and 
glatiramer acetate 
Outcome Required 
data 
Common placebo group Natalizumab Interferon beta-1a Glatiramer acetate 
Valu
es 
Source Value
s in 
place
bo 
arm 
Values 
in 
treatme
nt arm 
Source Value
s in 
place
bo 
arm 
Values 
in 
treatme
nt arm 
Source Value
s in 
place
bo 
arm 
Values 
in 
treatme
nt arm 
Source 
Relapse Number of 
relapses 
Patient-
years of 
follow-up 
494 
738 
Polman et al, 2006 494 
738 
294 
1338 
Polman et al, 
2006 
187 
228 
149 
223 
Jacobs 
et al, 
1996 
210 
250 
161 
273 
Johnso
n et al, 
1995 
Disability progression 2-year 
probability 
of  
disability 
progression 
Total 
number of 
patients 
Conversion 
factor * 
29% 
312 
0.79 
Polman et al, 2006 
Kappos et al, 2010 
29% 
312 
0.79 
17% 
627 
0.71 
Polman et al, 
2006 
Kappos et al, 
2010 
35% 
143 
n/a 
22% 
158 
n/a 
Jacobs 
et al, 
1996 
25% 
126 
0.79 
22% 
125 
0.71 
Johnso
n et al, 
1995 
Kappos 
et al, 
2010 
Herpes reactivation Number of 
events 
Number of 
patients 
0 
312 
Assumed none in 
Polman et al, 2006 
0 
312 
0 
627 
Assumed none in 
Polman et al, 
2006 
0 
143 
0 
158 
Assume
d none 
in 
Jacobs 
et al, 
1996 
0 
126 
0 
125 
Assume
d none 
in 
Johnso
n et al, 
1995 
PML Number of 
events 
Number of 
patients 
0 
n/a 
Assumed zero 
incidence 
n/a 212 
99751 
Bloomgren et al, 
2012 
n/a 0 
n/a 
Assume
d zero 
inciden
ce 
 0 
n/a 
Assume
d zero 
inciden
ce 
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Congenital 
abnormalities 
Number of 
events 
Number of 
patients 
0 
312 
Assumed none in 
Polman et al, 2006 
0 
312 
0 
627 
Assumed none in 
Polman et al, 
2006 
0 
143 
0 
158 
Assume
d none 
in 
Jacobs 
et al, 
1996 
0 
126 
0 
125 
Assume
d none 
in 
Johnso
n et al, 
1995 
Transaminases 
elevation 
Number of 
events 
Number of 
patients 
12 
312 
Polman et al, 2006 12 
312 
31 
627 
Polman et al, 
2006 
12 
312 
12 
312 
Assume
d same 
as 
placebo 
12 
312 
12 
312 
Assume
d same 
as 
placebo 
Seizures Number of 
events 
Number of 
patients 
0 
312 
Assumed none in 
Polman et al, 2006 
0 
312 
0 
627 
Assumed none in 
Polman et al, 
2006 
0 
143 
5 
158 
FDA** 0 
126 
0 
125 
Assume
d none 
in 
Johnso
n et al, 
1995 
Infusion/injection 
reactions 
Number of 
events 
Number of 
patients 
55 
312 
Polman et al, 2006 55 
312 
148 
627 
Polman et al, 
2006 
18 
143 
20 
158 
FDA** 74 
126 
113 
125 
Johnso
n et al, 
1995 
Hypersensitivity 
reactions 
Number of 
events 
Number of 
patients 
0 
312 
Polman et al, 2006 0 
312 
25 
627 
Polman et al, 
2006 
0 
312 
0 
312 
Assume
d same 
as 
placebo 
11 
564 
17 
563 
Packag
e 
insert*
** 
Flu-like reactions Number of 
events 
Number of 
patients 
57 
143 
Jacobs et al, 1996 57 
143 
57 
143 
Assumed same as 
placebo 
57 
143 
96 
158 
Jacobs 
et al, 
1996 
57 
143 
57 
143 
Assume
d same 
as 
placebo 
* for converting from disability progression sustained for 3 months to disability progression sustained for 6 months 
** these figures are understood to come from the same trial as the study by Jacobs et al, but were not published in that report 
*** available at http://druginserts.com/lib/rx/meds/copaxone/ 
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 Definitions 5.6.2
When examining how the three different benefit-risk methodologies can be used to elicit 
preferences from patients and the public, it was noted that the use of benefit-risk assessment 
terminology is often confusing and inconsistent.  For example, different authors may use different 
words to refer to the same process; alternatively, different authors may also use the same word to 
refer to different processes.  To prevent confusion, the following definitions provided in Table 5.8 
were adopted for terms relating to the methodologies in this protocol (Belton and Stewart, 2001). 
Table 5.8  Definitions of benefit-risk assessment terminology 
Term Definition 
Alternatives a The choice of treatment 
Criteria   The set of consequences which will be used to compare the 
alternatives  
Performance =       The measure of performance of alternative according to 
criteria   
Partial value function =   (     )  
      
Maps from the performance to a number called the value 
score.  
Weight =   
 
Reflects the importance of criterion   
Value =      ∑          The overall value of alternative a. In this protocol the benefit-
risk score. 
 
 Sample and ethics approval 5.6.3
Although it was desirable to elicit the preferences of RRMS patients specifically in WP5, it was not 
possible to complete the National Health Service (NHS) ethical application process in the specified 
time frame of IMI PROTECT and this thesis.  In lieu of this, ethical approval was sought from the 
Imperial College Research Ethics Committee (ICREC Reference Numbers: 12_4_5 and 12_2_8).  
However, this form of ethical approval has the limitation that it does not provide approval for direct 
access patients or their data through the NHS, and it is not possible for any of the research to take 
place on NHS premises or use NHS facilities.   
The recruitment process was initiated in March 2012.  Exploratory emails were sent to several MS 
organisations, requesting if they would be interested in participating in our study.  The MS Society 
replied positively, and asked for further details.  Following this, they offered to recruit participants 
for all three of the benefit-risk assessment methods via their website in December 2012.  The study 
was advertised to potential participants from 25th March 2013.    
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 Preliminary work prior to eliciting patient and public preferences 5.6.4
Some preliminary work was completed prior to eliciting preferences, in order to reduce the amount 
of demand placed on participants.  This included: a) creating the value tree, and b) defining the 
clinical consequences (i.e. outcomes represented by the efficacy and safety data) and, (c) defining 
the value functions. 
5.6.4.1 Creating the value tree 
MCDA swing-weighting, MACBETH, and AHP share a similarity; although value trees are not a formal 
necessity of the methodologies, they can be used with each of them to clearly represent the benefits 
and risks of RRMS treatments.   In Wave One, a value tree was created for the natalizumab case 
study.  However, this had to be modified for Wave Two because it was necessary to group all of the 
adverse events into two categories i.e. “less serious” or “more serious” according to perceived 
severity.  This was to satisfy the design principles of MCDA swing-weighting, AHP, and MACBETH.   
Ideally, the patient perspective should have been sought to assign each risk to either the “less 
serious” or “more serious” adverse event categories, or alternatively sought to provide buy-in for 
the resultant value tree.  However, this was not possible due to time constraints.  Instead, the 
categorisation of risk was achieved via a consensus of the WP5 PPI team, and included the 
perspective of a physician with clinical experience of the conditions.  The subsequent value tree can 
be viewed in Table 5.7.   
The same value tree will be used for MCDA swing-weighting, MACBETH, and AHP.  This is to ensure 
that the weights obtained via each method can be directly comparable against one another.     
5.6.4.2 Defining outcomes and clinical consequences 
When eliciting weights from patients and the public, a certain amount of clinical knowledge about 
the disease and adverse events of drugs for disease treatment is assumed.  However, for a successful 
elicitation process it is important for subjects to understand precisely what is meant by each benefit 
and risk criteria and also what the clinical consequences are for each of them.  Information was 
compiled to define what is meant by each criterion in the benefit-risk tree (Appendix 7), and what 
the short and long term implications are for each of them.  The preference elicitation methodologies 
used in the natalizumab case study all examine the same criteria. 
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Figure 5.1 Value tree used in the natalizumab case study for the benefit-risk methodologies of MCDA swing-weighting, 
MACBETH and AHP 
A significant amount of time was spent to develop the glossary and explain what was meant by the 
criteria under consideration.  This was because I presented some of the PPI work to members of the 
rare disease patient group EURORDIS (http://www.eurordis.org/).  They provided substantial 
recommendations regarding what a glossary should look like after being shown the WP5 Wave Two 
rimonabant case study example; they thought that the style of describing the outcomes was poor 
(one of the first statements was “This is not patient worded.”) and they thought that the terms were 
insufficient regarding the level of detail.   
Specifically, EURORDIS commented that: 
 They would like to see the frequency, severity, and duration of the outcome 
 They would like vignettes to describe the average patient experience with the outcome 
 They would like to know the implications of the outcomes and how they might affect certain 
quality of life aspects: daily living, ability to drive, school/education, work/earning a living, 
travel/holidays, mood, methods of coping, life expectancy, and burden of treatment 
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They believed that the outcomes were too brief and hypothetical, and that they did not have enough 
knowledge to participate and provide meaningful weights which may render the decision-making 
process abstract, and which would potentially compromise the validity of the benefit-risk methods.  
Although I did explain that we would have a physician on hand for future decision conferencing 
activities, they did not think it would be sufficient and said that it would be better to provide 
supplementary information beforehand.   
As the rimonabant glossary was very similar in style to the initial natalizumab glossary, I suggested 
changes to the natalizumab glossary; the use of language should be tailored more appropriately to 
the audience, further information should be provided on each outcome, and the use of vignettes 
was desirable.   It is important to effectively communicate the process and results of benefit-risk 
methodologies to patients and the public in a clear and understandable manner.  If there is poor 
communication of the benefits and risks for which we wish to elicit preference weights, and/or 
unclear articulation of the tasks participants are requested to complete, the results of involvement 
may be compromised and inaccurately represent the patient and public perspective.    
The participants need to be able to easily understand what the material we wish to communicate 
with them.  With this in mind, the level of understanding depends heavily on the level of health 
literacy possessed by the reader.  Health literacy is defined as an audience’s ability to, “access, 
understand, evaluate and communicate information to promote, maintain and improve health” 
(Health Canada, 2012).  It was recommended to PROTECT WP5 by the external advisory board that 
the effectiveness of the materials we plan to circulate to participants is evaluated through 
readability tests. 
The level of comprehension required to read the glossary was measured by applying several 
readability tests which aimed to measure the average educational background required to 
understand the text, and evaluate the clarity of our communication with the intended audience.  
Multiple different tests can be used to evaluate the readability of materials for their intended 
audience.  Most use mathematical formulas involving the word length, number of syllables per word, 
number of words per sentence and number of sentences per paragraph.  The Automated Readability 
Index, Coleman-Liau Index, Flesch-Kinaid Grade Level, Flesch Reading Ease, Fry Readability Formula, 
Gunning-Fog Index, and Simple Measure of Gobbledygook were applied.    
The results are displayed in Table 5.9.  Most of the readability tests were developed in the United 
States, and so approximate England and Wales equivalents corresponding to the US grade levels 
have also been noted in the table.   
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Table 5.9 Results of frequently used readability tests applied to the natalizumab glossary 
Readability test Formula or Steps Results 
Automated 
readability 
index (Smith 
and Kincaid, 
1970) 
 
                    (
 
 
)     (
 
 
)        
 
Whereby: 
C = number of characters 
W = number of words 
S = number of sentences 
US grade level 10.2 
(GCSE) 
Coleman-Liau 
Index (Coleman 
and Liau, 1975) 
 
 
                                   
Whereby: 
L =average number of letters per 100 words 
V = average number of sentences per 100 words 
US grade level 12.7 (A 
level) 
Flesch-Kincaid 
Grade Level 
(Kincaid et al., 
1975) 
 
 
                   (
 
 
)      (
 
 
) 
Whereby: 
W = number of words 
S = number of sentences 
Y = number of syllables 
US grade level 11.2 (A 
level) 
Flesch Reading 
Ease (Flesch, 
1948) 
 
 
                    (
 
 
)      (
 
 
) 
Whereby: 
W = number of words 
S = number of sentences 
Y = number of syllables 
46.5 (Key Stage 3) 
Fry Readability 
Formula (Fry, 
1968) 
 
Steps: 
1. Randomly select three 100 word passages 
2. Count the number of sentences in each sample 
3. Count the number of syllables in each sample 
4. Plot the average sentence length and the average 
number of syllables on the readability graph  
The border between US 
grade level 13 and 14 (an 
undergraduate 
university degree level) 
Gunning-Fog 
Index (Gunning, 
1968) 
 
 
                   [(
 
 
)     (
 
 
)] 
 
Whereby: 
W = number of words 
S = number of sentences 
P = number of words with more than three syllables 
US grade level 13.4 (an 
undergraduate 
university degree level) 
Simple measure 
of 
gobbledygook 
(McLaughlin, 
1969) 
 
 
                     √   
  
 
        
 
Whereby: 
P = number of words with more than three syllables 
S = number of sentences 
US grade level 10.1 
(GCSE) 
 
The results of the readability tests show that the level of literacy required to understand the glossary 
ranges from US grade levels 10.1 to 14; this corresponds to the reading levels of a Key Stage 3 old to 
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an undergraduate university degree level.  The results of the readability tests show that the glossary 
may be too complex for some members of the general public. 
However, there are limitations to the readability tests which I applied.  Firstly, although they are 
widely used, many have not been formally evaluated or validated (Redish and Selzer, 1985).  They 
may be misguided in assuming that factors such as the number of words, syllables and sentence 
length solely determine the required reading level.  Also, occasionally, rarely used technical words 
which do not have many syllables may be unfamiliar to readers, and may be equally or more 
confusing than longer more frequently used words.  Other factors such as text placement and use of 
images also may impact the level of understanding (Health Canada, 2012).  For example, whether 
the font size is 8 point or 12 point will affect the legibility of a document.  The Plain English 
Campaign (Plain English Campaign, 2013) believes that readability tests can be used to identify the 
simplicity of a document, but the a stronger focus should be placed on examining if the document is 
right for its intended audience through methods such as focus groups or one-to-one interviews.   
a) Linear and non-linear value functions 
All three benefit-risk assessment methodologies require the use of a value function.  AHP requires a 
value function based on the performance of each of the treatments under consideration, which can 
either be performed by constructing a matrix with multiple levels of outcome that cover the data 
ranges of the treatments under consideration, or directly comparing the exact data of the 
treatments within a matrix while blinding the names.  MCDA and MACBETH provide the option of 
either using a linear value function, or constructing a piecewise monotonous non-linear value 
function.   
In the team there were two schools of thought: 
1. To not ask patients for their value function preferences; assume that value function is 
linear, and use it in all subsequent analyses  
2. To ask patients for their value function preferences; derive the value function, and use 
the derived value function in all subsequent analyses  
Strong arguments were presented for both sides of the debate (Table 5.10). 
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Table 5.10 A Comparison of linear versus non-linear value functions 
Linear Non-linear 
Ethical basis: one life cannot be worth more 
than another, each case is of equal importance 
Logical basis: individual perception of risk 
probabilities is unlikely to be linear 
Regulatory, societal level and public health 
perspective 
Individual, personal level, and medical 
perspective 
Good for proportions and percentages Good for severities, and rare and serious 
adverse events that do not have a 
denominator (i.e. number of cases) 
Less burden on researcher and participant: 
fewer preference elicitation questions 
required 
Increased burden on researcher and 
participant: more preference elicitation 
questions required 
In most cases a linear value function is the best 
approximation when the real shape of the 
value function is not known, i.e. it is not 
feasible, or too difficult to obtain a preference 
based value function 
Ideal when it is both feasible and possible to 
obtain a preference based value function 
 
In total there were three options available: 
1. Assume linear value functions for all benefit and risk outcomes 
2. Elicit patient preferences to derive value functions for all benefit and risk outcomes 
3. Use a mixture of linear, and preference based value functions, i.e. elicit for the benefit and 
risk outcomes that were considered to have had the greatest importance in the natalizumab 
marketing authorisation decision, and use linear value functions for the remaining benefit 
and risk outcomes 
 
After extensive discussions, it was decided that a linear value function would be assumed for all 
three of the methodologies.  The rationale for this was to reduce the amount of cognitive burden on 
the participants, and reduce the amount of time required to complete the questionnaires and 
decision conferences.   
 The preference elicitation methodologies  5.6.5
The application of three different methods to elicit preferences to the natalizumab case study, i.e. 
MCDA swing-weighting, AHP, and MACBETH were carefully considered.  They were planned be used 
to evaluate three alternatives for the treatment of RRMS: natalizumab, beta interferon-1a, and 
glatiramer acetate.  The descriptions provided here relate to the process of eliciting preferences 
from patients and the public, and not the technical and statistical aspects.   
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5.6.5.1 MCDA swing-weighting 
Firstly, an information letter, consent form, glossary and MCDA swing-weighting questionnaire will 
be distributed to those who wish to participate in the study.  Next, two meetings will be scheduled in 
accordance with the availability of those willing to participate.  The first meeting will occur on an 
individual basis via telephone, and its purpose is to provide an overview of the project and to give 
instructions on how to complete the MCDA swing-weighting questionnaire (Appendix 9).  Each 
participant will be requested to complete the questionnaire between the two meetings.  The second 
meeting will be a group decision conference.  All of the participants will meet together in person to 
present their individual answers to the questionnaires, and then came to a group consensus for the 
elicited weights. 
This thesis focuses on the specific application of MCDA swing-weighting initiated in Wave Two, 
which will be completed by the PPI team.  This application is distinctly different from the Wave One 
application of MCDA due to the new specification of swing weights, and the sampling of patients and 
the public affected by RRMS. 
The MCDA swing-weighting method was used in the first wave of the natalizumab case study (Nixon 
et al., 2013a). This method will be used again but with a key difference which aims to overcome the 
issue of scale bias. Instead of the range of probabilities for each clinical event running from 0 to 1 
(the x-axis on the value function), these will instead be constrained to “the lowest plausible value” 
and the “highest plausible value” This has the effect of only eliciting values within the range of what 
is plausible, and not having to assess values for scenarios that are expected never to occur. 
Similar to Wave One, weights will be elicited throughout the hierarchy of the value tree. Starting 
with each outcome measure, the relative ranks of a swing from the best to the worst of each 
outcome within each category will be derived. Starting from where all outcome scores are at their 
worst, participants will be asked to choose the criteria they would most want to move to the best 
score. They will then be asked to rank the other outcomes in a similar way. This acts as a “thought 
stepping stone” for then assigning preference weights on these outcomes.  For this, the top ranked 
outcome is given a weight of 100 and marked on a visual analogue scale, and participants then place 
the other outcomes on the scale to reflect their relative importance.  
The same approach will be used to elicit weights between outcome categories, separately within 
favourable and unfavourable outcome criteria. The top-ranked criteria from each category will be 
used as a representative of its category. The top-ranked outcomes in each category will then ranked 
and weighted in the same way as before. Finally the criteria will be weighted using the same 
approach. 
 182 
 
5.6.5.2 MACBETH 
To begin the elicitation process, an information letter, consent form and glossary will be distributed 
to those interested in participating.  Next, a meeting will be scheduled according to the availability of 
those willing to take part in the MACBETH decision conference.  All of the participants will meet 
together in person to make pairwise comparisons of the benefit and risk outcomes. 
MACBETH is a decision-making methodology implemented through specialist software which aims to 
elicit and numerically represent qualitative value preferences to compare specific benefit and risk 
criteria.  Although specialist software exists, the MACBETH component on HiView3 is used in this 
thesis.  The first step in MACBETH is to construct a value tree to appraise the criteria under 
consideration which has previously been discussed and is shown in Figure 5.1. 
Next, participants are asked to rank the criteria at each node (i.e. at benefits, more serious SA, less 
serious SA, and decision).  The software presents a matrix for the group of criteria at each node; the 
constituent criteria within each group were labelled as the row and column headers (Figure 5.2).  
The group will then asked to decide the order of importance for the criteria at each node by 
responding to the question, “If you could change one of the criteria from the worst possible scenario 
to the best possible scenario, which one would it be?”  The column header containing their response 
is then dragged to the left hand side of the matrix.  This is repeated until all of criteria have been 
ranked, and the column headers range from the most important to the least important from left to 
right.  The matrix will be projected onto a large screen for participants to view. 
 
Figure 5.2 Ranking of criteria in the natalizumab case study for the benefit-risk methodology of MACBETH 
After this, participants will be asked for verbal judgements to complete the matrix, by evaluating the 
difference in attractiveness between the row and column header.  Preferences are elicited from the 
participants according to a predefined qualitative scale of seven options: neutral, very weak, weak, 
moderate, strong, very strong, and extreme.   Although hesitation between two neighbouring 
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qualitative preferences is allowed in MACBETH as multiple neighbouring options in the scale can be 
simultaneously selected when it is not possible to decide on only one option, the software always 
tests the compatibility of the information provided by the participants.  If there are incompatibilities, 
sources of inconsistency are identified by the software, along with suggested changes to overcome 
it.  At every step, in order to further proceed, the entered information must always be consistent.  A 
completed matrix for the more serious side effects is shown in Figure 5.3.  This matrix was 
completed when piloting the methodology with the PPI team.  In the figure, although the clinical 
severity of a case of PML was regarded as greater than herpes, members of the team considered a 
shift from the “worst” to the “best” probability of herpes, i.e.  20% to 0% of patients experiencing 
the outcome, as more attractive to avoid than a shift from the “worst” to “best” probability of PML, 
i.e. 2% to 0% of patients experiencing the outcome.  This matrix is an example; the results of the 
comparisons are subjective, and thus the results may vary according to whose preferences are 
elicited.   
 
Figure 5.3 Example of MACBETH matrix 
The program then derives value scale in accordance with preferences assigned by the participants.  
Qualitative information alone is not generally sufficient in MACBETH, as many possible scales can 
respect the elicited information.  Hence, the participants will be asked to observe the MACBETH 
scale axis and compare value intervals with the aid of a facilitator (Figure 5.4.). The interval between 
elements, i.e. the difference in attractiveness, will be adjusted within the limits that respect previous 
information, to generate a cardinal scale.   
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Figure 5.4 Fine tuning of weights in the natalizumab case study for the benefit-risk methodology of MACBETH 
Due to an unwillingness to place too much time and cognitive burden on the participants during 
decision conferencing, MACBETH will not be used to investigate the value function—it will therefore 
be assumed to be linear.   
5.6.5.3 Analytic Hierarchy Process 
Analytic hierarchy process (AHP) asks participants to perform pairwise comparisons between 
criteria, where preferences are assigned using a numeric scale (Table 5.11). These comparisons are 
then combined into a single scale of priorities, which are expressed as a single number for the best 
alternative, or by a vector of priorities that order alternatives proportionally.  
Table 5.11 The fundamental scale for pairwise comparisons used in analytic hierarchy process 
Intensity of 
importance 
Definition Explanation 
1 Equal importance Two elements contribute equally to the objective 
3 Moderate 
importance 
Experience and judgement moderately favour one 
element over another 
5 Strong 
importance 
Experience and judgement strongly favour one element 
over another 
7 Very strong 
importance 
One element is favoured very strongly over another; its 
dominance is demonstrated in practice 
9 Extreme 
importance 
The evidence favouring one element over another is of 
the highest possible order of affirmation 
Intensities of 2, 4, 6, and 8 can be used to express intermediate values.  Intensities of 1.1, 1.2, 1.3, 
etc. can be used for elements that are very close in importance.   
(Saaty, 1990) 
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Whereas MACBETH performs constant consistency checks during the decision-making process, AHP 
only performs a consistency check once the decision-making process has ended.  As it does not 
require amendments relating to consistency before progressing to the next stage, it was possible to 
format the AHP questions into a web survey.  The web survey will be advertised online via the MS 
Society website.    
Once all the values are assigned, the weight, referred as the priority, of each criterion is calculated. 
An estimate of inconsistency, which measures the amount of inconsistencies in assigned weights, 
was also be derived.  In order for the results to be declared valid, the consistency ratio should be 
0.10 or less.   
 
 
Figure 5.5 Adaption of analytic hierarchy process pairwise comparison tasks from a traditional matrix to a question 
format compatible with the online display options of SurveyMonkey 
 
 Comparison of the methodologies 5.6.6
Table 5.12 provides a comparison of the three methodologies.
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Table 5.12 Comparison of MCDA swing-weighting, MACBETH, and AHP 
 MCDA swing-weighting MACBETH AHP 
Format of weights and scale Numerical response: 1 to 100 Qualitative response: extreme, very 
strong, strong, moderate, weak, very 
weak, no difference 
Quantitative: 1 to 9 (1 is equal; 3 is 
moderate, 5 is strong, 7 is very strong, 9 
is extreme); decimals allowed 
Single or range of weights Only a single weight can be elicited for 
each criterion.  Multiple different 
weights can be tested later within a 
sensitivity analysis. 
Multiple adjacent weights (range) can be 
elicited for each criterion (or when 
comparing groups of criteria). 
Only a single weight can be elicited for 
each criterion (or when comparing 
groups of criteria). 
Format of elicitation method Decision conference.  Reason: highest 
ranking criteria, i.e. observations are 
carried forward.   
Decision conference.  Reason: elicited 
weights for each criterion must be 
consistent.   
Online Questionnaire.  Reason: 
Consistency not required, so a decision 
conference is not necessary. Weights 
not carried forward.  It gives us an 
opportunity to also look at individual 
level data for deriving distributions 
among a sample.  I.e. information on 
uncertainty and variability. 
Individual or group Group consensus. Group consensus. Individual level responses.  See above. 
Comparisons Multiple comparisons Pairwise comparisons Pairwise comparisons 
Swing weights Yes Yes No 
Questioning format How much more attractive is a swing in 
criterion x compared to a swing in 
criterion y? 
How much more attractive is a swing in 
criterion x compared to a swing in 
criterion y? 
What is the relative importance of 
criterion x over criterion y? 
Consistency N/A Finds inconsistent answers and makes 
suggestions.  Cannot progress further 
until inconsistencies have been resolved. 
Computes a consistency score (<0.1 is 
acceptable) 
Weight calculation of each criterion Direct Linear optimisation (plus tuning) Principal eigenvector 
Weight of each alternative Sum of (weight of each criteria x by 
performance) 
Sum of (weight of each criteria x by 
performance) 
Sum of (weight of each criteria x by 
performance) 
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 Evaluating the process of involvement from the participant perspective 5.6.7
One of the goals of this work is to report and evaluate the process of involvement in benefit-risk 
methodologies from a participant perspective.  The protocol has been reviewed by the International 
Alliance of Patient Organisations (IAPO); they have provided comments relating to the process which 
they felt would reflect the perspective of a participant.  Also, following each of the methodologies, 
participants will be asked how they felt about the preference elicitation process.  The Wave Two 
rimonabant case study DCE used two very broad open ended questions which were kept 
purposefully vague to scope out as much feedback as possible.  However, the PPI team believed that 
a more structured method of obtaining feedback was desirable for AHP, MCDA swing-weighting, and 
MACBETH. 
Likert questions were developed by the team to ask participants how they viewed the process of 
preference elicitation in the online survey.  Respondents will rate how strongly they agreed or 
disagreed with the following statements on a five point Likert scale: 
 "It was easy to find the survey and navigate my way through it." 
 "It was easy to make comparisons between the outcomes." 
 "I would be happy to take part in similar surveys in the future." 
 "The questions adequately reflect the aspects of relapsing remitting MS that I feel are 
important." 
 "Enough information was provided, in a clear and understandable format, to enable me to 
answer the questions." 
 "Having taken part in the survey, I would be interested in knowing more about this study." 
In addition to this, there were two questions where respondents had the option to provide free text 
responses: 
 Were any of the questions particularly difficult to answer? Please give details. 
 Please provide any additional comments or suggestions in the box below. 
5.7 Testing the feasibility of the PPI framework 
The feasibility of the preliminary PPI points to consider framework was tested by applying it to the 
natalizumab protocols for preference elicitation in Section 5.6.  This is being done during the 
recruitment stage of the studies.   
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 Application of the preliminary framework 5.7.1
The completed framework is provided in Table 5.13, and the experience of completing the 
framework and potential improvements are described in this section.
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Table 5.13 Preliminary application of the framework 
Step  Point to consider Application 
Determine the 
purpose of PPI 
What is the aim? The aim is to elicit the values and preferences of patients and the public directly affected by 
RRMS regarding the benefits and risks of natalizumab, glatiramer acetate, and interferon 
beta-1a.   
During which stage(s) of the 
methodology is involvement 
required and/or desired? 
Although it was desired to apply PPI to multiple stages of the decision-making process, this 
was infeasible due to the limited amount of resources which were available.  Because of this, 
PPI was applied to the analysis stage of decision-making, and the quantitative framework 
benefit-risk assessment methodologies of MCDA swing-weighting, MACBETH and AHP were 
used. 
What is the desired level of 
involvement for each stage? 
The desired level of involvement for the analysis stage was consultation.  We wanted to test 
the feasibility of obtaining patient and public values and preferences on the benefits and 
risks of treatments for RRMS and compare the results.   
Ethical approval Is ethical approval required?  
Who needs to approve ethics 
application? 
How long is needed to obtain ethics 
approval? 
Ethical approval was required.  
Imperial College Research Ethics Committee reviewed and approved the protocol. 
 
The Committee meets to review proposals once every two months and this was considered 
in the timeline of activities.   
Address potential 
barriers and negative 
outcomes 
What are the potential barriers to 
meaningful involvement? 
We encountered multiple barriers: 
 Lay language: describing (a) the benefits and risks, and (b) the tasks required to be 
completed by the participant while still maintaining medical/technical precision was 
extremely difficult. 
 Format: In PPI literature, there are multiple different methods of involving people.  
However, the literature does not explicitly state which works best, and/or would be 
most appropriate for our setting, e.g. one-on-one with a facilitator, focus group with 
a facilitator, paper questionnaires, online questionnaires. 
 Timescales: PPI activities were not originally built into the WP5 timeline.  Instead, 
they were later added as a “bolt-on” to the original activities, which meant that a 
limited extra time allowance could be allocated.  The additional time required as a 
result of unanticipated barriers, e.g. difficulty recruiting, was hard to handle.   
 Participant burden: Each of the methodologies require a relatively large number of 
questions which place a cognitive and time burden on participants.   
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Step  Point to consider Application 
What are the potential negative 
outcomes of involvement? 
We anticipated that a potential barrier might be the perceived expectation that the results 
will be explicitly incorporated into the final decision.   
How can the barriers and negative 
outcomes be alleviated? 
It is hard to know how recruitment, language, and format can be improved upon.  This is 
because PPI in benefit-risk assessment is a relatively new concept and there is an insufficient 
evidence base to guide how these issues can be addressed.  However, in future, we would 
recommend that PPI activities are carefully planned a priori to any project, and sufficient 
time is allocated for ethical approval processes and recruitment. 
Training Do participants require training and 
support?  If so, how will this be 
addressed? 
Is has been reported in the literature that the benefit-risk methodologies of MCDA swing-
weighting, MACBETH, and AHP have been successfully completed with lay people.  However, 
before involving participants, careful explanations of the processes need to be explained 
prior to involvement.  We plan to have a physician present during the MCDA swing-
weighting and MACBETH decision conferences who can inform participants if they have 
difficulties understanding the benefits and risks.  For AHP, an email address will be provided 
at the start of the online survey for participants to contact if there is any confusion.   
Do researchers require training and 
support?  If so, how will this be 
addressed? 
Training and support was necessary due to the complexity of the methodologies.  Training 
support for MCDA swing-weighting and MACBETH was provided by benefit-risk 
methodological experts; additional help was provided by staff at the MHRA for the 
development of the glossary.   
Recruitment Which group of participants will be 
used to represent patients and the 
public?  
Participants who responded to the MS Society or MS-UK advertisement will be used to 
represent the views of patients and the public. 
What is the sample size required for 
the methodology? 
There is no minimum sample size required for MCDA swing-weighting, MACBETH, or AHP.   
What are the methods of 
recruitment? 
Emails introducing to our study were sent to several national MS organisations in the UK 
with a request for help to recruit.  We followed this up with telephone calls.  The MS Society 
and MS-UK offered to place advertisements on their website.   
Design a statement 
of agreement 
between the 
researchers and 
participants 
Is it possible to provide full 
disclosure of the benefit-risk 
methodology being studied and the 
role and anticipated value of 
patient and public involvement? 
We did not provide full disclosure of all the tasks involved in the benefit-risk methodologies, 
e.g. statistical analysis.  This is because we believed too many technical details and would be 
daunting and confusing to patients and the public.  The role and anticipated value of patient 
and public involvement was carefully detailed to potential participants in the recruitment 
email and introduction to the study.  It was hoped that by describing the value of 
involvement, individuals would have greater motivation to participate. 
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Step  Point to consider Application 
What are the roles and 
responsibilities of both the 
researcher and the participant? 
In this study, we believed the role of the researchers were: 
o To design a scientifically accurate study 
o To ensure the study went through an external ethical review process and adhere to 
ethical principles (e.g. confidentiality and anonymity) 
o To limit the burden placed upon participants 
o To describe the study and tasks in a manner easily comprehensible so that 
participants clearly understand what is asked of them 
In this study, we believed the role of the participant was:  
o To be engaged, and provide truthful responses 
 
Have the expected needs and 
contribution of both the researcher 
and the participant been defined? 
This step was not completed.  See commentary.   
Do the participants know all of the 
confidentiality, anonymity, drop-
out, and acknowledgement 
policies? 
For MCDA swing-weighting and MACBETH, information on confidentiality, anonymity and 
dropping-out were detailed in the information sheet prior to participation.  For AHP, 
confidentiality and anonymity were detailed at the start of the questionnaire, and it was 
assumed that if people wished to drop out they would close the internet browser.   
 
Patient involvement 
activities 
What are the anticipated time 
scales for involvement activities? 
Originally we hoped we could complete MCDA swing-weighting, MACBETH, and AHP in WP5 
Wave Two.  Unfortunately, there were significant delays to this due to issues with 
recruitment. 
 
What is the method of 
communication? 
 AHP questionnaire: online survey 
 Participant information leaflets: email 
 Dates for decision conference: email and telephone 
 Decision conference: face to face 
 Dissemination of results: email 
 
What is the location of involvement 
activities (if applicable)? 
The decision-conference for MCDA swing-weighting and MACBETH took place at Imperial 
College, London.  It was held at a location which is wheelchair accessible.  AHP took the 
format of an online questionnaire.   
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Step  Point to consider Application 
Finances Are there finances in place to 
specifically support involvement? 
There were no finances specifically in place to support involvement at Imperial College, 
London.  These were later negotiated between PROTECT management and WP5 partners.   
Can participants receive adequate 
financial support for their expenses 
and contribution? 
For MCDA swing-weighting and MACBETH, participants were reimbursed £80 to cover 
expenses for their travel and time.  This is a standard amount for reimbursement per diem 
by patient organisations.  For AHP, the decision was made not to provide financial support 
for participant contribution.  This is because the level of burden placed upon the participant 
to complete an online questionnaire is low. 
Reporting of 
outcomes 
What were found to be the benefits 
of involvement? 
The preference elicitation work is still in progress, and so this step cannot be completed.   
What were the negative outcomes 
of patient involvement? 
 Recruitment of participants: We found it extremely difficult to recruit participants.  
This is because we could not approach patients directly within clinical settings, as 
research involving NHS patients, their data, or NHS premises or facilities requires 
IRAS or NRES ethical review.  The time required for this type of approval would have 
exceeded the timeframe of PROTECT WP5.  Instead, we approached multiple 
national MS organisations via email and telephone: although many saw the 
importance of our research, they were limited in the help which they could provide, 
e.g. they were willing to advertise on their website but could not help with more 
active methods of recruitment.  The number of responses from interested 
participants as a result of the website advertisements was few. 
   
Reporting of 
conflicting 
perspectives 
Did conflicting perspectives or 
disagreements occur?  
The preference elicitation work is still in progress, and so this step cannot be completed.   
At which stage of the process did 
they occur? 
The preference elicitation work is still in progress, and so this step cannot be completed.   
Who did they occur between? The preference elicitation work is still in progress, and so this step cannot be completed.   
What were the different 
perspectives? 
The preference elicitation work is still in progress, and so this step cannot be completed.   
How were they resolved? The preference elicitation work is still in progress, and so this step cannot be completed.   
Communication Is it necessary for participants to be 
periodically informed of the 
decision-making process as it 
progresses? 
Yes, both at the start (participant information sheets), and at the end of the process 
(circulation of results). 
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Step  Point to consider Application 
How will participants be informed 
about the results of their 
involvement? 
Participants were informed about the results of their involvement via email.   
How will the contribution of 
participants be explicitly 
acknowledged? 
We anticipated that the contribution of participants would be explicitly acknowledged, and 
they could opt for their names to be included in the report, while ensuring that the 
confidentiality of responses was maintained. 
How will the involvement process 
be reported to all stakeholders? 
The process will be reported to (a) participants, and (b) to patient organisations. 
How will the overall impact of the 
decision on patients be evaluated?   
In this study, we are examining the feasibility of eliciting preferences an authorisation 
decision is not being made.  However, we will record evaluative feedback from the 
participants once the results have been circulated.   
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5.7.1.1 Determine the purpose of PPI  
The aim of PPI is to test the feasibility of eliciting the values and preferences of individuals affected 
by RRMS regarding selected benefits and risks of natalizumab, glatiramer acetate, and interferon 
beta-1a.  Then, it can be examined if and/or how preferences may vary depending upon the 
elicitation method, and the subsequent impact this may have on the determination of the benefit-
risk balance.  Although it was desired to apply PPI to multiple stages of the decision-making process 
(i.e. planning, evidence gathering and data preparation, analysis, exploration, and decision and 
dissemination), this was infeasible with the given time frame and resources.  Because of this, PPI was 
applied to the analysis stage of decision-making, using the quantitative framework benefit-risk 
assessment methodologies of MCDA swing-weighting, MACBETH and AHP.  The desired level of 
involvement for the analysis stage was consultation.   
This step was relatively easy to complete.  However, a greater degree of clarity and relevance to the 
context could be introduced by clearly differentiating between two key concepts: (a) “Which benefit-
risk assessment methodology will be used?” and (b) “During which stage(s) of the methodology is 
involvement required and/or desired?” 
5.7.1.2 Ethical approval 
Imperial College, London states that any research which involves human participants requires ethical 
approval to, “safeguard the dignity, rights, safety, and wellbeing of the participants” (Imperial 
College London, 2012).  Therefore, ethical approval was required for this study, and obtained from 
the Imperial College Research Ethics Committee (ICREC).  The Committee meets to review proposals 
once every two months and this was considered and incorporated into the time line.   
If a greater amount of time was available for the study, it would have been possible to apply for 
National Research Ethics Service (NRES) or Integrated Research Application System (IRAS).  Although 
ICREC approval has the advantage of a more rapid review process than NRES or IRAS, it poses 
limitations on the study so that it is not possible to directly access patients or their data through the 
NHS, and it is not possible for any of the research to take place on NHS premises or use NHS 
facilities.  
5.7.1.3 Potential barriers and negative outcomes 
We found that it was easier to provide a response to this step once separating out issues related to 
the general practice of PPI, and issues relating to PPI in the benefit-risk assessment methodologies 
under consideration.   
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5.7.1.3.1 General aspects relating to the field of PPI 
We anticipated multiple potential barriers to meaningful involvement.  One fundamental issue is the 
best method of PPI is not known: there are multiple different methods of involving patients and the 
public (e.g. online questionnaires, focus groups, telephone interviews), and there are multiple 
different patient and public groups which can be targeted for recruitment (e.g. clinical trial 
participants, patients, carers, family members).  Although there are lots of examples of PPI in 
academic literature, the rationale for adopting specific types of involvement and specific 
methodological details are rarely reported.  This makes it extremely hard to compare the feasibility 
of the methodologies and validity of results across varying applications of PPI.  Closely related to 
this, it is unclear how PPI can be most meaningfully applied to the context of the benefit-risk 
assessment of medicines.   
We identified various potential barriers to meaningful involvement.  For example, feedback from 
EURORDIS indicated that technical language might confuse participants, and compromise the validity 
of their responses.  To address this, we dedicated a large amount of time to carefully describe the 
benefits and risks, and the tasks required to be completed by the participant while still maintaining 
technical and medical precision.  It is hard to know how language, and format can be improved 
upon.  This is because PPI in benefit-risk assessment is a relatively new concept and there is an 
insufficient evidence base to guide how these issues can be addressed.  However, in future, we 
would recommend that PPI activities are carefully planned a priori to any project, and sufficient time 
is allocated for ethical approval processes and recruitment. 
5.7.1.3.1.1 Specific aspects relating to the benefit-risk assessment methodologies 
The natalizumab weight elicitation activities were challenging to handle within the Wave 2 case 
study timelines.  Limited extra time allowance could be allocated.  The additional time required as a 
result of unanticipated barriers, e.g. difficulty recruiting, was hard to handle.  However, this work 
was then extended following Wave Two.  Lastly, a key barrier we identified was the level of burden 
participants might experience.  The methodologies we use require a relatively large number of 
questions which can place a cognitive and time burden on participants.   
We considered potential negative outcomes of our application of involvement from an 
administrative perspective to be that PPI was found to be overwhelmingly difficult, and discourage 
other researchers to engage in it.  This may result from the lack of methodological guidance 
provided in academic literature, not understanding which groups of participants to involve, and 
difficulties recruiting.  There are various challenges which could result in negative outcomes, e.g. 
assuming that the validity of our results is strong, and/or accidentally overgeneralising the results to 
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populations for which they are not representative.  This could potentially negatively impact patients 
if it affects regulations or prescribing, and could also incorrectly direct future research.  
There may also be negative outcomes for participants, as they become aware of the risks of 
treatments which they are potentially receiving, and can either correctly interpret or misunderstand 
the benefit and risk data.  Consequently, it may affect treatments which they may be receiving for 
relapsing remitting MS.  If it does affect their treatment preferences, they should consult their 
physician before ceasing treatment.  Another negative outcome is that participants might not 
understand or value the elicitation process and how this information feeds into benefit-risk 
assessment as a whole; they may think that it has little relevance or importance to the indication 
under consideration.  This may decrease their motivation to participate in future studies, or they 
may discourage others from participating.   
5.7.1.4 Training 
It has been reported in the literature that patients and the public have successfully participated in 
the benefit-risk methodologies of MCDA swing-weighting, MACBETH, and AHP.  However, these 
have not been in the context of medicines.  Careful explanations of the processes need to be 
explained prior to participation.  When participants had difficulties understanding the benefits and 
risks in the decision conference, support was provided by a physician who was present during the 
process.  For AHP, an email address was provided at the start of the online survey for participants to 
contact if there was any confusion.   
Training and support of the team was necessary due to the complexity of the methodologies.  
Training support for MCDA swing-weighting and MACBETH was provided by experts in the field and 
academic literature; additional help was provided by the MHRA for the development of the glossary.   
5.7.1.5 Recruitment 
Participants who responded to the MS Society or MS-UK advertisement were used to represent the 
views of patients and the public.  There is no minimum sample size required for MCDA swing-
weighting, MACBETH, or AHP.  Emails introducing our study were sent to several national MS 
organisations in the UK with a request for help to recruit.  We followed this up with telephone calls.  
The MS Society and MS UK offered to place advertisements on their website.   
We found it extremely difficult to recruit participants.  This is because we could not approach 
patients directly within clinical settings, as research involving NHS patients, their data, or NHS 
premises or facilities requires IRAS or NRES ethical review.  The time required for this type of 
approval would have exceeded the timeframe of PROTECT WP5.  Instead, we approached multiple 
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national MS organisations via email and telephone: although many saw the importance of our 
research, they were limited in the help which they could provide, e.g. they were willing to advertise 
on their website but could not provide additional help with more active methods of recruitment.   
5.7.1.5.1 Statement of agreement 
We did not provide full disclosure of the benefit-risk methodology.  This is because we believed too 
many technical details and would be daunting and confusing to members of the public.  The role and 
anticipated value of patient and public involvement was carefully detailed to potential participants 
in the recruitment email and introduction to the study.  It was hoped that by describing the value of 
involvement, individuals would have greater motivation to participate.  We limited the amount of 
technical detail included in the participant information leaflet (Appendix 8) as we thought that they 
might make it too daunting and confusing.  It is extremely hard to define the role and responsibility 
of participants as they do not have a duty to participate or complete the study due to its voluntary 
nature.   
In this study, we believed that our role was to design a scientifically accurate study with best 
available evidence, to ensure compliance with ethical principles (e.g. confidentiality and anonymity), 
to limit the burden placed upon participants, and to describe the study and tasks in a manner easily 
comprehensible so that participants can clearly understand what is asked of them.  We believe that 
the role of the participants to be attentive, provide truthful responses, and ask questions if they 
require further information or if anything requires clarification.  For MCDA swing-weighting and 
MACBETH, information on confidentiality, anonymity and dropping-out were detailed in the 
information sheet prior to participation.  For AHP, confidentiality and anonymity were detailed at 
the start of the questionnaire, and it was assumed that if people wished to drop out they would 
close the internet browser.   
One important note is that we believe that “participant information leaflet” would be more suitable 
than term “statement of agreement” as it better suits the semantic field.  Also, the WP5 PPI team 
decided to remove the step stating, “Have the expected needs and contribution of both the 
researcher and the participant been defined?”, as we judged it to not be relevant in the context of 
benefit-risk assessment.   
5.7.1.5.2 Patient involvement activities 
We chose our methods of communication to be: 
 AHP questionnaire: online survey 
 Participant information leaflets: email 
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 Dates for decision conference: email and telephone 
 Decision conference: face to face 
 Dissemination of results: email 
The decision-conference for MCDA swing-weighting and MACBETH will be taking place at Imperial 
College, London.  The location will be wheelchair accessible.  AHP will take the format of an online 
questionnaire.   
When considering RRMS, we realised that there would be special considerations when determining 
the location of involvement activities, e.g. wheelchair accessibility.  Therefore, the extra detail of 
asking if there are any special considerations will be included in the description of the step.   
5.7.1.5.3 Finances 
There were no finances specifically in place to support PPI at Imperial College, London.  These were 
later negotiated between PROTECT management and WP5 partners.  It was difficult to decide the 
level of financial support which would be considered adequate for their expenses and contribution.  
For MCDA swing-weighting and MACBETH, participants were reimbursed £80 to cover expenses for 
their travel and time.  This amount was suggested by IAPO, who reported that it is a standard 
amount for reimbursement per diem for patient organisations.  For AHP, the decision was made not 
to provide financial support for participant contribution.  This is because the level of burden placed 
upon the participant to complete an online questionnaire is low. 
5.7.1.5.4 Reporting of outcomes 
At the current time, i.e. while recruiting participants, it is not possible for us to test the feasibility of 
this point to consider. 
5.7.1.5.5 Reporting of conflicting perspectives 
Similarly to the reporting of outcomes, it is not possible for us to report the feasibility of this point to 
consider at this time. 
5.7.1.5.6 Communication 
We believe that it will be necessary for participants to be periodically informed of the decision-
making process as it progresses from the start (participant information sheets), during (online 
questionnaire and decision conference) and following the process (circulation of results). 
The description of this step is extremely open to interpretation.  We considered that it could 
perhaps be described in more depth and expanded upon, e.g. explore the use of visualisations. 
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5.7.1.6 Evaluation of the preliminary framework 
5.7.1.6.1 Level of comprehensiveness 
The framework covers a number of key points, some of which it are essential to consider 
prospectively.  Some points were very challenging, but are pertinent to PPI and it is desirable to 
carefully consider them.  The framework could be considered overly comprehensive, but it may be 
what is necessary for transparency and clear communication of the benefit-risk assessment process, 
and to help build a strong evidence base for future PPI.   
It was noted that although the framework covered many key points which document the process of 
involvement, an important consideration was missing: potential conflict(s) of interest.  For example, 
patient organisations and patients may interact and receive funding from industry; industry may 
potentially act as a knowledge source and impact their perception of the favourable and 
unfavourable effects of treatment.  Thus it is possible that these forms of interaction might affect or 
alter the decision regarding the benefit-risk balance.   
5.7.1.6.2 The context of benefit-risk assessment 
The framework was designed to comprehensively cover the indicators of PPI reported in the 
literature.  However, many were related to the general topic of PPI, and we discovered that the 
framework needed to be better adapted to suit the context of benefit-risk assessment.  The team 
realised that improvements to specific indicators were necessary.  For example, the point, “During 
which stage(s) of the methodology is involvement required and/or desired?” is confusing, as it could 
refer to two different concepts: (a) which stage of the decision-making process could PPI occur, and 
(b) which benefit-risk assessment methodologies will be used to elicit preferences.  Also, “participant 
information leaflet” would be more suitable than term “statement of agreement” as it better suits 
the semantic field.   
5.7.1.6.3 Planning versus reporting versus evaluation 
One thing noted when applying it was that there was slight confusion in understanding which points 
should (a) be addressed prospectively to aid planning and facilitate a clear approach and adoption of 
PPI and its principles; and (b) be addressed retrospectively to report and evaluate the process and 
results.  Therefore, this will be clarified in future versions of the framework, so it can be clear when 
each of the steps should be completed in the PPI process. 
5.7.1.6.4   Additional details 
Some of the points could have additional detail to help structure responses, e.g. the positive and 
negative outcomes of involvement might differ according to (a) the regulatory perspective, (b) the 
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administrative perspective, (c) the participants’ perspective, and (d) the patient and public 
perspective.  This could be specified in the description of the point to consider.   
 Final version of the framework 5.7.2
The final amended version of the framework is presented in Table 5.14. 
 
Table 5.14 Final version of the framework developed to guide the application of PPI to the benefit-risk assessment of 
medicines and regulatory decision-making 
 Step  Points to consider 
St
e
p
s 
to
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e 
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d
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u
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n
g 
p
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n
n
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Determine the purpose of PPI What is the aim? 
Which benefit-risk assessment 
methodology(/ies) are going to be used? 
During which stage(s) of the 
methodology(/ies) is involvement required 
and/or desired? 
What is the desired level of involvement for 
each stage? 
Ethical approval Is ethical approval required?  
Who needs to approve ethics application? 
How long is needed to obtain ethics 
approval? 
Conflict of interest declaration Do the researcher(s) have any potential 
conflicts of interest?   
Do the patient organisation(s) and/or the 
patients have any potential conflicts of 
interest? 
Address potential barriers and negative 
outcomes from (a) a patient and public 
involvement perspective, and (b) a benefit-
risk methodology perspective 
What are the potential barriers to 
meaningful involvement? 
What are the potential negative outcomes of 
involvement? 
How can the barriers and negative outcomes 
be alleviated? 
Training Do participants require training and support?  
If so, how will this be addressed? 
Do researchers require training and support?  
If so, how will this be addressed? 
Recruitment Which group of participants will be used to 
represent patients and the public?  
What is the sample size required for the 
methodology?  How many participants will 
be recruited? 
What are the methods and anticipated time 
scales for recruitment? 
Design a participant information sheet Is it possible to provide full disclosure of the 
benefit-risk methodology being studied and 
the role and anticipated value of patient 
involvement? 
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 Step  Points to consider 
What are the roles and responsibilities of 
both the researcher and the participant? 
Do the participants know all of the 
confidentiality, anonymity, drop-out, and 
acknowledgement policies? 
What are the anticipated time scales for 
involvement activities? 
Patient involvement activities What is the method of communication? 
What is the location of involvement activities 
(if applicable)?  Are there any special 
considerations, e.g. wheelchair accessibility? 
Are there finances in place to specifically 
support involvement? 
Finances Can participants receive adequate financial 
support for their expenses and contribution? 
What were found to be the positive 
outcomes of involvement? 
St
e
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 b
e 
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d
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n
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e
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Reporting of outcomes What were the negative outcomes of patient 
involvement? 
Did conflicting perspectives or disagreements 
occur?  
Reporting of conflicting perspectives At which stage of the process did they occur? 
Who did they occur between? 
What were the different perspectives? 
How were they resolved? 
Is it necessary for participants to be 
periodically informed of the decision-making 
process as it progresses? 
Dissemination How will participants be informed about the 
results of their involvement? 
How will participants evaluate the processes 
that they were involved in? 
How will the contribution of participants be 
explicitly acknowledged? 
How will the involvement process be 
reported to all stakeholders? 
How will the overall impact of the decision 
on patients be evaluated?   
 
5.8 Discussion 
The aim of this chapter was to develop a framework to guide the application, reporting, and 
evaluation of PPI in the benefit-risk assessment of medicines, and evaluate its feasibility by applying 
it to multiple different methods of eliciting preferences from patients and the public.  To meet this 
aim, a protocol was developed to compare the weight elicitation methodologies of MCDA swing-
weighting, MACBETH, and AHP; it was designed to elicit patient and public preferences on the 
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benefits and risks of treatments for RRMS.  While the protocol was being designed, the feasibility of 
the framework was applied to it so that it could guide the application and reporting of PPI. 
 Main findings 5.8.1
5.8.1.1 Development of the framework to guide the application, reporting, and evaluation 
of PPI in benefit-risk assessment 
The results of this chapter show that it is possible to develop a special framework created to 
investigate patient and public preferences in benefit-risk assessment.  After carefully considering key 
PPI documents, a preliminary version of a framework to design, conduct, and evaluate PPI in benefit-
risk assessment was designed.  The feasibility of the framework was tested when applied to the task 
of designing a protocol to assess and compare the process and results of different methods of 
eliciting patient and public preferences on the benefits and risks of natalizumab (i.e. MCDA swing-
weighting, AHP, MACBETH).  While applying the framework, it was noted that there were clear 
difficulties when adopting PPI: challenges related to the general practice of patient and public 
involvement (e.g. best methods of recruiting patients and the public for involvement activities), and 
also challenges related to the adaption of benefit-risk assessment methodologies for a patient and 
public context (e.g. limiting the amount of time required from participants by pre-defining the value 
tree and assuming a linear value function).  Also, several potential improvements were noted, e.g. 
tailoring to the specific context of benefit-risk assessment, and the framework was subsequently 
amended.   
5.8.1.2 Feasibility of the benefit-risk assessment methodologies 
The results of this chapter also show that theoretically, it is possible to use three different methods 
of benefit-risk assessment—i.e. MCDA swing-weighting, MACBETH, and AHP to elicit weights from 
patients and the public.  However, it can be difficult to understand how the processes of these 
methodologies vary from one another, as the terminology is often confusing and/or inconsistent 
when attempting to compare the stages of one methodology against another.   A value tree was 
created based on the favourable and unfavourable outcomes of treatment, and linear value 
functions were assigned to each of the outcomes following careful consideration.  The 
methodologies have not been primarily developed for the purpose of eliciting weights from patients 
and the public, and so there are some challenges when adopting them with a lay audience to elicit 
preferences on treatment outcomes.  For example, it was found that a relatively high level of health 
literacy –i.e. US Grade 10 to 14 was required to understand the glossary which describes all of the 
benefits and risks in the weight elicitation protocol.  Each of the methodologies elicits weights in a 
different manner, and they also calculate the weight of the treatment options differently: MCDA 
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swing-weighting uses a direct weight calculation, MACBETH uses linear optimisation, and AHP 
calculates the principle eigenvector.  
 Limitations of the case study 5.8.2
5.8.2.1 Application of PPI to alternative stages in the benefit-risk assessment process 
The efalizumab case study determined that PPI could theoretically be applied to almost every stage 
of the benefit-risk assessment process.  With this in mind, before embarking on the natalizumab 
case study, the aim, objectives, and resources available to the WP5 case study team were carefully 
evaluated and it was determined that PPI would be most desirable and valuable in the weighting 
stage of the benefit-risk methodologies.  However, other decision-makers might view PPI to be most 
desirable and/or feasible to apply PPI to alternative and/or additional stages of the benefit-risk 
assessment process.   
5.8.2.2 Application of PPI in the development of the protocol  
Adoption of PPI in developing the protocol was limited.  Although it was not possible to consult MS 
organisations or patients due to the extra time and resources which would have been required, 
representation of the patient perspective was provided by the International Alliance of Patient 
Organisations (IAPO).  While designing the protocol it became clear that PPI could have been applied 
at many different points of the weight elicitation process: e.g. inclusion and exclusion of favourable 
and unfavourable outcomes, piloting creating the value tree and categorising the risks as either “less 
serious” or “more serious”, of the glossary, assigning the value functions.   
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6 Conclusions 
In this chapter, I present a summary of findings (Section 6.1), and state strengths and limitations of 
the work in this thesis (Section 6.2 and Section 6.3).  Next, I discuss my reflections (Section 6.4), the 
contribution of the work to the literature (Section 6.5) and suggest recommendations for future 
research and improving regulatory decision-making (Section 6.5).  Lastly, I provide concluding 
remarks (Section 6.7).   
6.1 Summary of findings 
An overview of the findings is provided in this section; a full description of the findings relating to 
each of the case studies can be found in the relevant chapters.  The aim of this thesis, i.e. to test and 
evaluate how PPI can be applied to systematic methods of benefit-risk assessment in a regulatory 
context, addressed two themes: (1) applying systematic methods of benefit-risk assessment 
proposed for use within a regulatory context, (2) applying and evaluating how PPI can be 
incorporated into systematic methods of benefit-risk assessment. 
 Theme one: Applying systematic methods of benefit-risk assessment proposed for 6.1.1
use within a regulatory context 
This thesis demonstrated that it is feasible to apply systematic methods of benefit-risk assessment to 
real life regulatory case studies:   
a) In the efalizumab case study, the descriptive frameworks of PrOACT-URL and BRAT, and the 
quantitative frameworks of MCDA and SMAA were applied to evaluate the benefit-risk 
balance of the treatment in January 2009 following several cases of PML.  PrOACT-URL and 
BRAT did not formally analyse and/or integrate the benefits and risks of treatment to 
determine the benefit-risk balance of efalizumab.  The benefit-risk balance of efalizumab 
was found to be favourable when compared against placebo using MCDA and SMAA with 
weights elicited from the efalizumab case study team during a decision conference.  With 
MCDA, the benefit-risk score for efalizumab was 51, compared to 31 for placebo.  With 
SMAA, efalizumab was preferred over with a rank acceptability index of 0.67, 1.00, and 1.00 
using no preference information, ordinal preference information, and cardinal preference 
information, respectively.   
b) In the rimonabant case study, the utility survey technique of DCE, and quantitative 
framework of SMAA were applied to evaluate the benefit-risk balance of the treatment in 
April 2006 when marketing authorisation was first granted, and in October 2008 following 
the increased reporting of psychiatric adverse events. An online survey was designed to elicit 
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patient and public preferences from the members of the obesity organisation Weight 
Concern for two benefits (10% reduction in body weight, and improvements in HDL 
cholesterol) and three risks (psychiatric conditions, cardiovascular conditions, and 
gastrointestinal conditions) of rimonabant.  DCE responses were analysed using a 
conditional logistic regression and provided coefficients illustrating how a change in 
attribute performance influenced preference for a particular alternative.  Using a method 
developed in this thesis, DCE coefficients were combined with performance estimates to 
calculate the preference for rimonabant compared to placebo: in pre-approval and post-
approval, placebo was preferred over rimonabant 94.2% and 98.8% of the time, respectively.  
The ranking of attributes, also obtained from the questionnaire, was used as preference 
information in SMAA to calculate the ranking of rimonabant compared to placebo.  Using 12 
models with varying specification of the distribution of performance, the type of preference, 
and the time of decision-making, placebo was preferred over rimonabant in 9 of 12 models 
with a rank acceptability index ranging from 0.59 to 0.85. Therefore, the benefit-risk balance 
of the treatment was found to be negative at time of approval, and also once the increased 
risk of psychiatric AEs had been acknowledged for both applications.   
c) In the natalizumab case study, a protocol was designed to demonstrate the feasibility of 
applying MCDA swing-weighting, MACBETH, and AHP to evaluate the benefit-risk balance of 
the treatment in October 2009, following the increased reporting of PML. 
The systematic methods of benefit-risk assessment applied in this thesis made explicit the decision-
making process, and allowed participants to clearly communicate how they valued the significance 
and magnitude of favourable and unfavourable effects.  The methodologies also provided guidance 
on how to trade-off the favourable and unfavourable effects against each other to determine the 
benefit-risk balance of a treatment.  In principle, if used within a regulatory setting they can improve 
the transparency and communicability of marketing authorisation decisions.   
 Theme two: Applying and evaluating how PPI can be incorporated into systematic 6.1.2
methods of benefit-risk assessment 
This thesis evaluated how patients and the public can be involved in regulatory decision-making and 
demonstrated how it can be possible to elicit their preferences on the benefits and risks of 
treatment: 
a) In the efalizumab case study, it was critically evaluated where PPI may be desirable and/or 
be feasible in five stages of the benefit-risk assessment process: (1) planning, (2) evidence 
gathering and preparation, (3) analysis, (4) exploration, and (5) decision and dissemination.  
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PPI can in principal take place in every stage of the benefit-risk assessment process, and so it 
is important to consider the aim, objectives, and available resources before deciding how it 
could or should be applied.   
b) In the rimonabant case study, the feasibility of applying PPI to stage three of the benefit-risk 
assessment process—i.e. analysis, was evaluated.  Patient and public preferences were 
elicited on the benefits and risks of weight loss treatments with a DCE through an online 
survey.  Using a method developed in this thesis, it was possible to formally incorporate 
subjective values and preferences obtained from patients and the public to determine the 
benefit-risk balance of rimonabant.  Participants also provided feedback on other outcomes 
that they found important when deciding between weight loss treatments (e.g. diabetes, 
osteoarthritis), and improvements to the DCE survey (e.g. present a “neither” option next to 
the two treatment options) indicating how PPI could have also been useful in the planning 
stages of the process. 
c) In the natalizumab case study, a framework was developed to guide the design, conduct, 
and evaluate PPI in benefit-risk assessment.  Its feasibility was tested by applying it to a 
protocol which compares three different methods which can be used to elicit preferences 
from patients and the public on the benefits and risks of natalizumab, i.e. MCDA swing-
weighting, AHP, MACBETH.     
The application and evaluation of PPI to systematic methods of benefit-risk assessment in this thesis 
demonstrated that there are multiple stages in the benefit-risk assessment pathway where 
involvement can be applied, it is possible to elicit patient and public preferences on the benefits and 
risks of treatments, and provide guidance on how to design, conduct, and evaluate future work on 
PPI in the benefit-risk assessment of medicines.   
6.2 Strengths 
When beginning this thesis, there were many questions regarding how feasible it would be to 
incorporate PPI into systematic methods of benefit-risk assessment within a regulatory context to 
evaluate medicines.  This thesis has made a lot of progress into this field; the exploratory work has 
been very well received by many stakeholders, and there are many who support its continuation as 
an on-going area of research.   
The case studies used in this thesis represent real life regulatory decision-making scenarios, and use 
real life efficacy and safety data.  This allowed for a more rigorous testing of the methodologies; the 
complexity of handling real life case studies was much greater than that which would have been 
expected from handling a hypothetical scenario.  It provided an opportunity to view the scenario 
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from a regulatory perspective, and experience the difficulties with handling and interpreting large 
volumes of heterogeneous data from multiple sources with different sample sizes, patient 
comorbidities, outcome measures, indications, doses and duration of exposure.  It is unlikely that we 
could have created a hypothetical scenario with such realistic nuanced features.   
The work in this thesis took place in the context of WP5.  There is a wide range of stakeholders in 
WP5: academic, industry, regulatory, and patient organisation, which cover a wide range of skills, 
such as decision science, statistical, clinical, and patient knowledge.  The interdisciplinary nature of 
the IMI PROTECT project has allowed for rich discussions representing numerous perspectives from 
different backgrounds to be incorporated into this work.   
6.3 Limitations 
 The validity of the benefit-risk balance determined by the methodologies in the 6.3.1
case studies 
The primary focus of the case studies was to explore the feasibility of the methodologies and 
application of PPI using real life case studies.  One major limitation of all the benefit-risk assessment 
methodologies tested in this thesis is that, although care was taken to replicate the regulatory 
scenarios represented by these case studies, it was not possible to identically reconstruct the EMA 
regulatory decision-making scenarios.  Thus, this may have resulted in a different evaluation of the 
benefit-risk balance when comparing the case study to EMA decisions.  There are several potential 
reasons for this: 
a) Options for marketing authorisation: regulators have the option to grant, maintain, vary, or 
suspend the marketing authorisation of a treatment, depending on the stage of the product 
lifecycle.  This thesis only examined if marketing authorisation should be granted, 
maintained or suspended, and did not examine the effect of varying the authorisation.   
b) Favourable and unfavourable effect data: the publicly available data regarding the 
favourable and unfavourable effects of treatment in the regulatory documents which were 
used in the case studies might not be fully representative of the data available to regulators; 
regulators would have had access to additional confidential data.   
c) Preference data: the preferences of the regulators regarding the favourable and 
unfavourable effects of treatment at the time of decision-making may have differed from 
the preferences of those in the efalizumab case study team, and members of Weight 
Concern. 
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This section discusses further aspects of options for marketing authorisation, favourable and 
unfavourable effect data, and options for marketing authorisation, and describes how they may 
affect the validity and generalizability of determining the benefit-risk balance of a treatment.   
6.3.1.1 Options for marketing authorisation 
This thesis only examined if the authorisation should be granted, maintained or suspended for all 
three of the case studies; this was due to the difficulties associated with investigating how the 
marketing authorisation could have been varied; data were not available to determine population 
subsets for which the benefit-risk balance may have been more positive, and it was not possible to 
evaluate the benefit-risk balance with different time periods of exposure to treatment.   
All of the case study treatments in this thesis were compared against an inactive comparator.  
Placebo data was used as the comparator for clinical trials, but it can be extremely challenging to 
determine what would be an appropriate inactive comparator for post-marketing surveillance data.  
When reporting safety events, publicly available regulatory documents often present the absolute 
number of cases without reference to a comparator group who do not receive the treatment under 
consideration.  Comparators for clinical trial and post-marketing surveillance data are necessary for 
many benefit-risk assessment methodologies.  This can be an issue, as illustrated by the application 
of BRAT to the efalizumab case study.  BRAT requires information on the relative risk, and risk 
difference, and so data representing an inactive comparator is essential or else the outcome is 
excluded from the results of the methodology.  In order to avoid the exclusion of PML from the 
methodology—i.e. the outcome which precipitated the regulatory decision-making scenario, a 
background epidemiological rate was obtained from an academic publication.  It can be difficult to 
select which background epidemiological data to include, as the patient population with the 
indication might experience different rates of the outcome compared to the general population, and 
the occurrence of the outcome might vary across populations according to factors such as age, 
geographic location, and comorbid conditions.   
6.3.1.2 Favourable and unfavourable effect data   
All of the systematic methods of benefit-risk assessment used in this thesis required data on the 
favourable and unfavourable effects of treatment.  Regulators would have had access to additional 
data which was not available for the case studies, which might have substantially influenced the 
benefit-risk balance of the treatments.  In this thesis, data were extracted from publicly available 
regulatory documents, i.e. EPARs and PSURs.  Unfortunately, safety data were often missing, 
incomplete or inconsistent.  For example, clinical trials provide limited information regarding 
adverse events; for efalizumab, events were not publicly reported if they occurred in ≤3% of patients 
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within a treatment arm, for rimonabant, events were not publicly reported if they occurred in ≤1% 
to ≤5%, of patients within a treatment arm—the reporting threshold varied according to the 
document, and study.  However, excluding this data could lead to a potential underestimation or 
overestimation of risk, and assumes that safety events which occur below the stated percentage do 
not have consequences in the benefit-risk assessment; however, if they are outcomes for which 
stakeholders have strong preferences, it may be possible for them to affect the benefit-risk balance.   
One of the challenges of benefit-risk assessment is how to handle different sources of data.  The 
primary example of this in this thesis is the difference between clinical trial data and post-marketing 
surveillance data.  Clinical trials recruit a relatively small number of participants, who are enrolled in 
accordance with strict inclusion and exclusion criteria and are actively monitored.  Typically, patients 
are not allowed to receive concomitant treatments—or if they do, they are noted.  In contrast with 
this, a larger number of patients receive the treatment in the post-marketing surveillance period, 
with less strict inclusion and exclusion criteria.  They may also receive concomitant treatments, and 
take the treatment for shorter or longer durations than originally investigated in the clinical trial(s).  
An example of this is rimonabant; at the time of initial marketing authorisation the benefit-risk 
balance of the treatment was found to be positive based on clinical trial data.  However, post-
marketing surveillance data showed that the efficacy of the treatment was reduced because patients 
received the treatment for a shorter time than investigated in the clinical trials.  Also, psychiatric risk 
increased during post-marketing surveillance because it was not possible to exclude patients 
receiving treatment(s) for depression from taking rimonabant.   
A Bayesian random-effects meta-analysis model was used in this thesis to handle heterogeneous 
sources of data such as clinical trials with different study populations, and/or post-marketing 
surveillance data, and estimate overall treatment effects.  However, alternative methods could have 
been explored to synthesise the data.  The way in which data from different sources is synthesised 
can incorporate more or less uncertainty in estimates of the benefits and risks of treatments.  The 
level at which heterogeneity across data sources is accounted for (e.g. variations in inclusion and/or 
exclusion criteria, study duration, outcomes investigated, or in thresholds for reporting adverse 
events), may substantially alter estimates of the favourable and unfavourable effects of treatment, 
and thus potentially impact the benefit-risk balance of a treatment.   
The number of outcomes which could be investigated using a DCE in the rimonabant case study was 
limited.  The way how the Wave Two case study team addressed this was to create categories of 
similar outcomes, i.e. psychiatric conditions, cardiovascular conditions, and gastrointestinal 
conditions.  However, this might have affected the validity of responses because each category 
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represents a broad range of outcomes with varying severities.  Although other methodologies do not 
have such strict limitations on the number of outcomes which can be included, it needs to be 
considered how many outcomes should be included.  The inclusion of too many outcomes might 
overcomplicate the benefit-risk assessment, and place a high burden on participants due to the large 
amount of time and cognitive demands required for preference elicitation.  Alternatively, limiting 
the number of outcomes might lead to disagreements regarding which should be retained.  Clear 
communication between stakeholders is essential.  
6.3.1.3 Preference data 
The benefit-risk assessment methodologies used in this thesis are used to obtain preference data on 
the outcomes of treatment. However, PPI can be more extensively applied in the benefit-risk 
assessment process but due to resource limitations it was not possible to investigate how PPI could 
have been applied to additional stages of benefit-risk assessment.  One example of where PPI could 
have been applied is the selection of outcome measures: which outcomes are included or excluded 
in systematic methods of benefit-risk assessment might vary according to whose perspective is 
adopted.  Ideally, outcomes which most greatly influence the benefit-risk balance of a treatment 
should be included, and the case studies assumed that these were the outcomes described in 
publicly available regulatory documents.  However, patients and the public might have included or 
excluded different outcomes which could have been investigated.  A different group of individuals, 
with different professional, and personal backgrounds might have selected different favourable and 
unfavourable effects to be included in the model; this variations can potentially lead to different 
assessments of the benefit-risk balance.   
Unfortunately, although it was extremely desirable to include patient and public involvement in 
additional stages of the benefit-risk assessment process—rather than just limiting PPI to outcome 
preferences, it was outside of the scope and timescales of IMI PROTECT Work Package Five.   
Hypothetically, patient and public involvement could have been applied through focus groups, 
questionnaires, and/or Delphi processes.  Different favourable and unfavourable effects may have 
been added or removed from the model which may have had an impact on the resultant benefit-risk 
balance.  It is strongly recommended that further research in this field involves patients in the 
selection of outcomes.   
Ideally, outcomes which most greatly influence the benefit-risk balance of a treatment should be 
included, and the case studies assumed that these were the outcomes described in publicly available 
regulatory documents.  However, patients and the public might have included or excluded different 
outcomes which could have been investigated through questionnaires, focus groups and/or 
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meetings.  For example, participants who responded to the rimonabant DCE stated that they found 
outcomes such as osteoarthritis, cardiovascular fitness, and type two diabetes important if they 
were in a position to decide between treatments for weight loss—these were not outcomes which 
were reported in the regulatory documents, and subsequently were not considered in the DCE and 
SMAA.  If data had been collected for these outcomes, and if they were included in the benefit-risk 
methodologies, this might have affected the evaluation of the benefit-risk balance.   
Difficulties were experienced in all of the case studies when describing outcomes to non-clinician 
audiences.  From my personal experience, it was hard for clinicians in the efalizumab case study to 
communicate to me what is meant by PASI75—i.e. the clinical trial endpoint which was used by 
regulators to evaluate the efficacy of efalizumab.  I struggled to understand the clinical relevance of 
PASI; it is an aggregate score which is calculated through a formula based on the redness, thickness, 
scaling, body surface area and affected regions.  It was hard for other participants in the decision 
conference to provide me with a vignette describing a typical patient experience of PASI75 because 
the measure could represent many, many varying scenarios due to different improvements in 
differently weighted parameters.  Weights were also elicited from the efalizumab team for a point 
score indicating a mean improvement in DLQI.  DLQI is a patient reported outcome measure; many 
people believe that patient reported outcome measures are an important application of PPI as they 
evaluate the subjective patient experience of receiving a treatment.  However, it is extremely 
difficult to elicit preferences for patient reported outcomes in the context of benefit-risk 
assessment, as the patient feedback has been transposed into an aggregated score which is hard to 
understand.  I found it challenging to assign weights for a point score indicating a mean 
improvement in DLQI.   
 The generalizability of the treatment options considered when determining the 6.3.2
benefit-risk balance 
The generalizability of the treatment comparisons presented in this thesis, i.e. a single active 
treatment versus placebo, can be questioned; comparisons of this type may differ from the real life 
treatment decision-making scenarios faced by doctors. Placebo was used in all three case studies 
because the scenarios intended to replicate the regulatory perspective: in all of the publicly available 
EMA documents, there are not any comparisons or references to alternative active treatment 
options for the same indication.  However, there are important points to consider when only using 
placebo as a comparator in benefit-risk assessment:  The decision-making scenario represented by a 
single active comparator versus placebo may not be easily generalizable to clinical decision-making 
scenarios, i.e. patients and physicians are likely to consider a range of active treatment options.   For 
example, this may be extremely applicable to the rimonabant case study: there are a number of 
 213 
 
physical activity, dietary, and surgical interventions which are also available to patients.  Also, 
placebo is likely to perform less favourably than standard care and/or best available care.  This may 
mean that it is possible for a new treatment to be authorised with a less favourable benefit-risk 
balance (i.e. it may be less efficacious or result in more safety events) when compared to other 
treatments currently used for the same indication; this may raise ethical concerns.   
 PPI in benefit-risk assessment and the framework to aid its implementation 6.3.3
To aid the application of PPI within the benefit-risk assessment of treatments, a framework was 
developed in this thesis to evaluate how and where PPI can be incorporated to design, conduct and 
evaluation.  PPI is relatively new within the context of benefit-risk assessment, and thus the work 
presented in this thesis may not have covered the whole extent of possibilities where PPI can be 
incorporated, or the challenges which may arise. 
In this thesis, the incorporation of PPI was investigated in the rimonabant case study using a DCE, 
and in the natalizumab case study through the design of a protocol for eliciting preference weights 
using swing weighting, MACBETH, and AHP.  Although the potential stages where PPI could be 
incorporated within the benefit-risk assessment process were evaluated in detail, each benefit-risk 
assessment methodology may have specific areas best suited for PPI, and this was only evaluated 
within the preference elicitation stage of methodologies included in this thesis.  However, the 
framework should be sufficient to guide investigators in incorporating PPI regardless of the benefit-
risk methodology used, or the stage examined. 
One finding of the rimonabant case study was that alternative outcomes suggested by respondents 
of the DCE questionnaire had not been included within clinical trials, and thus could not be 
incorporated within the benefit-risk assessment even if discovered in the planning stages.  In this 
case, it might have been important to incorporate PPI in the design of trials when deciding which 
outcomes should be used to evaluate efficacy of the treatment.  This thesis did not consider how 
and where PPI could be incorporated in the design, implementation, and analysis of clinical trials: 
however, it is clear that in order to benefit most from PPI, it would have to be incorporated 
throughout the lifecycle of the treatment. 
 
6.4 Reflections 
This thesis examined the feasibility of PPI in systematic methods for benefit-risk assessment.  
However, a real challenge is how this knowledge can be transferred into a real life regulatory setting.  
At the moment, although many agree that PPI is a valuable area of research and should be 
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accounted for in regulatory process, there is debate over whose duty it should be to involve 
patients, and who would be in the most appropriate position to involve them.  When we examined 
who should be responsible for collecting benefit-risk preference data, availability of resources and of 
patients who are willing to participate were two challenges which were frequently cited.  There are 
questions over what the rights and responsibilities of each group of stakeholders are in benefit-risk 
assessment and how these can be mutually agreed.  Patient groups are unlikely to have sufficient 
skills and knowledge to elicit their benefit and risk preferences; despite this, they can be effective at 
identifying and motivating potential participants in benefit-risk assessment activities.  Thus, it is 
likely that the responsibility to collect benefit and risk preferences will fall upon regulators and/or 
pharmaceutical companies.   
If pharmaceutical companies are to be responsible for providing patient benefit-risk preferences in 
the submission dossier for authorisation decisions, there is an interesting dilemma regarding 
whether PPI should fall within a pre-competitive or competitive space.  It is questionable whether 
the PPI research to help determine the benefit-risk balance could be kept confidential within the 
company to maintain a competitive advantage.   For example, it is believed by some that when 
investigating therapeutic indications, the PPI activities, experiences and results of pharmaceutical 
companies fall into a pre-competitive space; however, once they engage in PPI and the research is 
specifically relevant to a treatment rather than a therapeutic indication or disease area, this is 
confidential.  That is, they do not mind making publicly available—or even collaborating with other 
companies to understand the impact of a disease, but they will not share details relating to the 
impact of a potential treatment which they are considering to authorise.  It poses a great problem if 
the process and results of PPI in benefit-risk assessment are made confidential but are also used as 
evidence in the submission dossier.  One of the primary purposes of systematic benefit-risk 
assessment methodologies is to make explicit and transparent the decision-making process, and for 
those who may not have directly participated to be offered the opportunity to understand and audit 
where and how decisions have been made.  If the decision-making process and benefit-risk 
preferences are made confidential, the use of formalized methodologies will no longer retain the 
advantage of transparency.  It will become incredibly difficult to understand how the benefits and 
risks have been traded-off against each other during regulatory decision-making.   
Although a broad definition of “patient and public” was adopted, it should be acknowledged that 
varying definitions of “patient and public” can be adopted in relation to the benefit-risk assessment 
of medicines.  For example, some may refrain from including “members of the public” in their 
definition, as they may not be directly affected by the indication under consideration, and/or 
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understand how it can affect quality of life.  Therefore, some may consider the involvement of the 
general public not to be desirable because their values and preferences might be considered less 
relevant and/or valid to the benefit-risk decision-making context than those directly affected by the 
condition.  This thesis adopted an inclusive definition of “patient and public” because its focus was 
to test “proof of concept” and demonstrate the feasibility of applying PPI to benefit-risk assessment 
methodologies, which concentrated on eliciting the values and preferences of lay people.   
There is a recurring discussion centered on who the most representative group of patients are so 
that they can be included in benefit-risk assessment to produce the most valid and generalisable 
preference estimates.  Patients are not a homogenous group of stakeholders; there can be 
heterogeneity in the severity of the condition and in demographic characteristics—e.g. gender, age, 
geographic location, — which may result in heterogeneity of elicited benefit and risk values and 
preferences. However, there are lots of uncertainties surrounding potential heterogeneity in values 
and preferences due to insufficient empirical evidence.  It has been commented that this possible 
heterogeneity should not hinder the adoption of PPI; very often we argue who is the “most 
representative patient”, but there are few comments on the “most representative physician” or the 
“most representative regulator,” who are assumed to be representative for evaluating benefit-risk.  
However, even when comparing regulator against regulator, it has been found that demographic 
characteristics—e.g. age and gender, affect individual benefit and risk preferences (EMA Benefit-Risk 
Methodology Project Team, 2011).   
Some have drawn a distinction between “normal” patients who experience a disease, and 
“professional” patients who act as advocates.  We need to be careful if we are to discriminate 
between the two as it can be difficult for patients to participate in benefit-risk methodologies.  
Patients are expected to fulfil multiple different roles and Achim Kautz (Vice President, European 
Liver Patients Association) has described this as almost having three lives to juggle: firstly, they have 
an illness which can affect their quality of life and how capable they are at coping and handling 
activities of daily living; secondly, they often have jobs which are demanding on their time and come 
with many tasks and responsibilities; lastly, they have social relationships to maintain with family 
and friends.  It can be an effort to juggle all these different roles, especially when experiencing a 
disease.  Providing patients with full time paid roles ensures that those willing to participate have 
adequate time to be involved, dedicate to political representation and raise awareness.  One 
consequence is that some may perceive that these individuals may become “professionals” so they 
no longer truly represent the lay patient perspective.  This may be undesirable to some as they may 
consider them to be distinctly different when compared to the population that some believe that 
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they are supposed to represent, although there is the benefit that they may have an increased 
understanding of regulatory process and require less training to fulfil their participation roles.  
Money, travel and time can be limiting factors to participation and need to be adequately addressed 
for successful involvement.  Benefit-risk assessment methodologies should not place unreasonable 
demands upon a patient—particularly with regards to time.  Most stakeholders believe that patients 
should be reimbursed for their travel and expenses when participating.  However, the amount they 
should be entitled to is disputable; it is questionable how much money a “fair” reimbursement might 
represent.   
6.5 Contribution to the field 
Although systematic methods of benefit-risk assessment have been widely used in other fields, their 
use has not been established in the context of the benefit-risk assessment of medicines.  This thesis 
provides evidence to suggest which systematic methods of benefit-risk assessment are feasible 
within a regulatory setting through demonstrating their application to real life regulatory case 
studies.  It also provides a framework to plan, report and evaluate PPI in the benefit-risk assessment 
of medicines; although there is a strong ethical belief that it is a democratic right for patients and 
the public to be involved in regulatory decisions which directly affect them, this thesis has built the 
foundation for  future research to investigate PPI in the context of benefit-risk assessment and 
regulatory decision-making.   
6.6 Future research 
There are multiple different ways patients and the public can be involved in systematic methods of 
benefit-risk assessment.  Although this thesis has begun to explore this topic, the field is still 
relatively new and requires further work. My experience with numerous stakeholders during the 
undertaking of this thesis and my participation in PROTECT WP5 has made me realise that many 
professionals and patient groups acknowledge that patients and the public have specialist insight, 
and it is desirable for to collaborate with them in order to produce medicines which can better meet 
patient needs.  However, there is still an insufficient evidence base to guide this work, and further 
research is necessary.   
 Comparison of stakeholder preferences 6.6.1
Many different groups of stakeholders are involved in the regulatory benefit-risk assessment of 
medicines.  When we examine these groups, it is necessary to recognise that each offers a unique 
type of expertise which can potentially enhance the regulatory process.  For example, a regulator is 
an expert at understanding and interpreting efficacy and safety outcomes and making decisions at a 
population level, pharmaceutical companies are experts in scientific knowledge and exploring unmet 
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need, and patients are experts in understanding the real life implications of signs and symptoms 
related to their condition and how these can affect their quality of life.  One of the aims of patient 
and public involvement is to recognise the skill sets and expertise offered by each group, and how 
this complementary knowledge can be integrated to produce high quality solutions to difficult 
decision-making scenarios.  Deciding if the significance and magnitude of risk is reasonable, given 
the significance and magnitude of the expected benefit might vary according to whom is making the 
decision.   
At the moment, very little research has examined how preferences might vary across stakeholder 
groups (e.g. regulators, physicians, patients) and within stakeholder groups—for example, potential 
variances in patient preferences due to severity of condition, age, and gender.  An interesting 
research question is to examine whether factors such as demographic characteristics (age and 
gender), and personal experience of a disease (e.g. time since diagnosis and degree of severity) and 
experience of other treatments (e.g. degree of success and occurrence of adverse events) affect an 
individual patient’s weighting of the favourable and unfavourable effects.   The rimonabant case 
study sought to investigate whether preferences varied by several characteristics including age, 
gender, and current obesity status: however, differences in values between these groups were not 
observed analytically which may have been due to small sample size.  For future work, information 
regarding these factors could be collected and subgroup analyses planned to examine how these 
different groups regard the benefit-risk balance could be compared, e.g. they could investigate how 
DCE or other utility survey techniques can be further developed in the design and analytical stage to 
capture heterogeneity in preferences.   
 Sensitivity analyses 6.6.2
There are two types of sensitivity analyses described by the methodologies applied in this thesis, i.e. 
sensitivity of benefit-risk balance to (a) the data used to measure the favourable and unfavourable 
effects of treatment, and (b) the elicited preference data.  Although assessing the benefit-risk 
balance with regards to this information is important, there are many other points in the 
methodologies where the sensitivity of different approaches to the benefit-risk balance could be 
compared.  Each of the methodologies require a number of subjective decisions to define the 
decision-making scenario; variations in these subjective decisions may impact whether the benefit-
risk balance is found to be positive or negative.  Therefore it would be valuable for future research to 
conduct sensitivity analyses which focus on: 
 How does the use of different comparators impact the evaluation of the benefit-risk 
balance?  For example, comparisons could be made between two difference scenarios: (a) 
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the active treatment under consideration versus placebo; and then (b) the active treatment 
under consideration versus other active treatments used for the same indication. 
 How does the use of different favourable and unfavourable effects impact the evaluation of 
the benefit-risk balance?  Hundreds of favourable and unfavourable effects are reported for 
each of the case study treatments in the relevant European Public Assessment Reports.  
Because the methodologies can only handle a limited number of outcomes, this number is 
significantly reduced in a subjective manner to produce a manageable number for 
preference elicitation.  Comparisons could be made between (a) adopting a set of outcomes 
patients find most important from the available data versus (b) adopting a set of outcomes 
regulators find most important from the available data.       
 Additional methodologies for benefit-risk assessment 6.6.3
Due to the limited time frame of this thesis, it was not possible to explore all of the methodologies 
which have been recommended for use within a benefit-risk assessment setting, particularly those 
falling under estimation techniques (Mt-Isa et al., 2013).  There is currently not a single widely 
accepted method within a regulatory setting.  Accordingly, multiple benefit-risk assessment 
methodologies could potentially be applied to determine the benefit-risk balance of a medicine; 
however, in cases where conclusions from different assessment methods diverge, it would be 
unclear how these could be incorporated to form a single coherent recommendation.  Nonetheless, 
different methodologies may be more suitable for addressing specific aims within a regulatory 
question, and it would be useful to address each using an appropriate assessment method.  Overall, 
it emerges as desirable to combine a descriptive framework, such as PrOACT-URL, with a 
quantitative method for estimating performance of the treatment, a preference elicitation method 
for estimating values (such as a DCE or MCDA), whilst addressing uncertainty in performance and 
preference using a probabilistic approach (such as SMAA or method proposed in this thesis for DCE).  
Therefore, further studies should evaluate how new frameworks can incorporate these multiple 
facets of the decision-making process into a feasible, transparent, reproducible, communicable, and 
generalizable method of appraising the benefit-risk balance of a treatment. 
 Patient and Public Involvement framework 6.6.4
In this thesis, a framework was developed to plan, conduct, and evaluate PPI in benefit-risk 
assessment.  The feasibility of the framework was evaluated for investigating the weighting stage of 
swing-weighting, MACBETH, and AHP for the treatment of RRMS.  However, further testing of the 
framework needs to be accomplished to develop and establish the suitability and feasibility of the 
framework to other benefit-risk assessment methodologies and decision-making stages. 
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Further development of the framework should allow for it to be used as a tool for successfully 
implementing PPI and providing a common methodology and vocabulary for investigators to refer to 
when addressing PPI and reporting results.  This would help make the process and dissemination of 
PPI more transparent and reproducible.  Future work can also enable the development of an 
evidence-base for the implementation of PPI to guide researchers;  results from previous studies 
using the framework can facilitate investigators to evaluate how PPI can best be implemented to suit 
their aims. 
 Communication and visualisations 6.6.5
When applying PPI to benefit-risk decision-making methodologies in WP5, it was discovered that 
there were multiple points in the benefit-risk decision-making process where Wave One, Wave Two 
and PPI teams could have communicated with participants and/or patients and the public when 
exploring, applying, or reporting the results of benefit-risk assessment methodologies.  Due to time 
and resource limitations, it was not possible for us to investigate all these points in sequence; 
communication and visualisation materials were subsequently developed on an ad hoc basis, and 
occurred where we felt it was important to clearly convey specific messages.  Further work should 
focus on how and where communication and visualisations have been developed, applied and 
presented to a patient and public audience in the benefit-risk assessment process.     
6.7 Concluding remarks 
One current barrier to PPI which many stakeholders recognise is the insufficient evidence base to 
support its practice.  Some stakeholders are unwilling to engage in it because they do not 
understand how to approach it and view the process and results with scepticism or suspicion.  
Although PPI in itself is regarded as intrinsically good in the regulatory process as it can improve the 
legitimacy, transparency, and quality of decision-making, there is not enough evidence to guide how 
it might best be applied or the subsequent potential positive and/or negative impact it may have on 
stakeholders.  Despite PPI being a relatively novel field of research in benefit-risk assessment and 
regulatory decision-making, the lack of evidence should not act as a barrier to dissuade stakeholders 
from engaging in it.  Although we are far from determining which may be the best methods of 
involvement, the continuing investigation of involvement activities, and importantly—involvement, 
should be clearly reported.  This will help to establish a strong evidence base and enable others to 
learn, evaluate and model upon previously conducted work.  Through collaboration it is possible to 
give patients and the public an effective, reliable, valid voice in the decision-making process, which 
will encourage other stakeholders to be more willing to adopt the important principle of PPI.   
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Appendix 2 Methods 
 
Appendix Figure 1 WinBUGS code for performing a random-effects meta-analysis model using trial-specific data 
(adapted from Ntzoufras (2011)) 
 
 
Appendix Figure 2 WinBUGS code for estimation of pooled mean for change from baseline with known mean, standard 
deviation, and sample size 
 
 
model{ 
for (o in 1:4) { 
for (k in 1:studies[o]) { 
 
for (i in 1:2) { 
 
N[k,i,o]<-Y[k,i,1,o]+Y[k,i,2,o] 
Y[k,i,1,o]~dbin(p[k,i,o],N[k,i,o]) 
logit(p[k,i,o])<-a[k,o]+theta[k,o]*equals(i,1)  
} 
theta[k,o]~dnorm(mu.theta[o], tau.theta[o]) 
a[k,o]~dnorm(mu.a[o],tau.a[o]) 
OR[k,o]<-exp(theta[k,o]) 
} 
mu.OR[o]<-exp(mu.theta[o]) 
RR[o]<-p.new[1,o]/p.new[2,o] 
diff[o]<-p.new[1,o]-p.new[2,o] 
 
for (i in 1:2) { 
logit(p.new[i,o])<-mu.a[o]+mu.theta[o]*equals(i,1) 
}} 
for (o in 1:4) { 
mu.a[o]~dnorm(0,0.01) 
tau.a[o]~dnorm(0,0.01)I(0,10) 
mu.theta[o]~dnorm(0,0.01) 
tau.theta[o]~dnorm(0,0.01)I(0,10) 
}} 
model { 
for (i in 1:5) { 
for (g in 1:2) { 
data[i,g]~dnorm(mn[i,g],tau[i,g]) 
tau[i,g]<-1/(sd[i,g]*sd[i,g]) 
mn[i,g]~dnorm(mn.p[g],taut[g]) 
}} 
for (g in 1:2) { 
mn.p[g]~dnorm(0,0.01) 
taut[g]~dnorm(0,0.001)I(0,1000) 
}} 
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Appendix Figure 3 WinBUGS code for estimating uncertainty in outcome measures reported for aggregated trials 
 
 
 
Appendix Figure 4 WinBUGS code for estimating uncertainty for post-marketing surveillance data using a Poisson model 
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Appendix 3 Efalizumab case study 
Appendix Table 1 Summary of the five pivotal clinical trials which were included in the submission dossier preceding the 
initial marketing authorisation decision 
Study number, 
Phase 
Study design Number of subjects 
entered/completed 
Duration (weeks) 
ACD2058g, Phase III  
Double-blind 
Raptiva XOMA subcutaneously 
1.0mg/kg/wk 
2.0mg/kg/wk 
Placebo 
Total: 498/445 
162/149 
166/145 
170/151 
12-24 
ACD2059g, Phase III 
Double-blind 
Raptiva XOMA subcutaneously 
1.0mg/kg/wk 
2.0mg/kg/wk 
Placebo 
2nd 12 week: 
1.0mg/kg/wk or 2.0mg/kg/wk 
or  
4.0 mg/kg/wk or placebo 
Total: 597/549 
232/211 
243/227 
122/111 
12-24 
ACD2390g, Phase III  
Double-blind 
Raptiva GNE subcutaneously 
1.0mg/kg/wk 
Placebo 
Total: 556/520 
369/345 
187/175 
12 
ACD 2600G, Phase III 
Double-blind 
Raptiva GNE subcutaneously 
1.0mg/kg/wk 
Placebo 
 
450/421 
236/218 
12 
IMP 24011, Phase III 
Double-blind 
Raptiva GNE subcutaneously 
1.0mg/kg/wk 
Placebo 
 
529/476 
264/247 
12 
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Appendix Table 2 Details of the five pivotal clinical trials which were included in the submission dossier preceding the 
initial marketing authorisation decision 
Study 
number, 
Phase 
Participants Allowed 
concomitant 
psoriasis 
treatments 
Treatments Objectives Endpoints 
ACD2058g, 
Phase III  
Double-
blind 
Subjects 
with 
moderate to 
severe 
plaque 
psoriasis.  
(Diagnosis 
for 6 
months, 
minimum 
PASI score 
of 12.0 at 
screening, 
plaque 
psoriasis 
covering 
≥10% of 
total body 
surface 
area, 
candidate 
for systemic 
treatment.   
Exclusion 
criteria:  
history of or 
on-going 
infections, 
presence of 
history of 
malignancy, 
HIV, 
pregnancy 
or lactation, 
history of 
severe or 
anaphylactic 
reactions to 
humanised 
monoclonal 
antibodies. 
Emollient 
cream, tar, 
salicylic acid 
preparations 
for the scalp, 
and low-
potency 
(Grade VI-VII) 
topical 
corticosteroids 
for lesions on 
the face, 
hands, feed, 
axillae, or 
groin 
Subjects 
received 
either 
1.0mg/kg/wk 
or 
2.0mg/kg/wk 
SC efalizumab 
or placebo for 
12 week first 
treatment (FT) 
period. 
Primary: 
To assess the 
efficacy of weekly 
SC dosing of 
efalizumab 1.0 or 
2.0mg/kg in 
patients with 
moderate to severe 
psoriasis versus 
placebo, as 
measured by the 
proportion of 
subjects achieving 
≥75% decrease 
from baseline in 
PASI at the end of 
FT. 
Secondary: 
To assess the 
efficacy of weekly 
SC dosing measured 
by secondary 
endpoints, versus 
placebo.  To assess 
efficacy and safety 
of a second 12-
week course 
initiated at time of 
relapse of 
efalizumab versus 
placebo.  Duration 
and time course of 
response.  In partial 
and non-
responders: safety, 
tolerability and 
efficacy of 24 weeks 
continuous 
efalizumab therapy 
and duration of 
response following 
24 week course.   
ACD2390g 
additionally 
included 
Primary 
endpoint:  
Proportion of 
subjects who 
had PASI75 
response 
from baseline 
when 
assessed 1 
week after 
the last of 12 
weekly doses 
of efalizumab.   
Secondary 
endpoints: 
Proportion of 
subjects 
achieving OLS 
rating of 
minimal or 
clear, mean 
improvement 
in the Itching 
Scale, 
Proportion of 
subjects with 
a PGA rating 
of cleared or 
excellent, 
mean 
improvement 
in the 
thickness 
component of 
the PASI 
score, mean 
improvement 
in the 
percentage of 
BSA affected 
by psoriasis. 
ACD2390g 
additionally 
included: 
PASI50 
ACD2059g, 
Phase III 
Double-
blind 
ACD2390g, 
Phase III  
Double-
blind 
Subjects were 
randomised in 
a 2:1 ratio to 
receive either 
1.0mg/kg/wk 
efalizumab, or 
matching 
placebo for 12 
weeks (FT 
period). 
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Study 
number, 
Phase 
Participants Allowed 
concomitant 
psoriasis 
treatments 
Treatments Objectives Endpoints 
pharmacokinetics 
and 
pharmacodynamics. 
improvement, 
mean percent 
PASI 
improvement 
over time, 
mean 
improvement 
in the DLQI, 
mean 
improvement 
in the 
frequency and 
severity 
subscales of 
the PSA. 
ACD 
2600G, 
Phase III 
Double-
blind 
Adults with 
moderate to 
severe 
plaque 
psoriasis.  A 
minimum 
PASI score 
of 12.0 at 
screening, 
plaque 
psoriasis 
covering 
≥10% of 
total body 
surface 
area, 
candidate 
for systemic 
treatment.  
Exclusion 
criteria:  
history of or 
on-going 
infections, 
HIV, 
pregnancy 
or lactation, 
history of 
severe or 
anaphylactic 
reactions to 
humanised 
Not listed. Subjects were 
randomised in 
a 2:1 ratio to 
receive 12 
weeks of 
1.0mg/kg SC 
efalizumab or 
placebo.  
Randomisation 
was stratified 
within each 
study centre 
by subjects’ 
Day 0 PASI 
score (≤16.0, 
≥16.1) and 
their prior 
treatment for 
psoriasis 
(naive to 
systemic 
treatment vs. 
prior systemic 
treatment) 
Primary: 
To evaluate the 
safety and 
tolerability of a 12-
week course of 
1.0mg/kg SC 
efalizumab relative 
to placebo.   
Secondary: 
Evaluate the 
efficacy of a 12-
week course of 
1.0mg/kg SC 
efalizumab relative 
to placebo, 
measured by the 
proportion of 
subjects who 
achieved a >75% 
improvement in 
PASI, OLS, the 
proportion of 
subjects who 
achieved a >50% 
improvement in 
PASI, and the PSA 
Primary 
endpoint:  
Proportion of 
subjects who 
had PASI75 
response 
after initial 12 
weeks of 
treatments.   
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Study 
number, 
Phase 
Participants Allowed 
concomitant 
psoriasis 
treatments 
Treatments Objectives Endpoints 
monoclonal 
antibodies.   
IMP 
24011, 
Phase III 
Double-
blind 
Subjects 
with 
moderate to 
severe 
plaque 
psoriasis.   
Not listed. Randomised in 
a 2:1 ratio to 
receive 
Raptiva 
1mg/kg or 
placebo SC 
once a week 
for 12 weeks.  
Randomisation 
was stratified 
by PASI (≤16.0, 
≥16.1) 
previous use 
of systemic 
treatment vs. 
prior systemic 
treatment, 
and country. 
Primary: 
To assess the safety 
and efficacy of 
1mg/kg Raptiva SC 
once a week 
compared to 
placebo. 
Secondary: 
Evaluate the safety 
and efficacy of 
Raptiva during the 
observation and re-
treatment periods. 
Extra notes: 
To prospectively 
assess the safety 
and efficacy of 
Raptiva in both the 
total study 
population of 
patients with 
moderate to severe 
plaque psoriasis 
and the subgroup of 
“high need” 
patients, defined as 
patients for whom 
at least 2 currently 
available systemic 
therapies were 
unsuitable because 
of lack of efficacy, 
intolerance or 
contraindication. 
Primary 
endpoint:  
Proportion of 
subjects who 
had PASI75 
response 
after initial 12 
weeks of 
treatments.  
The primary 
efficacy 
analysis 
population 
was the ITT 
population.  
Secondary 
endpoints 
similar to 
ACD2600g. 
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Appendix Table 3 Construction of an effects table for efalizumab: information on favourable and unfavourable effects 
Favourable Outcomes 
 Percent of patients with ≥75% improvement in PASI score at FT day 84 
 Subjects with OLS rating of Minimal or Clear at FT Day 84 
 Proportion of subjects achieving a PGA rating of Excellent or Cleared at FT Day 84 
 Mean (SD) improvement in PASI thickness component at FT day 84 
 Mean improvement (SD) from baseline in itching scale scores during FT period.  
Improvement was reflected by a decrease in the 5-point itching score 
 Mean (SD) in percent Psoriatic BSA during FT period 
 Mean improvement (SD) in DLQI overall score during FT treatment, which was reflected by a 
decrease in DLQI score 
Unfavourable Outcomes 
 Headache 
 Infection 
 Chills 
 Pain 
 Back pain 
 Fever 
 Flu syndrome 
 Asthenia 
 Accidental injury 
 Nausea 
 Diarrhoea  
 Muscoskeletal myalgia 
 Arthralgia 
 Pharyngitis 
 Rhinitis 
 Cough increased 
 Sinusitis 
 Herpes simplex 
 Acne 
 Pruritus 
 All AE 
 Infections 
 Arthritis related 
 Psoriasis related 
 Gastrointestinal disorders 
 Respiratory disorders 
 Acute AE 
 Severe AE 
 AE leading to withdrawal 
 SAE 
 Mild to moderate dose related acute flu-like symptoms (including headache, fever, chills, 
nausea, myalgia) 
 Serious adverse event/death 
 Infections:  percentage of subjects with at least one infection related adverse event 
 Incidence of infections and infestations 
 Infections:  incidence of infections requiring hospitalisation 
 Malignancy 
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 Recurrence of psoriasis after discontinuation 
 Erythrodermic psoriasis (during treatment or after discontinuation) 
 Pustular psoriasis (during treatment or after discontinuation) 
 Deafness 
 Thrombocytopenia 
 Arthritis 
 Athralgia 
 Back pain 
 Arthrosis 
 Leucocytosis and lymphocytosis 
 Thrombocytopenia 
 Hypersensitivity and allergic disorders 
 Malignancies 
 Septic meningitis, infections (including opportunistic infections as tuberculosis), immune 
related haemolytic anaemia, antibodies during vaccinations, interstitial pneumonitis, 
arthritis, erythema multiforme, inflammatory polyradiculoneuropathy, lymphomas and 
other malignancies, and liver disorders 
 Skin and subcutaneous tissue disorders (e.g. psoriasis flare up, erythemathous rash, 
rebounds, or other psoriasis-related adverse events) 
 General disorders and administration site conditions (e.g. weakness, fatigue, flu-like 
symptoms) 
 Nervous system disorders (e.g. headache) 
 Muscoskeletal and connective tissue disorders (e.g. myalgia, arthralgia) 
 Infections and infestations 
 Gastrointestinal disorders 
 Infections and infestations 
 Opportunistic infections 
 Neurological disorders 
 PML 
 Encephalopathy 
 Encephalitis 
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Appendix Table 4 Meta-analysis of trial data on benefits of efalizumab – overall risk difference and relative risk 
 
Risk difference Relative risk 
Outcome median 95% CrI median 95% CrI 
PASI75 0.244 0.151 0.362 7.82 5.00 12.38 
PGA 0.251 0.141 0.396 5.78 3.60 9.34 
OLS 0.254 0.145 0.392 7.81 4.73 13.27 
 
Appendix Table 5 Adverse events and PASI50 in treatment groups - risk difference and relative risk 
Adverse Risk difference (%) Relative risk 
event median 95% CrI median 95% CrI 
Body as a whole   
 
  
  
  
Headache 11.2 7.3 15 1.5 1.29 1.76 
Infection -1.5 -4.8 1.6 0.9 0.73 1.12 
Chills 8.2 5.9 10.4 2.8 1.99 4.07 
Pain 4.9 2.6 7.1 1.92 1.39 2.72 
Back pain 2.6 1.1 4 2.27 1.35 4.12 
Fever 4.4 2.4 6.2 2.27 1.51 3.54 
Flu syndrome 2.2 0.2 4 1.53 1.04 2.32 
Asthenia 2.1 0 4.1 1.41 1 2.02 
Accidental injury -0.5 -2.7 1.6 0.93 0.66 1.32 
Digestive          
Nausea 4.2 1.6 6.5 1.58 1.18 2.15 
Diarrhoea -0.5 -2.8 1.7 0.93 0.67 1.31 
Myalgia 3.3 1.2 5.3 1.67 1.18 2.43 
Arthralgia 1.4 -0.3 2.8 1.5 0.93 2.51 
Respiratory          
Pharyngitis 0.7 -1.6 2.9 1.11 0.81 1.55 
Rhinitis -0.4 -2.7 1.7 0.94 0.67 1.33 
Cough increased -0.4 -2.3 1.3 0.91 0.61 1.41 
Sinusitis -0.1 -2 1.7 0.99 0.68 1.48 
Skin / appendages          
Herpes simplex 1.2 -0.6 2.8 1.34 0.87 2.13 
Acne 2.8 1.7 3.9 5.36 2.33 15.73 
Pruritus -0.2 -2.3 1.8 0.97 0.69 1.41 
Efficacy       
PASI50 36.7 31.9 41.5 7.06 4.10 12.15 
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Appendix Table 6 Adverse events in trials 
Adverse event 
Efalizumab Risk difference (%) 
patients events treatment rate (%)      
(n) (n) median 95% CrI median 95% CrI 
ADR (mild to moderate) 3291 1349 40.99 39.30 42.67 28.88 26.20 31.48 
Erythroderma 3291 29 0.90 0.62 1.26 0.42 -0.20 0.91 
Thrombocytopenia 3291 8 0.26 0.13 0.48 0.18 -0.14 0.42 
Hypersensitivity  2516 202 8.01 6.99 9.12 0.90 -1.08 2.77 
Adverse event of arthritis 420 10 2.53 1.33 4.34 0.39 -2.32 2.70 
Adverse event 
Placebo Relative risk 
patients events treatment rate (%)     
(n) (n) median 95% CrI median 95% CrI 
ADR (mild to moderate) 979 118 12.10 10.15 14.23 3.39 2.86 4.05 
Erythroderma 979 4 0.48 0.17 1.04 1.88 0.79 5.63 
Thrombocytopenia 979 0 0.07 0.003 0.378 3.74 0.59 106 
Hypersensitivity  979 70 7.10 5.62 8.82 1.13 0.87 1.47 
Adverse event of arthritis 219 4 2.12 0.76 4.59 1.19 0.44 3.85 
 
 
Appendix Table 7 Incidence rate of adverse events in post-marketing surveillance per 10,000 patient-years 
Outcome median 95% CrI 
PML (all) 0.78 0.23 1.87 
ILD 3.75 2.27 5.80 
Opportunistic infections 23.49 19.41 28.17 
Haemolytic anaemia 5.03 3.27 7.34 
Polyradiculopathy 0.78 0.23 1.87 
Exacerbation Rebound 82.46 74.61 90.94 
Aseptic Meningitis 6.09 4.14 8.60 
Serious infections 60.73 54.03 68.08 
 
 
Appendix Table 8 Incidence rate per 10,000 patients-years of serious infections in clinical trials 
 
Raptiva Placebo 
 
mean 95% CrI mean 95% CrI 
Serious infections 
      <12 weeks treatment 282 201 383 137 37 350 
>12 to 144 weeks 183 143 232 
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Appendix Table 9 Effects table for efalizumab used in MCDA decision conference 
 Name Description Fixed 
Upper 
Fixed 
Lower 
Units Raptiva Placebo 
Fa
vo
ur
ab
le
 E
ffe
ct
s 
PASI75 Percentage of patients achieving 75% reduction in baseline PASI1 
at week 12.  
60.0 0.0 % 29.5 2.7 
PASI50 Percentage of patients achieving 50% reduction in baseline PASI1 
at week 12.  
60.0 0.0 % 54.9 16.7 
PGA Percentage of patients achieving Physician's Global Assessment2 
clear/almost clear at week12.  
40.0 0.0 % 29.5 5.1 
OLS Percentage of patients with Overall Lesion Severity rating of 
minimal or clear at FT (day 84). 
40.0 0.0 % 32.1 2.9 
DLQI Dermatology Life Quality Index3. Mean percentage of patients 
showing an improvement. 
10.0 0.0 Change 
score 
5.8 2.1 
U
nf
av
ou
ra
bl
e 
Ef
fe
ct
s 
AEs Percentage of patients exhibiting injection site reactions, mild to 
moderate dose-related acute flu like symptoms. 
50.0 20.0 %/100ptyrs 41.0 24.0 
Severe infections Proportion of patients experiencing infections serious enough to 
require hospitalisation. 
3.00 0.00 %/100ptyrs 2.83 1.4 
Severe 
Thrombocytopenia 
Number of cases exhibiting severe (grade 3 and above) 
thrombocytopenia4.  
10 0 number 9 0 
Psoriasis Severe Forms Percentage of patients developing severe forms of psoriasis 
(erythrodermic, pustular). 
4.0 0.0 % 3.2 1.4 
Common AEs as per 
SPC 
Percentage of patients exhibiting hypersensitivity reactions, 
arthralgia, psoriatic arthritis, flares, back pain, asthenia, ALT and 
Ph. Alk increase. 
10.0 0.0 % 5.0 0 
Interstitial Lung Disease 
(ILD) 
Number of cases of interstitial lung disease. 20 0 number 18 0 
Inflammatory 
Polyradiculopathy 
Number of cases of inflammatory polyradiculopathy. 5 0 Data 4 0 
Haemolytic Anaemia Number of cases of haemolytic anaemia. 25 0 number 24 0 
PML Number of cases of progressive multifocal leukoencephalopathy. 5 0 number 3 0 
Aseptic Meningitis Number of cases of aseptic meningitis. 30 0 number 29 0 
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1PASI is a measure of the average redness, thickness and scaliness of the lesions (each graded on a 0-4 scale), weighted by the body region and the area 
affected. PASI range is from 0 to 72. 
2PGA is a seven point scale with 7 being clear, 6 almost clear, 5 mild, 4 mild to moderate, 3 moderate, 2 moderately severe and 1 severe psoriasis. 
3DLQI is a 10-item quality of life index scored by the patient on a four point scale. 
4As shown in laboratory test results that indicate a decrease in number of platelets in a blood specimen. 
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Appendix 4 Rimonabant case study discrete choice experiment design in SAS 
Choice of obesity medicine 
 
                                 Final Results 
 
                           Design                726 
                           Choice Sets            16 
                           Alternatives            2 
                           Parameters             15 
                           Maximum Parameters     16 
                           D-Efficiency      10.2984 
                           Relative D-Eff    64.3650 
                           D-Error            0.0971 
                           1 / Choice Sets    0.0625 
                           Choice of obesity medicine 
 
    Set  Design  Efficiency  Index  Prob    n    f1  f2  x1  x2  x3  x4  x5 
 
      1    726     10.2984     672   0.5  23201   1   1   3   3   2   4   4 
           726     10.2984      38   0.5  23202   1   1   1   1   3   2   2 
      2    726     10.2984     968   0.5  23203   1   1   4   4   1   2   4 
           726     10.2984     281   0.5  23204   1   1   2   1   2   3   1 
      3    726     10.2984     270   0.5  23205   1   1   2   1   1   4   2 
           726     10.2984     875   0.5  23206   1   1   4   2   3   3   3 
      4    726     10.2984     176   0.5  23207   1   1   1   3   3   4   4 
           726     10.2984     498   0.5  23208   1   1   2   4   4   1   2 
      5    726     10.2984     547   0.5  23209   1   1   3   1   3   1   3 
           726     10.2984     954   0.5  23210   1   1   4   3   4   3   2 
      6    726     10.2984     115   0.5  23211   1   1   1   2   4   1   3 
           726     10.2984     745   0.5  23212   1   1   3   4   3   3   1 
      7    726     10.2984     523   0.5  23213   1   1   3   1   1   3   3 
           726     10.2984     484   0.5  23214   1   1   2   4   3   1   4 
      8    726     10.2984     213   0.5  23215   1   1   1   4   2   2   1 
           726     10.2984     814   0.5  23216   1   1   4   1   3   4   2 
      9    726     10.2984     219   0.5  23217   1   1   1   4   2   3   3 
           726     10.2984     629   0.5  23218   1   1   3   2   4   2   1 
     10    726     10.2984    1023   0.5  23219   1   1   4   4   4   4   3 
           726     10.2984     332   0.5  23220   1   1   2   2   1   3   4 
     11    726     10.2984     312   0.5  23221   1   1   2   1   4   2   4 
           726     10.2984     578   0.5  23222   1   1   3   2   1   1   2 
     12    726     10.2984     764   0.5  23223   1   1   3   4   4   3   4 
           726     10.2984     917   0.5  23224   1   1   4   3   2   2   1 
     13    726     10.2984     788   0.5  23225   1   1   4   1   2   1   4 
           726     10.2984     431   0.5  23226   1   1   2   3   3   4   3 
     14    726     10.2984     845   0.5  23227   1   1   4   2   1   4   1 
           726     10.2984     662   0.5  23228   1   1   3   3   2   2   2 
     15    726     10.2984     177   0.5  23229   1   1   1   3   4   1   1 
           726     10.2984     343   0.5  23230   1   1   2   2   2   2   3 
     16    726     10.2984     387   0.5  23231   1   1   2   3   1   1   3 
           726     10.2984      94   0.5  23232   1   1   1   2   2   4   2 
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Appendix 5 Rimonabant case study discrete choice experiment probit regression model 
results 
 
In the conditional probit regression model, all coefficients were statistically significant (p-value<0.001), 
indicating that all two benefits and three risks were important factors affecting treatment preference 
(Appendix Table 10).  Also, the alternative specific constant was not significant, meaning that 
respondents were not more likely to select a given alternative after adjustment for the attributes and 
their levels.  The ranking of attributes in this way was similar to the conditional logistic regression model 
(Table 4.11).  
 
Appendix Table 10 Results from a conditional probit regression model used to analyse a discrete choice experiment of weight 
loss drugs assuming linear preference functions 
 
Conditional probit 
 
regression model 
Attribute Coefficient 95% CI p-value 
10% weight loss (1% change) 0.0034 (0.0030 to 0.0039) <0.001 
Cholesterol (1 mmol/L change) 6.8006 (5.0075 to 8.5938) <0.001 
Psychiatric conditions (1% change) -0.0135 (-0.0159 to -0.0111) <0.001 
Cardiovascular conditions (1% change) -0.0095 (-0.0112 to -0.0078) <0.001 
Gastrointestinal conditions (1% change) -0.0036 (-0.0054 to -0.0019) <0.001 
    Alternative specific constant -0.1286 (-0.2644 to 0.0071) 0.063 
 
Appendix Table 11 presents the results of a categorical analysis of attributes.  For all of the attributes, 
the lowest level, representing the lowest level of risk or benefit, were used as a reference category.  
Seven terms out of 14 of interest were non-significant.  For several attributes, such as psychiatric 
conditions, the sizes of coefficients were smaller for higher levels of that attribute compared to lower 
ones. For example, the coefficient for the 1 out of 1000 level for psychiatric conditions was -1.78, 
compared to -0.89 for the 10 out of 1000 level, which would normally be interpreted as more favourable 
than the former level. 
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Appendix Table 11 Results from a conditional probit regression model used to analyse a discrete choice experiment of weight 
loss drugs assuming a categorical preference function 
 
Conditional probit regression model 
Attribute and level Coefficient 95% CI p-value 
10% weight loss 
   10 out of 1000 Reference 
150 out of 1000 -0.5305 (-2.5449 to 1.484) 0.606 
300 out of 1000 0.7876 (-0.3311 to 1.9064) 0.168 
450 out of 1000 1.3904 (0.9852 to 1.7957) <0.001 
HDL cholesterol 
   Got worse Reference 
No change -0.6794 (-2.7573 to 1.3986) 0.522 
Mild 0.6836 (-0.3408 to 1.708) 0.191 
Moderate 0.2268 (-0.9531 to 1.4067) 0.706 
Psychiatric conditions 
   0 out of 1000 Reference 
1 out of 1000 -1.7756 (-3.7185 to 0.1674) 0.073 
10 out of 1000 -0.8886 (-1.6879 to -0.0893) 0.029 
100 out of 1000 -1.4729 (-2.0538 to -0.892) <0.001 
Cardiovascular conditions 
   0 out of 1000 Reference 
1 out of 1000 -0.3679 (-1.4516 to 0.7159) 0.506 
10 out of 1000 -1.0927 (-2.1134 to -0.0721) 0.036 
100 out of 1000 -1.1817 (-1.6612 to -0.7023) <0.001 
Gastrointestinal conditions 
   0 or 1 out of 1000 Reference 
10 out of 1000 -2.5928 (-5.8914 to 0.7058) 0.123 
100 out of 1000 -1.4506 (-2.7307 to -0.1705) 0.026 
    Alternative specific constant 1.9361 (-1.1322 to 5.0044) 0.216 
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Coefficients obtained from logistic (Figure 4.2) and probit models (Appendix Figure 5) were very 
comparable when plotted, except for weight loss, where the increasing slope was smaller in the probit 
compared to logistic regression model.  
 
Appendix Figure 5 Graphical representation of probit regression model coefficients for the analysis of a discrete choice 
experiment for weight loss drugs with (A) linear or (B) categorical preference functions. 
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Appendix 6 Communication of DCE results to Weight Concern members 
 
 
 
 
 
Imperial College Study on Preferences for Obesity Treatments, August 2012 
Researchers based at Imperial College, London are interested in how the views of the public can be 
incorporated into regulatory decisions made by organisations such as the Medicines and Healthcare 
products Regulatory Agency (http://www.mhra.gov.uk/) and the European Medicines Agency 
(http://www.ema.europa.eu/) to formally decide which drugs work, are acceptably safe, and should 
be available for the treatment of obesity.  Many regulators are uncertain about the best way to take 
into account the views of members of the public in these decisions, and we are looking at how we 
can tackle this problem in a project called PROTECT (http://www.imi-protect.eu/).  PROTECT looks 
at how we can evaluate the benefits and risks of different medicines for a variety of indications, 
including weight loss.   
In August 2012, we asked the Big Panel a series of questions which measured how people value 
certain benefits and risks that relate to treatments for obesity.  This information can help inform 
regulators when they make their decisions.   Over 150 people replied.  The results are summarised 
below: 
How did the Big Panel value the benefits and risks of obesity treatments? 
In our study, we wanted to know how members of the Big Panel felt about two benefits (achieving a 
10% loss of bodyweight, and an improvement in HDL cholesterol) and three risks (psychiatric, 
cardiovascular, and gastrointestinal disorders) of obesity treatments.  We measured how 
respondents valued the different benefits and risks, and how they compared against one another.  
We found that the most important risk that influenced which treatment respondents selected for 
obesity was psychological disorders.  This was closely followed by cardiovascular disorders, and 
lastly by gastrointestinal disorders.   
How did the Big Panel find the experiment? 
Many found the survey straightforward and easy to complete.  Despite this, we also learned that 
there are a number of ways we can improve the experiment format.  Firstly, some thought that the 
page design was too similar for each question.  We hope to correct this in future surveys by clearly 
marking each question in order to avoid confusion and assure readers that it is a new page.  
Secondly, many of you felt that there was a need for a “Neither treatment” option for when you 
considered “Treatment A” and “Treatment B” to be undesirable.  In future surveys, we will consider 
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including a “Neither treatment” option if appropriate.  Lastly, some found that the wording we used 
was difficult to understand, and that the statistics we used to describe the benefits and risks were 
hard to interpret.  We will work on improving this and making it more user-friendly for future 
surveys.   
Which other treatment outcomes are important to the Big Panel? 
In our survey, we used five benefits and risks that were common in previous research into obesity 
treatments.  However, respondents suggested many more valuable benefit and risk outcomes that 
they would be interested in knowing about.  These other outcomes included the prevention and 
management of type two diabetes, arthritis and joint pain, and improvements in blood pressure.  
Respondents were also interested in other “less serious” outcomes, such as dizziness, and 
headaches. Also, when considering obesity treatments, availability and price mattered.  
Respondents also cared about how easy or difficult the medicine would be to take, and how often 
and long they would have to take it.   
Many also commented that they would like to know the impact that the treatment would have on 
their quality of life.  This included feeling better both physically and mentally, and being able to lead 
a normal lifestyle without the treatment impacting work or leisure activities, or affecting 
relationships with family and friends.   
Several also suggested that a 10% reduction in bodyweight would not be enough, and different 
methods to describe weight loss would be valuable, such as hip or waist inch loss, and percentage 
change in body fat.  The reason a 10% reduction in bodyweight was included in this study is because 
among health professionals this is thought to be a valuable outcome for improving obesity-related 
health conditions.   
How does the Big Panel feel towards treatments for obesity? 
There was a wide range in attitudes towards treatments for obesity.  A few were not interested in 
them at all.  Some did not want any treatment that would have potential side effects, whereas 
others felt that small short term risks were acceptable in exchange for valuable benefits.   
We noted with interest that many participants voiced their concern that drugs alone are not 
enough to treat obesity.  Many believe that a holistic approach to tackle obesity is needed, one 
which addresses the psychological aspects of weight loss in addition to a healthy diet and physical 
activity.   Also, to successfully maintain weight loss, participants believe that long term support from 
medical professionals and peers is desirable.   
A publically available copy of the full report will be available on the PROTECT website 
(http://www.imi-protect.eu/) at a later date. 
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Imperial College would like to thank the members of the Big Panel and Weight Concern for their 
participation and contribution to the PROTECT project.   
Tell us what you think:  If you have any questions or comments to make about the results of this 
study, please feel free to contact:  Kimberley Hockley (Kimberley.hockley08@imperial.ac.uk) 
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Appendix 7 Natalizumab case study finalised glossary 
Multiple sclerosis (source: Multiple Sclerosis Society):  “A substance called myelin protects the nerve 
fibers in the central nervous system.  In MS, the immune system which normally helps to fight off 
infections, mistakes myelin for a foreign body and attacks it. Therefore the nerves cannot perform 
anymore, leading to symptoms on sensitivity (visual function, numbness, electric shock sensations) or 
motricity (weakness, tremor). 
"Relapsing remitting" MS is the most common type of MS, affecting around 85 per cent of everyone 
diagnosed with MS. It means that symptoms appear (a relapse), and then fade away, either partially or 
completely (remitting).” 
Administration:  The convenience of a treatment for a patient is his or her subjective appreciation of the 
burden of the drug intake; for example, a patient would prefer an oral small pill taken twice a week for 2 
weeks rather than an intramuscular injection twice a day for 3 months. 
In addition the convenience can be affected by the need for blood tests to monitor the effectiveness or 
safety of the drug or the status of the disease. 
Various methods can be used to administer medicines, depending on route of administration, 
formulation, frequency of administration.  Examples are: 
 Route of administration: oral, injectable, into joints (intra-articular) etc. 
 Formulation: capsule, pill, syrup, injection, ointment, etc. 
 Frequency of administration: once or twice a day, twice a week, etc. 
The convenience of a treatment for you is your perspective of the burden of the drug intake; for 
example, most patients would prefer an oral small pill taken twice a week for 2 weeks rather than an 
intramuscular injection twice a day for 3 months. 
In addition the convenience can be affected by the need for blood tests to monitor the effectiveness or 
safety of the drug or the status of the disease. 
Benefits 
Relapse:  A relapse is defined by "the appearance of new symptoms, or the return of old symptoms, 
for a period of 24 hours or more – in the absence of a change in core body temperature or infection". 
Symptoms you have experienced before, or perhaps grown used to dealing with, might appear in a 
different part of the body. 
In relapses, symptoms usually come on over a short period of time – over hours or days. They often stay 
for a number of weeks, usually four to six, though this can vary from very short periods of only a few 
days to many months. 
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Relapses can vary from mild to severe. At their worst, acute relapses may need hospital treatment, but 
many relapses are managed at home, with the support of the GP, MS specialist nurse, and other care 
professionals.  
Symptoms which come and go can sometimes be considered a relapse – they don’t always have to be 
continuous. For example, some people experience a shock-like sensation when they bend their neck. 
This can be considered a relapse if it occurs every time they bend their neck for at least 24 hours. 
Medical staff might call relapses things like attack, flare-up, exacerbation, acute episode or clinical 
event. 
Disability progression:  Disability progression is quantified in MS by an increase in a score (called EDSS: 
Expanded Disability Status Scale).  This score consists in the addition of a score from 1 to 10 depending 
of the severity, in 8 functional systems (cerebral, mental, sensitivity, bowel, visual etc.) 
The EDSS Score is a 10-point scale to quantify disability in multiple sclerosis and to monitor changes in 
the level of disability over time. 
The EDSS score is based around the following 8 symptoms: 
■  weakness or difficulty moving limbs 
■ a loss of coordination or tremor 
■ problems with speech, swallowing, or your eyes darting around (nystagmus) 
■ numbness or loss of sensations 
■ bowel and bladder function 
■ visual function 
■ certain mental functions 
■ other functions 
If you are relatively mobile, your score will be less than 5.  
If your score is more than 5 you will also have difficulty walking.  
What a one-point change on the EDSS scale will mean for you depends on where you start. So for 
example, if you have a score of 3, you will have mild symptoms in 3 or 4 of the above, or moderate 
symptoms in 1 of them. However you will have no difficulty walking. If you then moved to a score of 4, 
you would have more disability, but you should be able to be up and about for 12 hours per day. 
A score of 5 will mean you have disability severe enough to impair full daily activities and will also impair 
your ability to work a full day without special provisions. However you will be able to walk without aid or 
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rest for 200 metres. If your score changes to 6, you will no longer be able to walk without a cane, and 
you can probably only manage to walk 100 metres. 
More Serious Side Effects 
Reactivation of serious herpes viral infections:  Herpes viruses may be present without any symptom 
for several years by healthy people. They carry the virus but this latter is “silent”. The virus may become 
active if something “wakes up” the capability of the virus to harm the patient; this can be another 
infection, a shock, or a decrease in the immune system caused by a treatment such as those used in MS. 
Then the virus can result in cold sores, shingles, genital herpes, and herpes dermatitis. 
Seizures:  A seizure is defined by uncontrolled electrical activity in the brain, and may cause 
involuntary changes in body movement or function, sensation, awareness, or behaviour. Seizures are 
often associated with a sudden and involuntary contraction of a group of muscles and loss of 
consciousness. They are usually quite short, often a few seconds.  
For most people this will be a one-off event, but your doctor will want to investigate this further as they 
try and rule out the possibility of there being any more. You will likely have to have more tests, and until 
the likelihood of further seizures has been ruled out, you may not be allowed to drive. 
PML (source: medicinenet.com):  “PML stands for progressive multifocal leukoencephalopathy, a 
rapidly progressive, often fatal viral infection of the brain.  The signs and symptoms of PML include 
headaches, memory loss, changes in mental status, speech and vision difficulties, loss of strength, limb 
weakness, seizures, partial paralysis and loss of coordination. The disease leads to coma and then to 
death.” This disease is seen almost only in severely immune-depressed patients. This depression in 
immunity can be caused by some diseases (e.g. HIV) or some very potent treatments against some 
immune diseases, such as MS. 
Miscarriage: Miscarriage is the loss of a pregnancy before the baby can survive. This happens in about 1 
in 4 pregnancies. Some drugs may cause an increased risk of miscarriage. 
Congenital abnormalities (source: medicinenet.com):  “Congenital abnormalities are physical defects 
present in a baby at birth that can involve various parts of the body, including the brain, heart, lungs, 
liver, bones, and intestinal tract. Examples include heart defects, cleft lip and palate, spina bifida, limb 
defects, and Down syndrome.” 
Less Serious Side Effects 
Infusion, injection site reactions:  Infusion or injection site reactions are when the skin reacts locally 
during or after treatment administration at the point where the injecting needle was applied to the skin.  
There may be redness, irritation, swelling, and/or pain. 
Hypersensitivity reactions:  Hypersensitivity reactions are generalized immune reactions: the body, 
which usually recognizes and eliminates foreign bodies through immune mechanisms, overreacts to 
exposure to these external aggression; these hypersensitivity reactions can be immediate or delayed. 
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Most common hypersensitivity reaction are allergies (to dust, to food, to drugs, etc.) Some immediate 
severe hypersensitivity reactions can cause a shock, or difficulty breathing, swelling of the body and 
collapse. 
Flu like reactions:  Flu like reactions are symptoms similar to experiencing flu, e.g.   fever, chills, fatigue, 
nausea and vomiting. They are also immune reactions. 
Transaminases elevation:  Transaminases are a type of liver enzyme. They can be measured in the 
blood. A moderate increase in transaminase is unlikely to produce symptoms. However, it can indicate 
liver damage. If the liver damage is more severe or chronic, the transaminases can increase to very high 
levels. In these cases the underlying liver disease is usually associated with additional symptoms. 
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Appendix 8 Natalizumab case study participant information leaflet for the weight elicitation 
activities 
 
 
8th May 2013 
Discussion group to assess the value that patients and the public place on the benefits and risks 
associated with treatments for relapsing remitting multiple sclerosis 
We are inviting you to participate in a study focusing on the benefits and risks of multiple sclerosis 
treatment.  The full title of the study is “Elicitation of utility values for multiple sclerosis treatments with 
the use of Measuring Attractiveness by a Categorical Based Evaluation Technique.”  Before you provide 
consent, it is important that you understand why we are conducting this study, and what it will involve.   
Please read the following information carefully.  Please do not hesitate to contact us if anything is 
unclear, or if you have more questions. 
Thank you for your cooperation.   
What is the purpose of the study? 
A group of researchers based at Imperial College, London, wish to assess the value that patients and the 
public place on the benefits and risks associated with treatments for relapsing remitting multiple 
sclerosis.  By knowing your preferences, we can help to improve public and patient involvement in 
policy, and make it more likely that your perspective can inform which drugs are available.  The person 
in charge of this study as the primary investigator is Professor Deborah Ashby at Imperial College, 
London.  Her area of expertise is decision-making methodology in the context of medicine regulation. 
Do I have to take part? 
You do not have to take part, you participation is voluntary.   If you do decide to take part, we request 
that you reply to this email with your name and telephone number.  By providing these details, we will 
assume this means that you understand the information we have provided, have no further questions, 
and wish to participate.  Later, before the decision conference, we will require signed consent before 
you participate.  For your records, a copy of the consent form is attached to the final page of this 
information sheet.  If you initially decide to participate but later change your mind, you will still be free 
to withdraw at any time without giving a reason.   
What happens if I would like to take part? 
After receiving your reply to this email with your name and telephone number showing you would like 
to participate, we will send you a questionnaire for you to complete before the elicitation meeting.  The 
 258 
 
questionnaire will ask about how you value specific benefits and risks associated with relapsing 
remitting multiple sclerosis treatments.   
We ask that before you begin filling it in, you wait for us to telephone you and provide instructions on 
how to answer the questionnaire, and discuss any further questions you may have about the study and 
participating.   
Lastly, you will be invited to attend a discussion group at Imperial College, London.  We will discuss 
everyone’s responses to the questionnaire together as a group.  The session is anticipated to last for 5 
hours (including breaks), and refreshments and lunch will be provided.  We will reimburse you £80 for 
your travel expenses and time.   
What do I have to do? 
To take part in this study you must be willing to do the following things: 
1. Reply to this email with your name, telephone number, and the times you would prefer us to 
call. 
2. Receive a telephone briefing about the study, where will describe the study and discuss any 
further questions you may have about the study and participating. 
3. Travel to the Imperial College Campus located in Paddington, London.  We will not be able to 
reimburse you specifically for your travel fees, but we will be providing £80 to participants for 
expenses and this amount should cover transport within London Zones 1 to 6 by bus, train or 
tube.  Unfortunately, we will not be able to reimburse participants more than this amount. 
4. Participate in a group discussion session to talk about your responses to the questionnaire. 
5. Be willing for the discussion to be recorded.  The recording will be anonymised, remain 
confidential and be securely stored. 
Will my taking part in this study be kept confidential? 
Your participation and personal information will be kept strictly confidential.  All of the responses you 
provide in the discussion will be anonymised.   
What will happen to the results of this research? 
The results of the research will be analysed and published in a PhD thesis, scientific journals and be 
presented at conferences. If you like, we can provide you with a copy of the results. 
Contact for further information: 
Please do not hesitate to contact us by email if anything is unclear, or if you have more questions:  
kimberley.hockley08@imperial.ac.uk.  
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Appendix 9 Natalizumab case study swing-weighting weight elicitation questionnaire 
Study investigating views on the benefits and risks of treatments for relapsing 
remitting multiple sclerosis 
Overview of Questionnaire 
It will be explained to you at the first meeting what the aims of this study are, how the information from 
this questionnaire will be used and how to fill out this questionnaire. 
A glossary is provided on the next page which gives details of different benefits and risks associated with 
relapsing remitting multiple sclerosis. This should be read first, and the definitions and consequences of 
the different benefits and risks understood.   
Firstly, in question 1, you are asked to rank different types of drug administration. From then on the 
next four questions (2A, 2B, 2C and 2D) ask you to rank a set of benefits or risk.  
We will then meet together for a decision conference, where the preference of the group will be 
assessed. During this conference the top ranked of the outcomes from the group are carried forward to 
the next questions, until everything has been compared. This is illustrated in diagram below.  
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Glossary 
Multiple sclerosis (source: Multiple Sclerosis Society):  “A substance called myelin protects the nerve 
fibres in the central nervous system.  In MS, the immune system which normally helps to fight off 
infections, mistakes myelin for a foreign body and attacks it. 
"Relapsing remitting" MS is the most common type of MS, affecting around 85 per cent of everyone 
diagnosed with MS. It means that symptoms appear (a relapse), and then fade away, either partially or 
completely (remitting).” 
Relapse (source: Multiple Sclerosis Society):  “A relapse is the appearance of new symptoms, or the 
return of old symptoms, for a period of 24 hours or more – in the absence of a change in core body 
temperature or infection. 
In relapses, symptoms usually come on over a short period of time – over hours or days. They often stay 
for a number of weeks, usually four to six, though this can vary from very short periods of only a few 
days to many months. 
Relapses can vary from mild to severe. At their worst, acute relapses may need hospital treatment, but 
many relapses are managed at home, with the support of the GP, MS specialist nurse, and other care 
professionals.  
Symptoms which come and go can sometimes be considered a relapse – they don’t always have to be 
continuous. For example, some people experience a shock-like sensation when they bend their neck. 
This can be considered a relapse if it occurs every time they bend their neck for at least 24 hours.” 
Disability progression:  Disability progression is measured by an increase in the Expanded Disability 
Status Scale score of one point or more, with a baseline score of 1 or less; or, an increase in score of 1.5 
points or more with a baseline score of 0.   
An increase in the EDSS score could represent a worsening of one or more of the following symptoms:  
weakness or difficulty moving limbs, loss of coordination or tremor, problems with speech swallowing or 
vision, numbness or loss of sensations, issues with bowel and bladder function, visual function and 
mental functions. 
Convenience:  Various different methods can be used to administer medicines.  Examples are: 
 A capsule to be swallowed once a day, every day. 
 A once monthly one hour intravenous infusion followed by one hour reaction monitoring at a 
hospital.  
 A daily self administered injection that goes just under the skin (subcutaneous).    
 A weekly self administered injection that goes into the muscle (intramuscular). 
Reactivation of serious herpes viral infections:  Herpes viruses may become active, e.g. treatment may 
result in cold sores, shingles, genital herpes, and herpes dermatitis. 
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PML (source: medicinenet.com):  “PML stands for progressive multifocal leukoencephalopathy, a 
rapidly progressive, often fatal viral infection of the brain.  The signs and symptoms of PML include 
headaches, memory loss, changes in mental status, speech and vision difficulties, loss of strength, limb 
weakness, seizures, partial paralysis and loss of coordination. The disease leads to coma and then to 
death.” 
Congenital abnormalities (source: medicinenet.com):  “Congenital abnormalities are physical defects 
present in a baby at birth that can involve many different parts of the body, including the brain, heart, 
lungs, liver, bones, and intestinal tract. Examples include heart defects, cleft lip and palate, spina bifida, 
limb defects, and Down syndrome.” 
Seizures:  Seizures are caused by uncontrolled electrical activity in the brain.  They can range from a wild 
thrashing bodily movement to a brief loss of awareness.  Uncontrolled seizures can cause brain damage, 
lowered intelligence, and permanent mental and physical impairment. 
Infusion, injection site reactions:  Infusion or injection site reactions are when the skin reacts to 
treatment during or after treatment administration.  There may be redness, irritation, swelling, and/or 
pain. 
Hypersensitivity reactions:  Hypersensitivity reactions are similar to infusion/injection site reactions.  
However, whereas infusion/injection site reactions affect only the skin, hypersensitivity reactions also 
affect the rest of the body through an allergic immune response.  In rare severe cases, it may result in 
difficulty breathing and collapse.   
Flu like reactions:  Flu like reactions are symptoms similar to experiencing flu, e.g.   fever, chills, fatigue, 
nausea and vomiting. 
Transaminases elevation:  Transaminases are a type of liver enzyme.  An increase in transaminase is 
unlikely to produce symptoms.  However, it can indicate liver damage. 
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Question 1 
This question is asking about your preferences for the way a drug for multiple sclerosis is administered and how often it is administered.  
There are four different ways a dug could be given to you in the table below. We ask you to assess your relative preferences for each of these 
methods.  
1) Give your most preferred method of administration a value of 100 
2) Give your least preferred method of administration a value of 0 
3) Gives values between 0 and 100 for the remaining methods of administration. 
  
Value 
Outcome   
Best = 100 
Worst = 0 
Oral once daily     
Intravenous infusion once monthly( in a hospital)     
Intra muscular injection once weekly     
Subcutaneous injection once daily   
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Question 2A 
Imagine a situation where all the outcomes are the worst they could be in the table below. 
Now imagine you can change one of them to be the best it could be. 
1) Give a rank of 1 to the outcome you would most like to change from its worst to best value (all the others stay at the worst value). 
2) Now rank the other outcomes the same way, according to how much you would like to change it from its worst to best value (all the others 
stay at the worst value). 
3) On the scale below, mark the he outcome given a rank of 1 with a value of 100.  
4) Now place the other outcomes on the scale to reflect their relative importance, and transfer these numbers to the final column of the table.  
(Note that unlike the question for convenience, the lowest ranked outcome does not have to have a value of 0) 
  
Outcomes 
   
Value 
Outcome How is it measured Worst Best   Ranking   Rank 1 = 100 
Relapse Total number of relapses in 100 
patients in two years 
200 0         
Disability 
progression 
Number of patients out of 100 who 
experience this in two years 
30 0         
Convenience Administration route and frequency Worst from 
question 1 
Best from 
question 1 
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Question 2B 
Imagine a situation where all the outcomes are the worst they could be in the table below. 
Now imagine you can change one of them to be the best it could be. 
1) Give a rank of 1 to the outcome you would most like to change from its worst to best value (all the others stay at the worst value). 
2) Now rank the other outcomes the same way, according to how much you would like to change it from its worst to best value (all the others 
stay at the worst value). 
3) On the scale below, mark the he outcome given a rank of 1 with a value of 100.  
4) Now place the other outcomes on the scale to reflect their relative importance, and transfer these numbers to the final column of the table.  
(Note that unlike the question for convenience, the lowest ranked outcome does not have to have a value of 0) 
  
Outcomes 
   
Value 
Outcome How is it measured Worst Best   Ranking   Rank 1 = 100 
Reactivation of 
serious herpes viral 
infections 
Number of patients out of 100 who 
experience this in two years 
20 0         
PML Number of patients out of 100 who 
experience this in two years 
2 0         
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Question 2C 
Imagine a population of women of child bearing potential 
Imagine a situation where all the outcomes are the worst they could be in the table below. 
Now imagine you can change one of them to be the best it could be. 
1) Give a rank of 1 to the outcome you would most like to change from its worst to best value (all the others stay at the worst value). 
2) Now rank the other outcomes the same way, according to how much you would like to change it from its worst to best value (all the others 
stay at the worst value). 
3) On the scale below, mark the he outcome given a rank of 1 with a value of 100.  
4) Now place the other outcomes on the scale to reflect their relative importance, and transfer these numbers to the final column of the table.  
(Note that unlike the question for convenience, the lowest ranked outcome does not have to have a value of 0) 
  
Outcomes 
   
Value 
Outcome How is it measured Worst Best   Ranking   Rank 1 = 100 
Abortion or 
congenital 
abnormalities 
Number of patients out of 100 who 
experience this in two years 
2 0         
Transaminases 
elevation 
Number of patients out of 100 who 
experience this in two years 
8 0         
Seizures Number of patients out of 100 who 
experience this in two years 
4 0         
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Question 2D 
Imagine a situation where all the outcomes are the worst they could be in the table below. 
Now imagine you can change one of them to be the best it could be. 
1) Give a rank of 1 to the outcome you would most like to change from its worst to best value (all the others stay at the worst value). 
2) Now rank the other outcomes the same way, according to how much you would like to change it from its worst to best value (all the others 
stay at the worst value). 
3) On the scale below, mark the he outcome given a rank of 1 with a value of 100.  
4) Now place the other outcomes on the scale to reflect their relative importance, and transfer these numbers to the final column of the table.  
(Note that unlike the question for convenience, the lowest ranked outcome does not have to have a value of 0) 
  
Outcomes 
   
Value 
Outcome How is it measured Worst Best   Ranking   Rank 1 = 100 
Infusion or injection 
site reactions 
Number of patients out of 100 who 
experience this in two years 
40 0         
Hypersensitivity 
reactions 
Number of patients out of 100 who 
experience this in two years 
20 0         
Flu-like reactions Number of patients out of 100 who 
experience this in two years 
80 0         
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